relevancy	row	span1	span2
0.9996797	0	[ (a) a therapeutically effective amount of a compound selected from the group consisting of an anti-inflammatory agent, a pro-inflammatory agent, a cytokinesterase inhibitor and a pro-inflammatory cytokine, wherein the compound comprises a first or second hydrophilic ring; and ]	[ A method of providing a therapeutic composition to a mammal, the therapeutic composition comprising a composition comprising: ]
0.010130435	1	[ wherein said compound is a polypeptide comprising a first amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO: ]	[ (a) a therapeutically effective amount of a compound selected from the group consisting of an anti-inflammatory agent, a pro-inflammatory agent, a cytokinesterase inhibitor and a pro-inflammatory cytokine, wherein the compound comprises a first or second hydrophilic ring; and ]
0.9981511	2	[ 2. ]	[ wherein said compound is a polypeptide comprising a first amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO: ]
0.9983646	3	[ 000 daltons, said method comprising: ]	[ A method of producing a polymeric composition comprising a polymeric component and at least one non-polymeric component, wherein said at least one non-polymeric component has an average molecular weight of less than 100, ]
0.99751604	4	[ a) contacting said at least one non-polymeric component with a first solvent to produce said polymeric component; ]	[ 000 daltons, said method comprising: ]
0.9999924	5	[ b) contacting said at least one non polymeric component with a second solvent to produce said non-polymeric component; ]	[ a) contacting said at least one non-polymeric component with a first solvent to produce said polymeric component; ]
0.9999924	6	[ c) contacting said at least one non-polymeric component with a third solvent to produce said non-polymeric component; and ]	[ b) contacting said at least one non polymeric component with a second solvent to produce said non-polymeric component; ]
0.999992	7	[ d) mixing said at least one non-polymeric component and said at least one non-polymeric component to form a mixture. ]	[ c) contacting said at least one non-polymeric component with a third solvent to produce said non-polymeric component; and ]
0.0054811332	8	[ a first end portion; ]	[ A device for treating a patient having an inflammatory bowel disease comprising: ]
0.99999034	9	[ a second end portion, the second end portion being adapted to be attached to the first end portion; ]	[ a first end portion; ]
0.9999906	10	[ an inner wall having an outer surface, a first end portion and at least one end portion extending from a second end portion, wherein the inner walls of the first end portion and the second end portion are adapted to be coupled to one another; ]	[ a second end portion, the second end portion being adapted to be attached to the first end portion; ]
0.9999913	11	[ a first adhesive disposed within the inner walls of the first and second end portions, the first adhesive having a surface that is adapted to be attached to a portion of the inner walls of the second and third end portions; ]	[ an inner wall having an outer surface, a first end portion and at least one end portion extending from a second end portion, wherein the inner walls of the first end portion and the second end portion are adapted to be coupled to one another; ]
0.99999225	12	[ an outer surface of the second and fourth end portions being disposed within the inner walls of the first and second end portions; ]	[ a first adhesive disposed within the inner walls of the first and second end portions, the first adhesive having a surface that is adapted to be attached to a portion of the inner walls of the second and third end portions; ]
0.9999902	13	[ wherein the first and second end portions have a length of from about 1.25 to about 2 inches and a thickness of from about 2 inches to about 4 inches, and ]	[ an outer surface of the second and fourth end portions being disposed within the inner walls of the first and second end portions; ]
0.9999831	14	[ the first and second end portions are each adapted to have an outer surface that is adapted to be attached to a portion of the inner walls of the first and second end portions. ]	[ wherein the first and second end portions have a length of from about 1.25 to about 2 inches and a thickness of from about 2 inches to about 4 inches, and ]
0.9996971	15	[ a) providing a first prosthetic leg comprising a first end and a second end, said first end and said second end having a first and a second axis; ]	[ A method for determining a position of a first and a second end of a prosthetic limb in a body of an operator, the method comprising: ]
0.99999225	16	[ b) providing a first prosthetic arm having a first end and a second end, said first and second ends having a first and a second axis; ]	[ a) providing a first prosthetic leg comprising a first end and a second end, said first end and said second end having a first and a second axis; ]
0.99999225	17	[ c) providing a second prosthetic arm having a first end and an opposite first axis, said first and second axis being substantially parallel to said first and second axes; ]	[ b) providing a first prosthetic arm having a first end and a second end, said first and second ends having a first and a second axis; ]
0.9999912	18	[ d) providing a first prosthetic leg and a second prosthetic arm, said first and second prosthetic arms being configured to be connected to each other by a pair of first and second prostheses, wherein each of said prostheses comprises a first and a second end, and ]	[ c) providing a second prosthetic arm having a first end and an opposite first axis, said first and second axis being substantially parallel to said first and second axes; ]
0.99999225	19	[ wherein each of said first and second prostheses comprises a first and a second axis; and ]	[ d) providing a first prosthetic leg and a second prosthetic arm, said first and second prosthetic arms being configured to be connected to each other by a pair of first and second prostheses, wherein each of said prostheses comprises a first and a second end, and ]
0.99999225	20	[ e) positioning the first and second end of each of said first and second prostheses relative to the first and second end of said first end and said second end, respectively. ]	[ wherein each of said first and second prostheses comprises a first and a second axis; and ]
0.9999856	21	[ an effective amount of a pharmaceutically acceptable salt or carrier, wherein said compound is selected from the group consisting of: ]	[ A method for treating a disease in an animal comprising administering to said animal a therapeutically effective amount of a compound selected from the group consisting of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, and ]
0.99715877	22	[ (i) a salt thereof, ]	[ an effective amount of a pharmaceutically acceptable salt or carrier, wherein said compound is selected from the group consisting of: ]
0.9999049	23	[ (ii) a pharmaceutically acceptable carrier thereof, and ]	[ (i) a salt thereof, ]
0.99992585	24	[ (iii) an effective amount of a pharmaceutically acceptable salt or carrier, ]	[ (ii) a pharmaceutically acceptable carrier thereof, and ]
0.9977016	25	[ wherein said animal is a mammal. ]	[ (iii) an effective amount of a pharmaceutically acceptable salt or carrier, ]
0.9988502	26	[ (a) administering to an individual in need thereof a therapeutically effective amount of an isolated peptide of the amino acid sequence of SEQ ID NO: ]	[ A method for treating an autoimmune condition, said method comprising: ]
0.9999325	27	[ 2, wherein the peptide comprises a sequence of SEQ ID NO: ]	[ (a) administering to an individual in need thereof a therapeutically effective amount of an isolated peptide of the amino acid sequence of SEQ ID NO: ]
0.0006815256	28	[ 2, ]	[ 2, wherein the peptide comprises a sequence of SEQ ID NO: ]
0.00128028	29	[ (b) contacting the peptide with a subject in need thereof, wherein the subject is an individual having a condition characterized by a disorder of the immune system; ]	[ 2, ]
0.99998236	30	[ (c) measuring the level of the peptide; ]	[ (b) contacting the peptide with a subject in need thereof, wherein the subject is an individual having a condition characterized by a disorder of the immune system; ]
0.9999914	31	[ (d) determining whether the level of the peptide in the individual has been reduced by the subject; and ]	[ (c) measuring the level of the peptide; ]
0.99998605	32	[ (e) administering to the individual a therapeutically effective amount of a therapeutically effective amount of an isolated peptide of SEQ ID NO: ]	[ (d) determining whether the level of the peptide in the individual has been reduced by the subject; and ]
0.9989772	33	[ 2 that comprises at least one of SEQ ID No: ]	[ (e) administering to the individual a therapeutically effective amount of a therapeutically effective amount of an isolated peptide of SEQ ID NO: ]
0.9999368	34	[ 2, SEQ ID No: ]	[ 2 that comprises at least one of SEQ ID No: ]
0.999974	35	[ 3, or SEQ ID NO: ]	[ 2, SEQ ID No: ]
0.999587	36	[ 4. ]	[ 3, or SEQ ID NO: ]
0.9999919	37	[ a second electrode configured to receive an electrical signal from a second electrode of the subject, wherein the electrical signal is generated by the first electrode and the electrical signals are coupled to each other, ]	[ A device for treating a subject, comprisinga first electrode configured to receive an electrical signal from a first electrode of the subject, and ]
0.99999154	38	[ a plurality of electrodes configured to receive the electrical signals, wherein each electrode is configured to generate a different electrical signal based on the electrical signals received from the plurality of electrodes, and ]	[ a second electrode configured to receive an electrical signal from a second electrode of the subject, wherein the electrical signal is generated by the first electrode and the electrical signals are coupled to each other, ]
0.999884	39	[ a plurality of conductive elements, wherein at least one of the plurality of conductive elements is configured to be electrically coupled to one of a plurality of electrodes of the first electrode and the second electrode, ]	[ a plurality of electrodes configured to receive the electrical signals, wherein each electrode is configured to generate a different electrical signal based on the electrical signals received from the plurality of electrodes, and ]
0.9999918	40	[ wherein each of the plurality of conductive elements comprises a plurality of conductive elements, ]	[ a plurality of conductive elements, wherein at least one of the plurality of conductive elements is configured to be electrically coupled to one of a plurality of electrodes of the first electrode and the second electrode, ]
0.9999914	41	[ wherein each of the plurality of conductive elements is configured to generate a different electrical signal based on the electrical signals received from the plurality of electrodes. ]	[ wherein each of the plurality of conductive elements comprises a plurality of conductive elements, ]
0.99976796	42	[ a) an amount effective amount of a polypeptide comprising a nucleic acid molecule having at least 95% sequence identity with SEQ ID NO: ]	[ A method of treating a patient having a cancer in a patient's body, comprising administering to the cancer an amount of a therapeutically effective amount of an effective amount of at least one of: ]
0.99372125	43	[ 1; and ]	[ a) an amount effective amount of a polypeptide comprising a nucleic acid molecule having at least 95% sequence identity with SEQ ID NO: ]
0.9839242	44	[ b) a compound that specifically binds to a TNF receptor, wherein the compound is capable of binding to TNF receptor and is capable of causing apoptosis. ]	[ 1; and ]
0.9906096	45	[ a body having a proximal end, a distal end, a distal end wall, and ]	[ A device for providing a patient with an implantable medical device, comprising: ]
0.97258955	46	[ a first end; ]	[ a body having a proximal end, a distal end, a distal end wall, and ]
0.9996388	47	[ a first end wall defining a first longitudinal axis; a first longitudinal axis defining a second longitudinal axis; ]	[ a first end; ]
0.99999213	48	[ a first end wall defining a second longitudinal axis; ]	[ a first end wall defining a first longitudinal axis; a first longitudinal axis defining a second longitudinal axis; ]
0.99999225	49	[ a second end wall defining a second longitudinal axis; ]	[ a first end wall defining a second longitudinal axis; ]
0.99999154	50	[ a first longitudinal axis defining a first longitudinal axis and a second longitudinal axis; ]	[ a second end wall defining a second longitudinal axis; ]
0.99999225	51	[ a second longitudinal axis defining a first longitudinal axis and a second longitudinal axis; ]	[ a first longitudinal axis defining a first longitudinal axis and a second longitudinal axis; ]
0.99371123	52	[ an implantable medical device having a first end and a second end; ]	[ a second longitudinal axis defining a first longitudinal axis and a second longitudinal axis; ]
0.9997836	53	[ a plurality of first and second actuators, each having a first end and a second end, each of the first and second ends having a proximal end and a distal end and a first and second longitudinal axes, each of the first and second longitudinal axes defining a first longitudinal axis and a second longitudinal axis, and ]	[ an implantable medical device having a first end and a second end; ]
0.999992	54	[ each of the first and second longitudinal axes defining a second longitudinal axis; and ]	[ a plurality of first and second actuators, each having a first end and a second end, each of the first and second ends having a proximal end and a distal end and a first and second longitudinal axes, each of the first and second longitudinal axes defining a first longitudinal axis and a second longitudinal axis, and ]
0.9999548	55	[ a first actuator having a first proximal end, a first distal end, a first longitudinal axis, and ]	[ each of the first and second longitudinal axes defining a second longitudinal axis; and ]
0.9999902	56	[ an actuator end, wherein the first proximal end and first distal end are disposed proximal to the first longitudinal axis, the first longitudinal axis is disposed proximal to the first longitudinal axis, the first longitudinal axis is disposed distal to the first longitudinal axis, and ]	[ a first actuator having a first proximal end, a first distal end, a first longitudinal axis, and ]
0.99999225	57	[ the first proximal end and first distal end are disposed distal to the second longitudinal axis. ]	[ an actuator end, wherein the first proximal end and first distal end are disposed proximal to the first longitudinal axis, the first longitudinal axis is disposed proximal to the first longitudinal axis, the first longitudinal axis is disposed distal to the first longitudinal axis, and ]
0.9969285	58	[ a) providing an active agent; ]	[ A method for producing a therapeutic agent, comprising: ]
0.9999902	59	[ b) contacting the active agent with a target tissue; ]	[ a) providing an active agent; ]
0.99999225	60	[ c) detecting the presence of a change in the concentration of the active agent in the target tissue; and ]	[ b) contacting the active agent with a target tissue; ]
0.9999895	61	[ d) administering the active agent to a patient. ]	[ c) detecting the presence of a change in the concentration of the active agent in the target tissue; and ]
0.99956053	62	[ 1, SEQ ID NO: ]	[ An isolated polypeptide, wherein said isolated polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: ]
0.99998844	63	[ 2, SEQ ID NO: ]	[ 1, SEQ ID NO: ]
0.99998915	64	[ 3, SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.9999895	65	[ 4, SEQ ID NO: ]	[ 3, SEQ ID NO: ]
0.9999685	66	[ 5, or SEQ ID NO: ]	[ 4, SEQ ID NO: ]
0.9995726	67	[ 6, and ]	[ 5, or SEQ ID NO: ]
0.99809545	68	[ wherein the polypeptide is selected from the group consisting of SEQ ID NO: ]	[ 6, and ]
0.9997433	69	[ 1, SEQ ID NO: ]	[ wherein the polypeptide is selected from the group consisting of SEQ ID NO: ]
0.99998844	70	[ 2, SEQ ID NO: ]	[ 1, SEQ ID NO: ]
0.99998915	71	[ 3, SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.9999895	72	[ 4, SEQ ID NO: ]	[ 3, SEQ ID NO: ]
0.99951947	73	[ 5, and ]	[ 4, SEQ ID NO: ]
0.9990879	74	[ SEQ ID NO: ]	[ 5, and ]
0.9997087	75	[ 6. ]	[ SEQ ID NO: ]
0.9993217	76	[ a) administering to a subject in need thereof an effective amount of at least one of a first and a second anti-T cell antibody, wherein the first and the second anti-T cell antibody are selected from the group consisting of: ]	[ A method for the treatment of an autoimmune condition comprising: ]
0.99962795	77	[ a) an antibody comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: ]	[ a) administering to a subject in need thereof an effective amount of at least one of a first and a second anti-T cell antibody, wherein the first and the second anti-T cell antibody are selected from the group consisting of: ]
0.99999213	78	[ 2; orb) a monoclonal antibody comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: ]	[ a) an antibody comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.9984452	79	[ 2; ]	[ 2; orb) a monoclonal antibody comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.9967373	80	[ c) administering to the subject in need thereof at least a first and a second anti-T cell antibody that is capable of binding a T-cell receptor, wherein the first and second anti-T cell antibodies are selected from the group consisting of: ]	[ 2; ]
0.99981314	81	[ a) a monoclonal antibody having a molecular weight of about 1, ]	[ c) administering to the subject in need thereof at least a first and a second anti-T cell antibody that is capable of binding a T-cell receptor, wherein the first and second anti-T cell antibodies are selected from the group consisting of: ]
0.012841925	82	[ 000 &#x3bc; ]	[ a) a monoclonal antibody having a molecular weight of about 1, ]
0.9953916	83	[ m; ]	[ 000 &#x3bc; ]
0.0061581116	84	[ b) a polypeptide having an amino acid sequence having at least 90% sequence identity to SEQ ID NO: ]	[ m; ]
0.9957403	85	[ 2, and ]	[ b) a polypeptide having an amino acid sequence having at least 90% sequence identity to SEQ ID NO: ]
0.9502336	86	[ c) a monoclonal antibody having a molecular weight of about 1, ]	[ 2, and ]
0.014716253	87	[ 000 &#x3bc; ]	[ c) a monoclonal antibody having a molecular weight of about 1, ]
0.9953916	88	[ m; ]	[ 000 &#x3bc; ]
0.00063217245	89	[ d) administering to the subject in need of the treatment an effective amount of an antibody comprising a polypeptide having a amino acid sequence having at least 90% sequence identity to SEQ ID NO: ]	[ m; ]
0.9954928	90	[ 2. ]	[ d) administering to the subject in need of the treatment an effective amount of an antibody comprising a polypeptide having a amino acid sequence having at least 90% sequence identity to SEQ ID NO: ]
0.97206736	91	[ a first device; ]	[ A system comprising: ]
0.9999795	92	[ a second device; and ]	[ a first device; ]
0.99998724	93	[ a third device, ]	[ a second device; and ]
0.9999627	94	[ wherein the first device is configured to receive a signal from the second device and the first device is configured to receive a signal from the second device. ]	[ a third device, ]
0.018088983	95	[ a housing having a first end; ]	[ An apparatus for providing a first treatment to a patient in need thereof comprising: ]
0.99993515	96	[ a first treatment device having a first end; ]	[ a housing having a first end; ]
0.99999213	97	[ a second treatment device; and ]	[ a first treatment device having a first end; ]
0.99999225	98	[ a second treatment device; ]	[ a second treatment device; and ]
0.012143325	99	[ wherein the housing comprises a first wall, a second wall, and ]	[ a second treatment device; ]
0.9961976	100	[ a first and a second side, ]	[ wherein the housing comprises a first wall, a second wall, and ]
0.99920636	101	[ wherein the first wall comprises a first portion and a second portion, the second wall comprises a first portion and a second portion, ]	[ a first and a second side, ]
0.9999906	102	[ wherein the first portion of the first wall is substantially parallel to the second wall, and ]	[ wherein the first wall comprises a first portion and a second portion, the second wall comprises a first portion and a second portion, ]
0.9999914	103	[ wherein the second portion of the first wall comprises a first portion and a second portion, and ]	[ wherein the first portion of the first wall is substantially parallel to the second wall, and ]
0.9999918	104	[ wherein the first portion of the second wall is substantially parallel to the first portion of the second wall; ]	[ wherein the second portion of the first wall comprises a first portion and a second portion, and ]
0.9999907	105	[ wherein a first portion of the first wall is disposed between the first and second portions, ]	[ wherein the first portion of the second wall is substantially parallel to the first portion of the second wall; ]
0.99999225	106	[ wherein a second portion of the first wall is disposed between the first and second portions, ]	[ wherein a first portion of the first wall is disposed between the first and second portions, ]
0.9999919	107	[ wherein the second portion of the first wall is substantially parallel to the second portion of the second wall, and ]	[ wherein a second portion of the first wall is disposed between the first and second portions, ]
0.99999166	108	[ wherein a third portion of the first wall is disposed between the first and second portions, and ]	[ wherein the second portion of the first wall is substantially parallel to the second portion of the second wall, and ]
0.99999225	109	[ wherein a fourth portion of the first wall is disposed between the first and second portions. ]	[ wherein a third portion of the first wall is disposed between the first and second portions, and ]
0.9993679	110	[ administering an effective amount to the subject of a therapeutically effective amount of an antibody that specifically binds to a human monoclonal antibody, wherein said antibody comprises the amino acid sequence set forth in SEQ ID NO: ]	[ A method for treating a disease or condition of a subject, comprising: ]
0.97462434	111	[ 1. ]	[ administering an effective amount to the subject of a therapeutically effective amount of an antibody that specifically binds to a human monoclonal antibody, wherein said antibody comprises the amino acid sequence set forth in SEQ ID NO: ]
0.9996766	112	[ a first patient support; ]	[ A system for treating a patient, comprising: ]
0.99999225	113	[ a second patient support; ]	[ a first patient support; ]
0.026401332	114	[ a plurality of first support members, each of said first and second support members having a first end and a second end and a first and second side, each of said first and second sides having a first edge, and ]	[ a second patient support; ]
0.9999913	115	[ a first and second side, respectively, extending between said first and second ends of said first support members; and ]	[ a plurality of first support members, each of said first and second support members having a first end and a second end and a first and second side, each of said first and second sides having a first edge, and ]
0.999992	116	[ a plurality of second support members, each of said second and third support members having a second end and a second end, each of said first and second sides, respectively, extending between said second and third ends of said first and second sides; ]	[ a first and second side, respectively, extending between said first and second ends of said first support members; and ]
0.999992	117	[ wherein said first and second side, each having a respective first edge and respective second edge, are configured to receive a first portion of said plurality of first support members, and ]	[ a plurality of second support members, each of said second and third support members having a second end and a second end, each of said first and second sides, respectively, extending between said second and third ends of said first and second sides; ]
0.99999225	118	[ said plurality of first support members are configured to receive a respective second portion of said plurality of first support members. ]	[ wherein said first and second side, each having a respective first edge and respective second edge, are configured to receive a first portion of said plurality of first support members, and ]
0.99999166	119	[ human CD4+ T cell receptor receptor. ]	[ A method of treating an inflammatory bowel disease comprising administering to a subject in need thereof a therapeutically effective amount of an isolated antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof binds to an antigen-binding site on an extracellular domain of an epitope of a human CD4+ T-cell receptor, wherein the extracellular domain of the epitope of the human CD4+ T cell receptor is selected from the group consisting of the human CD4+ T cell receptor, human CD4+ T cell receptor (HCT) receptor, human CD4+T cell receptor (HCTR) receptor, and ]
0.9728583	120	[ an implantable device configured to receive a blood vessel; ]	[ A system, comprising: ]
0.9999902	121	[ a blood vessel support having a proximal end configured to be coupled to the implantable device; ]	[ an implantable device configured to receive a blood vessel; ]
0.99999213	122	[ at least one sensor configured to be coupled to the proximal end of the blood vessel support and operable to sense blood vessel pressure; ]	[ a blood vessel support having a proximal end configured to be coupled to the implantable device; ]
0.9999763	123	[ an interface configured to receive a signal from the at least one sensor, the interface including: ]	[ at least one sensor configured to be coupled to the proximal end of the blood vessel support and operable to sense blood vessel pressure; ]
0.9999697	124	[ a first portion of the interface configured to receive a signal that indicates a vessel is in a vessel state; ]	[ an interface configured to receive a signal from the at least one sensor, the interface including: ]
0.9999924	125	[ a second portion of the interface configured to receive a signal that indicates a vessel is in a non-vascular state; and ]	[ a first portion of the interface configured to receive a signal that indicates a vessel is in a vessel state; ]
0.9999924	126	[ a first portion of the interface configured to receive a signal that indicates a vessel is not in a vessel state. ]	[ a second portion of the interface configured to receive a signal that indicates a vessel is in a non-vascular state; and ]
0.999992	127	[ (a) contacting an isolated antibody or antigen binding fragment of an antibody or antigen binding fragment of an isolated antibody or antigen binding fragment with an antibody that specifically binds to a human T cell; ]	[ A method of producing an isolated antibody or antigen binding fragment of an antibody or antigen binding fragment comprising: ]
0.99999225	128	[ (b) contacting a human T cell with an isolated antibody or antigen binding fragment of an antibody or antigen binding fragment of an antibody; ]	[ (a) contacting an isolated antibody or antigen binding fragment of an antibody or antigen binding fragment of an isolated antibody or antigen binding fragment with an antibody that specifically binds to a human T cell; ]
0.99999213	129	[ (c) detecting the binding activity of the isolated antibody or antigen binding fragment of the antibody or antigen binding fragment of the antibody; ]	[ (b) contacting a human T cell with an isolated antibody or antigen binding fragment of an antibody or antigen binding fragment of an antibody; ]
0.99999225	130	[ (d) determining whether the antibody or antigen binding fragment of the antibody or antigen binding fragment of the antibody is specifically binding to the human T cell; and ]	[ (c) detecting the binding activity of the isolated antibody or antigen binding fragment of the antibody or antigen binding fragment of the antibody; ]
0.99999225	131	[ (e) producing an antibody or antigen binding fragment of the antibody or antigen binding fragment of the antibody. ]	[ (d) determining whether the antibody or antigen binding fragment of the antibody or antigen binding fragment of the antibody is specifically binding to the human T cell; and ]
0.99998033	132	[ wherein said carrier is selected from the group consisting of a salt of a salt of a polypeptide of the disease, a salt of a salt of a polypeptide of the disease having a first amino acid sequence and a second amino acid sequence, and ]	[ A method of treating a patient with a disease comprising administering to the patient an effective amount of an effective amount of a pharmaceutically acceptable carrier for the disease, wherein said carrier is a pharmaceutically acceptable salt or a salt or derivative thereof, and ]
0.99999225	133	[ a salt of a salt of a polypeptide of the disease having a second amino acid sequence. ]	[ wherein said carrier is selected from the group consisting of a salt of a salt of a polypeptide of the disease, a salt of a salt of a polypeptide of the disease having a first amino acid sequence and a second amino acid sequence, and ]
0.9997818	134	[ (a) contacting an inflammatory disease patient with a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof; ]	[ A method for treating an inflammatory disease, the method comprising: ]
0.9999318	135	[ (b) administering to the patient an effective amount of the compound or a pharmaceutically acceptable salt thereof, wherein said effective amount is at least 50% less than the amount of the compound or the pharmaceutically acceptable salt thereof administered to the patient; and ]	[ (a) contacting an inflammatory disease patient with a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof; ]
0.9999839	136	[ (c) determining whether or not the inflammatory disease patient exhibits an increase in the amount of an inflammatory disease marker in the presence of the compound or a pharmaceutically acceptable salt thereof. ]	[ (b) administering to the patient an effective amount of the compound or a pharmaceutically acceptable salt thereof, wherein said effective amount is at least 50% less than the amount of the compound or the pharmaceutically acceptable salt thereof administered to the patient; and ]
0.9997631	137	[ administering to the patient a therapeutically effective amount of a compound having an amino acid sequence selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12 or 13. ]	[ A method for treating a patient having a disease or condition, comprising: ]
0.99999213	138	[ 2, a therapeutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]	[ A method of treating a disease or disorder, comprising administering to a patient in need thereof an amount of at least one of a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
0.99999225	139	[ 3, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]	[ 2, a therapeutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
0.99999225	140	[ 4, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]	[ 3, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
0.99999225	141	[ 5, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]	[ 4, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
0.99999225	142	[ 6, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]	[ 5, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
0.99999225	143	[ 7, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]	[ 6, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
0.99999225	144	[ 8, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]	[ 7, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
0.99999225	145	[ 9, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]	[ 8, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
0.99999225	146	[ 10, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]	[ 9, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
0.99999225	147	[ 11, or a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]	[ 10, a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
0.9996495	148	[ 12. ]	[ 11, or a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: ]
0.34494856	149	[ where R1 is a C-terminal amino group; ]	[ A method of treating a subject in need of such treatment comprising administering an effective amount of an antibody to a cell that comprises a protein of the formula I: ]
0.99891746	150	[ R2 is a C-terminal alanine or cysteine; ]	[ where R1 is a C-terminal amino group; ]
0.9999833	151	[ R3 is a C-terminal alanine, or a C-terminal alanine or a C-terminal alanine, and ]	[ R2 is a C-terminal alanine or cysteine; ]
0.015581635	152	[ a C-terminal amino group, ]	[ R3 is a C-terminal alanine, or a C-terminal alanine or a C-terminal alanine, and ]
0.00045124075	153	[ wherein the antibody binds to the protein, wherein the antibody is a monoclonal antibody, or a fragment thereof. ]	[ a C-terminal amino group, ]
0.9998951	154	[ providing a plurality of therapeutic agents to a patient; ]	[ A method for treating a patient having at least one disorder, the method comprising: ]
0.999992	155	[ providing a plurality of therapeutic agents in an amount effective to treat a disorder in the patient; and ]	[ providing a plurality of therapeutic agents to a patient; ]
0.99999225	156	[ determining whether the patient has a disorder by comparing at least one of the plurality of therapeutic agents with a threshold level for the at least one disorder to determine whether the at least one disorder is treated. ]	[ providing a plurality of therapeutic agents in an amount effective to treat a disorder in the patient; and ]
0.9871574	157	[ (a) a plurality of transgenic mice having a genome encoding a first gene; ]	[ A system for treating a disease or condition in a subject comprising: ]
0.999987	158	[ (b) an antibody that binds to the first gene; and ]	[ (a) a plurality of transgenic mice having a genome encoding a first gene; ]
0.99995947	159	[ (c) a pharmaceutical composition comprising an effective amount of the antibody, wherein the pharmaceutical composition is effective to treat the disease or condition in the subject. ]	[ (b) an antibody that binds to the first gene; and ]
0.032102548	160	[ providing a plurality of electrodes, each electrode comprising: ]	[ A method comprising the step of: ]
0.9974323	161	[ a first electrode; and ]	[ providing a plurality of electrodes, each electrode comprising: ]
0.9999306	162	[ a second electrode, ]	[ a first electrode; and ]
0.99923646	163	[ wherein each electrode has an electrode surface, ]	[ a second electrode, ]
0.99971145	164	[ wherein the electrodes are arranged in a first plane; and ]	[ wherein each electrode has an electrode surface, ]
0.99998987	165	[ wherein each electrode is arranged in a second plane that is different than the first plane. ]	[ wherein the electrodes are arranged in a first plane; and ]
0.9999857	166	[ R2 is a hydrogen atom or a hydrogen atom, or a salt thereof, or an isolated or purified derivative thereof. ]	[ A method for treating a disease or disorder in a patient comprising administering to said patient an effective amount, by a single administration, of a therapeutically effective amount of a compound of Formula (I) or an isolated or purified derivative thereof, wherein R1 is a first alkyl or aryl, or a salt thereof; and ]
0.9974758	167	[ administering a therapeutically effective amount of an isolated antibody or fragment thereof that specifically binds a polypeptide comprising the amino acid sequence of SEQ ID NO: ]	[ A method of treating a patient suffering from a condition comprising: ]
0.9956435	168	[ 1; and ]	[ administering a therapeutically effective amount of an isolated antibody or fragment thereof that specifically binds a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.98464465	169	[ administering an anti-inflammatory agent to the patient. ]	[ 1; and ]
0.9989619	170	[ an implantable device having a proximal end, a distal end, and ]	[ A device for the treatment of a patient having a tumor, the device comprising: ]
0.969715	171	[ a first end; ]	[ an implantable device having a proximal end, a distal end, and ]
0.9988462	172	[ a first electrode disposed on the proximal end of the implantable device, wherein the first electrode is configured to be positioned in a patient's skin; and ]	[ a first end; ]
0.99999225	173	[ a second electrode disposed on the distal end of the implantable device, wherein the second electrode is configured to be positioned in a patient's tissue; ]	[ a first electrode disposed on the proximal end of the implantable device, wherein the first electrode is configured to be positioned in a patient's skin; and ]
0.99997723	174	[ wherein the first electrode is positioned on the patient's skin; ]	[ a second electrode disposed on the distal end of the implantable device, wherein the second electrode is configured to be positioned in a patient's tissue; ]
0.9999894	175	[ wherein the first electrode is disposed in a first region of the skin, and ]	[ wherein the first electrode is positioned on the patient's skin; ]
0.99999225	176	[ wherein the second electrode is disposed in a second region of the skin. ]	[ wherein the first electrode is disposed in a first region of the skin, and ]
0.9997911	177	[ providing a patient with a plurality of electrodes; ]	[ A method for the treatment of a patient, said method comprising: ]
0.9999708	178	[ providing an implant comprising a plurality of electrodes, said implant comprising a plurality of electrodes, wherein each of said plurality of electrodes comprises a plurality of electrodes; ]	[ providing a patient with a plurality of electrodes; ]
0.9999906	179	[ inserting a plurality of surgical electrodes into said implant; and ]	[ providing an implant comprising a plurality of electrodes, said implant comprising a plurality of electrodes, wherein each of said plurality of electrodes comprises a plurality of electrodes; ]
0.99999225	180	[ applying an electrical current to said plurality of surgical electrodes to stimulate a region of the body of the patient. ]	[ inserting a plurality of surgical electrodes into said implant; and ]
0.9999912	181	[ a first treatment unit for providing a first treatment to a first subject, the first treatment unit having a first end and a second end, the first end of the first treatment unit configured to receive the first subject, and ]	[ An apparatus for providing a first treatment to a first subject, comprising: ]
0.99999225	182	[ the second end of the first treatment unit configured to be coupled with the first subject; ]	[ a first treatment unit for providing a first treatment to a first subject, the first treatment unit having a first end and a second end, the first end of the first treatment unit configured to receive the first subject, and ]
0.9999914	183	[ an input device for receiving input from the first subject and outputting a second treatment; and ]	[ the second end of the first treatment unit configured to be coupled with the first subject; ]
0.99999225	184	[ an input device for receiving input from the first subject and outputting a third treatment. ]	[ an input device for receiving input from the first subject and outputting a second treatment; and ]
0.9999577	185	[ a) providing a medical device having a plurality of electrodes, the medical device including a first electrode and a second electrode; ]	[ A method of providing a medical device to a patient comprising: ]
0.99997854	186	[ b) providing a first medical device electrode to a patient; ]	[ a) providing a medical device having a plurality of electrodes, the medical device including a first electrode and a second electrode; ]
0.99999225	187	[ c) placing a medical device electrode within a body cavity of the patient, the first medical device electrode including a first end electrode and a second end electrode; ]	[ b) providing a first medical device electrode to a patient; ]
0.9999889	188	[ d) providing a first electrical stimulation device electrode to a patient; ]	[ c) placing a medical device electrode within a body cavity of the patient, the first medical device electrode including a first end electrode and a second end electrode; ]
0.99999225	189	[ e) placing a first medical device stimulation device electrode in a first portion of the body cavity of the patient; ]	[ d) providing a first electrical stimulation device electrode to a patient; ]
0.99999213	190	[ f) placing a second medical device stimulation device electrode within a second portion of the body cavity of the patient; ]	[ e) placing a first medical device stimulation device electrode in a first portion of the body cavity of the patient; ]
0.999992	191	[ g) providing a second electrical stimulation device electrode to a patient; ]	[ f) placing a second medical device stimulation device electrode within a second portion of the body cavity of the patient; ]
0.9999924	192	[ h) providing a second electrical stimulation device electrode to a patient; and ]	[ g) providing a second electrical stimulation device electrode to a patient; ]
0.9999908	193	[ i) placing a second medical device stimulation device electrode in a third portion of the body cavity of the patient. ]	[ h) providing a second electrical stimulation device electrode to a patient; and ]
0.9734789	194	[ providing a first device comprising a plurality of first sensors and a plurality of second sensors, wherein each first sensor is configured to detect a first characteristic of a first object and each second sensor is configured to detect a second characteristic of the first object, ]	[ A method comprising, ]
0.99998915	195	[ wherein each first sensor is configured to detect a first signal from a first sensor, ]	[ providing a first device comprising a plurality of first sensors and a plurality of second sensors, wherein each first sensor is configured to detect a first characteristic of a first object and each second sensor is configured to detect a second characteristic of the first object, ]
0.99999225	196	[ each second sensor is configured to detect a second signal from a second sensor, and ]	[ wherein each first sensor is configured to detect a first signal from a first sensor, ]
0.99999213	197	[ wherein the first sensor is configured to detect the first signal and the second sensor is configured to detect the second signal. ]	[ each second sensor is configured to detect a second signal from a second sensor, and ]
0.99989665	198	[ a. providing a polymeric material having a thickness of less than 1 mm and a viscosity of less than about 10 mPa; ]	[ A method for producing a composition comprising a composition of a polymeric material and a pharmaceutically acceptable carrier, the method comprising the steps of: ]
0.9999238	199	[ b. forming a polymeric matrix having a plurality of polymers, wherein the plurality of polymers comprise a plurality of polymers of a first type, and ]	[ a. providing a polymeric material having a thickness of less than 1 mm and a viscosity of less than about 10 mPa; ]
0.99998045	200	[ a plurality of polymers of a second type, wherein the first type is a polymer having an average viscosity of less than about 10 mPa and the second type is a polymer having an average viscosity of greater than about 10 mPa, and ]	[ b. forming a polymeric matrix having a plurality of polymers, wherein the plurality of polymers comprise a plurality of polymers of a first type, and ]
0.9999906	201	[ wherein the polymeric matrix comprises a plurality of polymers having different viscosities, wherein the first type of polymers is a first polymer and the second type of polymers is a second polymer; and ]	[ a plurality of polymers of a second type, wherein the first type is a polymer having an average viscosity of less than about 10 mPa and the second type is a polymer having an average viscosity of greater than about 10 mPa, and ]
0.9975618	202	[ c. contacting the polymeric material with an effective amount of a pharmaceutically acceptable carrier. ]	[ wherein the polymeric matrix comprises a plurality of polymers having different viscosities, wherein the first type of polymers is a first polymer and the second type of polymers is a second polymer; and ]
0.99957186	203	[ providing a pharmaceutical composition comprising a pharmaceutically acceptable carrier; ]	[ A method of producing a composition for use with a pharmaceutical composition, the method comprising the steps of: ]
0.99999154	204	[ providing a pharmaceutical composition comprising a pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one other carrier; and ]	[ providing a pharmaceutical composition comprising a pharmaceutically acceptable carrier; ]
0.99999225	205	[ mixing the pharmaceutically acceptable carrier and at least one other carrier to form a pharmaceutical composition, ]	[ providing a pharmaceutical composition comprising a pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one other carrier; and ]
0.99999225	206	[ wherein the at least one other carrier comprises at least one other carrier having an amino acid sequence that is different from the amino acid sequence of the pharmaceutically acceptable carrier, and ]	[ mixing the pharmaceutically acceptable carrier and at least one other carrier to form a pharmaceutical composition, ]
0.9999924	207	[ wherein the pharmaceutically acceptable carrier and at least one other carrier are in the form of a single, continuous, continuous carrier, and ]	[ wherein the at least one other carrier comprises at least one other carrier having an amino acid sequence that is different from the amino acid sequence of the pharmaceutically acceptable carrier, and ]
0.9999913	208	[ wherein the at least one other carrier comprises at least one other carrier having a length that is greater than about 1&#xb0; ]	[ wherein the pharmaceutically acceptable carrier and at least one other carrier are in the form of a single, continuous, continuous carrier, and ]
0.9989365	209	[ 1 mm. A pharmaceutically acceptable carrier is one of a polymeric carrier, a polymeric monomer, a polymeric polymeric monomer, and ]	[ wherein the at least one other carrier comprises at least one other carrier having a length that is greater than about 1&#xb0; ]
0.99998724	210	[ a polymeric polymeric monomer. ]	[ 1 mm. A pharmaceutically acceptable carrier is one of a polymeric carrier, a polymeric monomer, a polymeric polymeric monomer, and ]
0.010989089	211	[ R1 and R2 each represent a hydroxyl group and a halogen atom; ]	[ A method of treating a patient, comprising administering to said patient a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein: ]
0.9999759	212	[ X1 and X2 each represent a hydrogen atom, and ]	[ R1 and R2 each represent a hydroxyl group and a halogen atom; ]
0.9999851	213	[ each of X1 and X2 represents a hydroxyl group; ]	[ X1 and X2 each represent a hydrogen atom, and ]
0.9978084	214	[ R3 represents hydrogen; ]	[ each of X1 and X2 represents a hydroxyl group; ]
0.999943	215	[ X4 represents a hydrogen atom, and ]	[ R3 represents hydrogen; ]
0.99986994	216	[ R5 represents an alkyl group, or a heteroaryl group. ]	[ X4 represents a hydrogen atom, and ]
0.9994018	217	[ a) providing a first treatment comprising a first amount of a therapeutically effective amount of a peptide selected from the group consisting of SEQ ID NO: ]	[ A method of treating a patient having a disease or condition in which the disease or condition is characterized by a reduction in the level of a specific protein in the blood or serum, the method comprising the steps of: ]
0.9993857	218	[ 1 and SEQ ID NO: ]	[ a) providing a first treatment comprising a first amount of a therapeutically effective amount of a peptide selected from the group consisting of SEQ ID NO: ]
0.9992415	219	[ 3; and ]	[ 1 and SEQ ID NO: ]
0.9967121	220	[ b) providing a second treatment comprising a second amount of the therapeutically effective amount of the peptide selected from the group consisting of SEQ ID NO: ]	[ 3; and ]
0.99932766	221	[ 1, SEQ ID NO: ]	[ b) providing a second treatment comprising a second amount of the therapeutically effective amount of the peptide selected from the group consisting of SEQ ID NO: ]
0.9999672	222	[ 2 and SEQ ID NO: ]	[ 1, SEQ ID NO: ]
0.99905723	223	[ 3. ]	[ 2 and SEQ ID NO: ]
0.99999046	224	[ wherein the first and second plurality of electrodes comprise a first and second electrode structure having an outer surface and a first and second inner surface, and ]	[ An implantable medical device comprising an implantable medical device housing, a first end portion, a second end portion and a first and second plurality of electrodes, wherein the first and second plurality of electrodes are arranged to be coupled to the first and second plurality of electrodes of the implantable medical device housing, and ]
0.9999919	225	[ wherein the outer surface is disposed between the first and second inner surface, ]	[ wherein the first and second plurality of electrodes comprise a first and second electrode structure having an outer surface and a first and second inner surface, and ]
0.0141456695	226	[ wherein the first and second plurality of electrodes comprise a first and second electrode structure comprising an electrode surface, a first and second electrode structure comprising an electrode layer, and ]	[ wherein the outer surface is disposed between the first and second inner surface, ]
0.9999883	227	[ a plurality of electrodes disposed between the first and second electrode structures, ]	[ wherein the first and second plurality of electrodes comprise a first and second electrode structure comprising an electrode surface, a first and second electrode structure comprising an electrode layer, and ]
0.9999907	228	[ wherein the first and second electrode structures comprise a first electrode structure having a first surface and a second surface, and ]	[ a plurality of electrodes disposed between the first and second electrode structures, ]
0.9999919	229	[ wherein the first and second surface of the first electrode structure is disposed between the first and second electrode structures, ]	[ wherein the first and second electrode structures comprise a first electrode structure having a first surface and a second surface, and ]
0.99999213	230	[ wherein the first and second surface of the second electrode structure is disposed between the first and second electrode structures, and ]	[ wherein the first and second surface of the first electrode structure is disposed between the first and second electrode structures, ]
0.99999213	231	[ wherein the second surface of the first electrode structure is disposed between the first and second electrode structures. ]	[ wherein the first and second surface of the second electrode structure is disposed between the first and second electrode structures, and ]
0.9994035	232	[ a patient-side support having at least one first end, at least one second end and a plurality of first and second ends; ]	[ An apparatus for treating a patient, comprising: ]
0.999992	233	[ a plurality of first electrodes disposed in a plurality of spaced apart locations along a first axis of the patient-side support, each of the plurality of first electrodes being electrically connected to a respective first end of the plurality of first electrodes; ]	[ a patient-side support having at least one first end, at least one second end and a plurality of first and second ends; ]
0.99999225	234	[ a plurality of second electrodes disposed in a plurality of spaced apart locations along a second axis of the patient-side support, each of the plurality of second electrodes being electrically connected to a respective second end of the plurality of second electrodes; and ]	[ a plurality of first electrodes disposed in a plurality of spaced apart locations along a first axis of the patient-side support, each of the plurality of first electrodes being electrically connected to a respective first end of the plurality of first electrodes; ]
0.99999225	235	[ a plurality of third electrodes disposed in a plurality of spaced apart locations along a third axis of the patient-side support, each of the plurality of third electrodes being electrically connected to a respective third end of the plurality of third electrodes; ]	[ a plurality of second electrodes disposed in a plurality of spaced apart locations along a second axis of the patient-side support, each of the plurality of second electrodes being electrically connected to a respective second end of the plurality of second electrodes; and ]
0.9999919	236	[ wherein the first, second and third axes of the patient-side support define a plurality of patient-side surfaces, wherein the first and second axes of the patient-side support have a first and a second axis, and ]	[ a plurality of third electrodes disposed in a plurality of spaced apart locations along a third axis of the patient-side support, each of the plurality of third electrodes being electrically connected to a respective third end of the plurality of third electrodes; ]
0.005558208	237	[ wherein the plurality of first electrodes, the plurality of second electrodes, and ]	[ wherein the first, second and third axes of the patient-side support define a plurality of patient-side surfaces, wherein the first and second axes of the patient-side support have a first and a second axis, and ]
0.9999844	238	[ the plurality of third electrodes are positioned along the first, second and third axes. ]	[ wherein the plurality of first electrodes, the plurality of second electrodes, and ]
0.017181573	239	[ an electronic device; ]	[ A system for monitoring a patient's blood pressure, comprising: ]
0.027692145	240	[ a blood pressure monitoring unit configured for monitoring the patient's blood pressure; ]	[ an electronic device; ]
0.9999918	241	[ at least one blood pressure measuring unit configured for measuring blood pressure; and ]	[ a blood pressure monitoring unit configured for monitoring the patient's blood pressure; ]
0.9999924	242	[ a processor configured for processing the blood pressure monitoring unit and the at least one blood pressure measuring unit, wherein the processor is further configured to: ]	[ at least one blood pressure measuring unit configured for measuring blood pressure; and ]
0.9996549	243	[ receive an input from the patient; and ]	[ a processor configured for processing the blood pressure monitoring unit and the at least one blood pressure measuring unit, wherein the processor is further configured to: ]
0.9999831	244	[ determine a blood pressure value of the patient from the at least one blood pressure measuring unit based upon the input. ]	[ receive an input from the patient; and ]
0.99992526	245	[ administering to the patient an effective amount of an immunosuppressant, wherein the immunosuppressant is a peptide, and ]	[ A method for treating a patient with an autoimmune disorder, comprising: ]
0.9999907	246	[ wherein the immunosuppressant inhibits the activity of a polypeptide comprising a polypeptide having the amino acid sequence of SEQ ID NO: 2. ]	[ administering to the patient an effective amount of an immunosuppressant, wherein the immunosuppressant is a peptide, and ]
0.9979657	247	[ a first electrode for electrically coupling to a first electrode of a medical device; ]	[ An apparatus for the treatment of a patient, comprising: ]
0.99999225	248	[ a second electrode for electrically coupling to a second electrode of the medical device; ]	[ a first electrode for electrically coupling to a first electrode of a medical device; ]
0.99992514	249	[ a first conductive layer disposed between the first and second electrodes and electrically coupled to the first electrode; and ]	[ a second electrode for electrically coupling to a second electrode of the medical device; ]
0.9999918	250	[ a second conductive layer disposed between the first and second electrodes and electrically coupled to the second electrode, wherein the first conductive layer and the second conductive layer are configured such that a current flowing from the first conductive layer is sufficient to conduct a current to the second electrode. ]	[ a first conductive layer disposed between the first and second electrodes and electrically coupled to the first electrode; and ]
0.9973143	251	[ a) providing a polymeric material having at least one polymer component, wherein the polymer component is selected from the group comprising: (1) poly(dimethylamino)carbonyl, poly(dimethylamino)carbonyloxy, poly(dimethylamino)carbonyl, poly(dimethylamino)carbonyloxycarbonyl, poly(dimethylamino)carbonylamino, and ]	[ A method for producing a biocompatible polymer comprising: ]
0.9999894	252	[ poly(dimethylamino)carbonylaminocarbonyl, and ]	[ a) providing a polymeric material having at least one polymer component, wherein the polymer component is selected from the group comprising: (1) poly(dimethylamino)carbonyl, poly(dimethylamino)carbonyloxy, poly(dimethylamino)carbonyl, poly(dimethylamino)carbonyloxycarbonyl, poly(dimethylamino)carbonylamino, and ]
0.9997942	253	[ wherein the polymeric material is selected from the group consisting of: (a) poly(dimethylsiloxane), poly(dimethylsiloxane)carbonyl, poly(dimethylsiloxane)carbonyloxycarbonyl, poly(dimethylsiloxane)carbonylcarbonyloxycarbonyl, poly(dimethylsiloxane)carbonylamino, poly(dimethylsiloxane)carbonylaminocarbonyl, poly(dimethylsiloxane)carbonyloxycarbonyl, and ]	[ poly(dimethylamino)carbonylaminocarbonyl, and ]
0.9999919	254	[ poly(dimethylsiloxane)carbonyloxycarbonyl, ]	[ wherein the polymeric material is selected from the group consisting of: (a) poly(dimethylsiloxane), poly(dimethylsiloxane)carbonyl, poly(dimethylsiloxane)carbonyloxycarbonyl, poly(dimethylsiloxane)carbonylcarbonyloxycarbonyl, poly(dimethylsiloxane)carbonylamino, poly(dimethylsiloxane)carbonylaminocarbonyl, poly(dimethylsiloxane)carbonyloxycarbonyl, and ]
0.9898449	255	[ (b) a polymerizable component having a polymerizable structure having at least one polymerized polymerizable component component, wherein the polymerizable component comprises a polymerizable component having at least one polymerizable component component, ]	[ poly(dimethylsiloxane)carbonyloxycarbonyl, ]
0.99999225	256	[ (c) a polymerizable polymerizable component having a polymerizable structure having at least one polymerizable polymerizable component component, and ]	[ (b) a polymerizable component having a polymerizable structure having at least one polymerized polymerizable component component, wherein the polymerizable component comprises a polymerizable component having at least one polymerizable component component, ]
0.99999225	257	[ (d) a polymeric component having a polymeric structure having at least one polymerizable polymerizable component component. ]	[ (c) a polymerizable polymerizable component having a polymerizable structure having at least one polymerizable polymerizable component component, and ]
0.9999896	258	[ a first patient-specific medical treatment device; ]	[ A system for providing a patient-specific medical treatment to a patient, the system comprising: ]
0.999992	259	[ a second patient-specific medical treatment device; and ]	[ a first patient-specific medical treatment device; ]
0.999992	260	[ a controller coupled to the first and second patient-specific medical treatment devices, the controller configured to: ]	[ a second patient-specific medical treatment device; and ]
0.99999213	261	[ receive a first medical treatment protocol from the second patient-specific medical treatment device; ]	[ a controller coupled to the first and second patient-specific medical treatment devices, the controller configured to: ]
0.99999225	262	[ determine a first medical treatment parameter for the first patient-specific medical treatment device based on the first medical treatment protocol; ]	[ receive a first medical treatment protocol from the second patient-specific medical treatment device; ]
0.9999924	263	[ determine a second medical treatment protocol for a second patient-specific patient device based on the first and second medical treatment protocols; ]	[ determine a first medical treatment parameter for the first patient-specific medical treatment device based on the first medical treatment protocol; ]
0.99999213	264	[ communicate with a patient-specific device to provide a patient-specific medical treatment protocol; ]	[ determine a second medical treatment protocol for a second patient-specific patient device based on the first and second medical treatment protocols; ]
0.999992	265	[ receive a second medical treatment protocol from the second patient-specific medical treatment device; ]	[ communicate with a patient-specific device to provide a patient-specific medical treatment protocol; ]
0.99999213	266	[ determine a second medical treatment parameter based on the second medical treatment protocol and the first medical treatment protocol; and ]	[ receive a second medical treatment protocol from the second patient-specific medical treatment device; ]
0.99999225	267	[ communicate the determined second medical treatment parameter to the patient-specific device. ]	[ determine a second medical treatment parameter based on the second medical treatment protocol and the first medical treatment protocol; and ]
0.99999213	268	[ 4, or an antigen-binding fragment thereof that specifically binds to the polypeptide of SEQ ID NO: ]	[ A method for treating a subject having an inflammatory bowel disease, the method comprising administering to said subject an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to the polypeptide of SEQ ID NO: ]
0.99995875	269	[ 4, wherein said antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof. ]	[ 4, or an antigen-binding fragment thereof that specifically binds to the polypeptide of SEQ ID NO: ]
0.004884852	270	[ a housing comprising an inner wall and an outer wall; ]	[ An implantable cardiac pacemaker comprising: ]
0.99975437	271	[ a first electrical circuit disposed within said housing, said first circuit comprising an electrical signal generator and an electrical signal processing unit, the electrical signal processing unit comprising a signal processor and an output device; ]	[ a housing comprising an inner wall and an outer wall; ]
0.9999914	272	[ an output device disposed within said housing; and ]	[ a first electrical circuit disposed within said housing, said first circuit comprising an electrical signal generator and an electrical signal processing unit, the electrical signal processing unit comprising a signal processor and an output device; ]
0.9936972	273	[ a second electrical circuit comprising an output signal processor, an output signal processing unit and an input device, ]	[ an output device disposed within said housing; and ]
0.9999902	274	[ wherein said output device comprises: ]	[ a second electrical circuit comprising an output signal processor, an output signal processing unit and an input device, ]
0.9824133	275	[ a first output port; ]	[ wherein said output device comprises: ]
0.021014083	276	[ a first electrical connection disposed within said housing and connected to said output device; and ]	[ a first output port; ]
0.9999924	277	[ a second electrical connection disposed within said housing and connected to said input device, ]	[ a first electrical connection disposed within said housing and connected to said output device; and ]
0.9999881	278	[ wherein said first output port and said first electrical connection are connected to a first power source and a second electrical connection is connected to said second power source; ]	[ a second electrical connection disposed within said housing and connected to said input device, ]
0.9999919	279	[ said first electrical connection is connected to an electrical signal generator, said second electrical connection is connected to a second power source, ]	[ wherein said first output port and said first electrical connection are connected to a first power source and a second electrical connection is connected to said second power source; ]
0.9999918	280	[ wherein said first electrical connection and said second electrical connection are electrically connected to said electrical signal processing unit; ]	[ said first electrical connection is connected to an electrical signal generator, said second electrical connection is connected to a second power source, ]
0.99999225	281	[ wherein said first electrical connection and said second electrical connection are connected to a first voltage source; ]	[ wherein said first electrical connection and said second electrical connection are electrically connected to said electrical signal processing unit; ]
0.9999912	282	[ wherein said first voltage source is connected to a first power source; ]	[ wherein said first electrical connection and said second electrical connection are connected to a first voltage source; ]
0.99999225	283	[ wherein said first power source is connected to a second voltage source; ]	[ wherein said first voltage source is connected to a first power source; ]
0.9999913	284	[ wherein said second voltage source is connected to a second voltage generator, and ]	[ wherein said first power source is connected to a second voltage source; ]
0.99998975	285	[ wherein said output signal processor is connected to a first voltage source; ]	[ wherein said second voltage source is connected to a second voltage generator, and ]
0.9999232	286	[ said output device further comprises an input device, wherein said input device is connected to a second power source; ]	[ wherein said output signal processor is connected to a first voltage source; ]
0.9995479	287	[ wherein said output signal processor is connected to a second voltage source. ]	[ said output device further comprises an input device, wherein said input device is connected to a second power source; ]
0.9994117	288	[ 2 or SEQ ID NO: ]	[ A method of treating an inflammatory disease, the method comprising administering to an individual suffering from an inflammatory disease, a therapeutically effective amount of a polypeptide comprising a sequence of SEQ ID NO: ]
0.9994272	289	[ 4, wherein said polypeptide comprises a sequence of SEQ ID NOs: ]	[ 2 or SEQ ID NO: ]
0.0012243959	290	[ 2-4. ]	[ 4, wherein said polypeptide comprises a sequence of SEQ ID NOs: ]
0.0002909115	291	[ providing an isolated polypeptide comprising a first amino acid sequence and a second amino acid sequence different from the first, wherein the first amino acid sequence comprises the amino acid sequence of SEQ ID NO: ]	[ A method for producing a biodegradable composition, comprising: ]
0.9973157	292	[ 2; ]	[ providing an isolated polypeptide comprising a first amino acid sequence and a second amino acid sequence different from the first, wherein the first amino acid sequence comprises the amino acid sequence of SEQ ID NO: ]
0.9965211	293	[ contacting the isolated polypeptide with a biodegradable composition; ]	[ 2; ]
0.99766576	294	[ wherein the first amino acid sequence is selected from the group consisting of: ]	[ contacting the isolated polypeptide with a biodegradable composition; ]
0.9991534	295	[ SEQ ID NO: ]	[ wherein the first amino acid sequence is selected from the group consisting of: ]
0.99993646	296	[ 1, SEQ ID NO: ]	[ SEQ ID NO: ]
0.9993255	297	[ 2, and ]	[ 1, SEQ ID NO: ]
0.99885654	298	[ SEQ ID NO: ]	[ 2, and ]
0.9997687	299	[ 4; ]	[ SEQ ID NO: ]
0.9971873	300	[ wherein the second amino acid sequence is selected from the group consisting of: ]	[ 4; ]
0.99897146	301	[ SEQ ID NO: ]	[ wherein the second amino acid sequence is selected from the group consisting of: ]
0.999926	302	[ 2, SEQ ID NO: ]	[ SEQ ID NO: ]
0.9997918	303	[ 4, and ]	[ 2, SEQ ID NO: ]
0.99934655	304	[ SEQ ID NO: ]	[ 4, and ]
0.9997979	305	[ 6; ]	[ SEQ ID NO: ]
0.99818844	306	[ wherein the first and second amino acid sequences are complementary, ]	[ 6; ]
0.001187618	307	[ wherein the composition comprises at least one biodegradable polymer; and ]	[ wherein the first and second amino acid sequences are complementary, ]
0.004575006	308	[ wherein the first and second amino acids are complementary. ]	[ wherein the composition comprises at least one biodegradable polymer; and ]
0.9996086	309	[ 2, SEQ ID NO: ]	[ A method of treating a disease or disease condition in a patient, comprising administering to said patient in need thereof a composition comprising an effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: ]
0.99983585	310	[ 3, and, in a second amino acid sequence selected from the group consisting of SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.99991167	311	[ 4, SEQ ID NO: ]	[ 3, and, in a second amino acid sequence selected from the group consisting of SEQ ID NO: ]
0.9999887	312	[ 6, SEQ ID NO: ]	[ 4, SEQ ID NO: ]
0.9999857	313	[ 7, SEQ ID NO: ]	[ 6, SEQ ID NO: ]
0.99998665	314	[ 8, SEQ ID NO: ]	[ 7, SEQ ID NO: ]
0.9999883	315	[ 9, SEQ ID NO: ]	[ 8, SEQ ID NO: ]
0.99998844	316	[ 10, SEQ ID NO: ]	[ 9, SEQ ID NO: ]
0.99999034	317	[ 11, SEQ ID NO: ]	[ 10, SEQ ID NO: ]
0.9999887	318	[ 12, SEQ ID NO: ]	[ 11, SEQ ID NO: ]
0.9999893	319	[ 13, SEQ ID NO: ]	[ 12, SEQ ID NO: ]
0.99998903	320	[ 14, SEQ ID NO: ]	[ 13, SEQ ID NO: ]
0.99997675	321	[ 15, or SEQ ID NO: ]	[ 14, SEQ ID NO: ]
0.9999095	322	[ 16; ]	[ 15, or SEQ ID NO: ]
0.998669	323	[ wherein said polypeptide comprises at least 95% identity to SEQ ID NO: ]	[ 16; ]
0.9997931	324	[ 2, SEQ ID NO: ]	[ wherein said polypeptide comprises at least 95% identity to SEQ ID NO: ]
0.999974	325	[ 3, or SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.9996406	326	[ 6, and, in a third amino acid sequence selected from the group consisting of SEQ ID NO: ]	[ 3, or SEQ ID NO: ]
0.9999001	327	[ 7, SEQ ID NO: ]	[ 6, and, in a third amino acid sequence selected from the group consisting of SEQ ID NO: ]
0.9999733	328	[ 8, or SEQ ID NO: ]	[ 7, SEQ ID NO: ]
0.9998989	329	[ 9, the polypeptide comprises at least 95% identity to SEQ ID NO: ]	[ 8, or SEQ ID NO: ]
0.99072707	330	[ 3. ]	[ 9, the polypeptide comprises at least 95% identity to SEQ ID NO: ]
0.0026668706	331	[ a first body having an outer surface and at least one interior surface; ]	[ An apparatus for the treatment of an animal having an immune response, the apparatus comprising: ]
0.9969764	332	[ a first implant configured to receive an antigen, the first implant having a first end and a second end, the first implant having a first surface and a second surface; ]	[ a first body having an outer surface and at least one interior surface; ]
0.9999795	333	[ an antibody configured to bind to the first surface; ]	[ a first implant configured to receive an antigen, the first implant having a first end and a second end, the first implant having a first surface and a second surface; ]
0.9999695	334	[ an antibody-binding fragment of the antibody; and ]	[ an antibody configured to bind to the first surface; ]
0.9999919	335	[ a second implant configured to receive an antibody fragment, the second implant having a third end, the second implant having a second surface, the second surface having a first surface and a second surface, wherein the second surface is different from the first surface and wherein the first surface and the second surface have an identical surface area, the first implant and the second implant being configured to be implanted in the animal and the antibody-binding fragment being configured to bind to the antibody fragment. ]	[ an antibody-binding fragment of the antibody; and ]
0.9631918	336	[ a plurality of electrodes, wherein at least one electrode of the plurality of electrodes is configured to receive a signal; and ]	[ A system comprising: ]
0.999992	337	[ a controller configured to control a plurality of electrodes of the plurality of electrodes to receive the signal, the controller configured to control the at least one of the plurality of electrodes to receive the signal based upon a signal intensity of the signal, wherein the controller is configured to: ]	[ a plurality of electrodes, wherein at least one electrode of the plurality of electrodes is configured to receive a signal; and ]
0.99999213	338	[ (a) determine an average signal intensity for the signal received by each of the at least one electrode of the plurality of electrodes; and ]	[ a controller configured to control a plurality of electrodes of the plurality of electrodes to receive the signal, the controller configured to control the at least one of the plurality of electrodes to receive the signal based upon a signal intensity of the signal, wherein the controller is configured to: ]
0.9999907	339	[ (b) determine a signal intensity threshold based at least in part on a signal intensity of the signal, the signal intensity threshold being different than a signal intensity of the signal. ]	[ (a) determine an average signal intensity for the signal received by each of the at least one electrode of the plurality of electrodes; and ]
0.9998294	340	[ administering to the patient a therapeutically effective amount of a composition comprising a pharmaceutically acceptable salt of a polypeptide selected from the group consisting of: ]	[ A method of treating a patient, comprising: ]
0.99971586	341	[ (i) a polypeptide having the amino acid sequence of SEQ ID NO: ]	[ administering to the patient a therapeutically effective amount of a composition comprising a pharmaceutically acceptable salt of a polypeptide selected from the group consisting of: ]
0.9980647	342	[ 2; and ]	[ (i) a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.998251	343	[ (ii) a polypeptide having the amino acid sequence of SEQ ID NO: ]	[ 2; and ]
0.9974355	344	[ 3; ]	[ (ii) a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.9953615	345	[ wherein said composition is administered in a single dose, and ]	[ 3; ]
0.99995947	346	[ said composition comprises a polypeptide having a molecular weight greater than 1, ]	[ wherein said composition is administered in a single dose, and ]
0.9982932	347	[ 000 daltons. ]	[ said composition comprises a polypeptide having a molecular weight greater than 1, ]
0.9999552	348	[ providing a heart disease treatment device; and ]	[ A method of treating a patient having a heart disease, comprising: ]
0.9999908	349	[ administering a first drug to the heart disease treatment device, wherein the heart disease treatment device is configured to deliver a first dose of a therapeutically effective amount of a first drug to the heart disease treatment device. ]	[ providing a heart disease treatment device; and ]
0.061267372	350	[ providing an isolated peptide comprising the amino acid sequence of SEQ ID NO: 1; ]	[ A method for producing a therapeutic agent for treating a patient, comprising: ]
0.9999888	351	[ introducing the isolated peptide into a cell; and ]	[ providing an isolated peptide comprising the amino acid sequence of SEQ ID NO: 1; ]
0.999992	352	[ administering the isolated peptide to a cell. ]	[ introducing the isolated peptide into a cell; and ]
0.99983287	353	[ administering an effective amount of a therapeutically effective amount of an anti-CD20 antibody to said patient, wherein said antibody binds to CD20, and ]	[ A method for treating an autoimmune disorder in a patient in need thereof, comprising: ]
0.9998561	354	[ wherein said patient is a human with an autoantibody; ]	[ administering an effective amount of a therapeutically effective amount of an anti-CD20 antibody to said patient, wherein said antibody binds to CD20, and ]
0.99993145	355	[ wherein said anti-CD20 antibody is a monoclonal antibody selected from the group consisting of CD40, CD40L, CD40L&#x2212; ]	[ wherein said patient is a human with an autoantibody; ]
0.99977475	356	[ CD20, and ]	[ wherein said anti-CD20 antibody is a monoclonal antibody selected from the group consisting of CD40, CD40L, CD40L&#x2212; ]
0.99980897	357	[ CD40L&#x2212; ]	[ CD20, and ]
0.9999547	358	[ CD20L; and ]	[ CD40L&#x2212; ]
0.0027963822	359	[ wherein the monoclonal antibody is a polyclonal antibody. ]	[ CD20L; and ]
0.014958421	360	[ a) providing a plurality of sensors for monitoring a patient's body, wherein the plurality of sensors includes: ]	[ A method comprising the steps of: ]
0.9999914	361	[ i) at least two sensors for measuring the patient's body temperature; and ]	[ a) providing a plurality of sensors for monitoring a patient's body, wherein the plurality of sensors includes: ]
0.99999225	362	[ ii) one sensor for measuring the patient's body pressure, wherein at least one of the at least two sensors for measuring the patient's body temperature is positioned at an angle with respect to the patient; and ]	[ i) at least two sensors for measuring the patient's body temperature; and ]
0.99744344	363	[ b) determining a first physiological characteristic of the patient based at least partly on the first physiological characteristic of the patient, wherein the first physiological characteristic comprises a first value that is different than a second value that is different than the first value. ]	[ ii) one sensor for measuring the patient's body pressure, wherein at least one of the at least two sensors for measuring the patient's body temperature is positioned at an angle with respect to the patient; and ]
0.9998872	364	[ a first medical device having a first implantable medical device port and a second implantable medical device port, wherein the second implantable medical device port includes a first implantable medical device interface; and ]	[ A system for providing an implantable medical device to a patient, comprising: ]
0.99999225	365	[ a first implantable medical device port connector configured to receive the first implantable medical device port and to connect to the first medical device port, wherein the first implantable medical device port connector includes an implantable medical device port connector, and ]	[ a first medical device having a first implantable medical device port and a second implantable medical device port, wherein the second implantable medical device port includes a first implantable medical device interface; and ]
0.9999924	366	[ wherein the first implantable medical device port connector is configured to connect to a first implantable medical device port connector and a first medical device port connector, wherein the first medical device port connector includes a first medical device interface and wherein the first implantable medical device port connector is configured to connect to the second medical device port connector. ]	[ a first implantable medical device port connector configured to receive the first implantable medical device port and to connect to the first medical device port, wherein the first implantable medical device port connector includes an implantable medical device port connector, and ]
0.99822	367	[ a plurality of electrodes; ]	[ An apparatus for the treatment of a patient with a disease comprising: ]
0.99994063	368	[ a plurality of electrodes arranged in a first region and a second region, wherein each electrode is configured to be positioned within a first region of a body of the patient and configured to be positioned in an area adjacent a second region of the body of the patient, the first region being configured to be a first portion of the body of the patient and the second region being a second portion of the body of the patient; ]	[ a plurality of electrodes; ]
0.99995613	369	[ a first electrical connection between a first electrode and a first electrode region of the plurality of electrodes and a second electrical connection between a second electrode and a second electrode region of the plurality of electrodes, each of said first and second electrical connections configured to be electrically connected to a first electrode and a second electrode; and ]	[ a plurality of electrodes arranged in a first region and a second region, wherein each electrode is configured to be positioned within a first region of a body of the patient and configured to be positioned in an area adjacent a second region of the body of the patient, the first region being configured to be a first portion of the body of the patient and the second region being a second portion of the body of the patient; ]
0.99999213	370	[ a second electrical connection between a second electrode and a second electrode region of the plurality of electrodes and a third electrical connection configured to be electrically connected to a third electrode. ]	[ a first electrical connection between a first electrode and a first electrode region of the plurality of electrodes and a second electrical connection between a second electrode and a second electrode region of the plurality of electrodes, each of said first and second electrical connections configured to be electrically connected to a first electrode and a second electrode; and ]
0.9866108	371	[ (a) providing an implantable device; and ]	[ A method for producing and delivering a therapeutic dose of a compound comprising a pharmaceutically acceptable carrier and a pharmaceutically acceptable delivery device, the method comprising: ]
0.9999907	372	[ (b) providing an infusion system, wherein the implantable device comprises an implantable device housing and a delivery device; ]	[ (a) providing an implantable device; and ]
0.99999106	373	[ wherein the delivery device comprises an infusion device housing, a delivery device and a delivery device housing, ]	[ (b) providing an infusion system, wherein the implantable device comprises an implantable device housing and a delivery device; ]
0.99999213	374	[ wherein the delivery device housing comprises: ]	[ wherein the delivery device comprises an infusion device housing, a delivery device and a delivery device housing, ]
0.9991455	375	[ (i) at least one delivery channel; and ]	[ wherein the delivery device housing comprises: ]
0.99983454	376	[ (ii) an inlet channel; ]	[ (i) at least one delivery channel; and ]
0.011126938	377	[ wherein the delivery device housing is configured for delivery of an infusion of the compound to a subject; and ]	[ (ii) an inlet channel; ]
0.99999166	378	[ wherein the infusion device housing comprises: ]	[ wherein the delivery device housing is configured for delivery of an infusion of the compound to a subject; and ]
0.000403531	379	[ (i) at least one channel; and ]	[ wherein the infusion device housing comprises: ]
0.9999645	380	[ (ii) an outlet channel. ]	[ (i) at least one channel; and ]
0.99976856	381	[ a first medical device configured to be implanted within a patient; ]	[ A system for providing a medical device, the system comprising: ]
0.9999908	382	[ a first medical device interface configured to be coupled to the first medical device, the first medical device interface configured to be configured to receive data related to the medical device; ]	[ a first medical device configured to be implanted within a patient; ]
0.9999912	383	[ a first medical device control module configured to receive a first medical device control signal, the first medical device control signal configured to be received by the first medical device interface; and ]	[ a first medical device interface configured to be coupled to the first medical device, the first medical device interface configured to be configured to receive data related to the medical device; ]
0.99999225	384	[ a second medical device coupled to the first medical device interface, the second medical device configured to be configured to receive a second medical device control signal, the second medical device control signal configured to be received by the second medical device, ]	[ a first medical device control module configured to receive a first medical device control signal, the first medical device control signal configured to be received by the first medical device interface; and ]
0.999992	385	[ wherein the first medical device control module is configured to control the first medical device interface to provide a first medical device control signal to the second medical device, the first medical device control module configured to receive a second medical device control signal, the second medical device control signal configured to be received by the second medical device, and ]	[ a second medical device coupled to the first medical device interface, the second medical device configured to be configured to receive a second medical device control signal, the second medical device control signal configured to be received by the second medical device, ]
0.9999924	386	[ the first medical device control module is configured to receive a second medical device control signal, the second medical device control signal configured to be received by the second medical device. ]	[ wherein the first medical device control module is configured to control the first medical device interface to provide a first medical device control signal to the second medical device, the first medical device control module configured to receive a second medical device control signal, the second medical device control signal configured to be received by the second medical device, and ]
0.99990296	387	[ administering to the mammal an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an epitope of a human CDR5, wherein the epitope is selected from the group consisting of CDR1, CDR2, CDR3, CDR4, and ]	[ A method for treating a disease or condition in a mammal, comprising: ]
0.99999046	388	[ CDR5; ]	[ administering to the mammal an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an epitope of a human CDR5, wherein the epitope is selected from the group consisting of CDR1, CDR2, CDR3, CDR4, and ]
0.9999875	389	[ administering to the mammal an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an epitope of a human CDR5, wherein the epitope is selected from the group consisting of CDR1, CDR2, CDR3, CDR4, and ]	[ CDR5; ]
0.99999046	390	[ CDR5; ]	[ administering to the mammal an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an epitope of a human CDR5, wherein the epitope is selected from the group consisting of CDR1, CDR2, CDR3, CDR4, and ]
0.9999907	391	[ wherein the antibody binds to a human CDR5 and the antigen-binding fragment binds to a human CDR5; and ]	[ CDR5; ]
0.99999225	392	[ administering to the mammal an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to a human CDR5, wherein the antigen-binding fragment is a fragment of a human CDR5 that is not a human antigen-binding fragment of a human antigen, and ]	[ wherein the antibody binds to a human CDR5 and the antigen-binding fragment binds to a human CDR5; and ]
0.9999924	393	[ wherein the fragment of the human antigen-binding fragment is a fragment of a human CDR5 that is a human antigen-binding fragment. ]	[ administering to the mammal an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to a human CDR5, wherein the antigen-binding fragment is a fragment of a human CDR5 that is not a human antigen-binding fragment of a human antigen, and ]
0.99997663	394	[ a first oxygen supply unit for providing oxygen to the body; ]	[ A system for providing an effective amount of oxygen to a body, comprising: ]
0.99999225	395	[ a second oxygen supply unit for supplying oxygen to the body; and ]	[ a first oxygen supply unit for providing oxygen to the body; ]
0.99999213	396	[ a third oxygen supply unit for supplying oxygen to the body, ]	[ a second oxygen supply unit for supplying oxygen to the body; and ]
0.99999225	397	[ wherein the first oxygen supply unit comprises an oxygen source for supplying the first oxygen supply unit and a first supply port for supplying oxygen to a first portion of the body; ]	[ a third oxygen supply unit for supplying oxygen to the body, ]
0.99999225	398	[ wherein a first portion of the first portion of the body is located in a first position and is in contact with the first oxygen supply unit; ]	[ wherein the first oxygen supply unit comprises an oxygen source for supplying the first oxygen supply unit and a first supply port for supplying oxygen to a first portion of the body; ]
0.9999924	399	[ wherein a second portion of the first portion of the body is located in a second position and is in contact with the first oxygen supply system and is located between a first portion of the second portion of the body and a second portion of the second portion of the body; and ]	[ wherein a first portion of the first portion of the body is located in a first position and is in contact with the first oxygen supply unit; ]
0.99999225	400	[ wherein an oxygen supply port in the second oxygen supply unit is configured to receive a first portion of the first portion of the body, wherein the first portion of the first portion of the body is in contact with the first oxygen supply unit and wherein the first oxygen supply system is configured to supply the first portion of the first portion of the body to a first portion of the first portion of the body. ]	[ wherein a second portion of the first portion of the body is located in a second position and is in contact with the first oxygen supply system and is located between a first portion of the second portion of the body and a second portion of the second portion of the body; and ]
0.97978127	401	[ a processor; ]	[ A system comprising: ]
0.99146855	402	[ a storage unit; ]	[ a processor; ]
0.9956195	403	[ a memory; and ]	[ a storage unit; ]
0.9886397	404	[ a communication device configured to: ]	[ a memory; and ]
0.9988557	405	[ receive a plurality of data packets from a plurality of different data sources; ]	[ a communication device configured to: ]
0.9999919	406	[ store each of the plurality of data packets in the memory; ]	[ receive a plurality of data packets from a plurality of different data sources; ]
0.99998677	407	[ receive a first data packet from a first data source; ]	[ store each of the plurality of data packets in the memory; ]
0.99999213	408	[ store the first data packet in the memory; ]	[ receive a first data packet from a first data source; ]
0.9999918	409	[ receive a second data packet from a second data source; and ]	[ store the first data packet in the memory; ]
0.999992	410	[ store the second data packet in the memory. ]	[ receive a second data packet from a second data source; and ]
0.9999628	411	[ 1, wherein the polypeptide is selected from the group consisting of: ]	[ A method for producing a composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.9999355	412	[ a) a polypeptide of SEQ ID NO: ]	[ 1, wherein the polypeptide is selected from the group consisting of: ]
0.99984205	413	[ 1 having the amino acid sequence of SEQ ID NO: ]	[ a) a polypeptide of SEQ ID NO: ]
0.9999871	414	[ 1, wherein the polypeptide has the amino acid sequence as set forth in SEQ ID NO: ]	[ 1 having the amino acid sequence of SEQ ID NO: ]
0.99523854	415	[ 1; and ]	[ 1, wherein the polypeptide has the amino acid sequence as set forth in SEQ ID NO: ]
0.9940844	416	[ b) a polypeptide of SEQ ID NO: ]	[ 1; and ]
0.99991643	417	[ 1 having a polypeptide structure having the amino acid sequence as set forth in SEQ ID NO: ]	[ b) a polypeptide of SEQ ID NO: ]
0.9917127	418	[ 1. ]	[ 1 having a polypeptide structure having the amino acid sequence as set forth in SEQ ID NO: ]
0.99998105	419	[ 2, wherein said polypeptide is selected from SEQ ID NO: ]	[ A method of treating an inflammatory condition comprising administering to a patient an effective amount of a therapeutically effective amount of a polypeptide having the amino acid sequence set forth in SEQ ID NO: ]
0.9998301	420	[ 3 and SEQ ID NO: ]	[ 2, wherein said polypeptide is selected from SEQ ID NO: ]
0.9996728	421	[ 6, and ]	[ 3 and SEQ ID NO: ]
0.99770325	422	[ wherein said polypeptide has an amino acid sequence having a sequence length of from about 5 amino acids to about 30 amino acids. ]	[ 6, and ]
0.023032434	423	[ 1. ]	[ A method of treating an infection in a patient comprising administering to the patient an amount of an effective amount of an anti-human IgG antibody, wherein said anti-human IgG antibody is produced by hybridoma cell culture and wherein said anti-human IgG antibody is capable of binding to human IgG and wherein said anti-human IgG antibody is capable of inhibiting the binding of the human IgG to human IgG, wherein said anti-human IgG antibody comprises a nucleic acid sequence encoding a human IgG antibody that comprises the amino acid sequence set forth in SEQ ID NO: ]
0.9999244	424	[ at least one sensor configured to detect a physiological characteristic of the patient; and ]	[ A system for monitoring a patient's health, comprising: ]
0.99999046	425	[ a processor operatively coupled to the at least one sensor and the at least one sensor, the processor configured to: ]	[ at least one sensor configured to detect a physiological characteristic of the patient; and ]
0.99999166	426	[ receive the physiological characteristic from the at least one sensor; ]	[ a processor operatively coupled to the at least one sensor and the at least one sensor, the processor configured to: ]
0.9999913	427	[ determine a physiological condition of the patient based at least in part on the physiological characteristic; and ]	[ receive the physiological characteristic from the at least one sensor; ]
0.999984	428	[ provide a signal to a patient monitoring system, the signal being indicative of the patient's health condition, the signal comprising a physiological condition of a patient, a physiological characteristic of the patient, a physiological condition of a medical device, or both, ]	[ determine a physiological condition of the patient based at least in part on the physiological characteristic; and ]
0.99996495	429	[ wherein the signal comprises at least one of: ]	[ provide a signal to a patient monitoring system, the signal being indicative of the patient's health condition, the signal comprising a physiological condition of a patient, a physiological characteristic of the patient, a physiological condition of a medical device, or both, ]
0.9994854	430	[ a signal of the patient's heart rate, a signal of a heart rate of a patient, a signal of a heart rate of a medical device, and ]	[ wherein the signal comprises at least one of: ]
0.999992	431	[ a signal of a heart rate of a medical device, and ]	[ a signal of the patient's heart rate, a signal of a heart rate of a patient, a signal of a heart rate of a medical device, and ]
0.99999	432	[ wherein the signal of the patient's heart rate is a signal of the patient's heart rate and the signal of the heart rate of a patient is a signal of the patient's heart rate. ]	[ a signal of a heart rate of a medical device, and ]
0.99999213	433	[ wherein the cell line comprises an epitope that specifically binds to the antibody or fragment thereof. ]	[ A method of treating a cancer in a subject, the method comprising administering to the subject an effective amount of an antibody or antigen binding fragment thereof to a cell line that is capable of inducing apoptosis, and ]
0.9816601	434	[ administering to a patient in need thereof an effective amount of a therapeutically effective amount of a compound of the following structure: ]	[ A method for treating an inflammatory disease, the method comprising: ]
0.99951243	435	[ (I) or a pharmaceutically acceptable salt thereof; and ]	[ administering to a patient in need thereof an effective amount of a therapeutically effective amount of a compound of the following structure: ]
0.99992514	436	[ (II) or a pharmaceutically acceptable salt thereof, wherein: ]	[ (I) or a pharmaceutically acceptable salt thereof; and ]
0.99963045	437	[ (a) R1 is a hydrogen atom; ]	[ (II) or a pharmaceutically acceptable salt thereof, wherein: ]
0.9996037	438	[ (b) R2 is a hydrogen atom, a substituted alkyl group having 1 to 5 carbon atoms, or a substituted alkoxy group having 1 to 5 carbon atoms; ]	[ (a) R1 is a hydrogen atom; ]
0.9991353	439	[ (c) R1 and R2 are each independently selected from the group consisting of: &#x2014; ]	[ (b) R2 is a hydrogen atom, a substituted alkyl group having 1 to 5 carbon atoms, or a substituted alkoxy group having 1 to 5 carbon atoms; ]
0.99651706	440	[ CH2; ]	[ (c) R1 and R2 are each independently selected from the group consisting of: &#x2014; ]
0.9901225	441	[ &#x2014; ]	[ CH2; ]
0.97421956	442	[ CH3; ]	[ &#x2014; ]
0.9882691	443	[ &#x2014; ]	[ CH3; ]
0.9712993	444	[ CH2; ]	[ &#x2014; ]
0.9901225	445	[ &#x2014; ]	[ CH2; ]
0.009860376	446	[ C(O)R3; ]	[ &#x2014; ]
0.9850065	447	[ &#x2014; ]	[ C(O)R3; ]
0.9712993	448	[ CH2; ]	[ &#x2014; ]
0.9901225	449	[ &#x2014; ]	[ CH2; ]
0.02165686	450	[ C(O)R4; and ]	[ &#x2014; ]
0.97487587	451	[ &#x2014; ]	[ C(O)R4; and ]
0.99603647	452	[ &#x2014; ]	[ &#x2014; ]
0.9712993	453	[ CH2; ]	[ &#x2014; ]
0.983922	454	[ (d) R3 is a hydroxyl group; and ]	[ CH2; ]
0.9995741	455	[ (e) R4 is a hydrogen atom. ]	[ (d) R3 is a hydroxyl group; and ]
0.99995995	456	[ 1, wherein the antibody or fragment is selected from the group consisting of: ]	[ A method of treating an inflammatory condition in a mammal, comprising administering to the mammal an effective amount of an anti-TNF antibody or an anti-TNF antibody fragment comprising the amino acid sequence of SEQ ID NO: ]
0.9999542	457	[ (a) a monoclonal antibody or fragment thereof; and ]	[ 1, wherein the antibody or fragment is selected from the group consisting of: ]
0.99998844	458	[ (b) an anti-TNF antibody or fragment thereof. ]	[ (a) a monoclonal antibody or fragment thereof; and ]
0.9480562	459	[ receiving an input of a plurality of commands, the input of the plurality of commands comprising: ]	[ A method comprising: ]
0.99939525	460	[ a first command; and ]	[ receiving an input of a plurality of commands, the input of the plurality of commands comprising: ]
0.9999883	461	[ a second command, wherein the first command is associated with one of a first and a second command; ]	[ a first command; and ]
0.99998343	462	[ determining, based on the input of the plurality of commands, a plurality of commands that are not associated with the first command; and ]	[ a second command, wherein the first command is associated with one of a first and a second command; ]
0.99999225	463	[ determining, based on the determined plurality of commands that are not associated with the first command, a first command that is associated with the first command and a second command that is associated with the second command; ]	[ determining, based on the input of the plurality of commands, a plurality of commands that are not associated with the first command; and ]
0.99999213	464	[ wherein the first and second commands are associated with different commands, and ]	[ determining, based on the determined plurality of commands that are not associated with the first command, a first command that is associated with the first command and a second command that is associated with the second command; ]
0.9999906	465	[ wherein the first command is associated with a command to perform a function, wherein the function is associated with a command to perform an act, and ]	[ wherein the first and second commands are associated with different commands, and ]
0.99999225	466	[ wherein the second command is associated with a command to perform an action; ]	[ wherein the first command is associated with a command to perform a function, wherein the function is associated with a command to perform an act, and ]
0.99998856	467	[ determining, based on a result of the determining, whether to perform the first command, the first command, or a different command; and ]	[ wherein the second command is associated with a command to perform an action; ]
0.99999225	468	[ performing, based on the result, the first command, the first command, or the different command. ]	[ determining, based on a result of the determining, whether to perform the first command, the first command, or a different command; and ]
0.9981213	469	[ a first medical device comprising a first medical device interface; and ]	[ A system for treating an individual with a disease comprising: ]
0.99999166	470	[ a second medical device comprising a second medical device interface, wherein said first medical device and said second medical device interfaces are configured to communicate with each other via a first medical device interface, wherein said first medical device interface includes a first medical device port and said second medical device interface includes a second medical device port, and ]	[ a first medical device comprising a first medical device interface; and ]
0.99999225	471	[ wherein said first medical device port includes a first medical device connector and a second medical device connector, ]	[ a second medical device comprising a second medical device interface, wherein said first medical device and said second medical device interfaces are configured to communicate with each other via a first medical device interface, wherein said first medical device interface includes a first medical device port and said second medical device interface includes a second medical device port, and ]
0.9999924	472	[ said first medical device port and said second medical device port each having an opening for receiving a first medical device and a second medical device, ]	[ wherein said first medical device port includes a first medical device connector and a second medical device connector, ]
0.99999225	473	[ wherein said first medical device port includes a first medical device connector for connecting said first medical device port to said second medical device port, ]	[ said first medical device port and said second medical device port each having an opening for receiving a first medical device and a second medical device, ]
0.99999225	474	[ wherein said first medical device port and said second medical device port are configured for communication via said opening, ]	[ wherein said first medical device port includes a first medical device connector for connecting said first medical device port to said second medical device port, ]
0.999992	475	[ wherein said opening is configured to receive a first medical device, and ]	[ wherein said first medical device port and said second medical device port are configured for communication via said opening, ]
0.99999225	476	[ wherein said opening is configured to receive a second medical device, ]	[ wherein said opening is configured to receive a first medical device, and ]
0.99999225	477	[ wherein said first medical device is configured to be connected to said opening, and ]	[ wherein said opening is configured to receive a second medical device, ]
0.9999924	478	[ wherein said first medical device is configured to be connected to said opening through an electrical connection, ]	[ wherein said first medical device is configured to be connected to said opening, and ]
0.99999213	479	[ wherein said opening is a first electrical connection and a second electrical connection, wherein said first medical device and said second medical device are configured to communicate with said first medical device port via said first electrical connection, and ]	[ wherein said first medical device is configured to be connected to said opening through an electrical connection, ]
0.9999924	480	[ wherein said opening is configured to communicate with a second medical device through said second electrical connection. ]	[ wherein said opening is a first electrical connection and a second electrical connection, wherein said first medical device and said second medical device are configured to communicate with said first medical device port via said first electrical connection, and ]
0.9974819	481	[ 2. ]	[ An isolated antibody or antigen-binding fragment thereof that binds to a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, wherein said antibody or antigen-binding fragment thereof has the amino acid sequence of SEQ ID NO: ]
0.13434143	482	[ wherein: ]	[ A method of producing a compound having the formula: ]
0.9948959	483	[ R1 is a C1 to C4 alkyl; ]	[ wherein: ]
0.99997234	484	[ R3 and R4 are independently selected from C1 to C4 alkyl; ]	[ R1 is a C1 to C4 alkyl; ]
0.9979315	485	[ R5 is a C3 to C6 cycloalkyl; and ]	[ R3 and R4 are independently selected from C1 to C4 alkyl; ]
0.99988854	486	[ R6 is a C1 to C4 alkyl; ]	[ R5 is a C3 to C6 cycloalkyl; and ]
0.9663467	487	[ wherein: ]	[ R6 is a C1 to C4 alkyl; ]
0.9968798	488	[ R1 and R2 are independently selected from C1 to C4 alkyl; and ]	[ wherein: ]
0.9856596	489	[ R3 and R4 each have the formula (C1-C4-C6)n&#x2212; ]	[ R1 and R2 are independently selected from C1 to C4 alkyl; and ]
0.98094016	490	[ &#x2003; ]	[ R3 and R4 each have the formula (C1-C4-C6)n&#x2212; ]
0.9929519	491	[ (CH2)n&#x2003; ]	[ &#x2003; ]
0.994259	492	[ , wherein n is 1 to 3. ]	[ (CH2)n&#x2003; ]
0.9975126	493	[ a. administering to a patient in need of treatment a therapeutically effective amount of an effective amount of a composition comprising a pharmaceutically acceptable salt thereof; ]	[ A method for treating a disease comprising: ]
0.9999907	494	[ b. administering to said patient a therapeutically effective amount of an active agent; and ]	[ a. administering to a patient in need of treatment a therapeutically effective amount of an effective amount of a composition comprising a pharmaceutically acceptable salt thereof; ]
0.999992	495	[ c. treating said patient with said active agent in a manner that reduces a disease severity associated with said disease. ]	[ b. administering to said patient a therapeutically effective amount of an active agent; and ]
0.9587819	496	[ a plurality of first and second electrodes, the plurality of first and second electrodes each having a plurality of conductive layers and each having a first conductive layer and a second conductive layer, the first and second conductive layers having different conductive characteristics; and ]	[ An apparatus comprising: ]
0.9999883	497	[ a first conductor layer disposed between the plurality of first and second conductive layers and having a first electrical conductivity and having a second conductive layer disposed between the plurality of first and second conductive layers and having an opposite conductive characteristic from the first and second conductive layers. ]	[ a plurality of first and second electrodes, the plurality of first and second electrodes each having a plurality of conductive layers and each having a first conductive layer and a second conductive layer, the first and second conductive layers having different conductive characteristics; and ]
0.998602	498	[ administering to a patient, a pharmaceutical composition, wherein the pharmaceutical composition comprises an active ingredient, and ]	[ A method for treating a disease or disorder comprising: ]
0.9999902	499	[ wherein the active ingredient is an anti-inflammatory agent. ]	[ administering to a patient, a pharmaceutical composition, wherein the pharmaceutical composition comprises an active ingredient, and ]
0.9991721	500	[ 3 and SEQ ID NO: ]	[ A method of treating a patient in need of such treatment, comprising administering a therapeutically effective amount of a compound having an amino acid sequence selected from the group consisting of SEQ ID NO: ]
0.999729	501	[ 4. ]	[ 3 and SEQ ID NO: ]
0.997799	502	[ a lens assembly comprising a lens, a first lens element and a second lens element; ]	[ A system for treating an eye, comprising: ]
0.9991003	503	[ an optical system including a lens, an optical fiber, and ]	[ a lens assembly comprising a lens, a first lens element and a second lens element; ]
0.9879287	504	[ a light emitting element; and ]	[ an optical system including a lens, an optical fiber, and ]
0.988882	505	[ a lens assembly comprising a lens, a first lens element and a second lens element, wherein the lens assembly is configured to be coupled to the lens assembly. ]	[ a light emitting element; and ]
0.96157664	506	[ providing a first sensor configured to detect a first signal and a second sensor configured to detect a second signal, the first sensor and the second sensor being coupled to a first processor; ]	[ A method comprising: ]
0.99999213	507	[ determining whether the first sensor is configured to detect at least one first signal; and, ]	[ providing a first sensor configured to detect a first signal and a second sensor configured to detect a second signal, the first sensor and the second sensor being coupled to a first processor; ]
0.9999924	508	[ if the first sensor is configured to detect at least one first signal, determining whether the first sensor is configured to detect at least one second signal. ]	[ determining whether the first sensor is configured to detect at least one first signal; and, ]
0.999992	509	[ a second connection means of each of the first connection means is connected to a second connection point on the patient, wherein each of the first and second connection means are configured for connection to a respective one of the plurality of first connection means, wherein each of the first connection means comprises a first end portion and a second end portion, and ]	[ An apparatus for providing a patient with a medical device, the apparatus comprising a first body having a first end portion and a second end portion, the first and second ends of the first body being connected together by a first connection means for connecting to the first body, the second end portion being connected to the apparatus via a second connection means, the apparatus comprising a plurality of first connection means for connecting the first end portion to a patient, wherein the plurality of first connection means are arranged such that a first connection means of each of the first connection means is connected to a first connection point on the patient, and ]
0.99999225	510	[ wherein the first connection means are connected to a first end of the first body via the first connection means, wherein the first connection means are connected to a second end of the first body via a second connection means, wherein the second connection means is configured for connection to a second end of the first body via the second connection means, and ]	[ a second connection means of each of the first connection means is connected to a second connection point on the patient, wherein each of the first and second connection means are configured for connection to a respective one of the plurality of first connection means, wherein each of the first connection means comprises a first end portion and a second end portion, and ]
0.9999919	511	[ wherein each of the plurality of connection means comprises at least one connection element. ]	[ wherein the first connection means are connected to a first end of the first body via the first connection means, wherein the first connection means are connected to a second end of the first body via a second connection means, wherein the second connection means is configured for connection to a second end of the first body via the second connection means, and ]
0.9998234	512	[ 2, wherein the nucleotide is selected from SEQ ID NO: ]	[ An isolated nucleic acid comprising the sequence set forth in SEQ ID NO: ]
0.9997876	513	[ 3, SEQ ID NO: ]	[ 2, wherein the nucleotide is selected from SEQ ID NO: ]
0.9999895	514	[ 4, SEQ ID NO: ]	[ 3, SEQ ID NO: ]
0.99998796	515	[ 5, SEQ ID NO: ]	[ 4, SEQ ID NO: ]
0.99998975	516	[ 6, SEQ ID NO: ]	[ 5, SEQ ID NO: ]
0.9999857	517	[ 7, SEQ ID NO: ]	[ 6, SEQ ID NO: ]
0.99998665	518	[ 8, SEQ ID NO: ]	[ 7, SEQ ID NO: ]
0.9999883	519	[ 9, SEQ ID NO: ]	[ 8, SEQ ID NO: ]
0.99998844	520	[ 10, SEQ ID NO: ]	[ 9, SEQ ID NO: ]
0.99999034	521	[ 11, SEQ ID NO: ]	[ 10, SEQ ID NO: ]
0.9999887	522	[ 12, SEQ ID NO: ]	[ 11, SEQ ID NO: ]
0.9999893	523	[ 13, SEQ ID NO: ]	[ 12, SEQ ID NO: ]
0.99998903	524	[ 14, SEQ ID NO: ]	[ 13, SEQ ID NO: ]
0.9999882	525	[ 15, SEQ ID NO: ]	[ 14, SEQ ID NO: ]
0.9999913	526	[ 16, SEQ ID NO: ]	[ 15, SEQ ID NO: ]
0.99997914	527	[ 17 and SEQ ID NO: ]	[ 16, SEQ ID NO: ]
0.99976486	528	[ 18. ]	[ 17 and SEQ ID NO: ]
0.9999819	529	[ 2 and wherein the polypeptide is selected from the group consisting of SEQ ID NO: ]	[ A method for treating a disease comprising administering to the disease a therapeutically effective amount of a composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.9997707	530	[ 2, SEQ ID NO: ]	[ 2 and wherein the polypeptide is selected from the group consisting of SEQ ID NO: ]
0.99994767	531	[ 3 and SEQ ID N: ]	[ 2, SEQ ID NO: ]
0.9989549	532	[ 3. ]	[ 3 and SEQ ID N: ]
0.99995327	533	[ administering to the individual a therapeutically effective amount of at least one of a pharmaceutically active agent, a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising at least one of the following components: ]	[ A method of treating an individual having a disease or disorder, comprising the steps of: ]
0.16277818	534	[ a compound having a molecular weight of at least 50, ]	[ administering to the individual a therapeutically effective amount of at least one of a pharmaceutically active agent, a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising at least one of the following components: ]
0.9959479	535	[ 000; ]	[ a compound having a molecular weight of at least 50, ]
0.00037426397	536	[ a pharmaceutically acceptable carrier; ]	[ 000; ]
0.99987864	537	[ at least one pharmaceutically acceptable carrier salt, wherein at least a portion of the at least one carrier salt is present as a carrier in the compound; ]	[ a pharmaceutically acceptable carrier; ]
0.9983627	538	[ wherein the compound is selected from the group consisting of: a compound having a molecular weight of between about 50, ]	[ at least one pharmaceutically acceptable carrier salt, wherein at least a portion of the at least one carrier salt is present as a carrier in the compound; ]
0.999713	539	[ 000 and about 100, ]	[ wherein the compound is selected from the group consisting of: a compound having a molecular weight of between about 50, ]
0.9989324	540	[ 000; and ]	[ 000 and about 100, ]
0.0001705856	541	[ a pharmaceutically acceptable salt thereof. ]	[ 000; and ]
0.985609	542	[ a) a pharmaceutically acceptable salt thereof, ]	[ A method of producing a pharmaceutical composition comprising a pharmaceutical composition comprising a pharmaceutically active agent, said pharmaceutically active agent having an effective amount of at least one of the following: ]
0.99997115	543	[ b) a pharmaceutically acceptable carrier, ]	[ a) a pharmaceutically acceptable salt thereof, ]
0.999252	544	[ c) an organic acid, or ]	[ b) a pharmaceutically acceptable carrier, ]
0.9907532	545	[ d) a pharmaceutically acceptable salt thereof, wherein the pharmaceutically active agent comprises a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, and ]	[ c) an organic acid, or ]
0.9993007	546	[ a pharmaceutically acceptable organic acid. ]	[ d) a pharmaceutically acceptable salt thereof, wherein the pharmaceutically active agent comprises a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, and ]
0.99255604	547	[ (a) a compound of formula I or a pharmaceutically acceptable salt thereof, and ]	[ A method for treating a subject having an immune system disorder comprising administering to the subject a therapeutically effective amount of a composition comprising a compound selected from the group consisting of the following compounds: ]
0.0005992388	548	[ (b) an antibody that binds to a human CD4 cell. ]	[ (a) a compound of formula I or a pharmaceutically acceptable salt thereof, and ]
0.98145676	549	[ a first step of providing an organic compound having a first structure, wherein the first structure of the organic compound is selected from the group consisting of a first structure, a second structure, a third structure and a fourth structure; and ]	[ A method of producing a composition comprising: ]
0.99999213	550	[ a second step of providing an organic compound having a second structure, wherein the second structure of the organic compound is selected from the group consisting of a second structure, a third structure, a fourth structure and a fifth structure. ]	[ a first step of providing an organic compound having a first structure, wherein the first structure of the organic compound is selected from the group consisting of a first structure, a second structure, a third structure and a fourth structure; and ]
0.9999875	551	[ (a) contacting said nucleic acid molecule with a therapeutically effective amount of a pharmaceutically acceptable salt; ]	[ A method of treating a patient with a condition that causes an increase in a concentration in an isolated nucleic acid molecule, said nucleic acid molecule having a sequence having at least 95% sequence identity with SEQ ID NO: 2, comprising: ]
0.99999	552	[ (b) contacting said nucleic acid molecule with a nucleic acid molecule having an isolated sequence having a nucleotide sequence at least 90% identical to the nucleotide sequence in the nucleic acid molecule having the condition; and ]	[ (a) contacting said nucleic acid molecule with a therapeutically effective amount of a pharmaceutically acceptable salt; ]
0.999982	553	[ (c) treating the patient with the nucleic acid molecule that has an increased concentration in the nucleic acid molecule. ]	[ (b) contacting said nucleic acid molecule with a nucleic acid molecule having an isolated sequence having a nucleotide sequence at least 90% identical to the nucleotide sequence in the nucleic acid molecule having the condition; and ]
0.9989754	554	[ an implantable medical device; ]	[ An apparatus for treating a patient with a disease comprising: ]
0.9999907	555	[ an implantable medical device controller; ]	[ an implantable medical device; ]
0.9953365	556	[ a processor; and ]	[ an implantable medical device controller; ]
0.9939188	557	[ an implantable medical device interface, the processor being operable to control the implantable medical device controller, the implantable medical device interface being operable to communicate with the implantable medical device controller, wherein the implantable medical device controller is operable to: ]	[ a processor; and ]
0.9999416	558	[ (i) receive a patient-specific medical device identifier; ]	[ an implantable medical device interface, the processor being operable to control the implantable medical device controller, the implantable medical device interface being operable to communicate with the implantable medical device controller, wherein the implantable medical device controller is operable to: ]
0.99999213	559	[ (ii) receive a patient-specific medical device identifier from a patient; ]	[ (i) receive a patient-specific medical device identifier; ]
0.999992	560	[ (iii) determine whether the patient-specific medical device identifier matches a patient-specific identifier of a patient; ]	[ (ii) receive a patient-specific medical device identifier from a patient; ]
0.99999225	561	[ (iv) when the patient-specific medical device identifier matches the patient-specific identifier, transmit an implantable medical device identifier to the implantable medical device controller; and ]	[ (iii) determine whether the patient-specific medical device identifier matches a patient-specific identifier of a patient; ]
0.99999225	562	[ (v) if the patient-specific medical device identifier does not match the patient-specific identifier, determine whether the patient-specific medical device identifier is a patient-specific identifier of the patient. ]	[ (iv) when the patient-specific medical device identifier matches the patient-specific identifier, transmit an implantable medical device identifier to the implantable medical device controller; and ]
0.98741406	563	[ 1, wherein: ]	[ A method for producing a compound that binds to a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.9979522	564	[ the polypeptide comprises the amino acid sequence of SEQ ID NO: ]	[ 1, wherein: ]
0.9954319	565	[ 1; ]	[ the polypeptide comprises the amino acid sequence of SEQ ID NO: ]
0.99779177	566	[ the polypeptide comprises the amino acid sequence of SEQ ID NO: ]	[ 1; ]
0.9969387	567	[ 2; ]	[ the polypeptide comprises the amino acid sequence of SEQ ID NO: ]
0.99842095	568	[ the polypeptide comprises a sequence of SEQ ID NO: ]	[ 2; ]
0.9983241	569	[ 3; and ]	[ the polypeptide comprises a sequence of SEQ ID NO: ]
0.9988875	570	[ the polypeptide comprises the sequence of SEQ ID NO: ]	[ 3; and ]
0.9991721	571	[ 4. ]	[ the polypeptide comprises the sequence of SEQ ID NO: ]
0.9976882	572	[ 2. ]	[ A method of treating cancer in a subject, the method comprising administering to said subject an isolated antibody that binds to a human CD4+ T-cell receptor, wherein the antibody comprises the amino acid sequence of SEQ ID NO: ]
0.9937238	573	[ 3. ]	[ A method of treating a patient having a condition in which a blood vessel is located in the body of the patient, said method comprising administering to said patient an effective amount of a therapeutically effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.999514	574	[ 1, SEQ ID NO: ]	[ A method of treating an inflammatory disease comprising administering to a subject a therapeutically effective amount of a composition comprising a polypeptide comprising an amino acid sequence of SEQ ID NO: ]
0.99998844	575	[ 2, SEQ ID NO: ]	[ 1, SEQ ID NO: ]
0.9988059	576	[ 3, and ]	[ 2, SEQ ID NO: ]
0.9991086	577	[ SEQ ID NO: ]	[ 3, and ]
0.9996711	578	[ 4, wherein the polypeptide comprises a first amino acid sequence and a second amino acid sequence different from the first amino acid sequence, wherein the first and second amino acids comprise the same amino acid sequence, and ]	[ SEQ ID NO: ]
0.99993944	579	[ wherein the polypeptide is effective for treating the inflammatory disease, ]	[ 4, wherein the polypeptide comprises a first amino acid sequence and a second amino acid sequence different from the first amino acid sequence, wherein the first and second amino acids comprise the same amino acid sequence, and ]
0.993769	580	[ wherein the composition comprises a pharmaceutically acceptable carrier. ]	[ wherein the polypeptide is effective for treating the inflammatory disease, ]
0.9999769	581	[ SEQ ID NO: 1: 2. ]	[ A method for the treatment of an inflammatory disorder, the method comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a polypeptide comprising a nucleic acid sequence encoding a peptide that comprises at least 90% sequence identity with SEQ ID NO: 1, wherein the polypeptide is selected from the group consisting of: SEQ ID NO: 1: 1, SEQ ID NO: 1: 1, and ]
0.038493957	582	[ a housing; ]	[ An apparatus for the placement of a prosthetic device, the apparatus comprising: ]
0.9987357	583	[ a prosthetic device disposed in said housing, said prosthetic device having an outer surface, a first end, an inner surface, a second end, a proximal end, and ]	[ a housing; ]
0.942386	584	[ an intermediate surface; ]	[ a prosthetic device disposed in said housing, said prosthetic device having an outer surface, a first end, an inner surface, a second end, a proximal end, and ]
0.008767488	585	[ a first actuator disposed in said housing, said first actuator being operable to move a first part of said outer surface of said prosthetic device relative to said inner surface of said prosthetic device; and ]	[ an intermediate surface; ]
0.99999213	586	[ a first control device operable to control the first actuator to move said first part of said outer surface of said prosthetic device relative to said inner surface of said prosthetic device. ]	[ a first actuator disposed in said housing, said first actuator being operable to move a first part of said outer surface of said prosthetic device relative to said inner surface of said prosthetic device; and ]
0.99966526	587	[ 1, SEQ ID NO: ]	[ A method for treating a patient with a condition that is associated with a decrease in the level of a receptor that binds the polypeptide comprising the amino acid sequence of SEQ ID NO: 1, comprising administering to the patient a composition comprising an effective amount of a polypeptide selected from the group consisting of SEQ ID NO: ]
0.9999906	588	[ 4, SEQ ID NO: ]	[ 1, SEQ ID NO: ]
0.9999877	589	[ 8, SEQ ID NO: ]	[ 4, SEQ ID NO: ]
0.9999876	590	[ 12, SEQ ID NO: ]	[ 8, SEQ ID NO: ]
0.99997103	591	[ 16 and SEQ ID NO: ]	[ 12, SEQ ID NO: ]
0.999848	592	[ 18. ]	[ 16 and SEQ ID NO: ]
0.99998474	593	[ 4, wherein the nucleic acid sequence comprises a first nucleic acid sequence and at least one second nucleic acid sequence. ]	[ An isolated polypeptide, comprising a nucleic acid sequence having at least 90% sequence identity with SEQ ID NO: ]
0.999619	594	[ 4, SEQ ID NO: ]	[ A method of treating an autoimmune condition, comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of the amino acid sequence of SEQ ID NO: ]
0.9999645	595	[ 5 and SEQ ID NO: ]	[ 4, SEQ ID NO: ]
0.9995993	596	[ 6. ]	[ 5 and SEQ ID NO: ]
0.008144161	597	[ providing a first device, comprising: ]	[ A method for the treatment of a disease in a subject, the method comprising: ]
0.008461722	598	[ at least one sensor; ]	[ providing a first device, comprising: ]
0.99997747	599	[ at least one sensor controller; ]	[ at least one sensor; ]
0.9999813	600	[ at least one sensor processor; and ]	[ at least one sensor controller; ]
0.98553187	601	[ a memory; and ]	[ at least one sensor processor; and ]
0.007909167	602	[ providing a second device, comprising: ]	[ a memory; and ]
0.0073639327	603	[ a first processor; ]	[ providing a second device, comprising: ]
0.99933463	604	[ a first memory; and ]	[ a first processor; ]
0.9967693	605	[ a processor; ]	[ a first memory; and ]
0.9937318	606	[ the first processor, the first memory, and ]	[ a processor; ]
0.99508935	607	[ the processor cooperating in a manner to: ]	[ the first processor, the first memory, and ]
0.9964904	608	[ receive data from the first device; ]	[ the processor cooperating in a manner to: ]
0.9993235	609	[ generate a first set of data; and ]	[ receive data from the first device; ]
0.9999864	610	[ store the first set of data in the first device; ]	[ generate a first set of data; and ]
0.9980799	611	[ the first processor, the first memory, and ]	[ store the first set of data in the first device; ]
0.99508935	612	[ the processor cooperating in a manner to: ]	[ the first processor, the first memory, and ]
0.9965378	613	[ determine whether the first device is in use; ]	[ the processor cooperating in a manner to: ]
0.9999914	614	[ if the first device is in use, generate a first data signal; and ]	[ determine whether the first device is in use; ]
0.99999225	615	[ if the first device is not in use, generate a second signal; and ]	[ if the first device is in use, generate a first data signal; and ]
0.9999831	616	[ the first data signal is used to control a first device of the first device. ]	[ if the first device is not in use, generate a second signal; and ]
0.99999225	617	[ administering to said patient an amount sufficient to inhibit the GFR in a tissue; ]	[ A method of treating a patient suffering from a condition that inhibits the growth factor receptor (GFR) in a tissue, comprising: ]
0.9991937	618	[ wherein the amount of the drug is administered in a dosage form that does not contained in a dosage form that contains a pharmaceutically acceptable salt or a solvate of a pharmaceutically acceptable salt. ]	[ administering to said patient an amount sufficient to inhibit the GFR in a tissue; ]
0.9999769	619	[ 4, a polypeptide comprising the amino acid sequence of SEQ ID NO: 4, and ]	[ A method of producing a composition comprising a composition comprising a composition comprising a polypeptide, the composition comprising a polypeptide comprising a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.9999901	620	[ a polypeptide comprising the amino acid sequence of SEQ ID NO: ]	[ 4, a polypeptide comprising the amino acid sequence of SEQ ID NO: 4, and ]
0.9992643	621	[ 5. ]	[ a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.9995338	622	[ a) a nucleotide sequence encoding a protein comprising a first amino acid sequence having at least 90% sequence identity to SEQ ID NO: ]	[ An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: ]
0.99678063	623	[ 2, and ]	[ a) a nucleotide sequence encoding a protein comprising a first amino acid sequence having at least 90% sequence identity to SEQ ID NO: ]
0.99302423	624	[ b) a nucleotide sequence comprising a second amino acid sequence having at least 90% sequence identity to SEQ ID NO: ]	[ 2, and ]
0.99929476	625	[ 3; wherein said protein is a polypeptide. ]	[ b) a nucleotide sequence comprising a second amino acid sequence having at least 90% sequence identity to SEQ ID NO: ]
0.99999213	626	[ 1, a light chain variable region comprising a light chain variable region of SEQ ID NO: ]	[ An isolated nucleic acid comprising a nucleic acid sequence encoding an antibody that is specifically capable of binding to a human monoclonal antibody, wherein the antibody comprises a heavy chain variable region comprising a heavy chain variable region of SEQ ID NO: ]
0.99873966	627	[ 2, and ]	[ 1, a light chain variable region comprising a light chain variable region of SEQ ID NO: ]
0.9983785	628	[ a heavy chain variable region comprising a heavy chain variable region of SEQ ID NO: ]	[ 2, and ]
0.9983834	629	[ 3. ]	[ a heavy chain variable region comprising a heavy chain variable region of SEQ ID NO: ]
0.0008389265	630	[ a) a catheter having an elongate body having an inner surface, an outer surface, and ]	[ A system for the treatment of a subject, comprising: ]
0.9909774	631	[ a distal end; ]	[ a) a catheter having an elongate body having an inner surface, an outer surface, and ]
0.99902296	632	[ b) a catheter guide having a proximal end and a distal end, the distal end of the catheter guide configured to be coupled to the elongate body, and ]	[ a distal end; ]
0.99999034	633	[ a distal end and an inner surface of the catheter guide; wherein: ]	[ b) a catheter guide having a proximal end and a distal end, the distal end of the catheter guide configured to be coupled to the elongate body, and ]
0.99999225	634	[ c) the distal end of the catheter guide is configured to extend through an inner surface of the catheter guide; and ]	[ a distal end and an inner surface of the catheter guide; wherein: ]
0.99999225	635	[ d) the elongate body of the catheter guide is configured to extend through a portion of the distal end of the catheter guide; and ]	[ c) the distal end of the catheter guide is configured to extend through an inner surface of the catheter guide; and ]
0.9999919	636	[ e) an elongate member having a distal end, an inner surface of the elongate member configured to be coupled to the inner surface of the catheter guide, and ]	[ d) the elongate body of the catheter guide is configured to extend through a portion of the distal end of the catheter guide; and ]
0.99998593	637	[ an outer surface of the elongate member, wherein: ]	[ e) an elongate member having a distal end, an inner surface of the elongate member configured to be coupled to the inner surface of the catheter guide, and ]
0.99996233	638	[ f) the elongate member comprises a first portion and a second portion, wherein the first portion is configured to be coupled to the distal end of the catheter guide and the second portion is configured to be coupled to a portion of the inner surface of the catheter guide. ]	[ an outer surface of the elongate member, wherein: ]
0.9993649	639	[ a lens; ]	[ A system for treating an eye, comprising: ]
0.9998963	640	[ a lens cover; and ]	[ a lens; ]
0.9999751	641	[ at least a first and a second lens, wherein each lens comprises a plurality of lens elements and each lens element has a plurality of lenses disposed thereon, wherein the first and the second lens cover are configured to cover a first portion of the lens and the second portion of the lens is configured to cover a second portion of the lens, ]	[ a lens cover; and ]
0.99999213	642	[ wherein the first and the second lenses are configured to cover a first portion of the eye and the second portion of the eye is configured to cover a second portion of the eye, wherein the lens cover comprises a first portion of a lens and a second portion of a lens, and ]	[ at least a first and a second lens, wherein each lens comprises a plurality of lens elements and each lens element has a plurality of lenses disposed thereon, wherein the first and the second lens cover are configured to cover a first portion of the lens and the second portion of the lens is configured to cover a second portion of the lens, ]
0.99999166	643	[ wherein a portion of the lens cover is configured to be placed on a surface of a patient's eye, ]	[ wherein the first and the second lenses are configured to cover a first portion of the eye and the second portion of the eye is configured to cover a second portion of the eye, wherein the lens cover comprises a first portion of a lens and a second portion of a lens, and ]
0.99999166	644	[ wherein a first portion of the first portion of the first lens is configured to be positioned on the surface of the patient's eye, and ]	[ wherein a portion of the lens cover is configured to be placed on a surface of a patient's eye, ]
0.99999225	645	[ wherein a portion of the second portion of the lens is positioned on the surface of the patient's eye. ]	[ wherein a first portion of the first portion of the first lens is configured to be positioned on the surface of the patient's eye, and ]
0.99728405	646	[ providing a first treatment agent; ]	[ A method for treating a disease or condition in a patient comprising: ]
0.99999225	647	[ delivering the first treatment agent to the patient; and ]	[ providing a first treatment agent; ]
0.99999225	648	[ administering to the patient a second treatment agent in a dosage form that is different than the first treatment agent. ]	[ delivering the first treatment agent to the patient; and ]
0.9992174	649	[ or a pharmaceutically acceptable salt thereof. ]	[ A method of treating a patient suffering from a disease or disorder comprising administering to a patient in need of treatment a therapeutically effective amount of a compound of the formula (I): ]
4.844067e-05	650	[ a) an amino acid sequence of SEQ ID NO: ]	[ A method of treating a patient in need thereof comprising administering to the patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of: ]
0.00091352063	651	[ 2, ]	[ a) an amino acid sequence of SEQ ID NO: ]
2.434394e-05	652	[ b) a nucleic acid sequence of SEQ ID NO: ]	[ 2, ]
0.9977088	653	[ 2, and ]	[ b) a nucleic acid sequence of SEQ ID NO: ]
0.9949352	654	[ c) a nucleic acid sequence of SEQ ID NO: ]	[ 2, and ]
0.99942565	655	[ 4. ]	[ c) a nucleic acid sequence of SEQ ID NO: ]
0.9958715	656	[ 3. ]	[ A method of treating an inflammatory condition comprising administering an effective amount of an antibody or antigen-binding fragment thereof to the patient, wherein the antibody or antigen-binding fragment comprises the amino acid sequence set forth in SEQ ID NO: ]
0.9748457	657	[ a housing having a first end; ]	[ A device for the delivery of a drug to the brain of a patient, comprising: ]
0.999887	658	[ a first delivery device having a second end, wherein the first end of the first delivery device is configured for the delivery of a drug, and ]	[ a housing having a first end; ]
0.999992	659	[ the first delivery device further comprises a plurality of first electrodes, wherein each of the first electrodes is configured for the delivery of a drug to the brain of the patient; and ]	[ a first delivery device having a second end, wherein the first end of the first delivery device is configured for the delivery of a drug, and ]
0.9999924	660	[ an implantable medical device configured for delivery of a drug to the brain of the patient, wherein the implantable medical device comprises a plurality of second electrodes, wherein each of the plurality of second electrodes is configured for the delivery of a drug to the brain of the patient. ]	[ the first delivery device further comprises a plurality of first electrodes, wherein each of the first electrodes is configured for the delivery of a drug to the brain of the patient; and ]
0.99526274	661	[ 000, comprising the steps of: ]	[ A method for producing a compound having a molecular weight of less than about 100, ]
0.024838941	662	[ a) contacting the compound with an organic solvent; ]	[ 000, comprising the steps of: ]
0.99999154	663	[ b) contacting the compound with an organic solvent comprising a solvent selected from a group consisting of a solvent comprising a hydrocarbon group having a molecular weight less than about 50, ]	[ a) contacting the compound with an organic solvent; ]
0.99998903	664	[ 000 and a solvent comprising a hydrocarbon group having a molecular weight of less than about 50, ]	[ b) contacting the compound with an organic solvent comprising a solvent selected from a group consisting of a solvent comprising a hydrocarbon group having a molecular weight less than about 50, ]
0.9990627	665	[ 000; and ]	[ 000 and a solvent comprising a hydrocarbon group having a molecular weight of less than about 50, ]
0.063869946	666	[ c) reacting the organic solvent with the compound, thereby producing an organic solvent having a molecular weight of less than about 10, ]	[ 000; and ]
0.9851789	667	[ 000, ]	[ c) reacting the organic solvent with the compound, thereby producing an organic solvent having a molecular weight of less than about 10, ]
0.9938212	668	[ wherein said organic solvent comprises a hydrocarbon group having a molecular weight of less than about 50, ]	[ 000, ]
0.9999895	669	[ 000 and a hydrocarbon group having a molecular weight of less than about 50, ]	[ wherein said organic solvent comprises a hydrocarbon group having a molecular weight of less than about 50, ]
0.9987043	670	[ 000. ]	[ 000 and a hydrocarbon group having a molecular weight of less than about 50, ]
0.99833775	671	[ (A) a polymeric composition comprising at least one of an amino acid sequence and a polymeric peptide; and ]	[ A method of treating a patient suffering from an inflammatory disorder comprising administering to the patient an effective amount of a composition comprising: ]
0.0015125488	672	[ (B) a therapeutically effective amount of a pharmaceutically acceptable carrier. ]	[ (A) a polymeric composition comprising at least one of an amino acid sequence and a polymeric peptide; and ]
0.99046665	673	[ (a) an amino acid having at least 95% identity to the amino acid sequence of SEQ ID NO: ]	[ A method for producing a composition comprising a composition comprising an active ingredient, wherein the active ingredient comprises an amino acid selected from the group consisting of: ]
0.9985936	674	[ 2; and ]	[ (a) an amino acid having at least 95% identity to the amino acid sequence of SEQ ID NO: ]
0.9431252	675	[ (b) a salt of at least one salt of the amino acid, wherein said salt is selected from the group consisting of: ]	[ 2; and ]
0.99965715	676	[ (i) a salt having a pH of at least 7.8, and ]	[ (b) a salt of at least one salt of the amino acid, wherein said salt is selected from the group consisting of: ]
0.99999154	677	[ (ii) a salt having a pH of at least 8.0. ]	[ (i) a salt having a pH of at least 7.8, and ]
0.999992	678	[ a pharmaceutically acceptable carrier-soluble polymeric component; and ]	[ A method for treating a disease in a subject, the method comprising administering to said subject a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically acceptable carrier-soluble component, wherein said carrier is selected from the group consisting of a polymeric carrier, a pharmaceutically acceptable carrier-soluble component, and ]
0.99999106	679	[ a pharmaceutically acceptable salt thereof, wherein said salt is selected from the group consisting of a salt thereof, a salt of an organic solvent, a salt of an organic solvent-soluble polymeric component, and ]	[ a pharmaceutically acceptable carrier-soluble polymeric component; and ]
0.999992	680	[ a salt of an organic solvent-soluble polymeric component-soluble component. ]	[ a pharmaceutically acceptable salt thereof, wherein said salt is selected from the group consisting of a salt thereof, a salt of an organic solvent, a salt of an organic solvent-soluble polymeric component, and ]
0.99993706	681	[ a) providing a breast cancer treatment comprising a therapeutically effective amount of a composition comprising: ]	[ A method of providing a treatment for a patient having a cancer, said cancer being a breast, the method comprising the steps of: ]
0.9995763	682	[ i) an effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ]	[ a) providing a breast cancer treatment comprising a therapeutically effective amount of a composition comprising: ]
0.9999914	683	[ 1, wherein said polypeptide is selected from the group consisting of a polypeptide having the amino acid sequence of SEQ ID NO: ]	[ i) an effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.99999094	684	[ 1, a polypeptide having the amino acid sequence of SEQ ID NO: ]	[ 1, wherein said polypeptide is selected from the group consisting of a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.99999166	685	[ 2, a polypeptide having the amino acid sequence of SEQ ID NO: ]	[ 1, a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.9999912	686	[ 3 and a polypeptide having the amino acid sequence of SEQ ID NO: ]	[ 2, a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.99992037	687	[ 4, wherein said polypeptide has a molecular weight of less than 1, ]	[ 3 and a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.036927782	688	[ 000, ]	[ 4, wherein said polypeptide has a molecular weight of less than 1, ]
0.9999038	689	[ 000, ]	[ 000, ]
0.9995827	690	[ 000 and ]	[ 000, ]
0.9992731	691	[ 000, wherein said polypeptide is present in a concentration of less than 0.5% by weight of a total amount of said composition; and ]	[ 000 and ]
0.012205804	692	[ ii) an effective amount of an anti-TNF-1 antibody; and ]	[ 000, wherein said polypeptide is present in a concentration of less than 0.5% by weight of a total amount of said composition; and ]
0.99992216	693	[ b) administering to said breast cancer treatment a therapeutically effective amount of said composition. ]	[ ii) an effective amount of an anti-TNF-1 antibody; and ]
0.0075758863	694	[ a) a container; ]	[ An apparatus for the delivery of a pharmaceutical composition comprising: ]
0.99996126	695	[ b) a first dispenser having at least one outlet, the first dispenser being configured to receive the pharmaceutical composition from the container; and ]	[ a) a container; ]
0.99999213	696	[ c) a second dispenser, configured to receive the pharmaceutical composition from the container, the second dispenser being configured to be in fluid communication with the first dispenser; ]	[ b) a first dispenser having at least one outlet, the first dispenser being configured to receive the pharmaceutical composition from the container; and ]
0.99999213	697	[ d) the first dispenser being configured to be in fluid communication with the second dispenser and the second dispenser being configured to be in fluid communication with the first dispenser, wherein: ]	[ c) a second dispenser, configured to receive the pharmaceutical composition from the container, the second dispenser being configured to be in fluid communication with the first dispenser; ]
0.999992	698	[ i) the first dispenser is configured to receive the pharmaceutical composition from the container and the second dispenser is configured to be in fluid communication with the container, and ]	[ d) the first dispenser being configured to be in fluid communication with the second dispenser and the second dispenser being configured to be in fluid communication with the first dispenser, wherein: ]
0.99999213	699	[ ii) the first dispenser and the second dispenser are configured to be in fluid communication with each other. ]	[ i) the first dispenser is configured to receive the pharmaceutical composition from the container and the second dispenser is configured to be in fluid communication with the container, and ]
0.99726886	700	[ a plurality of cameras, each camera having a camera lens, a first camera lens and a camera body, the first camera lens being configured to focus on an object in a first direction and the first camera lens being configured to focus on a second direction, the camera body being configured to be disposed on a surface of a body, the camera body being configured to receive a light beam from a source of light; ]	[ A system for providing an image, comprising: ]
0.9999875	701	[ a processor, configured to process a first image of the object in the first direction and a second image of the object in the second direction, wherein the processor is further configured to determine an orientation of the first and second images, the processor being further configured to calculate an angle between the first and second images, and ]	[ a plurality of cameras, each camera having a camera lens, a first camera lens and a camera body, the first camera lens being configured to focus on an object in a first direction and the first camera lens being configured to focus on a second direction, the camera body being configured to be disposed on a surface of a body, the camera body being configured to receive a light beam from a source of light; ]
0.99999213	702	[ the processor being further configured to calculate a distance between the first and second images, and ]	[ a processor, configured to process a first image of the object in the first direction and a second image of the object in the second direction, wherein the processor is further configured to determine an orientation of the first and second images, the processor being further configured to calculate an angle between the first and second images, and ]
0.9999913	703	[ wherein the processor is further configured to determine an orientation of the first image and the orientation of a second image based on the calculated angle; and ]	[ the processor being further configured to calculate a distance between the first and second images, and ]
0.999902	704	[ a display, configured to display the orientation of the first and second photos. ]	[ wherein the processor is further configured to determine an orientation of the first image and the orientation of a second image based on the calculated angle; and ]
0.9886651	705	[ a first housing; ]	[ A device for a patient, the device comprising: ]
0.99997175	706	[ a first electrode disposed on the first housing, the first electrode configured to be coupled to a first nerve in the patient; ]	[ a first housing; ]
0.99999225	707	[ a first sensor disposed on the first housing, the first sensor configured to receive electrical signals from the first nerve, the first sensor configured to be coupled to a second electrode in the device, the second electrode configured to be coupled to the patient's nerve; and ]	[ a first electrode disposed on the first housing, the first electrode configured to be coupled to a first nerve in the patient; ]
0.999992	708	[ a second electrode disposed on the device, the second electrode configured to be coupled to a second nerve, the second electrode configured to receive electrical signals from the second nerve, ]	[ a first sensor disposed on the first housing, the first sensor configured to receive electrical signals from the first nerve, the first sensor configured to be coupled to a second electrode in the device, the second electrode configured to be coupled to the patient's nerve; and ]
0.010134004	709	[ wherein the first and second sensors are disposed in the first housing. ]	[ a second electrode disposed on the device, the second electrode configured to be coupled to a second nerve, the second electrode configured to receive electrical signals from the second nerve, ]
0.99590164	710	[ a housing comprising a first portion, a first side, a first wall, and ]	[ An implant for use in an implantable medical device, the implant comprising: ]
0.9998914	711	[ a first opening, the first opening being in communication with a first end of a first portion of the housing; ]	[ a housing comprising a first portion, a first side, a first wall, and ]
0.9999665	712	[ a plurality of first transducers disposed within the first opening; and ]	[ a first opening, the first opening being in communication with a first end of a first portion of the housing; ]
0.01768128	713	[ an implant member having a first portion, a first end portion, and ]	[ a plurality of first transducers disposed within the first opening; and ]
0.99994814	714	[ a first side, the first side of the first transducer disposed between the first portion of the housing and the implant portion, wherein the first transducer comprises: ]	[ an implant member having a first portion, a first end portion, and ]
0.012254416	715	[ a plurality of first electrodes disposed within the first opening; ]	[ a first side, the first side of the first transducer disposed between the first portion of the housing and the implant portion, wherein the first transducer comprises: ]
0.9999882	716	[ a first transducer coil disposed within the first opening; ]	[ a plurality of first electrodes disposed within the first opening; ]
0.99999213	717	[ a first transducer element disposed within the first opening; and ]	[ a first transducer coil disposed within the first opening; ]
0.9999734	718	[ a first coil disposed within the first opening, the first coil being in communication with the first electrode; ]	[ a first transducer element disposed within the first opening; and ]
0.99688137	719	[ wherein, when the first transducer element is in contact with a first end of the first transducer, the first transducer coil is configured to generate an electrical signal that is received by a first transducer element; and ]	[ a first coil disposed within the first opening, the first coil being in communication with the first electrode; ]
0.99999225	720	[ wherein when the first transducer coil is disposed within a first portion of the first portion of the housing, the first transducer element is configured to generate an electrical signal that is received by a first transducer element. ]	[ wherein, when the first transducer element is in contact with a first end of the first transducer, the first transducer coil is configured to generate an electrical signal that is received by a first transducer element; and ]
0.008558169	721	[ a housing having a first end and a second end, said housing having an open bottom and a bottom wall, said housing having a top wall and a bottom wall, said bottom wall being substantially parallel to said bottom wall, said bottom wall having an opening at a bottom edge of said bottom wall, said opening having a top edge; ]	[ An apparatus comprising: ]
0.99994075	722	[ a first handle disposed in said housing, said first handle having an open top surface and a closed bottom surface; ]	[ a housing having a first end and a second end, said housing having an open bottom and a bottom wall, said housing having a top wall and a bottom wall, said bottom wall being substantially parallel to said bottom wall, said bottom wall having an opening at a bottom edge of said bottom wall, said opening having a top edge; ]
0.999992	723	[ a second handle disposed in said housing, said second handle having an open top surface and a closed bottom surface, said second handle having a first end and a second end, said second handle having said open top surface and said closed bottom surface, said first and second ends of said first and second handles each being disposed in a substantially parallel relationship with said open top surface of said first handle and said closed bottom surface of said second handle; and ]	[ a first handle disposed in said housing, said first handle having an open top surface and a closed bottom surface; ]
0.99997556	724	[ a plurality of first and second arms, said first arm being disposed in a substantially parallel relationship with said bottom wall of said bottom wall, said first and second arms each having a first end and a second end, each of said first arms having a first end and a second end, said first end being disposed substantially parallel to said top edge of said bottom wall of said bottom wall of said housing, said second arm being disposed substantially parallel to said bottom wall of said bottom wall of said housing, said second arm having a first end and a second end, said second end disposed substantially parallel to said bottom wall of said bottom wall of said housing, and ]	[ a second handle disposed in said housing, said second handle having an open top surface and a closed bottom surface, said second handle having a first end and a second end, said second handle having said open top surface and said closed bottom surface, said first and second ends of said first and second handles each being disposed in a substantially parallel relationship with said open top surface of said first handle and said closed bottom surface of said second handle; and ]
0.99999225	725	[ each of the first and second arms having an open top surface, said first and second ends being disposed in a substantially parallel relationship with said top edge of said bottom wall of said bottom wall of said housing, said first and second ends of said first and second arms each being disposed in a substantially parallel relationship with said top edge of said bottom wall of said housing, and ]	[ a plurality of first and second arms, said first arm being disposed in a substantially parallel relationship with said bottom wall of said bottom wall, said first and second arms each having a first end and a second end, each of said first arms having a first end and a second end, said first end being disposed substantially parallel to said top edge of said bottom wall of said bottom wall of said housing, said second arm being disposed substantially parallel to said bottom wall of said bottom wall of said housing, said second arm having a first end and a second end, said second end disposed substantially parallel to said bottom wall of said bottom wall of said housing, and ]
0.9999881	726	[ wherein said open bottom of said housing has an opening at an upper end thereof, said opening having a top edge. ]	[ each of the first and second arms having an open top surface, said first and second ends being disposed in a substantially parallel relationship with said top edge of said bottom wall of said bottom wall of said housing, said first and second ends of said first and second arms each being disposed in a substantially parallel relationship with said top edge of said bottom wall of said housing, and ]
0.99972695	727	[ 1, wherein said antibody is selected from the group consisting of: ]	[ An isolated antibody or antigen binding fragment thereof that specifically binds to the polypeptide of SEQ ID NO: ]
0.999826	728	[ a) an immunoglobulin antibody; ]	[ 1, wherein said antibody is selected from the group consisting of: ]
0.9999316	729	[ b) an antibody that specifically binds to the polypeptide of SEQ ID NO: ]	[ a) an immunoglobulin antibody; ]
0.9999633	730	[ 1; or c) an immunoglobulin fragment of SEQ ID NO: ]	[ b) an antibody that specifically binds to the polypeptide of SEQ ID NO: ]
0.98365605	731	[ 1. ]	[ 1; or c) an immunoglobulin fragment of SEQ ID NO: ]
0.9993125	732	[ providing a first pharmaceutical composition comprising a first active agent and a first pharmaceutical carrier; ]	[ A method of providing a therapeutic effect of an effective amount, said method comprising: ]
0.9999919	733	[ delivering said first active agent to a first site of an animal's body, the first active agent comprising a first compound selected from the group consisting of: ]	[ providing a first pharmaceutical composition comprising a first active agent and a first pharmaceutical carrier; ]
0.9987808	734	[ (a) an anti-inflammatory agent, ]	[ delivering said first active agent to a first site of an animal's body, the first active agent comprising a first compound selected from the group consisting of: ]
0.99997866	735	[ (b) an anti-cancer agent, ]	[ (a) an anti-inflammatory agent, ]
0.99997413	736	[ (c) a chemopreventive agent, and ]	[ (b) an anti-cancer agent, ]
0.99998724	737	[ (d) a chemopreventive agent, wherein the first active agent is a pharmaceutically acceptable salt of the first compound; and ]	[ (c) a chemopreventive agent, and ]
0.9999881	738	[ delivering said second active agent to a second site of the animal's body, ]	[ (d) a chemopreventive agent, wherein the first active agent is a pharmaceutically acceptable salt of the first compound; and ]
0.9996357	739	[ wherein said first pharmaceutical composition comprises a second pharmaceutical carrier; and, ]	[ delivering said second active agent to a second site of the animal's body, ]
0.9998288	740	[ administering said second active agent to a second site of the animal's body. ]	[ wherein said first pharmaceutical composition comprises a second pharmaceutical carrier; and, ]
0.9999871	741	[ a plurality of tissue layers, the wound being treated by a surgical instrument comprising: ]	[ An apparatus for treating a wound in a patient, said wound comprising a first surface of the wound, a second surface of the wound, and ]
0.9995974	742	[ a cutting blade having a first end and a second end and having a cutting surface, the blade having a first cutting edge, the first cutting edge having an outer edge, an inner edge, a plurality of first and second edges, and ]	[ a plurality of tissue layers, the wound being treated by a surgical instrument comprising: ]
0.9999919	743	[ an inner surface extending between the first and second cutting edges; and ]	[ a cutting blade having a first end and a second end and having a cutting surface, the blade having a first cutting edge, the first cutting edge having an outer edge, an inner edge, a plurality of first and second edges, and ]
0.99968374	744	[ at least one tissue layer comprising a tissue, the at least one tissue layer having a first outer surface, a second inner surface, and ]	[ an inner surface extending between the first and second cutting edges; and ]
0.9999919	745	[ a plurality of second and third surfaces, each of which is adjacent to the outer surface of the tissue, the plurality of second and third surfaces including at least one of a first surface and a second surface, the first and second surfaces being substantially parallel to one another, the at least one tissue layer being disposed within the tissue layer. ]	[ at least one tissue layer comprising a tissue, the at least one tissue layer having a first outer surface, a second inner surface, and ]
0.97503847	746	[ a first electrode configured to receive an electrical current; ]	[ A device for the treatment of a patient, comprising: ]
0.99768996	747	[ an electrode support configured to support a first portion of the electrode and a second portion of the electrode; and ]	[ a first electrode configured to receive an electrical current; ]
0.9999883	748	[ an electrode guide configured to guide an electrode portion of the electrode support toward a patient, ]	[ an electrode support configured to support a first portion of the electrode and a second portion of the electrode; and ]
0.9999789	749	[ wherein the electrode support is configured to be disposed in a first position relative to the electrode support and to be disposed in a second position relative to the first portion of the electrode, the first position including a first position of the electrode support and a second position of the electrode support, the first position being substantially perpendicular to the second position, the electrode support being disposed in the first position when the device is in the first position and being disposed in the second position when the device is in the second position. ]	[ an electrode guide configured to guide an electrode portion of the electrode support toward a patient, ]
0.9999908	750	[ (i) the epitope selected from the group consisting of SEQ ID NO: ]	[ A method of treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an effective amount of an antibody that specifically binds to an epitope of a protein selected from the group consisting of: ]
0.9994574	751	[ 2, SEQ ID NO: ]	[ (i) the epitope selected from the group consisting of SEQ ID NO: ]
0.99998915	752	[ 3, SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.9999895	753	[ 4, SEQ ID NO: ]	[ 3, SEQ ID NO: ]
0.99998796	754	[ 5, SEQ ID NO: ]	[ 4, SEQ ID NO: ]
0.99998975	755	[ 6, SEQ ID NO: ]	[ 5, SEQ ID NO: ]
0.99950707	756	[ 7, and ]	[ 6, SEQ ID NO: ]
0.99945503	757	[ SEQ ID NO: ]	[ 7, and ]
0.0007170417	758	[ 8, ]	[ SEQ ID NO: ]
0.0031098833	759	[ (ii) an antigen-binding domain, and ]	[ 8, ]
0.99990857	760	[ (iii) a nucleic acid sequence that specifically binds to said epitope. ]	[ (ii) an antigen-binding domain, and ]
0.99977523	761	[ providing a sample; ]	[ A method for determining a concentration of a compound in a sample, comprising: ]
0.996579	762	[ providing a solution of a compound having a molecular weight of about 2, ]	[ providing a sample; ]
0.997436	763	[ 000 to about 4, ]	[ providing a solution of a compound having a molecular weight of about 2, ]
0.9934556	764	[ 000 &#x3bc; ]	[ 000 to about 4, ]
0.9953916	765	[ m; ]	[ 000 &#x3bc; ]
0.9690832	766	[ (c) adding a first solvent to the sample; ]	[ m; ]
0.99999154	767	[ (d) adding a second solvent; ]	[ (c) adding a first solvent to the sample; ]
0.99997735	768	[ (e) mixing the solution of the compound with the first solvent and the second solvent; ]	[ (d) adding a second solvent; ]
0.9999893	769	[ (f) separating the first solvent from the second solvent by a solvent separation process; ]	[ (e) mixing the solution of the compound with the first solvent and the second solvent; ]
0.99999225	770	[ (g) separating the first solvent from the second solvent by a solvent separation process, wherein the first solvent has a molecular weight of about 2, ]	[ (f) separating the first solvent from the second solvent by a solvent separation process; ]
0.998142	771	[ 000 to about 4, ]	[ (g) separating the first solvent from the second solvent by a solvent separation process, wherein the first solvent has a molecular weight of about 2, ]
0.9934556	772	[ 000 &#x3bc; ]	[ 000 to about 4, ]
0.99469405	773	[ m; and ]	[ 000 &#x3bc; ]
0.7680691	774	[ (h) mixing a first solvent and a second solvent to obtain a solution of at least one compound having a molecular weight of about 2, ]	[ m; and ]
0.9927443	775	[ 000 and 4, ]	[ (h) mixing a first solvent and a second solvent to obtain a solution of at least one compound having a molecular weight of about 2, ]
0.99889684	776	[ 000 &#x3bc; ]	[ 000 and 4, ]
0.9968364	777	[ m. ]	[ 000 &#x3bc; ]
0.99998736	778	[ a) providing the polymer to be biodegradable, wherein the polymer comprises a first polymer and a second polymer; ]	[ A method for producing a biodegradable composition comprising a biodegradable polymer, the method comprising: ]
0.9999366	779	[ b) contacting said first polymer and said second polymer with a solvent to form a polymer mixture; ]	[ a) providing the polymer to be biodegradable, wherein the polymer comprises a first polymer and a second polymer; ]
0.99999213	780	[ c) contacting said first polymer with a biodegradable polymer to form a biodegradable polymer; and ]	[ b) contacting said first polymer and said second polymer with a solvent to form a polymer mixture; ]
0.99998736	781	[ d) removing the solvent from said polymer mixture, wherein said solvent is selected from the group consisting of a water soluble polymer and an alkali metal, wherein the biodegradable polymer is selected from the group consisting of a polymer having a molecular weight of from 1 to 100, and ]	[ c) contacting said first polymer with a biodegradable polymer to form a biodegradable polymer; and ]
0.99999106	782	[ wherein said biodegradable polymer is selected from the group consisting of a polymer having a molecular weight of less than 100. ]	[ d) removing the solvent from said polymer mixture, wherein said solvent is selected from the group consisting of a water soluble polymer and an alkali metal, wherein the biodegradable polymer is selected from the group consisting of a polymer having a molecular weight of from 1 to 100, and ]
0.0006360233	783	[ a first implantable device having a first implantable device housing and a first device, the first device having a first implantable device housing and a first device, the first device having a first implantable device housing and a first device, the first device having a first implantable device housing and a first device, the first device having a first implantable device housing and a first device; ]	[ A system for treating an eye comprising: ]
0.99999225	784	[ a second implantable device having a second device housing and a second device, the second device having a second device housing and a second device, the second device having a second device housing and a second device, the second device having a second device housing and a second device, wherein the first device is configured to be implanted into the eye; and ]	[ a first implantable device having a first implantable device housing and a first device, the first device having a first implantable device housing and a first device, the first device having a first implantable device housing and a first device, the first device having a first implantable device housing and a first device, the first device having a first implantable device housing and a first device; ]
0.999987	785	[ a first implantation system configured to be implanted into the eye, wherein the first implantation system is configured to be implanted into the eye and wherein the first implantation system comprises a first implantable device housing and a first implantable device, wherein the first implantable device housing and the first device are configured to be implanted into the eye, wherein the first implantation system further comprises a first implantable device housing and a first implantable device; ]	[ a second implantable device having a second device housing and a second device, the second device having a second device housing and a second device, the second device having a second device housing and a second device, the second device having a second device housing and a second device, wherein the first device is configured to be implanted into the eye; and ]
0.9999913	786	[ wherein the second device is configured to be implanted into a patient's eye; ]	[ a first implantation system configured to be implanted into the eye, wherein the first implantation system is configured to be implanted into the eye and wherein the first implantation system comprises a first implantable device housing and a first implantable device, wherein the first implantable device housing and the first device are configured to be implanted into the eye, wherein the first implantation system further comprises a first implantable device housing and a first implantable device; ]
0.99999213	787	[ wherein the first implantable device housing and the second device are configured to be implanted in the patient's eye; and ]	[ wherein the second device is configured to be implanted into a patient's eye; ]
0.99999225	788	[ wherein the first device and the second device are configured to be implanted into the patient's eye. ]	[ wherein the first implantable device housing and the second device are configured to be implanted in the patient's eye; and ]
0.9999465	789	[ wherein the patient is a subject with a disease characterized by a high level of IL-4 expression. ]	[ A method of treating a patient with an inflammatory disease comprising administering an antibody to the patient that specifically binds to the CDR5-5 of the human IL-4 receptor, wherein the antibody is selected from the group consisting of a human IL-4 receptor antagonist and a human IL-4 receptor antagonist with a CDR5-5 binding activity that is greater than 50% by weight of that of the CDR5-5 of the human IL-4 receptor, and ]
0.99937856	790	[ administering a therapeutically effective amount of a pharmaceutically acceptable salt or salt thereof, wherein the salt or salt is administered in the form of an oral dosage form, and ]	[ A method for treating a patient having a tumor comprising the steps of: ]
0.99964464	791	[ wherein the pharmaceutically acceptable salt or salt is a pharmaceutically acceptable salt or salt thereof, a salt of a salt of a pharmaceutically acceptable salt or salt thereof, a salt of a salt of a pharmaceutically acceptable salt or salt thereof, an salt of a pharmaceutically acceptable salt or salt thereof, a salt of a salt of a pharmaceutically acceptable salt or salt thereof, or a salt of a salt of a pharmaceutically acceptable salt or salt thereof. ]	[ administering a therapeutically effective amount of a pharmaceutically acceptable salt or salt thereof, wherein the salt or salt is administered in the form of an oral dosage form, and ]
0.9899961	792	[ a housing; ]	[ An implantable medical device comprising: ]
0.013503395	793	[ a first electrode configured to couple to a first portion of a patient's body, the first electrode comprising a first electrode layer and a second electrode layer, wherein the first electrode is configured to couple to the first portion of the patient's body; and ]	[ a housing; ]
0.99999225	794	[ a second electrode, wherein the second electrode is configured to couple to a second portion of the patient's body, the second electrode layer being different in shape from the first electrode layer and the second electrode layer comprising an outer surface, ]	[ a first electrode configured to couple to a first portion of a patient's body, the first electrode comprising a first electrode layer and a second electrode layer, wherein the first electrode is configured to couple to the first portion of the patient's body; and ]
0.99999225	795	[ wherein the first electrode is configured to couple to an area of the patient's body that is not adjacent a second electrode layer, the area of the patient's body being adjacent to the second electrode layer. ]	[ a second electrode, wherein the second electrode is configured to couple to a second portion of the patient's body, the second electrode layer being different in shape from the first electrode layer and the second electrode layer comprising an outer surface, ]
0.9905455	796	[ a body; and, ]	[ An implantable medical device comprising: ]
0.0021991157	797	[ an implantable medical device controller configured to: ]	[ a body; and, ]
0.99985564	798	[ detect a condition of a patient; ]	[ an implantable medical device controller configured to: ]
0.99999106	799	[ determine whether the condition of the patient is in the range of normal to abnormal, wherein a condition of a patient that does not meet one or more conditions of the normal to abnormal condition of the patient is not abnormal; and ]	[ detect a condition of a patient; ]
0.99998975	800	[ determine a treatment for the abnormal condition based on the detected condition. ]	[ determine whether the condition of the patient is in the range of normal to abnormal, wherein a condition of a patient that does not meet one or more conditions of the normal to abnormal condition of the patient is not abnormal; and ]
0.9993001	801	[ R1 and R2 are independently selected from the group consisting of hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy, C1 to C6 alkoxyalkyl or C1 to C6 alkoxyalkylalkyl; ]	[ A method of treating a patient having a disease or condition, comprising administering to said patient in need thereof an effective amount of a composition comprising a compound of formula I, wherein: ]
0.9999914	802	[ X and Z are independently selected from the group consisting of hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy, C1 to C6 alkoxyalkyl or C1 to C6 alkoxyalkylalkyl; ]	[ R1 and R2 are independently selected from the group consisting of hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy, C1 to C6 alkoxyalkyl or C1 to C6 alkoxyalkylalkyl; ]
0.9997155	803	[ R1 is a C1-6 alkyl or C1 to C6 alkyl; ]	[ X and Z are independently selected from the group consisting of hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy, C1 to C6 alkoxyalkyl or C1 to C6 alkoxyalkylalkyl; ]
0.9999907	804	[ R2 is a C1-6 alkyl or C1 to C6 alkyl; ]	[ R1 is a C1-6 alkyl or C1 to C6 alkyl; ]
0.9980252	805	[ Y is independently selected from the group consisting of hydrogen, C1 to C6 alkoxy, C1 to C6 alkoxyalkyl, C1 to C6 alkoxyalkylalkyl or C1 to C6 alkoxyalkylalkyl; and ]	[ R2 is a C1-6 alkyl or C1 to C6 alkyl; ]
0.9999908	806	[ X and Z are each independently selected from the group consisting of hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy, and ]	[ Y is independently selected from the group consisting of hydrogen, C1 to C6 alkoxy, C1 to C6 alkoxyalkyl, C1 to C6 alkoxyalkylalkyl or C1 to C6 alkoxyalkylalkyl; and ]
0.9999821	807	[ C1 to C6 alkoxyalkyl. ]	[ X and Z are each independently selected from the group consisting of hydrogen, C1 to C6 alkyl, C1 to C6 alkoxy, and ]
0.9978509	808	[ receiving, by an implantable medical device, a first image from a medical image sensor, the medical image sensor having an image sensor array and a first image sensor; ]	[ A method for determining a position of a patient, the method comprising: ]
0.99999225	809	[ receiving, by a processor, a second image from the medical image sensor, the second image having a second image sensor array and an image sensor array; ]	[ receiving, by an implantable medical device, a first image from a medical image sensor, the medical image sensor having an image sensor array and a first image sensor; ]
0.9999906	810	[ determining, by the processor, a first position of the patient based on the first image; ]	[ receiving, by a processor, a second image from the medical image sensor, the second image having a second image sensor array and an image sensor array; ]
0.9999924	811	[ determining, by the processor, a second position of the patient based on the second image; ]	[ determining, by the processor, a first position of the patient based on the first image; ]
0.99999213	812	[ determining, by the processor, a distance between the patient and the first position; ]	[ determining, by the processor, a second position of the patient based on the second image; ]
0.9999924	813	[ determining, by the processor, a distance between the patient and the second position; ]	[ determining, by the processor, a distance between the patient and the first position; ]
0.9999918	814	[ determining, by the processor, a distance between the first position and the second position; and ]	[ determining, by the processor, a distance between the patient and the second position; ]
0.99999046	815	[ displaying the first position and the second position on a display device. ]	[ determining, by the processor, a distance between the first position and the second position; and ]
0.0021595436	816	[ a) a first dispensing container; and ]	[ An apparatus for providing a patient with a therapeutic dose of a pharmaceutical composition, the apparatus comprising: ]
0.99999225	817	[ b) a second dispensing container; ]	[ a) a first dispensing container; and ]
0.9998716	818	[ c) a first delivery device configured to be disposed in a first patient compartment of a first delivery device; ]	[ b) a second dispensing container; ]
0.99999225	819	[ d) a second delivery device configured to be disposed in a second patient compartment of the first delivery device; ]	[ c) a first delivery device configured to be disposed in a first patient compartment of a first delivery device; ]
0.99999225	820	[ e) a first delivery device control unit configured to receive a first delivery device control command to control a first delivery device of the first delivery device; ]	[ d) a second delivery device configured to be disposed in a second patient compartment of the first delivery device; ]
0.99999225	821	[ f) a second delivery device control unit configured to receive a second delivery device control command to control a second delivery device of the first delivery device; ]	[ e) a first delivery device control unit configured to receive a first delivery device control command to control a first delivery device of the first delivery device; ]
0.99999225	822	[ g) a first delivery device control unit configured to receive a first delivery device control command to control a first delivery device of the first delivery device; and ]	[ f) a second delivery device control unit configured to receive a second delivery device control command to control a second delivery device of the first delivery device; ]
0.99999225	823	[ h) a second delivery device control unit configured to receive a second delivery device control command to control a second delivery device of the second delivery device. ]	[ g) a first delivery device control unit configured to receive a first delivery device control command to control a first delivery device of the first delivery device; and ]
0.999992	824	[ 1, wherein the HBD domain comprises the amino acid sequence of SEQ ID NO: ]	[ A method for treating an autoimmune disorder comprising administering to a subject having an autoimmune disorder a therapeutically effective amount of an antibody that binds to a humanized antigen-binding domain of a humanized antigen-binding protein (HAP), wherein the HAP comprises a humanized antigen-binding protein (HAP) domain and a humanized antigen binding domain (HBD) domain, wherein the HAP domain comprises the amino acid sequence of SEQ ID NO: ]
0.99999225	825	[ 2, wherein the HBD domain is selected from the group consisting of the amino acid sequence of SEQ ID NO: ]	[ 1, wherein the HBD domain comprises the amino acid sequence of SEQ ID NO: ]
0.9995535	826	[ 1, SEQ ID NO: ]	[ 2, wherein the HBD domain is selected from the group consisting of the amino acid sequence of SEQ ID NO: ]
0.99998844	827	[ 2, SEQ ID NO: ]	[ 1, SEQ ID NO: ]
0.99998915	828	[ 3, SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.9999895	829	[ 4, SEQ ID NO: ]	[ 3, SEQ ID NO: ]
0.99998796	830	[ 5, SEQ ID NO: ]	[ 4, SEQ ID NO: ]
0.99998975	831	[ 6, SEQ ID NO: ]	[ 5, SEQ ID NO: ]
0.9999857	832	[ 7, SEQ ID NO: ]	[ 6, SEQ ID NO: ]
0.99998665	833	[ 8, SEQ ID NO: ]	[ 7, SEQ ID NO: ]
0.9999883	834	[ 9, SEQ ID NO: ]	[ 8, SEQ ID NO: ]
0.99998844	835	[ 10, SEQ ID NO: ]	[ 9, SEQ ID NO: ]
0.99999034	836	[ 11, SEQ ID NO: ]	[ 10, SEQ ID NO: ]
0.9999887	837	[ 12, SEQ ID NO: ]	[ 11, SEQ ID NO: ]
0.9999808	838	[ 13, or SEQ ID NO: ]	[ 12, SEQ ID NO: ]
0.9998049	839	[ 14. ]	[ 13, or SEQ ID NO: ]
0.0020139704	840	[ administering to the patient a therapeutically effective amount of at least one compound selected from the group consisting of a pharmaceutically acceptable salt of at least one compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound, ]	[ A method of treating a patient with an autoimmune disorder in which the immune system of the patient is impaired or defective in causing the autoimmune disorder in a patient, the method comprising: ]
0.0045713806	841	[ wherein the at least one compound comprises a polypeptide comprising the amino acid sequence of SEQ ID NO: 1. ]	[ administering to the patient a therapeutically effective amount of at least one compound selected from the group consisting of a pharmaceutically acceptable salt of at least one compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound, ]
0.9999385	842	[ administering to the patient a therapeutically effective amount of a therapeutically acceptable composition, comprising: ]	[ A method of treating a patient with an inflammatory bowel disease, the method comprising: ]
0.99637514	843	[ a first agent, wherein the first agent comprises a first agent selected from the group consisting of a peptide and a peptide having a peptide sequence that is at least 95% identical to SEQ ID NO: ]	[ administering to the patient a therapeutically effective amount of a therapeutically acceptable composition, comprising: ]
0.99375254	844	[ 1; and ]	[ a first agent, wherein the first agent comprises a first agent selected from the group consisting of a peptide and a peptide having a peptide sequence that is at least 95% identical to SEQ ID NO: ]
0.9960084	845	[ a second agent, wherein the second agent comprises a second agent selected from the group consisting of a polypeptide, a peptide having a peptide sequence that is at least 95% identical to SEQ ID NO: ]	[ 1; and ]
0.99066204	846	[ 1, and ]	[ a second agent, wherein the second agent comprises a second agent selected from the group consisting of a polypeptide, a peptide having a peptide sequence that is at least 95% identical to SEQ ID NO: ]
0.0006005793	847	[ a pharmaceutically acceptable carrier, wherein the first agent and the second agent are administered to the patient in a dose effective to treat the inflammatory bowel disease; ]	[ 1, and ]
0.9999472	848	[ administering to the patient at least one other agent; and, ]	[ a pharmaceutically acceptable carrier, wherein the first agent and the second agent are administered to the patient in a dose effective to treat the inflammatory bowel disease; ]
0.9999918	849	[ administering to the patient at least one other agent selected from a group consisting of: a pharmaceutically acceptable salt of a polypeptide, a pharmaceutically acceptable salt of a peptide having a peptide sequence that is at least 95% identical to SEQ ID NO: ]	[ administering to the patient at least one other agent; and, ]
0.99999154	850	[ 1 and a pharmaceutically acceptable salt, wherein the at least one agent is administered to the patient. ]	[ administering to the patient at least one other agent selected from a group consisting of: a pharmaceutically acceptable salt of a polypeptide, a pharmaceutically acceptable salt of a peptide having a peptide sequence that is at least 95% identical to SEQ ID NO: ]
0.9999914	851	[ 2, wherein said antibody or antigen-binding fragment has the amino acid sequence of SEQ ID NO: ]	[ A method of treating a patient suffering from an inflammatory bowel disease, comprising administering an effective amount of an antibody or antigen-binding fragment thereof to the patient, wherein the antibody or antigen-binding fragment comprises a nucleic acid sequence encoding an anti-inflammatory peptide comprising the amino acid sequence of SEQ ID NO: ]
0.9983564	852	[ 2. ]	[ 2, wherein said antibody or antigen-binding fragment has the amino acid sequence of SEQ ID NO: ]
0.99999225	853	[ a) an antibody that binds to a CDR1 region of an antigen-binding fragment of the human CD8+ T cell receptor, and ]	[ A method for treating a patient with a cancer comprising administering to the patient an effective amount of an antibody or antigen binding fragment thereof that specifically binds to a human CD8+ T cell receptor, wherein the human CD8+ T cell receptor consists of a T cell receptor domain comprising a CDR1 region, CDR2 region and CDR3 region, wherein the antibody or antigen binding fragment is a fragment of an antibody or antigen binding fragment that binds to the human CD8+ T cell receptor, wherein the antibody or antigen binding fragment is selected from the group consisting of: ]
0.99999225	854	[ b) a fragment of an antibody or antigen binding fragment that binds to the human CD8+ T cell receptor that comprises a fragment of the antigen-binding fragment that is a fragment of the CDR1 region of the antigen-binding fragment of the human CD8+ T cell receptor. ]	[ a) an antibody that binds to a CDR1 region of an antigen-binding fragment of the human CD8+ T cell receptor, and ]
0.9999908	855	[ acquiring an image of the object in the imaging system; ]	[ A method for producing a non-invasive image of an object in an imaging system, comprising: ]
0.99999213	856	[ determining a position of the object in the imaging system; ]	[ acquiring an image of the object in the imaging system; ]
0.99999225	857	[ identifying a plurality of regions in the imaging system that correspond to the identified position of the object in the imaging system; ]	[ determining a position of the object in the imaging system; ]
0.9999919	858	[ generating a plurality of image signals from the image of the object in the imaging system; ]	[ identifying a plurality of regions in the imaging system that correspond to the identified position of the object in the imaging system; ]
0.99999225	859	[ identifying a plurality of regions in the image signals, each region corresponding to a different region in the imaging system; ]	[ generating a plurality of image signals from the image of the object in the imaging system; ]
0.99999225	860	[ determining a plurality of spatial coordinates for each region in the imaging system based on the identified spatial coordinates; ]	[ identifying a plurality of regions in the image signals, each region corresponding to a different region in the imaging system; ]
0.99999166	861	[ identifying a plurality of image features in the image of the object in the imaging system based on the identified spatial features; and ]	[ determining a plurality of spatial coordinates for each region in the imaging system based on the identified spatial coordinates; ]
0.99999225	862	[ generating a plurality of image features from the image of the object in the imaging system based at least in part on the identified spatial features and the identified image feature. ]	[ identifying a plurality of image features in the image of the object in the imaging system based on the identified spatial features; and ]
0.9999919	863	[ providing a first sample of a compound having an active ingredient; ]	[ A method for producing a compound having an effective amount of an active ingredient, comprising: ]
0.99999225	864	[ contacting a second sample of a compound having an active ingredient with a first compound selected from the group consisting of an amino acid sequence of SEQ ID NO: ]	[ providing a first sample of a compound having an active ingredient; ]
0.0026684043	865	[ 2 and a pharmaceutically acceptable carrier; ]	[ contacting a second sample of a compound having an active ingredient with a first compound selected from the group consisting of an amino acid sequence of SEQ ID NO: ]
0.9999782	866	[ contacting a second sample of the compound having an active ingredient with a second compound selected from the group consisting of an amino acid sequence of SEQ ID NO: 3 and a pharmaceutically acceptable carrier; and ]	[ 2 and a pharmaceutically acceptable carrier; ]
0.9999913	867	[ producing a compound having an effective amount of the active ingredient, the compound being selected from the group consisting of a pharmaceutically acceptable salt, a pharmaceutically acceptable salt-containing salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable salt-containing carrier, a pharmaceutically acceptable salt-containing salt, and ]	[ contacting a second sample of the compound having an active ingredient with a second compound selected from the group consisting of an amino acid sequence of SEQ ID NO: 3 and a pharmaceutically acceptable carrier; and ]
0.99995756	868	[ a pharmaceutically acceptable carrier-containing salt. ]	[ producing a compound having an effective amount of the active ingredient, the compound being selected from the group consisting of a pharmaceutically acceptable salt, a pharmaceutically acceptable salt-containing salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable salt-containing carrier, a pharmaceutically acceptable salt-containing salt, and ]
0.99999166	869	[ 2, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: ]	[ A method of treating a patient suffering from a chronic disease, comprising administering to the patient a therapeutically effective amount of an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.99996436	870	[ 3 or the amino acid sequence of SEQ ID NO: ]	[ 2, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: ]
0.99956816	871	[ 4. ]	[ 3 or the amino acid sequence of SEQ ID NO: ]
0.0019401523	872	[ a) providing an isolated protein; ]	[ A method for producing a composition comprising: ]
0.99989986	873	[ b) contacting the protein with an effective amount of a compound that inhibits the activity of the protein, the compound being selected from the group consisting of a compound selected from the group consisting of: ]	[ a) providing an isolated protein; ]
0.9903121	874	[ (i) the polypeptide of SEQ ID NO: ]	[ b) contacting the protein with an effective amount of a compound that inhibits the activity of the protein, the compound being selected from the group consisting of a compound selected from the group consisting of: ]
0.9854375	875	[ 1, and ]	[ (i) the polypeptide of SEQ ID NO: ]
0.9867742	876	[ (ii) an amino acid sequence of SEQ ID NO: ]	[ 1, and ]
0.99401665	877	[ 1; ]	[ (ii) an amino acid sequence of SEQ ID NO: ]
0.9915673	878	[ c) determining the activity of the protein in a test subject; and ]	[ 1; ]
0.99999225	879	[ d) determining the activity of the protein in a control subject; and ]	[ c) determining the activity of the protein in a test subject; and ]
0.9938692	880	[ e) providing the compound to produce the composition. ]	[ d) determining the activity of the protein in a control subject; and ]
0.011389047	881	[ providing a first device having an external surface, the device comprising: ]	[ A method of treating a patient, comprising: ]
0.9991449	882	[ a first surface; ]	[ providing a first device having an external surface, the device comprising: ]
0.9289163	883	[ a first electrode; ]	[ a first surface; ]
0.9999759	884	[ a second electrode; ]	[ a first electrode; ]
0.99992657	885	[ a first contact portion disposed on the first electrode; ]	[ a second electrode; ]
0.99999213	886	[ a second contact portion disposed on the second electrode; ]	[ a first contact portion disposed on the first electrode; ]
0.999992	887	[ a first electrode contact portion disposed on the first electrode; and ]	[ a second contact portion disposed on the second electrode; ]
0.999992	888	[ a second electrode contact portion disposed on the second electrode; ]	[ a first electrode contact portion disposed on the first electrode; and ]
0.0032788226	889	[ providing a second device having an externally surface, the device comprising: ]	[ a second electrode contact portion disposed on the second electrode; ]
0.99770856	890	[ a first surface; and ]	[ providing a second device having an externally surface, the device comprising: ]
0.9975827	891	[ a second electrode disposed on the external surface of the first device; and ]	[ a first surface; and ]
0.9999906	892	[ providing a third device having an externally surface, the device comprising: ]	[ a second electrode disposed on the external surface of the first device; and ]
0.99999106	893	[ a second electrode disposed on the externally surface of the third device, the second electrode having an electrode surface that is different from the first electrode; and ]	[ providing a third device having an externally surface, the device comprising: ]
0.99999213	894	[ a second contact portion disposed on the externally surface of the third device, the second contact portion having a first electrode contact portion that contacts a first contact portion on the first electrode, a second electrode contact portion that contacts a second contact portion on the second electrode, and ]	[ a second electrode disposed on the externally surface of the third device, the second electrode having an electrode surface that is different from the first electrode; and ]
0.99999225	895	[ a third contact portion that contacts a third contact portion on the second electrode; and ]	[ a second contact portion disposed on the externally surface of the third device, the second contact portion having a first electrode contact portion that contacts a first contact portion on the first electrode, a second electrode contact portion that contacts a second contact portion on the second electrode, and ]
0.9964888	896	[ providing a fourth electrode disposed on the externally surface of the fourth device, the fourth electrode having an electrode surface that is different from the first electrode, ]	[ a third contact portion that contacts a third contact portion on the second electrode; and ]
0.005177239	897	[ wherein the first contact portion is located on the second contact portion and the second contact portion is located on the third contact portion; and ]	[ providing a fourth electrode disposed on the externally surface of the fourth device, the fourth electrode having an electrode surface that is different from the first electrode, ]
0.999992	898	[ wherein the third contact portion is located on the fourth electrode. ]	[ wherein the first contact portion is located on the second contact portion and the second contact portion is located on the third contact portion; and ]
0.9894757	899	[ a housing; ]	[ An implantable medical device, comprising: ]
0.99921715	900	[ a plurality of electrodes arranged within the housing and configured to be implanted into a subject, the electrodes including: ]	[ a housing; ]
0.9999893	901	[ a first electrode configured to be implanted into a tissue of the subject and configured to be electrically coupled to a first electrical power source; and ]	[ a plurality of electrodes arranged within the housing and configured to be implanted into a subject, the electrodes including: ]
0.9999924	902	[ a second electrode configured to be implanted into a tissue of the subject and configured to be electrically coupled to a second electrical power source; ]	[ a first electrode configured to be implanted into a tissue of the subject and configured to be electrically coupled to a first electrical power source; and ]
0.99989045	903	[ a plurality of transistors arranged within the housing and configured to be electrically coupled to the first and second electrodes; and ]	[ a second electrode configured to be implanted into a tissue of the subject and configured to be electrically coupled to a second electrical power source; ]
0.99994826	904	[ a control circuit configured to control the plurality of transistors to be electrically coupled to the first and second electrical power sources, ]	[ a plurality of transistors arranged within the housing and configured to be electrically coupled to the first and second electrodes; and ]
0.9996623	905	[ wherein the control circuit is configured to: ]	[ a control circuit configured to control the plurality of transistors to be electrically coupled to the first and second electrical power sources, ]
0.9990426	906	[ receive electrical data from at least one of the first and second electrical power sources; and ]	[ wherein the control circuit is configured to: ]
0.99995816	907	[ control the plurality of transistors to be electrically coupled to the first and second electric sources to produce a first electrical signal and a second electrical signal. ]	[ receive electrical data from at least one of the first and second electrical power sources; and ]
0.99915135	908	[ an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an antigen of a humanized antigen-binding protein (HAP) comprising the amino acid sequence set forth in SEQ ID NO: ]	[ A method for treating an autoimmune disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising: ]
0.99448615	909	[ 1; and ]	[ an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an antigen of a humanized antigen-binding protein (HAP) comprising the amino acid sequence set forth in SEQ ID NO: ]
0.00016917297	910	[ a pharmaceutically acceptable carrier; ]	[ 1; and ]
0.9980781	911	[ wherein the antibody or antigen-binding fragment is an antibody or antigen binding fragment that is a humanized antibody. ]	[ a pharmaceutically acceptable carrier; ]
0.99943286	912	[ (a) an amino acid sequence having at least 95% sequence identity to a nucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12 and/or SEQ ID NO: 14; and ]	[ An isolated nucleic acid molecule encoding a polypeptide comprising: ]
0.99999166	913	[ (b) a nucleic acid sequence having at least 95% sequence identity to the nucleotide sequence selected from SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and/or SEQ ID NO: 14. ]	[ (a) an amino acid sequence having at least 95% sequence identity to a nucleotide sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12 and/or SEQ ID NO: 14; and ]
0.9976852	914	[ providing at least one pharmaceutically acceptable salt of a compound selected from the group consisting of an anti-cancer agent, a chemotherapeutic agent, an immunogenic agent, an anti-inflammatory agent, a chemotherapeutic agent, and ]	[ A method of producing a pharmaceutical composition comprising: ]
0.9956346	915	[ a pharmaceutically acceptable carrier; and ]	[ providing at least one pharmaceutically acceptable salt of a compound selected from the group consisting of an anti-cancer agent, a chemotherapeutic agent, an immunogenic agent, an anti-inflammatory agent, a chemotherapeutic agent, and ]
0.9995233	916	[ contacting the at least one pharmaceutically acceptable salt with a pharmaceutical composition. ]	[ a pharmaceutically acceptable carrier; and ]
0.9892278	917	[ a housing; and ]	[ A system for providing an implantable medical device, comprising: ]
0.98783445	918	[ a first and second housing side walls, wherein the first and second housing side walls define a first and second longitudinal axis, respectively, and wherein the first and second housing side walls define a first and second longitudinal axis, respectively; ]	[ a housing; and ]
0.9999896	919	[ wherein the first and second longitudinal axis defines a center of gravity of the system; and ]	[ a first and second housing side walls, wherein the first and second housing side walls define a first and second longitudinal axis, respectively, and wherein the first and second housing side walls define a first and second longitudinal axis, respectively; ]
0.9999919	920	[ wherein the first and second longitudinal axis defines a first and second axis of rotation, respectively, of the system, wherein the first longitudinal axis is in the first plane and the second longitudinal axis is in the second plane; wherein the first longitudinal axis is perpendicular to the first plane; and ]	[ wherein the first and second longitudinal axis defines a center of gravity of the system; and ]
0.99999154	921	[ wherein the second longitudinal axis is parallel to the first longitudinal axis. ]	[ wherein the first and second longitudinal axis defines a first and second axis of rotation, respectively, of the system, wherein the first longitudinal axis is in the first plane and the second longitudinal axis is in the second plane; wherein the first longitudinal axis is perpendicular to the first plane; and ]
0.9975382	922	[ providing a pharmaceutically acceptable carrier; and ]	[ A method of producing a pharmaceutical composition, the method comprising: ]
0.99996185	923	[ introducing the carrier into the patient's blood, wherein the carrier comprises: ]	[ providing a pharmaceutically acceptable carrier; and ]
0.91730565	924	[ a) a first polymer; ]	[ introducing the carrier into the patient's blood, wherein the carrier comprises: ]
0.9999912	925	[ b) a second polymer; and ]	[ a) a first polymer; ]
0.9999918	926	[ c) a third polymer; ]	[ b) a second polymer; and ]
0.99999166	927	[ wherein the third polymer is a polymer having a molecular mass in the range of about 1, ]	[ c) a third polymer; ]
0.99864346	928	[ 000 to about 1, ]	[ wherein the third polymer is a polymer having a molecular mass in the range of about 1, ]
0.048930287	929	[ 10, ]	[ 000 to about 1, ]
0.9824253	930	[ 000, and ]	[ 10, ]
0.9854277	931	[ wherein the first polymer and the third polymer are present in the carrier in the presence of the pharmaceutical composition. ]	[ 000, and ]
0.006873048	932	[ (a) an antibody that binds to a protein of a human T-cell receptor, and ]	[ A method of treating a patient with an inflammatory disorder, the method comprising administering to the patient an amount of a compound selected from the group consisting of: ]
0.9999889	933	[ that specifically binds to a human T-cell receptor, wherein the human T-cell receptor comprises a T-cell-derived antigen, and ]	[ (a) an antibody that binds to a protein of a human T-cell receptor, and ]
0.9998472	934	[ wherein the antibody is a humanized antibody; and ]	[ that specifically binds to a human T-cell receptor, wherein the human T-cell receptor comprises a T-cell-derived antigen, and ]
0.99998677	935	[ (b) a compound that binds to the humanized antibody. ]	[ wherein the antibody is a humanized antibody; and ]
0.9967272	936	[ (a) administering a therapeutically effective amount of a therapeutically effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ]	[ A method of treating a disease comprising: ]
0.9989146	937	[ 2 to a subject in need thereof; ]	[ (a) administering a therapeutically effective amount of a therapeutically effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.99985445	938	[ (b) detecting a change in expression of a gene of a disease in the subject in need of the therapy; ]	[ 2 to a subject in need thereof; ]
0.9997832	939	[ (c) administering a therapeutically effective amount of a therapeutically effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ]	[ (b) detecting a change in expression of a gene of a disease in the subject in need of the therapy; ]
0.9995865	940	[ 3 to the subject in need thereof; ]	[ (c) administering a therapeutically effective amount of a therapeutically effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.99985826	941	[ (d) determining whether the subject has the disease; and ]	[ 3 to the subject in need thereof; ]
0.99991	942	[ (e) administering a therapeutically effective amount of a therapeutically effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ]	[ (d) determining whether the subject has the disease; and ]
0.9975625	943	[ 4 to the subject in need thereof if the subject does not have the disease; ]	[ (e) administering a therapeutically effective amount of a therapeutically effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.9952667	944	[ wherein the polypeptide has the amino acid sequence of SEQ ID NO: ]	[ 4 to the subject in need thereof if the subject does not have the disease; ]
0.99973387	945	[ 3, SEQ ID NO: ]	[ wherein the polypeptide has the amino acid sequence of SEQ ID NO: ]
0.9999653	946	[ 4 or SEQ ID NO: ]	[ 3, SEQ ID NO: ]
0.9994137	947	[ 5. ]	[ 4 or SEQ ID NO: ]
0.018976657	948	[ a body portion having a first end portion and a first end portion opposite said first end portion, said first end portion being disposed in a first position; ]	[ An implantable medical device for use in a surgical procedure comprising: ]
0.9999919	949	[ a plurality of electrodes disposed on said first end portion of said body portion, said plurality of electrodes being configured to generate electrical signals; ]	[ a body portion having a first end portion and a first end portion opposite said first end portion, said first end portion being disposed in a first position; ]
0.99999225	950	[ a plurality of conductors disposed on said first end portion of said body portion, said plurality of conductors being configured to conduct electrical power to said plurality of electrodes; ]	[ a plurality of electrodes disposed on said first end portion of said body portion, said plurality of electrodes being configured to generate electrical signals; ]
0.9999919	951	[ a first electrical connector disposed on said plurality of electrodes; and ]	[ a plurality of conductors disposed on said first end portion of said body portion, said plurality of conductors being configured to conduct electrical power to said plurality of electrodes; ]
0.99999166	952	[ a second electrical connector disposed on said plurality of conductors. ]	[ a first electrical connector disposed on said plurality of electrodes; and ]
0.0029947704	953	[ (a) providing an apparatus comprising a body member, the body member having an upper surface, a lower surface and a central axis, wherein the lower surface is substantially flat, the upper surface is substantially flat, and ]	[ A method for treating a subject with a condition that causes the subject to be unable to move, in a body part, in an upright position, the method comprising: ]
0.99999213	954	[ the central axis is substantially parallel to the lower surface; and ]	[ (a) providing an apparatus comprising a body member, the body member having an upper surface, a lower surface and a central axis, wherein the lower surface is substantially flat, the upper surface is substantially flat, and ]
0.99849546	955	[ (b) providing a first treatment element, the first treatment element comprising a first treatment element having a first surface and a first side, wherein the first surface and the first side are substantially flat and the first side of the first treatment element is substantially parallel to a first axis of the body member; ]	[ the central axis is substantially parallel to the lower surface; and ]
0.999992	956	[ (c) providing a second treatment element, the second treatment element comprising an intermediate treatment element having a second surface and a second side, wherein the second surface and the second side of the second treatment element are substantially flat and the second side of the intermediate treatment element is substantially parallel to a second axis of the body member; ]	[ (b) providing a first treatment element, the first treatment element comprising a first treatment element having a first surface and a first side, wherein the first surface and the first side are substantially flat and the first side of the first treatment element is substantially parallel to a first axis of the body member; ]
0.999992	957	[ (d) applying a force to the first treatment element to cause the first side of the first treatment element to move to a first position, and ]	[ (c) providing a second treatment element, the second treatment element comprising an intermediate treatment element having a second surface and a second side, wherein the second surface and the second side of the second treatment element are substantially flat and the second side of the intermediate treatment element is substantially parallel to a second axis of the body member; ]
0.99999225	958	[ applying a force to the first treatment element to cause the second side of the first treatment element to move to a second position; ]	[ (d) applying a force to the first treatment element to cause the first side of the first treatment element to move to a first position, and ]
0.99999225	959	[ (e) applying a force to the intermediate treatment element to cause the first side of the intermediate treatment element to move to a third position; and ]	[ applying a force to the first treatment element to cause the second side of the first treatment element to move to a second position; ]
0.99999225	960	[ (f) applying a force to the second treatment element to cause the second side of the intermediate treatment element to move to a fourth position. ]	[ (e) applying a force to the intermediate treatment element to cause the first side of the intermediate treatment element to move to a third position; and ]
0.99751246	961	[ a) a first implantable medical device having a plurality of electrodes; ]	[ A system for treating an acute inflammatory disorder, comprising: ]
0.99999225	962	[ b) a second implantable medical device having a plurality of electrodes; ]	[ a) a first implantable medical device having a plurality of electrodes; ]
0.99999106	963	[ c) at least one sensor configured for monitoring a first condition of an patient, the at least one sensor being configured for detecting a first signal from the first implantable medical device and the at least one sensor being configured for detecting a second signal from the second implantable medical device; and ]	[ b) a second implantable medical device having a plurality of electrodes; ]
0.9999906	964	[ d) at least one processing device configured for processing the first signal and the second signal to determine a first treatment condition and a second treatment condition, wherein determining the first treatment condition comprises determining that the first condition is a condition of a first patient and that the second condition is a condition of a second patient. ]	[ c) at least one sensor configured for monitoring a first condition of an patient, the at least one sensor being configured for detecting a first signal from the first implantable medical device and the at least one sensor being configured for detecting a second signal from the second implantable medical device; and ]
0.9987826	965	[ a) a pharmaceutically acceptable salt or salt form, and ]	[ A method for treating a patient having a cancer comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of: ]
0.0014872362	966	[ b) an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: ]	[ a) a pharmaceutically acceptable salt or salt form, and ]
0.9973194	967	[ 2. ]	[ b) an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: ]
0.9999777	968	[ 1 or the amino acid sequence of SEQ ID NO: ]	[ A method of treating an autoimmune disorder comprising administering to a patient in need thereof a composition comprising an antibody or fragment thereof which is specifically capable of binding to a protein of an autoimmune disease, wherein the antibody or fragment thereof is selected from the group consisting of the amino acid sequence of SEQ ID NO: ]
0.9997025	969	[ 4, wherein the protein of the autoimmune disease is a humanized monocyte-derived monoclonal antibody or fragment thereof. ]	[ 1 or the amino acid sequence of SEQ ID NO: ]
0.99997854	970	[ wherein said protein is a polypeptide. ]	[ An isolated nucleic acid encoding a protein, wherein said protein comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 1, and ]
0.99922264	971	[ a pharmaceutically acceptable excipient. ]	[ A method of treating a disease or disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound or compound compound combination, comprising a first compound and a second compound, wherein the compound or compound combination comprises a pharmaceutically acceptable carrier, and ]
0.9999372	972	[ wherein the immune cell is an interleukin-1 receptor-1 (IL-1R-1) cell. ]	[ A method for treating an autoimmune disease, comprising administering to a subject in need thereof an effective amount to a target site of an immune cell, wherein the target site is located in a tissue of the target subject, and ]
0.9934164	973	[ a) a first end, a second end and a plurality of first and second projections, wherein the first end is disposed proximate to the second end; ]	[ An implant for use in an eye, comprising: ]
0.9997558	974	[ b) a first electrode, a first electrode portion, a second electrode portion and a plurality of second and third electrodes, wherein the first electrode portion comprises a plurality of first electrodes and the second and third electrodes comprise a plurality of second and third electrodes, wherein the first, second and third electrodes comprise a plurality of electrodes; and ]	[ a) a first end, a second end and a plurality of first and second projections, wherein the first end is disposed proximate to the second end; ]
0.99971217	975	[ c) an outer surface of said implant, wherein said inner surface of said implant comprises a plurality of first and second electrodes. ]	[ b) a first electrode, a first electrode portion, a second electrode portion and a plurality of second and third electrodes, wherein the first electrode portion comprises a plurality of first electrodes and the second and third electrodes comprise a plurality of second and third electrodes, wherein the first, second and third electrodes comprise a plurality of electrodes; and ]
0.9995161	976	[ an implant for insertion into a body, the system comprising a body support and at least one support structure, ]	[ A system for treating a disease comprising: ]
0.9976815	977	[ a first implantable medical device (IMD); and ]	[ an implant for insertion into a body, the system comprising a body support and at least one support structure, ]
0.9999851	978	[ a second implantable medical device (IMD2) adapted to be inserted into the body and having a first implantable medical device (IMD) and an IMD-specific device (IMD2) adapted to be implanted in the IMD, the IMD-specific device (IMD2) having a second implantable medical device (IMD2) and an IMDM-specific device (IMDM2) adapted to be inserted into the IMDM, the second implantable medical device (IMD2) and the second IMD-specific device (IMDM2) being configured to communicate with each other, ]	[ a first implantable medical device (IMD); and ]
0.99999213	979	[ wherein the IMD-specific device (IMD2) is adapted to be implanted in a patient, and ]	[ a second implantable medical device (IMD2) adapted to be inserted into the body and having a first implantable medical device (IMD) and an IMD-specific device (IMD2) adapted to be implanted in the IMD, the IMD-specific device (IMD2) having a second implantable medical device (IMD2) and an IMDM-specific device (IMDM2) adapted to be inserted into the IMDM, the second implantable medical device (IMD2) and the second IMD-specific device (IMDM2) being configured to communicate with each other, ]
0.99999225	980	[ the IMDM-specific device (IMDM2) is adapted to be implanted in a patient. ]	[ wherein the IMD-specific device (IMD2) is adapted to be implanted in a patient, and ]
0.9995235	981	[ a) providing an implant body having a distal end; ]	[ A method of producing an implant comprising the steps of: ]
0.99997234	982	[ b) providing a proximal end of the body, the proximal end of the body being configured to engage a proximal end of a bone; ]	[ a) providing an implant body having a distal end; ]
0.999966	983	[ c) providing a first portion of a bone implant, the first portion of the bone implant comprising a plurality of bone fragments; ]	[ b) providing a proximal end of the body, the proximal end of the body being configured to engage a proximal end of a bone; ]
0.99999106	984	[ d) providing a second portion of the bone implant, the second portion of the bone implant comprising an outer surface of the bone implant, the outer surface of the bone implant being configured to engage a surface of the bone implant, the second portion of the bone implant having a first surface and a second surface opposite the first surface, wherein the first and second surfaces are configured to engage the outer surface of the bone implant; ]	[ c) providing a first portion of a bone implant, the first portion of the bone implant comprising a plurality of bone fragments; ]
0.9999732	985	[ e) providing an implant material having an elastic property, wherein the implant material is configured to be inserted through a bone; ]	[ d) providing a second portion of the bone implant, the second portion of the bone implant comprising an outer surface of the bone implant, the outer surface of the bone implant being configured to engage a surface of the bone implant, the second portion of the bone implant having a first surface and a second surface opposite the first surface, wherein the first and second surfaces are configured to engage the outer surface of the bone implant; ]
0.99999166	986	[ f) providing a first portion of the implant material, and ]	[ e) providing an implant material having an elastic property, wherein the implant material is configured to be inserted through a bone; ]
0.99998796	987	[ a second portion of the implant material, the first and second portions of the implant material being configured to be inserted through a bone; ]	[ f) providing a first portion of the implant material, and ]
0.99999213	988	[ g) inserting the first portion of the implant material through the bone, wherein the implant material is configured to be disposed in a cavity formed in a bone of the implant body; ]	[ a second portion of the implant material, the first and second portions of the implant material being configured to be inserted through a bone; ]
0.99999225	989	[ h) inserting the second portion of the implant material through the cavity; and ]	[ g) inserting the first portion of the implant material through the bone, wherein the implant material is configured to be disposed in a cavity formed in a bone of the implant body; ]
0.99999225	990	[ i) inserting the second portion of the implant material into the cavity. ]	[ h) inserting the second portion of the implant material through the cavity; and ]
0.9999654	991	[ (a) administering an effective amount of an anti-cancer agent to the patient; and ]	[ A method for treating a patient with a cancer, the method comprising: ]
0.99997425	992	[ (b) monitoring the patient for the presence of a tumor in the patient; ]	[ (a) administering an effective amount of an anti-cancer agent to the patient; and ]
0.9999734	993	[ wherein the tumor is selected from the group consisting of a prostate, a breast, a colon, a lung, a bladder, a liver, and ]	[ (b) monitoring the patient for the presence of a tumor in the patient; ]
0.9998983	994	[ a kidney. ]	[ wherein the tumor is selected from the group consisting of a prostate, a breast, a colon, a lung, a bladder, a liver, and ]
0.99993193	995	[ administering to the subject a therapeutically effective amount of a therapeutically effective amount or combination of therapeutically effective amounts or combinations thereof of a pharmaceutically acceptable salt, and ]	[ A method for treating a disease or disorder in the body of a subject in need thereof, comprising: ]
0.99988914	996	[ an effective amount of a pharmaceutically acceptable carrier, wherein the effective amount is effective to treat the disease or disorder. ]	[ administering to the subject a therapeutically effective amount of a therapeutically effective amount or combination of therapeutically effective amounts or combinations thereof of a pharmaceutically acceptable salt, and ]
0.9998385	997	[ a compound of formula (V) or a combination thereof. ]	[ A method of treating a disease or condition in a mammal, said method comprising administering to the mammal a therapeutically effective amount of a compound selected from the group consisting of a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and ]
0.98486626	998	[ a. A is a first amino acid; ]	[ A method of treating a patient having a heart condition comprising administering to a patient in need of a therapy, an effective amount of an isolated polypeptide of the formulawherein: ]
0.99999046	999	[ b. A is a second amino acid, a third amino acid, or a fourth amino acid; ]	[ a. A is a first amino acid; ]
0.9999906	1000	[ c. A and b each have the amino acid sequence of SEQ ID NO: ]	[ b. A is a second amino acid, a third amino acid, or a fourth amino acid; ]
0.99773276	1001	[ 3; ]	[ c. A and b each have the amino acid sequence of SEQ ID NO: ]
0.99858934	1002	[ d. A and b have the amino acid sequence of SEQ ID NO: ]	[ 3; ]
0.99944264	1003	[ 4; ]	[ d. A and b have the amino acid sequence of SEQ ID NO: ]
0.99378306	1004	[ e. A is a first amino acid; ]	[ 4; ]
0.9999913	1005	[ f. A is a second amino acid, a third amino acid, or a fourth amino acid; ]	[ e. A is a first amino acid; ]
0.9999912	1006	[ g. A and b each have the amino acid sequence of SEQ ID NO: ]	[ f. A is a second amino acid, a third amino acid, or a fourth amino acid; ]
0.9993119	1007	[ 6; ]	[ g. A and b each have the amino acid sequence of SEQ ID NO: ]
0.9994286	1008	[ h. A and b each have the amino acid sequence of SEQ ID NO: ]	[ 6; ]
0.99952066	1009	[ 7; ]	[ h. A and b each have the amino acid sequence of SEQ ID NO: ]
0.99916625	1010	[ i. A has the amino acid sequence of SEQ ID NO: ]	[ 7; ]
0.99898595	1011	[ 8. ]	[ i. A has the amino acid sequence of SEQ ID NO: ]
0.9999857	1012	[ 2, wherein said polypeptide is selected from the group consisting of: ]	[ A method for treating an autoimmune disorder in a subject, comprising administering to said subject a therapeutically effective amount of an isolated antibody or fragment thereof which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.9984842	1013	[ (i) the amino acid sequence of SEQ ID NO: 2, ]	[ 2, wherein said polypeptide is selected from the group consisting of: ]
0.99999046	1014	[ (ii) the amino acid sequence of SEQ ID NO: ]	[ (i) the amino acid sequence of SEQ ID NO: 2, ]
0.000116555115	1015	[ 3, ]	[ (ii) the amino acid sequence of SEQ ID NO: ]
0.00016650696	1016	[ (iii) the amino acid sequence of SEQ ID NO: ]	[ 3, ]
0.99923086	1017	[ 4, and ]	[ (iii) the amino acid sequence of SEQ ID NO: ]
0.99876463	1018	[ (iv) the amino acid sequence of SEQ ID NO: ]	[ 4, and ]
0.9993243	1019	[ 5. ]	[ (iv) the amino acid sequence of SEQ ID NO: ]
0.9999366	1020	[ a medical device; ]	[ A system for providing a medical device to a user, the system comprising: ]
0.9999819	1021	[ an interface configured to communicate with the medical device; and ]	[ a medical device; ]
0.99991703	1022	[ an input device for receiving input from a user, the input device including a display configured to display a medical device image and a user interface configured to receive a command to perform a function, the user interface including: ]	[ an interface configured to communicate with the medical device; and ]
0.9999683	1023	[ a first portion configured to display an indication of a status of the medical device, and ]	[ an input device for receiving input from a user, the input device including a display configured to display a medical device image and a user interface configured to receive a command to perform a function, the user interface including: ]
0.99999213	1024	[ a second portion configured to display an indication of a user interface associated with the medical device; ]	[ a first portion configured to display an indication of a status of the medical device, and ]
0.9999919	1025	[ wherein the first portion and the second portion are configured to display a first indication of the status of the medical device, and ]	[ a second portion configured to display an indication of a user interface associated with the medical device; ]
0.9999924	1026	[ the first indication of the status of the medical device is configured to indicate that the status of the medical device is in a non-operational state. ]	[ wherein the first portion and the second portion are configured to display a first indication of the status of the medical device, and ]
0.99999	1027	[ a first patient-specific device configured to provide a medical treatment to the individual; and ]	[ A system for providing a medical treatment to an individual, comprising: ]
0.9999918	1028	[ a second patient-specific device configured to receive the medical treatment, the first and second device being configured to be coupled to a patient-specific medical device, wherein the first and second device are further configured to be configured to receive a first treatment and a second treatment, wherein the first treatment comprises a medical treatment and the second treatment comprises an exercise, and ]	[ a first patient-specific device configured to provide a medical treatment to the individual; and ]
0.999992	1029	[ wherein the first device and the second device are configured to be configured to provide a first treatment to the patient-specific device and a second treatment to a second patient-specific device. ]	[ a second patient-specific device configured to receive the medical treatment, the first and second device being configured to be coupled to a patient-specific medical device, wherein the first and second device are further configured to be configured to receive a first treatment and a second treatment, wherein the first treatment comprises a medical treatment and the second treatment comprises an exercise, and ]
0.9999914	1030	[ 2, wherein said antibody specifically binds to the polypeptide. ]	[ A method of treating a disease in a mammal comprising administering to the mammal an effective amount of an antibody that specifically binds to a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.99930024	1031	[ administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising a compound selected from the group consisting of a polypeptide, a polysaccharide or a polysaccharide fragment, wherein said compound is an amino acid sequence of SEQ ID NO: ]	[ A method of treating a disease comprising: ]
0.9996178	1032	[ 2, SEQ ID NO: ]	[ administering to a subject in need of such treatment a therapeutically effective amount of a composition comprising a compound selected from the group consisting of a polypeptide, a polysaccharide or a polysaccharide fragment, wherein said compound is an amino acid sequence of SEQ ID NO: ]
0.99998915	1033	[ 2, SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.99999	1034	[ 4, SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.9999895	1035	[ 4, SEQ ID NO: ]	[ 4, SEQ ID NO: ]
0.9999887	1036	[ 6, SEQ ID NO: ]	[ 4, SEQ ID NO: ]
0.9999857	1037	[ 7, SEQ ID NO: ]	[ 6, SEQ ID NO: ]
0.99998665	1038	[ 8, SEQ ID NO: ]	[ 7, SEQ ID NO: ]
0.9999889	1039	[ 8, SEQ ID NO: ]	[ 8, SEQ ID NO: ]
0.9999597	1040	[ 11, or a polypeptide having at least 95% amino acid identity to SEQ ID NO: ]	[ 8, SEQ ID NO: ]
0.9998356	1041	[ 2 or SEQ ID NO: ]	[ 11, or a polypeptide having at least 95% amino acid identity to SEQ ID NO: ]
0.999228	1042	[ 6, and ]	[ 2 or SEQ ID NO: ]
0.9978981	1043	[ wherein said polypeptide is selected from the group consisting of a polypeptide having at least 95% amino acid identity to SEQ ID NO: ]	[ 6, and ]
0.99929464	1044	[ 2 or SEQ ID NO: ]	[ wherein said polypeptide is selected from the group consisting of a polypeptide having at least 95% amino acid identity to SEQ ID NO: ]
0.9998054	1045	[ 6, a polypeptide having at least 95% amino acid identity to SEQ ID NO: ]	[ 2 or SEQ ID NO: ]
0.999992	1046	[ 4, a polypeptide having at least 95% amino acid identity to SEQ ID NO: ]	[ 6, a polypeptide having at least 95% amino acid identity to SEQ ID NO: ]
0.9997534	1047	[ 6, and ]	[ 4, a polypeptide having at least 95% amino acid identity to SEQ ID NO: ]
0.9992163	1048	[ a polypeptide having at least 95% amino acid identity to SEQ ID NO: ]	[ 6, and ]
0.999516	1049	[ 11. ]	[ a polypeptide having at least 95% amino acid identity to SEQ ID NO: ]
0.99882513	1050	[ providing a first polymer, the first polymer comprising a first polymerizable moiety and a second polymerizable moiety; ]	[ A method of producing a polymeric composition comprising: ]
0.99999225	1051	[ providing a second polymer, the second polymer comprising a second polymerizable moiety and a third polymerizable moiety; and ]	[ providing a first polymer, the first polymer comprising a first polymerizable moiety and a second polymerizable moiety; ]
0.9999919	1052	[ forming a polymer matrix from the first and second polymerizable moieties, the polymer matrix having a thickness and a cross-sectional dimension that are greater than a cross-sectional dimension of the first and second polymers. ]	[ providing a second polymer, the second polymer comprising a second polymerizable moiety and a third polymerizable moiety; and ]
0.9996358	1053	[ a) providing a surgical device having a proximal end and a distal end, the surgical device comprising a first end and a second end; ]	[ A method for producing an implant for use in a surgical procedure, the method comprising the steps of: ]
0.99998856	1054	[ b) providing a plurality of surgical instruments, each of the plurality of surgical instruments including a proximal end, a distal end, and ]	[ a) providing a surgical device having a proximal end and a distal end, the surgical device comprising a first end and a second end; ]
0.99998033	1055	[ a first and second end, wherein each surgical instrument is configured to be implanted into a patient, wherein the first end and the second end of each surgical instrument are configured to be inserted into a patient's body and the distal end and the proximal end of each surgical instrument are configured to be inserted into a patient's body; and ]	[ b) providing a plurality of surgical instruments, each of the plurality of surgical instruments including a proximal end, a distal end, and ]
0.9999913	1056	[ c) positioning a first end and a second end of the surgical instrument in the proximal end, wherein the first and second ends of the surgical instrument are positioned in a first location and the distal end of the surgical instrument is positioned in a second location different than the first location. ]	[ a first and second end, wherein each surgical instrument is configured to be implanted into a patient, wherein the first end and the second end of each surgical instrument are configured to be inserted into a patient's body and the distal end and the proximal end of each surgical instrument are configured to be inserted into a patient's body; and ]
0.9999895	1057	[ (a) providing an implantable medical device having a plurality of electrodes and at least one conductive element, the implantable medical device having a first electrode and at least one second electrode, the first electrode and second electrode being connected to a first conductive element; ]	[ A method of providing an implantable medical device comprising: ]
0.9999924	1058	[ (b) providing a plurality of electrodes and at least one conductive element, the first and second electrodes being connected to a second conductive element; ]	[ (a) providing an implantable medical device having a plurality of electrodes and at least one conductive element, the implantable medical device having a first electrode and at least one second electrode, the first electrode and second electrode being connected to a first conductive element; ]
0.99997866	1059	[ (c) providing an electrode array, the electrode array including at least one electrode and at least one electrode layer; ]	[ (b) providing a plurality of electrodes and at least one conductive element, the first and second electrodes being connected to a second conductive element; ]
0.99998677	1060	[ (d) providing a plurality of electrodes and an array of conductive elements; and ]	[ (c) providing an electrode array, the electrode array including at least one electrode and at least one electrode layer; ]
0.99999166	1061	[ (e) connecting the at least one conductive element to at least one of the electrodes in the array of conductive elements, ]	[ (d) providing a plurality of electrodes and an array of conductive elements; and ]
0.9999924	1062	[ wherein at least one of the electrodes in the array of conductive elements includes a first electrode and a second electrode. ]	[ (e) connecting the at least one conductive element to at least one of the electrodes in the array of conductive elements, ]
0.9757593	1063	[ 1. ]	[ A method for treating a patient with a disease or disorder, comprising administering to the patient a composition comprising a therapeutically effective amount of an anti-inflammatory agent and a therapeutically effective amount of a polypeptide, the anti-inflammatory agent being a polypeptide having the amino acid sequence as set forth in SEQ ID NO: ]
0.0087379515	1064	[ a body having an inner surface and an outer surface; ]	[ An implantable medical device, comprising: ]
0.9999052	1065	[ an inner surface of the body defining a first region of a plurality of first electrodes, wherein the first region comprises a first electrode and a second region of the plurality of first electrodes that is adjacent the first region, wherein a first electrode is positioned on the outer surface of the first region and a second electrode is positioned on the outer surface of the first region; and ]	[ a body having an inner surface and an outer surface; ]
0.99999225	1066	[ a second region of the plurality of first electrodes, wherein the second region comprises an electrode positioned on the inner surface of the second region and a first electrode and a second electrode, wherein: ]	[ an inner surface of the body defining a first region of a plurality of first electrodes, wherein the first region comprises a first electrode and a second region of the plurality of first electrodes that is adjacent the first region, wherein a first electrode is positioned on the outer surface of the first region and a second electrode is positioned on the outer surface of the first region; and ]
0.99999213	1067	[ a first electrode of the first region is positioned on the inner surface of the second region; and ]	[ a second region of the plurality of first electrodes, wherein the second region comprises an electrode positioned on the inner surface of the second region and a first electrode and a second electrode, wherein: ]
0.99999225	1068	[ a second electrode of the second region is positioned on the outer surface of the first region; ]	[ a first electrode of the first region is positioned on the inner surface of the second region; and ]
0.99999225	1069	[ a first electrode of the first region is positioned on the inner surface of the first region; and ]	[ a second electrode of the second region is positioned on the outer surface of the first region; ]
0.99999225	1070	[ a second electrode of the second region is positioned on the outer surface of the first region; and ]	[ a first electrode of the first region is positioned on the inner surface of the first region; and ]
0.99963164	1071	[ a first conductive element of the first electrode and a second conductive element of the second electrode, ]	[ a second electrode of the second region is positioned on the outer surface of the first region; and ]
0.99991	1072	[ wherein a first portion of the first electrode and a second portion of the second electrode are located on the inner surface of the body, and ]	[ a first conductive element of the first electrode and a second conductive element of the second electrode, ]
0.9999713	1073	[ wherein the first portion of the first electrode is disposed in the first region and the second portion of the second electrode is disposed in the second region. ]	[ wherein a first portion of the first electrode and a second portion of the second electrode are located on the inner surface of the body, and ]
0.9786664	1074	[ a housing having an interior; ]	[ An implantable medical device comprising: ]
0.99907386	1075	[ an electrical connection between an electrical device and the housing, the electrical connection including an electrically conductive portion, a first electrode and a second electrode; and ]	[ a housing having an interior; ]
0.9999553	1076	[ an electrically conductive layer on the interior of the housing, the electrically conductive layer having a first thickness and a second thickness, wherein the first thickness is greater than the second thickness. ]	[ an electrical connection between an electrical device and the housing, the electrical connection including an electrically conductive portion, a first electrode and a second electrode; and ]
0.99856937	1077	[ providing at least one device that is capable of receiving and transmitting signals from at least one of a plurality of different sources; ]	[ A method for treating a patient with a disorder in the central nervous system, the method comprising: ]
0.99999225	1078	[ providing at least one device that is capable of receiving and transmitting signals from at least one of a plurality of different sources; ]	[ providing at least one device that is capable of receiving and transmitting signals from at least one of a plurality of different sources; ]
0.99999213	1079	[ receiving at least one signal from the at least one of the plurality of different sources; ]	[ providing at least one device that is capable of receiving and transmitting signals from at least one of a plurality of different sources; ]
0.99999225	1080	[ determining, by the at least one device, whether the received at least one signal is indicative of the at least one of the plurality of different sources; ]	[ receiving at least one signal from the at least one of the plurality of different sources; ]
0.99999213	1081	[ determining, by the at least one device, that the received at least one signal is indicative of the at least one of the plurality of different sources; and ]	[ determining, by the at least one device, whether the received at least one signal is indicative of the at least one of the plurality of different sources; ]
0.99999225	1082	[ if the received at least one signal is not indicative of the at least one of the plurality of different sources: ]	[ determining, by the at least one device, that the received at least one signal is indicative of the at least one of the plurality of different sources; and ]
0.99999213	1083	[ transmitting the received at least one signal to a source that is capable of receiving and transmitting signals from at least one of a plurality of different sources; and ]	[ if the received at least one signal is not indicative of the at least one of the plurality of different sources: ]
0.99999225	1084	[ transmitting the received at least one signal to a source that is capable of receiving and transmitting signals from at least one of a plurality of different sources. ]	[ transmitting the received at least one signal to a source that is capable of receiving and transmitting signals from at least one of a plurality of different sources; and ]
0.99981564	1085	[ a sensor configured to sense a heart rate signal; ]	[ A system for the monitoring of the movement of a patient's heart, said system comprising: ]
0.9999919	1086	[ a processor configured to determine a heart rate signal value for the heart rate signal; ]	[ a sensor configured to sense a heart rate signal; ]
0.998744	1087	[ at least one processor coupled to the processor and to the sensor, the at least one processor configured to: ]	[ a processor configured to determine a heart rate signal value for the heart rate signal; ]
0.99788624	1088	[ receive a heart rate signal value for a first heart rate signal; ]	[ at least one processor coupled to the processor and to the sensor, the at least one processor configured to: ]
0.9999924	1089	[ determine a first heart rate signal value based upon a first heart rate signal value for the first heart rate signal; and ]	[ receive a heart rate signal value for a first heart rate signal; ]
0.9999924	1090	[ determine a second heart rate signal value based upon a second heart rate signal value, the first heart rate signal value being different from the second heart rate signal value, the first heart rate signal value being a heart rate signal value that is indicative of the heart rate of the patient; ]	[ determine a first heart rate signal value based upon a first heart rate signal value for the first heart rate signal; and ]
0.9983822	1091	[ a processor configured to: ]	[ determine a second heart rate signal value based upon a second heart rate signal value, the first heart rate signal value being different from the second heart rate signal value, the first heart rate signal value being a heart rate signal value that is indicative of the heart rate of the patient; ]
0.99895537	1092	[ determine an amount of time that a patient's heart rate is at its highest heart rate; and ]	[ a processor configured to: ]
0.99999225	1093	[ determine an amount of time that a user's heart rate has been at its highest heart rate. ]	[ determine an amount of time that a patient's heart rate is at its highest heart rate; and ]
0.9999875	1094	[ providing a medical device to a patient, the medical device having an implantable device and a medical device housing; ]	[ A method of providing a medical device to a patient, comprising: ]
0.99999106	1095	[ providing an implantable medical device to a patient in a medical device housing, the implantable medical device being adapted to be implanted in a patient, the implantable medical device housing being adapted to be received within a patient, the implantable medical device having a plurality of ports for connecting a plurality of medical devices, the implantable medical device housing having a first port configured for insertion into a first medical device; and ]	[ providing a medical device to a patient, the medical device having an implantable device and a medical device housing; ]
0.9999924	1096	[ connecting a first medical device to a first port of the implantable medical device housing, the first port configured for insertion into a first medical device. ]	[ providing an implantable medical device to a patient in a medical device housing, the implantable medical device being adapted to be implanted in a patient, the implantable medical device housing being adapted to be received within a patient, the implantable medical device having a plurality of ports for connecting a plurality of medical devices, the implantable medical device housing having a first port configured for insertion into a first medical device; and ]
0.01677996	1097	[ an elongated member having an outer surface, a first end, and ]	[ An implantable device comprising: ]
0.99995136	1098	[ an inner surface; and ]	[ an elongated member having an outer surface, a first end, and ]
0.99897206	1099	[ a plurality of electrodes arranged on an outer surface of said elongated member, ]	[ an inner surface; and ]
0.99998736	1100	[ wherein each of said plurality of electrodes is arranged in a first configuration and a second configuration, wherein said first and second configurations are different from each other, and ]	[ a plurality of electrodes arranged on an outer surface of said elongated member, ]
0.9999919	1101	[ wherein the plurality of electrodes are arranged in a first configuration that has the outer surface of said elongated member and the inner surface of said elongated member is substantially parallel to the inner surface of said elongated member, wherein the first configuration is arranged on a first portion of said elongated member, the second configuration is arranged on a second portion of said elongated member, and ]	[ wherein each of said plurality of electrodes is arranged in a first configuration and a second configuration, wherein said first and second configurations are different from each other, and ]
0.9996288	1102	[ the first portion and the second portion are substantially parallel, and ]	[ wherein the plurality of electrodes are arranged in a first configuration that has the outer surface of said elongated member and the inner surface of said elongated member is substantially parallel to the inner surface of said elongated member, wherein the first configuration is arranged on a first portion of said elongated member, the second configuration is arranged on a second portion of said elongated member, and ]
0.014926927	1103	[ wherein the inner surface of said elongated member is substantially flat, and ]	[ the first portion and the second portion are substantially parallel, and ]
0.9999913	1104	[ wherein the plurality of electrodes are arranged on a first surface of said elongated member and a second surface of said elongated member, wherein the second surface of said elongated member has an outer surface that is substantially flat, and ]	[ wherein the inner surface of said elongated member is substantially flat, and ]
0.99999225	1105	[ wherein the first and second surfaces of said elongated member are substantially parallel. ]	[ wherein the plurality of electrodes are arranged on a first surface of said elongated member and a second surface of said elongated member, wherein the second surface of said elongated member has an outer surface that is substantially flat, and ]
0.9609243	1106	[ a first housing; ]	[ An apparatus comprising: ]
0.99169356	1107	[ a first support member; ]	[ a first housing; ]
0.9999895	1108	[ a first support member member having a first end and a second end, wherein the first support member member member includes a first end and a second end; ]	[ a first support member; ]
0.99999225	1109	[ a first support member member having a first end and a second end, wherein the first support member member member includes a first end and a second end, wherein the first support member member member is configured for placement within the first housing and wherein the first support member member member is configured to be attached to a first end of the first housing; ]	[ a first support member member having a first end and a second end, wherein the first support member member member includes a first end and a second end; ]
0.996763	1110	[ a first support structure; ]	[ a first support member member having a first end and a second end, wherein the first support member member member includes a first end and a second end, wherein the first support member member member is configured for placement within the first housing and wherein the first support member member member is configured to be attached to a first end of the first housing; ]
0.99979347	1111	[ a first support member member; ]	[ a first support structure; ]
0.9999908	1112	[ a first support member member having a first end and a second end, wherein the first support member member member includes a first end and a second end, wherein the first support member member member is configured for placement within the first housing and wherein the first support member member is configured to be attached to a second end of the first housing; and ]	[ a first support member member; ]
0.999992	1113	[ a second housing, the first support member member, the second housing, the first support member member, and ]	[ a first support member member having a first end and a second end, wherein the first support member member member includes a first end and a second end, wherein the first support member member member is configured for placement within the first housing and wherein the first support member member is configured to be attached to a second end of the first housing; and ]
0.999992	1114	[ the second support member member are disposed within the second housing. ]	[ a second housing, the first support member member, the second housing, the first support member member, and ]
0.9997081	1115	[ a patient-specific device; ]	[ A system for the treatment of a patient, comprising: ]
0.9999881	1116	[ a patient-specific implant; and ]	[ a patient-specific device; ]
0.009631105	1117	[ a plurality of electrodes, ]	[ a patient-specific implant; and ]
0.9999908	1118	[ wherein the plurality of electrodes comprises: ]	[ a plurality of electrodes, ]
0.9988882	1119	[ a first electrode disposed on an outer surface of a first electrode-shaped portion of the patient-specific device and configured to be implanted into a patient's tissue; ]	[ wherein the plurality of electrodes comprises: ]
0.9999924	1120	[ a second electrode disposed on an inner surface of the first electrode-shaped portion of the patient-specific device and configured to be implanted into the patient's tissue, the second electrode being disposed in a position different from the first electrode-shaped portion of the patient-specific device; and ]	[ a first electrode disposed on an outer surface of a first electrode-shaped portion of the patient-specific device and configured to be implanted into a patient's tissue; ]
0.99999225	1121	[ a plurality of electrodes, each electrode-shaped portion having a plurality of electrodes, wherein the plurality of electrodes are disposed in a position different from the patient-specific device. ]	[ a second electrode disposed on an inner surface of the first electrode-shaped portion of the patient-specific device and configured to be implanted into the patient's tissue, the second electrode being disposed in a position different from the first electrode-shaped portion of the patient-specific device; and ]
0.9999882	1122	[ a light source for illuminating the pupil of the eye; ]	[ An apparatus for treating an eye of a patient, the eye having a pupil, the apparatus comprising: ]
0.9999193	1123	[ a first lens for focusing the illuminating light; ]	[ a light source for illuminating the pupil of the eye; ]
0.9999912	1124	[ a second lens having a first end and a second end, the second lens having a first lens surface, the first lens surface configured for focusing the illuminating light; and ]	[ a first lens for focusing the illuminating light; ]
0.99999154	1125	[ a first filter for selectively filtering light from the second lens, the first filter comprising a first filter surface and an intermediate layer of the light source and the first lens surface, ]	[ a second lens having a first end and a second end, the second lens having a first lens surface, the first lens surface configured for focusing the illuminating light; and ]
0.9999919	1126	[ wherein the first filter surface is configured for focusing the illumination light to a first portion of the pupil of the eye, ]	[ a first filter for selectively filtering light from the second lens, the first filter comprising a first filter surface and an intermediate layer of the light source and the first lens surface, ]
0.99999225	1127	[ wherein the first filter surface is configured for focusing the light from the second lens to a second portion of the pupil of the eye, and ]	[ wherein the first filter surface is configured for focusing the illumination light to a first portion of the pupil of the eye, ]
0.9999844	1128	[ wherein the second portion of the pupil is not illuminated by the illumination of the first portion of the pupil. ]	[ wherein the first filter surface is configured for focusing the light from the second lens to a second portion of the pupil of the eye, and ]
0.9997321	1129	[ a patient support; ]	[ A device for providing a patient with a treatment, comprising: ]
0.9999913	1130	[ a first electrode disposed in a first region of the patient support, the first electrode having an electrode surface; and ]	[ a patient support; ]
0.9999906	1131	[ a plurality of electrodes disposed on the first electrode, each electrode having an electrode surface, ]	[ a first electrode disposed in a first region of the patient support, the first electrode having an electrode surface; and ]
0.014619131	1132	[ wherein the first region includes a first region of the patient support, ]	[ a plurality of electrodes disposed on the first electrode, each electrode having an electrode surface, ]
0.99999225	1133	[ wherein a first electrode is disposed in the first region of the patient support, ]	[ wherein the first region includes a first region of the patient support, ]
0.9999496	1134	[ wherein the first electrode has a first electrode surface, and ]	[ wherein a first electrode is disposed in the first region of the patient support, ]
0.9984232	1135	[ wherein the electrode surface is substantially flat. ]	[ wherein the first electrode has a first electrode surface, and ]
0.98808634	1136	[ an implantable medical device having a proximal end and a distal end; and ]	[ A system for treating an eye, comprising: ]
0.9998679	1137	[ an implantable medical device controller configured to: ]	[ an implantable medical device having a proximal end and a distal end; and ]
0.9990717	1138	[ receive a signal from a first device; ]	[ an implantable medical device controller configured to: ]
0.99982893	1139	[ determine a first treatment parameter from the signal; ]	[ receive a signal from a first device; ]
0.99999225	1140	[ determine a second treatment parameter from the signal; and<|span|> determine an eye treatment parameter from a second device, ]	[ determine a first treatment parameter from the signal; ]
0.9999832	1141	[ wherein the first device is a first device configured to treat an eye and the second device is a second device configured to treat an eye, and ]	[ determine a second treatment parameter from the signal; and<|span|> determine an eye treatment parameter from a second device, ]
0.99904925	1142	[ wherein the first and second treatment parameters are associated with the implantable medical device. ]	[ wherein the first device is a first device configured to treat an eye and the second device is a second device configured to treat an eye, and ]
0.9996679	1143	[ providing a patient with a first implant; ]	[ A method for treating a patient, comprising: ]
0.99988854	1144	[ providing a first infusion device for administering a first infusion of a first fluid to the patient; ]	[ providing a patient with a first implant; ]
0.9999924	1145	[ providing a first infusion pump for delivering the first fluid to the patient; ]	[ providing a first infusion device for administering a first infusion of a first fluid to the patient; ]
0.9999914	1146	[ administering a first infusion to the first infusion device; and ]	[ providing a first infusion pump for delivering the first fluid to the patient; ]
0.9991903	1147	[ providing a first fluid to the first fluid pump; ]	[ administering a first infusion to the first infusion device; and ]
0.99824345	1148	[ administering a second infusion to the patient; and ]	[ providing a first fluid to the first fluid pump; ]
0.99999225	1149	[ delivering a second infusion to the patient; ]	[ administering a second infusion to the patient; and ]
0.9999732	1150	[ wherein the first infusion device and the first infusion pump are configured for use in a single infusion cycle, wherein each infusion cycle comprises a single dose of a first infusion of a first fluid and a single dose of a second infusion of the first fluid, wherein the second infusion is administered at a different time than the first infusion. ]	[ delivering a second infusion to the patient; ]
0.9999734	1151	[ providing a tissue-selective antibody that specifically binds a tumor specific antigen, wherein the tumor specific antigen is a human T-cell antigen; ]	[ A method of treating a patient having a tumor in an organ, comprising: ]
0.999992	1152	[ administering the tissue-selective antibody to the patient; and ]	[ providing a tissue-selective antibody that specifically binds a tumor specific antigen, wherein the tumor specific antigen is a human T-cell antigen; ]
0.9999815	1153	[ administering an effective amount of an anti-T-cell antibody to the patient, wherein the anti-T-cell antibody specifically binds the tumor specific antigen. ]	[ administering the tissue-selective antibody to the patient; and ]
0.999514	1154	[ 1 or SEQ ID NO: ]	[ A method for the treatment of a patient having a tumor, comprising administering to said patient a therapeutically effective amount of an effective amount of an anti-tumor agent comprising a polypeptide comprising a sequence of SEQ ID NO: ]
0.9996569	1155	[ 2 and wherein the anti-tumor agent is a polypeptide having the amino acid sequence of SEQ ID NO: 2, ]	[ 1 or SEQ ID NO: ]
0.9999918	1156	[ wherein the anti-tumor agent is administered in a dose effective to treat said patient. ]	[ 2 and wherein the anti-tumor agent is a polypeptide having the amino acid sequence of SEQ ID NO: 2, ]
0.9990176	1157	[ a) providing a first delivery device having an outer surface and an inner surface, the inner surface of the delivery device being configured to be disposed within an internal space of the subject; and ]	[ A method of providing a therapeutic agent to a subject in need thereof in a manner that does not require a pharmaceutically acceptable carrier, the method comprising: ]
0.99999213	1158	[ b) providing a second delivery device having an outer surface and a plurality of electrodes disposed on the inner surface of the delivery device, the plurality of electrodes being configured to be disposed within the internal space of the subject, wherein: ]	[ a) providing a first delivery device having an outer surface and an inner surface, the inner surface of the delivery device being configured to be disposed within an internal space of the subject; and ]
0.99999225	1159	[ i) a) the plurality of electrodes are disposed within an inner surface of the delivery device; and ]	[ b) providing a second delivery device having an outer surface and a plurality of electrodes disposed on the inner surface of the delivery device, the plurality of electrodes being configured to be disposed within the internal space of the subject, wherein: ]
0.9999924	1160	[ ii) the plurality of electrodes are configured to be disposed in the inner surface of the delivery device to be electrically coupled to the inner surface of the delivery device; ]	[ i) a) the plurality of electrodes are disposed within an inner surface of the delivery device; and ]
0.9999918	1161	[ c) the plurality of electrodes are configured to provide a therapeutic agent; and ]	[ ii) the plurality of electrodes are configured to be disposed in the inner surface of the delivery device to be electrically coupled to the inner surface of the delivery device; ]
0.99999213	1162	[ d) the plurality of electrodes are configured to deliver the therapeutic agent to the subject. ]	[ c) the plurality of electrodes are configured to provide a therapeutic agent; and ]
0.99891984	1163	[ (i) a pharmaceutically acceptable salt thereof; and ]	[ A method for treating a patient having an inflammatory bowel disease, comprising administering to the patient a therapeutically effective amount of a compound selected from the group consisting of: ]
0.9999126	1164	[ (ii) a pharmaceutically acceptable carrier. ]	[ (i) a pharmaceutically acceptable salt thereof; and ]
0.9993624	1165	[ (a) a pharmaceutically effective amount of an antibody comprising a nucleic acid sequence selected from the group consisting of: ]	[ A method of treating a condition in a mammal comprising administering to the mammal a therapeutically effective amount of a composition comprising: ]
0.9998783	1166	[ (i) SEQ ID NO: 1, ]	[ (a) a pharmaceutically effective amount of an antibody comprising a nucleic acid sequence selected from the group consisting of: ]
0.9999895	1167	[ (ii) SEQ ID NO: 2, ]	[ (i) SEQ ID NO: 1, ]
0.9999889	1168	[ (iii) SEQ ID NO: 4, and ]	[ (ii) SEQ ID NO: 2, ]
0.9999896	1169	[ (iv) SEQ ID NO: 7; and ]	[ (iii) SEQ ID NO: 4, and ]
0.00059514557	1170	[ (b) a pharmaceutically effective amount of a pharmaceutically acceptable carrier; ]	[ (iv) SEQ ID NO: 7; and ]
0.9869791	1171	[ wherein the antibody is selected from the group consisting of: ]	[ (b) a pharmaceutically effective amount of a pharmaceutically acceptable carrier; ]
0.9998715	1172	[ (i) an antibody comprising a nucleic acid sequence having a sequence that encodes the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8; ]	[ wherein the antibody is selected from the group consisting of: ]
0.9999924	1173	[ (ii) an antibody comprising a nucleic acid sequence having a sequence that encodes the amino acid sequence of SEQ ID NO: 1; and ]	[ (i) an antibody comprising a nucleic acid sequence having a sequence that encodes the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8; ]
0.9999924	1174	[ (iii) an antibody comprising a nucleic acid sequence that encodes a sequence having a amino acid sequence having a sequence having a sequence that encodes SEQ ID NO: 1; ]	[ (ii) an antibody comprising a nucleic acid sequence having a sequence that encodes the amino acid sequence of SEQ ID NO: 1; and ]
0.99996126	1175	[ wherein said antibody is a humanized antibody, and ]	[ (iii) an antibody comprising a nucleic acid sequence that encodes a sequence having a amino acid sequence having a sequence having a sequence that encodes SEQ ID NO: 1; ]
0.9999871	1176	[ wherein said antibody is selected from the group consisting of humanized antibody, humanized antibody with a humanized antibody sequence having a sequence having an amino acid sequence that encodes SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8. ]	[ wherein said antibody is a humanized antibody, and ]
4.261121e-05	1177	[ (i) an isolated peptide comprising the amino acid sequence of SEQ ID NO: ]	[ A method for treating a patient suffering from a chronic pain syndrome, the method comprising administering to the patient a therapeutically effective amount of a compound selected from the group consisting of: ]
0.996152	1178	[ 1; and ]	[ (i) an isolated peptide comprising the amino acid sequence of SEQ ID NO: ]
0.9965759	1179	[ (ii) a compound that inhibits the binding of an amino acid sequence of SEQ ID NO: ]	[ 1; and ]
0.99991107	1180	[ 1 to a peptide of SEQ ID NO: ]	[ (ii) a compound that inhibits the binding of an amino acid sequence of SEQ ID NO: ]
0.9986848	1181	[ 2. ]	[ 1 to a peptide of SEQ ID NO: ]
0.9633915	1182	[ a housing; ]	[ An apparatus comprising: ]
0.9996872	1183	[ a first and second electrode assembly disposed on the housing and configured to be disposed within a first and a second cavity; ]	[ a housing; ]
0.9999924	1184	[ a first electrical connector disposed within the first cavity and configured to be disposed within a first and a second electrode assembly disposed within a second cavity; ]	[ a first and second electrode assembly disposed on the housing and configured to be disposed within a first and a second cavity; ]
0.99999225	1185	[ a second electrical connector disposed within the second cavity and configured to be disposed within a second and a third cavity; ]	[ a first electrical connector disposed within the first cavity and configured to be disposed within a first and a second electrode assembly disposed within a second cavity; ]
0.9999914	1186	[ a plurality of conductive elements disposed within the first cavity and disposed within the second cavity and configured to be disposed within the first cavity and the second cavity; ]	[ a second electrical connector disposed within the second cavity and configured to be disposed within a second and a third cavity; ]
0.9999924	1187	[ a plurality of conductive elements disposed within the second cavity and disposed within the third cavity and configured to be disposed within the third cavity; ]	[ a plurality of conductive elements disposed within the first cavity and disposed within the second cavity and configured to be disposed within the first cavity and the second cavity; ]
0.9999924	1188	[ a plurality of conductive elements disposed within the third cavity and disposed within the fourth cavity; ]	[ a plurality of conductive elements disposed within the second cavity and disposed within the third cavity and configured to be disposed within the third cavity; ]
0.9999924	1189	[ a plurality of conductive elements disposed within the fourth cavity and disposed within the fifth cavity; and ]	[ a plurality of conductive elements disposed within the third cavity and disposed within the fourth cavity; ]
0.99999225	1190	[ a plurality of conductive elements disposed within the fifth cavity and configured to be disposed within the fifth cavity. ]	[ a plurality of conductive elements disposed within the fourth cavity and disposed within the fifth cavity; and ]
0.9999759	1191	[ a first electrode configured to deliver a drug to an implant; ]	[ An implantable medical device for delivering a drug to the body comprising: ]
0.99994147	1192	[ a first electrode support configured to support a first electrode; ]	[ a first electrode configured to deliver a drug to an implant; ]
0.99999046	1193	[ an implantable electrode support configured to support a second electrode; and ]	[ a first electrode support configured to support a first electrode; ]
0.9999918	1194	[ an implantable electrode support support comprising: ]	[ an implantable electrode support configured to support a second electrode; and ]
0.9982146	1195	[ a first electrode support member configured to support a first electrode; ]	[ an implantable electrode support support comprising: ]
0.99999154	1196	[ a first electrode support member support member configured to support a second electrode; and ]	[ a first electrode support member configured to support a first electrode; ]
0.9999908	1197	[ a second electrode support member configured to support a second electrode; wherein the first electrode support member support member is configured to support a first portion of the first electrode and the second electrode support member support member is configured to support a second portion of the second electrode, ]	[ a first electrode support member support member configured to support a second electrode; and ]
0.9999919	1198	[ wherein the first electrode support member and the second electrode support member support member are configured to support a first portion of the drug, and ]	[ a second electrode support member configured to support a second electrode; wherein the first electrode support member support member is configured to support a first portion of the first electrode and the second electrode support member support member is configured to support a second portion of the second electrode, ]
0.99999166	1199	[ wherein at least a portion of the first electrode and the second electrode support member are configured to support a first portion of the first electrode. ]	[ wherein the first electrode support member and the second electrode support member support member are configured to support a first portion of the drug, and ]
0.99991465	1200	[ (ii) a salt thereof; and ]	[ A method of treating cancer comprising administering to a mammal in need thereof a compound selected from the group consisting of: (a) a pharmaceutically acceptable salt thereof; (b) a salt of a compound selected from the group consisting of: (i) an amino acid salt thereof, and ]
0.9996086	1201	[ (c) a pharmaceutically acceptable carrier; wherein the cancer is cancer in situ or metastasis of a cell. ]	[ (ii) a salt thereof; and ]
0.9998969	1202	[ providing at least one patient with a first therapeutic agent, the at least one patient having a first condition; ]	[ A method for treating a disease comprising: ]
0.99999225	1203	[ administering to the first patient at least one second therapeutic agent, the at least one second therapeutic agent having a second condition; ]	[ providing at least one patient with a first therapeutic agent, the at least one patient having a first condition; ]
0.9999924	1204	[ administering to the first and second conditions at least one third therapeutic agent; and ]	[ administering to the first patient at least one second therapeutic agent, the at least one second therapeutic agent having a second condition; ]
0.99999225	1205	[ administering to the first and second conditions at least one third therapeutic agent having a fourth condition. ]	[ administering to the first and second conditions at least one third therapeutic agent; and ]
0.99999225	1206	[ providing a first implant for implantation in the body tissue, the first implant comprising a first implant body and a second implant body, the first implant body and the second implant body being different from one another, and ]	[ A method of providing an implant for implantation in a body tissue, the method comprising: ]
0.99999225	1207	[ wherein the first implant body is adapted to be implanted in a first region of a body tissue and the second implant body is adapted to be implanted in a second region of the body tissue; and ]	[ providing a first implant for implantation in the body tissue, the first implant comprising a first implant body and a second implant body, the first implant body and the second implant body being different from one another, and ]
0.99999225	1208	[ providing a second implant for implantation in the body tissue, the second implant body comprising a second implant body and a third implant body, the third implant body and the second implant body being different from one another and wherein the third implant body is adapted to be implanted in a third region of the body tissue and the second implant body is adapted to be implanted in a fourth region of the body tissue, ]	[ wherein the first implant body is adapted to be implanted in a first region of a body tissue and the second implant body is adapted to be implanted in a second region of the body tissue; and ]
0.99999225	1209	[ wherein the first implant body is adapted to be implanted in a first region of the first region of the body tissue and the second implant body comprises an elongate member having a first end and a second end. ]	[ providing a second implant for implantation in the body tissue, the second implant body comprising a second implant body and a third implant body, the third implant body and the second implant body being different from one another and wherein the third implant body is adapted to be implanted in a third region of the body tissue and the second implant body is adapted to be implanted in a fourth region of the body tissue, ]
0.9999914	1210	[ 4, 5 or 6 to a patient, wherein the therapeutically effective amount is effective to treat the autoimmune condition. ]	[ A method of treating an autoimmune condition comprising administering a therapeutically effective amount of a polypeptide having a sequence of SEQ ID NOS: ]
0.99951005	1211	[ a compound selected from the group consisting of: ]	[ A method for treating a subject having an inflammatory disease comprising administering to the subject a composition having an effective amount of a compound selected from the group consisting of: ]
0.998251	1212	[ (i) a pharmaceutically acceptable salt thereof and (ii) one or more pharmaceutically acceptable esters thereof; and ]	[ a compound selected from the group consisting of: ]
0.9989374	1213	[ a pharmaceutically acceptable carrier. ]	[ (i) a pharmaceutically acceptable salt thereof and (ii) one or more pharmaceutically acceptable esters thereof; and ]
0.99825615	1214	[ a) at least one of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable carrier-in-vitro, a pharmaceutically acceptable adjuvant-in-vitro, and ]	[ A method of treating an autoimmune disorder comprising administering to a subject in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising: ]
0.9999906	1215	[ a therapeutically acceptable carrier-in-vitro; and ]	[ a) at least one of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable carrier-in-vitro, a pharmaceutically acceptable adjuvant-in-vitro, and ]
0.99998844	1216	[ b) at least one of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable carrier-in-vitro, a pharmaceutically acceptable adjuvant-in-vitro, and ]	[ a therapeutically acceptable carrier-in-vitro; and ]
0.99999225	1217	[ a pharmaceutically acceptable adjuvant-in-vitro, wherein the at least one of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable carrier-in-vitro, a pharmaceutically acceptable adjuvant-in-vitro and a pharmaceutically acceptable adjuvant-in-vitro comprises a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable carrier-in-vitro, a pharmaceutically acceptable adjuvant-in-vitro, and ]	[ b) at least one of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable carrier-in-vitro, a pharmaceutically acceptable adjuvant-in-vitro, and ]
0.9999912	1218	[ a pharmaceutically acceptable adjuvant-in-vitro. ]	[ a pharmaceutically acceptable adjuvant-in-vitro, wherein the at least one of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable carrier-in-vitro, a pharmaceutically acceptable adjuvant-in-vitro and a pharmaceutically acceptable adjuvant-in-vitro comprises a pharmaceutically acceptable carrier, a pharmaceutically acceptable adjuvant, a pharmaceutically acceptable carrier-in-vitro, a pharmaceutically acceptable adjuvant-in-vitro, and ]
0.99996185	1219	[ a first implantable device; and<|span|> a second implantable device, the second implantable device being adapted to provide a first electrical stimulation to a first nerve of the patient; ]	[ A system for providing an implantable device to a patient, comprising: ]
0.9999919	1220	[ wherein the first implantable device is adapted to be implanted in a patient's body; ]	[ a first implantable device; and<|span|> a second implantable device, the second implantable device being adapted to provide a first electrical stimulation to a first nerve of the patient; ]
0.99999213	1221	[ wherein the second implantable device is adapted to be implanted in the patient's body, wherein the second implantable device is adapted to provide a second electrical stimulation to a second nerve of the patient, wherein the first electrical stimulation is delivered to the first nerve and the second electrical stimulation is delivered to the second nerve, and ]	[ wherein the first implantable device is adapted to be implanted in a patient's body; ]
0.99999225	1222	[ wherein the first and second electrical stimulations provide a first stimulation to the patient and a second stimulation to the patient, wherein the second stimulation is provided at least partially by a second electrical stimulation. ]	[ wherein the second implantable device is adapted to be implanted in the patient's body, wherein the second implantable device is adapted to provide a second electrical stimulation to a second nerve of the patient, wherein the first electrical stimulation is delivered to the first nerve and the second electrical stimulation is delivered to the second nerve, and ]
0.98763776	1223	[ providing a first body having a first end and a second end; ]	[ A method of providing a patient-side support for a surgical instrument comprising: ]
0.99999225	1224	[ providing a second body including a first end and a second end; ]	[ providing a first body having a first end and a second end; ]
0.9999635	1225	[ providing a first body support member including a first body support member body and a second body support member body, the first body support member body being disposed within the second body support member body, and ]	[ providing a second body including a first end and a second end; ]
0.999992	1226	[ the second body support member body being disposed within the first body support member body; ]	[ providing a first body support member including a first body support member body and a second body support member body, the first body support member body being disposed within the second body support member body, and ]
0.9999888	1227	[ attaching the first body support member to a surgical instrument; ]	[ the second body support member body being disposed within the first body support member body; ]
0.99999225	1228	[ attaching the second body support member to the second end of the surgical instrument; and ]	[ attaching the first body support member to a surgical instrument; ]
0.9985252	1229	[ providing a support member having a first end portion and a second end portion, the first end portion of the support member having a first end and a second end, the second end portion of the support member having a third end, the first end portion of the support member including a first end support surface and a second end support surface; ]	[ attaching the second body support member to the second end of the surgical instrument; and ]
0.99998915	1230	[ attaching the support member to the second end of the surgical instrument; ]	[ providing a support member having a first end portion and a second end portion, the first end portion of the support member having a first end and a second end, the second end portion of the support member having a third end, the first end portion of the support member including a first end support surface and a second end support surface; ]
0.9998153	1231	[ attaching the second body support member including a second body support member body and a first body support member body to the first body support member; ]	[ attaching the support member to the second end of the surgical instrument; ]
0.99999225	1232	[ attaching the first body support member to the second end of the surgical instrument; ]	[ attaching the second body support member including a second body support member body and a first body support member body to the first body support member; ]
0.99999225	1233	[ attaching the second body support member including a first body support member body and a second body support member body to the second end of the surgical instrument; and ]	[ attaching the first body support member to the second end of the surgical instrument; ]
0.99999225	1234	[ attaching the support member to the second end of the surgical instrument. ]	[ attaching the second body support member including a first body support member body and a second body support member body to the second end of the surgical instrument; and ]
0.99639183	1235	[ providing an implantable medical device comprising: ]	[ A method of providing a treatment to a subject, the method comprising: ]
0.99558735	1236	[ a first electrode configured to be electrically connected to a blood vessel; and ]	[ providing an implantable medical device comprising: ]
0.9999912	1237	[ a second electrode, wherein said first electrode is configured to be electrically connected to the blood vessel and said second electrode is configured to be electrically disconnected from the blood vessel; and ]	[ a first electrode configured to be electrically connected to a blood vessel; and ]
0.013769247	1238	[ providing a treatment to the subject. ]	[ a second electrode, wherein said first electrode is configured to be electrically connected to the blood vessel and said second electrode is configured to be electrically disconnected from the blood vessel; and ]
0.9991731	1239	[ (a) an antibody or antigen-binding fragment thereof that specifically binds to a human CD4+ T cell receptor, ]	[ A method for treating a subject having a tumor comprising administering to the patient an amount of an effective amount of an anti-cancer agent selected from the group consisting of: ]
0.99999213	1240	[ (b) an antibody or antigen-binding fragment thereof that specifically binds to an anti-cancer cell-cell receptor, ]	[ (a) an antibody or antigen-binding fragment thereof that specifically binds to a human CD4+ T cell receptor, ]
0.99999225	1241	[ (c) an antibody or antigen-binding fragment thereof that specifically binds to a tumor-cell receptor, ]	[ (b) an antibody or antigen-binding fragment thereof that specifically binds to an anti-cancer cell-cell receptor, ]
0.99999225	1242	[ (d) an antibody or antigen-binding fragment thereof that specifically binds to an anti-tumor cell-cell receptor, and ]	[ (c) an antibody or antigen-binding fragment thereof that specifically binds to a tumor-cell receptor, ]
0.99999225	1243	[ (e) an antibody or antigen-binding fragment thereof that specifically binds to a tumor-cell receptor. ]	[ (d) an antibody or antigen-binding fragment thereof that specifically binds to an anti-tumor cell-cell receptor, and ]
0.033460207	1244	[ an inner surface; ]	[ A device, comprising: ]
0.9999883	1245	[ an outer surface; ]	[ an inner surface; ]
0.98339385	1246	[ an elongated member having a proximal portion, a distal portion, and ]	[ an outer surface; ]
0.99999094	1247	[ a longitudinal axis, the elongated member having a first portion and a second portion; and ]	[ an elongated member having a proximal portion, a distal portion, and ]
0.99998426	1248	[ a plurality of elongate members extending from the proximal portion to the distal portion of the elongated member and extending in a longitudinal direction, wherein the plurality of elongate members have a plurality of elongate members extending in parallel with each other, the plurality of elongate members having a first end and a second end and the first end being disposed between the first and second portions of the elongated member and the second end being disposed between the proximal portion and the distal portion of the elongated member, and ]	[ a longitudinal axis, the elongated member having a first portion and a second portion; and ]
0.999992	1249	[ the elongated member being disposed between the first portion and the second portion of the elongated member; ]	[ a plurality of elongate members extending from the proximal portion to the distal portion of the elongated member and extending in a longitudinal direction, wherein the plurality of elongate members have a plurality of elongate members extending in parallel with each other, the plurality of elongate members having a first end and a second end and the first end being disposed between the first and second portions of the elongated member and the second end being disposed between the proximal portion and the distal portion of the elongated member, and ]
0.9998128	1250	[ a first elongate member having a first end, a first portion and a second portion, the first portion of the elongate member having a length that is shorter than the first portion of the elongate member, the second portion having a length that is longer than the length of the first portion of the elongate member; and ]	[ the elongated member being disposed between the first portion and the second portion of the elongated member; ]
0.99999225	1251	[ a second elongate member having a first portion and a second portion, the first portion of the elongate member having a length that is shorter than the length of the second portion, the second portion of the elongate member having a length that is longer than the length of the first portion of the elongate member. ]	[ a first elongate member having a first end, a first portion and a second portion, the first portion of the elongate member having a length that is shorter than the first portion of the elongate member, the second portion having a length that is longer than the length of the first portion of the elongate member; and ]
0.9997991	1252	[ SEQ ID NO: 5. ]	[ A method of treating a disease, comprising administering to an individual having the disease a therapeutically effective amount of an effective amount of a polypeptide comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and ]
0.9999914	1253	[ wherein the fragment is at least 90% identical to the nucleotide sequence of SEQ ID NO: ]	[ An isolated nucleic acid comprising a nucleotide sequence that is at least 90% identical to SEQ ID NO: 2 or a fragment thereof, ]
0.99831176	1254	[ 2. ]	[ wherein the fragment is at least 90% identical to the nucleotide sequence of SEQ ID NO: ]
0.99971217	1255	[ R1 is H, C1-C6 alkyl, C1-C4 alkoxy, C1-C4 alkylamino or C1-C6 alkylaminoalkyl, ]	[ A method for producing a compound having an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein: ]
0.99901485	1256	[ R2 and R3 independently of each other are each independently a hydrogen, C1-C4 alkylene, a C1-C4 alkyloxy, a C1-C4 alkoxyalkyl, a C1-C4 alkenyl or a C1-C3 alkynyl, ]	[ R1 is H, C1-C6 alkyl, C1-C4 alkoxy, C1-C4 alkylamino or C1-C6 alkylaminoalkyl, ]
0.99985623	1257	[ R4 is a C1-C4 alkyl, C1-C4 alkoxy or C1-C4 alkylaminoalkyl or a pharmaceutically acceptable salt thereof, ]	[ R2 and R3 independently of each other are each independently a hydrogen, C1-C4 alkylene, a C1-C4 alkyloxy, a C1-C4 alkoxyalkyl, a C1-C4 alkenyl or a C1-C3 alkynyl, ]
0.9999907	1258	[ R5 is a C1-C4 alkyl, C1-C4 alkoxy or C1-C4 alkylaminoalkyl, and ]	[ R4 is a C1-C4 alkyl, C1-C4 alkoxy or C1-C4 alkylaminoalkyl or a pharmaceutically acceptable salt thereof, ]
0.9997969	1259	[ R6 is H, C3-C6 alkyl, C3-C6 alkylamino or C3-C6 alkylaminoalkyl. ]	[ R5 is a C1-C4 alkyl, C1-C4 alkoxy or C1-C4 alkylaminoalkyl, and ]
0.0491755	1260	[ providing an implantable medical device; ]	[ A method comprising: ]
0.99999213	1261	[ providing an implantable medical device interface configured to be coupled to the implantable medical device; ]	[ providing an implantable medical device; ]
0.99584454	1262	[ providing a plurality of electrodes, each electrode comprising: ]	[ providing an implantable medical device interface configured to be coupled to the implantable medical device; ]
0.08370485	1263	[ a first electrode configured to be coupled to a first portion of an implantable medical device, the first electrode configured to be coupled to a second portion of the implantable medical device; ]	[ providing a plurality of electrodes, each electrode comprising: ]
0.99999225	1264	[ a second electrode configured to be coupled to a second portion of the implantable medical device, the second electrode configured to be coupled to a third portion of the implantable medical device; and ]	[ a first electrode configured to be coupled to a first portion of an implantable medical device, the first electrode configured to be coupled to a second portion of the implantable medical device; ]
0.99999225	1265	[ a third electrode configured to be coupled to a fourth portion of the implantable medical device; ]	[ a second electrode configured to be coupled to a second portion of the implantable medical device, the second electrode configured to be coupled to a third portion of the implantable medical device; and ]
0.9999918	1266	[ providing a first electrode interface configured to receive a first portion of the implantable medical device; and ]	[ a third electrode configured to be coupled to a fourth portion of the implantable medical device; ]
0.9999924	1267	[ delivering a first electrical signal to the first electrode interface to cause the first portion of the implantable medical device to be electrically coupled to the first electrode; and ]	[ providing a first electrode interface configured to receive a first portion of the implantable medical device; and ]
0.99999225	1268	[ providing a second electrode interface configured to receive a second portion of the implantable medical device; ]	[ delivering a first electrical signal to the first electrode interface to cause the first portion of the implantable medical device to be electrically coupled to the first electrode; and ]
0.9999906	1269	[ wherein the first electrode interface is configured to receive the first electrical signal and the second electrode interface is configured to receive the second electrical signal, wherein the third electrode is configured to be coupled to the second portion of the implantable medical device and the fourth electrode is configured to be coupled to the third portion of the implantable medical device. ]	[ providing a second electrode interface configured to receive a second portion of the implantable medical device; ]
0.99948174	1270	[ R1 and R2 are independently selected from the group consisting of hydrogen, aryl, heteroaryl, heterocyclyl or heteroalkyl; ]	[ A method for treating a patient in need thereof comprising administering to the patient in need thereof an effective amount of a compound of Formula II: wherein: ]
0.030757774	1271	[ R1 and R2 each have an integer value from 0 to 3, ]	[ R1 and R2 are independently selected from the group consisting of hydrogen, aryl, heteroaryl, heterocyclyl or heteroalkyl; ]
0.010693192	1272	[ &#x2014; ]	[ R1 and R2 each have an integer value from 0 to 3, ]
0.9712993	1273	[ CH2; ]	[ &#x2014; ]
0.99505603	1274	[ R1 and R2 each have a hydrogen atom; ]	[ CH2; ]
0.9988181	1275	[ R1 is independently selected from the group consisting of a hydrogen atom, a heterocyclyl group, a heteroalkyl group, a heteroaryl group, a heterocyclyl group, a heteroalkyl group, a heteroalkyl group, a heteroaryl group or a heterocyclyl group; ]	[ R1 and R2 each have a hydrogen atom; ]
0.99576735	1276	[ R1 has an integer value from 0 to 3, ]	[ R1 is independently selected from the group consisting of a hydrogen atom, a heterocyclyl group, a heteroalkyl group, a heteroaryl group, a heterocyclyl group, a heteroalkyl group, a heteroalkyl group, a heteroaryl group or a heterocyclyl group; ]
0.009448241	1277	[ &#x2014; ]	[ R1 has an integer value from 0 to 3, ]
0.9794723	1278	[ CH2; and ]	[ &#x2014; ]
0.9557834	1279	[ R2 has an integer value from 0 to 3, ]	[ CH2; and ]
0.01141534	1280	[ &#x2014; ]	[ R2 has an integer value from 0 to 3, ]
0.9904828	1281	[ CH2. ]	[ &#x2014; ]
0.99972576	1282	[ providing a first pharmaceutical composition comprising an effective amount of an anti-inflammatory agent; and ]	[ A method of treating a patient suffering from a condition comprising: ]
0.9999914	1283	[ delivering a second pharmaceutical composition to the patient, wherein the second pharmaceutical composition comprises a pharmaceutically acceptable carrier. ]	[ providing a first pharmaceutical composition comprising an effective amount of an anti-inflammatory agent; and ]
0.9996666	1284	[ a medical treatment system including a first medical treatment device, a second medical treatment device, and ]	[ A system for providing a patient-specific medical treatment to a patient, the system comprising: ]
0.9999902	1285	[ a patient-specific device for providing a first treatment to the patient, wherein the medical treatment system is configured to provide a first treatment to the patient and a second treatment, wherein the first and the second treatment are provided by the same medical treatment device and the first and second treatment devices are coupled together in a single device; ]	[ a medical treatment system including a first medical treatment device, a second medical treatment device, and ]
0.99998415	1286	[ a patient interface configured for receiving a user-specified medical treatment request from a patient; ]	[ a patient-specific device for providing a first treatment to the patient, wherein the medical treatment system is configured to provide a first treatment to the patient and a second treatment, wherein the first and the second treatment are provided by the same medical treatment device and the first and second treatment devices are coupled together in a single device; ]
0.9997383	1287	[ a patient device for providing the first treatment; ]	[ a patient interface configured for receiving a user-specified medical treatment request from a patient; ]
0.9999404	1288	[ a patient interface for receiving a user-specified medical treatment request from a patient; and ]	[ a patient device for providing the first treatment; ]
0.9999696	1289	[ a first medical treatment device for delivering a first treatment to the patient; and ]	[ a patient interface for receiving a user-specified medical treatment request from a patient; and ]
0.99999225	1290	[ a second medical treatment device for delivering a second treatment to the patient. ]	[ a first medical treatment device for delivering a first treatment to the patient; and ]
4.9169732e-05	1291	[ (a) an isolated nucleic acid molecule encoding a polypeptide having the amino acid sequence of SEQ ID NO: ]	[ A method for treating a disease or disorder in a mammal, comprising administering to said mammal a therapeutically effective amount of an effective amount of a compound selected from the group consisting of: ]
0.99764425	1292	[ 3; ]	[ (a) an isolated nucleic acid molecule encoding a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.99673414	1293	[ (b) a polypeptide having the amino acid sequence of SEQ ID NO: ]	[ 3; ]
0.99921155	1294	[ 4; and ]	[ (b) a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.9987495	1295	[ (c) a polypeptide having the amino acid sequence of SEQ ID NO: ]	[ 4; and ]
0.99898	1296	[ 5. ]	[ (c) a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.01819366	1297	[ (1) wherein: ]	[ A method for treating a patient with a disease or condition in the patient, the method comprising administering to the patient a composition comprising an effective amount of a compound having the structure: ]
0.99673104	1298	[ (A) a) and (B) are independently selected from the group consisting of: ]	[ (1) wherein: ]
0.99720544	1299	[ (i) a) an amino acid sequence having at least 95% identity to SEQ ID NO: 2, and ]	[ (A) a) and (B) are independently selected from the group consisting of: ]
0.9999647	1300	[ (ii) a sequence selected from the group consisting of SEQ ID NO: 2, ]	[ (i) a) an amino acid sequence having at least 95% identity to SEQ ID NO: 2, and ]
0.9999746	1301	[ (iii) a nucleic acid sequence having at least 95% identity to SEQ ID NO: 3, and ]	[ (ii) a sequence selected from the group consisting of SEQ ID NO: 2, ]
0.999987	1302	[ (iv) a sequence selected from the group consisting of SEQ ID NO: 3, and ]	[ (iii) a nucleic acid sequence having at least 95% identity to SEQ ID NO: 3, and ]
0.9999794	1303	[ (v) a nucleic acid sequence having at least 95% identity to SEQ ID NO: 4; and ]	[ (iv) a sequence selected from the group consisting of SEQ ID NO: 3, and ]
0.0075317873	1304	[ (b) a pharmaceutically acceptable carrier; ]	[ (v) a nucleic acid sequence having at least 95% identity to SEQ ID NO: 4; and ]
0.9997223	1305	[ (2) wherein the composition is administered to the patient by means of a pharmaceutical delivery system. ]	[ (b) a pharmaceutically acceptable carrier; ]
0.99624807	1306	[ (a) a pharmaceutically acceptable salt of a polypeptide having the structure of SEQ ID NO: ]	[ A method for treating a patient having a disease comprising administering to said patient a therapeutically effective amount of a pharmaceutically acceptable composition comprising an active agent and an anti-inflammatory agent, wherein the active agent and the anti-inflammatory agent comprise at least one compound selected from the following group consisting of a compound selected from the group consisting of: ]
0.99802905	1307	[ 3; ]	[ (a) a pharmaceutically acceptable salt of a polypeptide having the structure of SEQ ID NO: ]
0.9977405	1308	[ (b) a polypeptide having the structure of SEQ ID NO: ]	[ 3; ]
0.99933404	1309	[ 4; and ]	[ (b) a polypeptide having the structure of SEQ ID NO: ]
0.9988255	1310	[ (c) a polypeptide having the structure of SEQ ID NO: ]	[ 4; and ]
0.9991836	1311	[ 5. ]	[ (c) a polypeptide having the structure of SEQ ID NO: ]
0.9999602	1312	[ (i) contacting a composition comprising a composition of a polypeptide comprising an anti-inflammatory agent with a first anti-inflammatory agent, the anti-inflammatory agent having an affinity for a target tissue, and ]	[ A method for the production of an effective amount of an anti-inflammatory agent comprising the steps of: ]
0.99999213	1313	[ the first anti-inflammatory agent being a polypeptide comprising a polypeptide of SEQ ID NO: ]	[ (i) contacting a composition comprising a composition of a polypeptide comprising an anti-inflammatory agent with a first anti-inflammatory agent, the anti-inflammatory agent having an affinity for a target tissue, and ]
0.9996326	1314	[ 2, SEQ ID NO: ]	[ the first anti-inflammatory agent being a polypeptide comprising a polypeptide of SEQ ID NO: ]
0.99998915	1315	[ 3, SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.9999895	1316	[ 4, SEQ ID NO: ]	[ 3, SEQ ID NO: ]
0.99998796	1317	[ 5, SEQ ID NO: ]	[ 4, SEQ ID NO: ]
0.9999709	1318	[ 6 and SEQ ID NO: ]	[ 5, SEQ ID NO: ]
0.9993605	1319	[ 7; ]	[ 6 and SEQ ID NO: ]
0.99250925	1320	[ (ii) contacting a composition comprising a composition of a polypeptide comprising an anti-inflammatory agent with a second anti-inflammatory agent; ]	[ 7; ]
0.9999924	1321	[ (iii) contacting a composition comprising a composition comprising a polypeptide comprising an anti-inflammatory agent with a third anti-inflammatory agent; and ]	[ (ii) contacting a composition comprising a composition of a polypeptide comprising an anti-inflammatory agent with a second anti-inflammatory agent; ]
0.99999225	1322	[ (iv) contacting a composition comprising a composition comprising a polypeptide comprising a polypeptide of SEQ ID NO: ]	[ (iii) contacting a composition comprising a composition comprising a polypeptide comprising an anti-inflammatory agent with a third anti-inflammatory agent; and ]
0.99957937	1323	[ 2, SEQ ID NO: ]	[ (iv) contacting a composition comprising a composition comprising a polypeptide comprising a polypeptide of SEQ ID NO: ]
0.99998915	1324	[ 3, SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.9999895	1325	[ 4, SEQ ID NO: ]	[ 3, SEQ ID NO: ]
0.9999645	1326	[ 5 and SEQ ID NO: ]	[ 4, SEQ ID NO: ]
0.9995993	1327	[ 6. ]	[ 5 and SEQ ID NO: ]
0.99999213	1328	[ (a) preparing a first compound comprising a pharmaceutically acceptable salt of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3; ]	[ A method for the production of a compound having an effective amount of a pharmaceutically acceptable salt of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3, comprising: ]
0.99999213	1329	[ (b) contacting a first pharmaceutically acceptable salt with a first pharmaceutically acceptable salt of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3, wherein the first compound is a pharmaceutically acceptable salt of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3; and ]	[ (a) preparing a first compound comprising a pharmaceutically acceptable salt of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3; ]
0.99999225	1330	[ (c) contacting a second compound comprising a pharmaceutically acceptable salt of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3 with the first compound, wherein the second compound has the same effective amount of the pharmaceutically acceptable salt of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3 as the first compound. ]	[ (b) contacting a first pharmaceutically acceptable salt with a first pharmaceutically acceptable salt of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3, wherein the first compound is a pharmaceutically acceptable salt of SEQ ID NO: 1 or SEQ ID NO: 1 or SEQ ID NO: 3; and ]
0.99997044	1331	[ (a) obtaining an implant having a proximal end and a distal end; ]	[ A method for producing an implant for a patient comprising: ]
0.9999684	1332	[ (b) forming a first portion of the implant into a first cavity; ]	[ (a) obtaining an implant having a proximal end and a distal end; ]
0.99999225	1333	[ (c) forming a second portion of the implant into a second cavity; ]	[ (b) forming a first portion of the implant into a first cavity; ]
0.9999907	1334	[ (d) forming a first seal between the first portion and the second portion of the implant to prevent the first and second portions from moving; ]	[ (c) forming a second portion of the implant into a second cavity; ]
0.99999225	1335	[ (e) forming a first seal seal between the first portion and the second portion of the implant, wherein the first seal seal comprises a first seal member; ]	[ (d) forming a first seal between the first portion and the second portion of the implant to prevent the first and second portions from moving; ]
0.99999225	1336	[ (f) forming a second seal seal between the first seal member and the second seal seal member to prevent the first and second portions from moving, the first seal seal member comprising a second seal member; and ]	[ (e) forming a first seal seal between the first portion and the second portion of the implant, wherein the first seal seal comprises a first seal member; ]
0.99999213	1337	[ (g) applying a first pressure to a first portion of the first cavity and a second portion of the first cavity to form a first sealing member, the first seal member and the second seal member forming a seal, wherein the first seal member and the second seal member form a seal seal, wherein the first and second portions of the implant are positioned in a first and second cavities of the first and second cavities, respectively, and ]	[ (f) forming a second seal seal between the first seal member and the second seal seal member to prevent the first and second portions from moving, the first seal seal member comprising a second seal member; and ]
0.9999924	1338	[ wherein the first and second portions of the implant are positioned in the first and second cavities of the first and second cavities respectively. ]	[ (g) applying a first pressure to a first portion of the first cavity and a second portion of the first cavity to form a first sealing member, the first seal member and the second seal member forming a seal, wherein the first seal member and the second seal member form a seal seal, wherein the first and second portions of the implant are positioned in a first and second cavities of the first and second cavities, respectively, and ]
0.9994411	1339	[ (a) providing a therapeutically effective amount of a compound of formula (I): ]	[ A method of treating a disease comprising: ]
0.99907625	1340	[ whereinR1, R2, R3, R4, R5, R6, R7, R8, R9 are each optionally substituted with one or more hydrogen atoms, and ]	[ (a) providing a therapeutically effective amount of a compound of formula (I): ]
0.9998388	1341	[ each R1 is optionally substituted with a hydrogen atom selected from the group consisting of hydrogen, oxygen, nitrogen, sulfur, and ]	[ whereinR1, R2, R3, R4, R5, R6, R7, R8, R9 are each optionally substituted with one or more hydrogen atoms, and ]
0.0063646617	1342	[ a C1 to C4 alkyl group, and ]	[ each R1 is optionally substituted with a hydrogen atom selected from the group consisting of hydrogen, oxygen, nitrogen, sulfur, and ]
0.008522658	1343	[ each R2 is optionally substituted with one or more hydrogen atoms, ]	[ a C1 to C4 alkyl group, and ]
0.9999839	1344	[ R9 and R10 are each optionally substituted with one or more hydrogen atoms, and ]	[ each R2 is optionally substituted with one or more hydrogen atoms, ]
0.99994516	1345	[ wherein R9 is optionally substituted with one or more hydrogen atoms selected from the group consisting of hydrogen and oxygen, and ]	[ R9 and R10 are each optionally substituted with one or more hydrogen atoms, and ]
0.9999713	1346	[ R10 is optionally substituted with one or more hydrogen atoms selected from the group consisting of hydrogen and sulfur, and ]	[ wherein R9 is optionally substituted with one or more hydrogen atoms selected from the group consisting of hydrogen and oxygen, and ]
0.9999763	1347	[ wherein R9 and R10 are each optionally substituted with one or more hydrogen atoms selected from the group consisting of hydrogen and oxygen, and ]	[ R10 is optionally substituted with one or more hydrogen atoms selected from the group consisting of hydrogen and sulfur, and ]
0.9999858	1348	[ wherein R11 is optionally substituted with one or more hydrogen atoms selected from the group consisting of hydrogen and oxygen. ]	[ wherein R9 and R10 are each optionally substituted with one or more hydrogen atoms selected from the group consisting of hydrogen and oxygen, and ]
0.004668959	1349	[ a) a first body having a first proximal end; ]	[ A device for providing an implantation site for a surgical procedure to a patient, comprising: ]
0.999992	1350	[ b) a second body having a second proximal end, wherein the first and second bodies are disposed in a first and second parallel longitudinal direction, wherein the second body is disposed in the first direction; ]	[ a) a first body having a first proximal end; ]
0.9997788	1351	[ c) a first support structure having a first support member and a first support member support structure; ]	[ b) a second body having a second proximal end, wherein the first and second bodies are disposed in a first and second parallel longitudinal direction, wherein the second body is disposed in the first direction; ]
0.99999213	1352	[ d) a second support structure having a second support member and a second support member support structure; ]	[ c) a first support structure having a first support member and a first support member support structure; ]
0.99998844	1353	[ e) a first shaft having a first shaft member and a first shaft member support structure; ]	[ d) a second support structure having a second support member and a second support member support structure; ]
0.99999225	1354	[ f) a second shaft having a second shaft member and a second shaft member support structure; ]	[ e) a first shaft having a first shaft member and a first shaft member support structure; ]
0.99999225	1355	[ g) a first shaft member having a first shaft member support structure and a second shaft member support structure; ]	[ f) a second shaft having a second shaft member and a second shaft member support structure; ]
0.99999225	1356	[ h) a second shaft member having a second shaft member support structure and a second shaft member support structure; and ]	[ g) a first shaft member having a first shaft member support structure and a second shaft member support structure; ]
0.99999213	1357	[ i) a third shaft member having a third shaft member support structure; ]	[ h) a second shaft member having a second shaft member support structure and a second shaft member support structure; and ]
0.0028473171	1358	[ wherein the first support structure and the second support structure are disposed in a first and second parallel longitudinal direction, wherein the first support structure is disposed in the first direction and the second support structure is disposed in the second direction, and ]	[ i) a third shaft member having a third shaft member support structure; ]
0.9999882	1359	[ wherein the first shaft and the second shaft are disposed in the same longitudinal direction. ]	[ wherein the first support structure and the second support structure are disposed in a first and second parallel longitudinal direction, wherein the first support structure is disposed in the first direction and the second support structure is disposed in the second direction, and ]
0.9960284	1360	[ X represents a hydrogen atom or a substituted or unsubstituted hydrogen atom, ]	[ A method of treating a subject having a heart defect, the method comprising administering a compound of formula (I) to a subject having a heart defect, wherein: ]
0.99709404	1361	[ R1 is hydrogen or an alkyl group, ]	[ X represents a hydrogen atom or a substituted or unsubstituted hydrogen atom, ]
0.9998307	1362	[ R2 is hydrogen, or an alkyl group; or R3 is a hydrogen atom or an alkyl group; or R4 and R4&#x2032; ]	[ R1 is hydrogen or an alkyl group, ]
0.9975605	1363	[ R5 represent a hydrogen atom or an alkyl group, ]	[ R2 is hydrogen, or an alkyl group; or R3 is a hydrogen atom or an alkyl group; or R4 and R4&#x2032; ]
0.020061318	1364	[ wherein the compound is selected from the group consisting of an amino acid substitution, a substitution for a substituted or unsubstituted amino acid or a substitution for a substituted or unsubstituted alkyl group, and ]	[ R5 represent a hydrogen atom or an alkyl group, ]
0.9999459	1365	[ a substitution for an alkyl group. ]	[ wherein the compound is selected from the group consisting of an amino acid substitution, a substitution for a substituted or unsubstituted amino acid or a substitution for a substituted or unsubstituted alkyl group, and ]
0.9999777	1366	[ (a) providing a first integrated circuit module; ]	[ A method of providing an integrated circuit comprising an integrated circuit module, the method comprising: ]
0.99999225	1367	[ (b) providing a second integrated circuit module; ]	[ (a) providing a first integrated circuit module; ]
0.9999906	1368	[ (c) coupling the first and second integrated circuit modules together to form a single unit, wherein the single unit is configured to provide a first integrated circuit module to a first device; and ]	[ (b) providing a second integrated circuit module; ]
0.99999225	1369	[ (d) coupling the second integrated circuit module and the first integrated circuit module to form an integrated circuit module; ]	[ (c) coupling the first and second integrated circuit modules together to form a single unit, wherein the single unit is configured to provide a first integrated circuit module to a first device; and ]
0.99866533	1370	[ wherein each integrated circuit module includes: ]	[ (d) coupling the second integrated circuit module and the first integrated circuit module to form an integrated circuit module; ]
0.9999746	1371	[ (1) a first integrated circuit module; and ]	[ wherein each integrated circuit module includes: ]
0.9999864	1372	[ (2) a first logic module; wherein the first logic module comprises a first integrated circuit module and a first integrated circuit module, the first integrated circuit module and the first integrated circuit module are coupled to each other, and ]	[ (1) a first integrated circuit module; and ]
0.9999906	1373	[ wherein each integrated circuit module is configured to be coupled to the first integrated circuit module to form a single integrated circuit module. ]	[ (2) a first logic module; wherein the first logic module comprises a first integrated circuit module and a first integrated circuit module, the first integrated circuit module and the first integrated circuit module are coupled to each other, and ]
0.9776037	1374	[ a first electrode having an electrode surface; and ]	[ An implantable medical device comprising: ]
0.9998565	1375	[ a second electrode, wherein said first electrode and said second electrode are disposed in a first configuration and wherein said first configuration has a first electrode surface and said second configuration has a second electrode surface, wherein said first electrode surface is configured to contact the medical device and wherein said second electrode surface is configured to contact a patient, and ]	[ a first electrode having an electrode surface; and ]
0.999992	1376	[ wherein a first portion of said first electrode surface has a first electrode surface shape and a second portion of said first electrode surface is configured to contact a patient, and ]	[ a second electrode, wherein said first electrode and said second electrode are disposed in a first configuration and wherein said first configuration has a first electrode surface and said second configuration has a second electrode surface, wherein said first electrode surface is configured to contact the medical device and wherein said second electrode surface is configured to contact a patient, and ]
0.9998079	1377	[ wherein the second electrode is disposed in a third configuration that is different than said first configuration, wherein said third configuration is different than said first configuration, and ]	[ wherein a first portion of said first electrode surface has a first electrode surface shape and a second portion of said first electrode surface is configured to contact a patient, and ]
0.9993579	1378	[ wherein said first portion of said first electrode surface has a first electrode surface shape and a second portion of said first electrode surface is configured to contact a patient, wherein said first electrode surface has a first surface shape that is substantially the same as the first surface shape of said second electrode surface, and ]	[ wherein the second electrode is disposed in a third configuration that is different than said first configuration, wherein said third configuration is different than said first configuration, and ]
0.99999225	1379	[ wherein said second electrode surface has a second surface shape that is substantially the same as the second surface shape of said second electrode surface. ]	[ wherein said first portion of said first electrode surface has a first electrode surface shape and a second portion of said first electrode surface is configured to contact a patient, wherein said first electrode surface has a first surface shape that is substantially the same as the first surface shape of said second electrode surface, and ]
0.9970824	1380	[ b) a pharmaceutically acceptable carrier. ]	[ A method of treating a patient suffering from an inflammatory disease, comprising administering to the patient a composition comprising: a) an effective amount of a polypeptide having the amino acid sequence as set forth in SEQ ID NO: 2; and ]
0.99836606	1381	[ (a) SEQ ID NO: ]	[ An isolated polypeptide consisting of a nucleic acid sequence selected from the group consisting of: ]
0.98614997	1382	[ 1; ]	[ (a) SEQ ID NO: ]
0.993807	1383	[ (b) SEQ ID NO: ]	[ 1; ]
0.0011736763	1384	[ 1, ]	[ (b) SEQ ID NO: ]
0.0017859412	1385	[ (c) SEQ ID NO: ]	[ 1, ]
0.001006241	1386	[ 1, ]	[ (c) SEQ ID NO: ]
0.0018515764	1387	[ (d) SEQ ID NO: ]	[ 1, ]
0.9986786	1388	[ 2; ]	[ (d) SEQ ID NO: ]
0.99700963	1389	[ (e) SEQ ID NO: ]	[ 2; ]
0.9962565	1390	[ 2, and ]	[ (e) SEQ ID NO: ]
0.99571085	1391	[ (f) SEQ ID NO: ]	[ 2, and ]
0.99819654	1392	[ 3. ]	[ (f) SEQ ID NO: ]
0.9999448	1393	[ 1 or a nucleic acid sequence comprising the amino acid sequence set forth in SEQ ID NO: ]	[ An isolated nucleic acid molecule encoding a protein comprising a nucleic acid sequence comprising SEQ ID NO: ]
0.9996747	1394	[ 1, wherein the nucleic acid molecule is selected from the group consisting of: ]	[ 1 or a nucleic acid sequence comprising the amino acid sequence set forth in SEQ ID NO: ]
0.99997103	1395	[ a) a nucleic acid molecule comprising a first amino acid sequence having the sequence of SEQ ID NO: ]	[ 1, wherein the nucleic acid molecule is selected from the group consisting of: ]
0.9938836	1396	[ 1; ]	[ a) a nucleic acid molecule comprising a first amino acid sequence having the sequence of SEQ ID NO: ]
0.99103206	1397	[ b) a nucleic acid molecule comprising a second amino acid sequence having the sequence of SEQ ID NO: ]	[ 1; ]
0.99392104	1398	[ 1; and ]	[ b) a nucleic acid molecule comprising a second amino acid sequence having the sequence of SEQ ID NO: ]
0.9910705	1399	[ c) a nucleic acid molecule comprising a third amino acid sequence having the sequence of SEQ ID NO: ]	[ 1; and ]
0.99998283	1400	[ 1, wherein the third amino acid sequence is not identical to the first amino acid sequence. ]	[ c) a nucleic acid molecule comprising a third amino acid sequence having the sequence of SEQ ID NO: ]
0.99999225	1401	[ (4) a nucleic acid encoding a fragment of the human immunodeficiency virus, wherein the antibody or antigen binding fragment comprises a nucleic acid sequence that is at least 90% identical to the sequence of the human immunodeficiency virus, and ]	[ A method for the treatment of an inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of an antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment comprises a sequence that is at least 90% identical to the sequence of the human immunodeficiency virus type 1 (HIV-1) antigen, wherein the antibody or antigen binding fragment is selected from the group consisting of: (1) the human immunodeficiency virus type 1 (HIV-1) antigen, (2) the human immunodeficiency virus type 1 (HIV-1) antigen, (3) an antibody or antigen binding fragment thereof, and ]
0.9999914	1402	[ the method further comprises administering to the patient in need thereof a therapeutically effective amount of at least one other antibody or antigen binding fragment of the human immunodeficiency virus type 1 (HIV-1) antigen. ]	[ (4) a nucleic acid encoding a fragment of the human immunodeficiency virus, wherein the antibody or antigen binding fragment comprises a nucleic acid sequence that is at least 90% identical to the sequence of the human immunodeficiency virus, and ]
0.9999906	1403	[ an interface device configured to be coupled with the implantable medical device and configured to receive a first set of instructions from a user, the first set of instructions comprising a plurality of instructions, the plurality of instructions including instructions for: ]	[ A system for providing an implantable medical device, comprising: ]
0.9999876	1404	[ providing an implantable medical device; and ]	[ an interface device configured to be coupled with the implantable medical device and configured to receive a first set of instructions from a user, the first set of instructions comprising a plurality of instructions, the plurality of instructions including instructions for: ]
0.99999154	1405	[ providing a first user interface device configured to be configured to be coupled with the implantable medical device and configured to receive a second set of instructions from the user, the second set of instructions comprising instructions for: ]	[ providing an implantable medical device; and ]
0.9999882	1406	[ providing a first user interface device; ]	[ providing a first user interface device configured to be configured to be coupled with the implantable medical device and configured to receive a second set of instructions from the user, the second set of instructions comprising instructions for: ]
0.999992	1407	[ displaying a first image on the first user interface device; ]	[ providing a first user interface device; ]
0.9999901	1408	[ receiving an instruction from the first user interface device; and ]	[ displaying a first image on the first user interface device; ]
0.9999895	1409	[ providing a second user interface device; ]	[ receiving an instruction from the first user interface device; and ]
0.9999368	1410	[ wherein the first and second user interfaces are coupled together and configured to communicate with the implantable medical device. ]	[ providing a second user interface device; ]
0.9999629	1411	[ providing an implant having a first surface and a second surface, wherein the first surface is configured to receive a plurality of electrodes; ]	[ A method of providing an implant for use in an implantable medical device, the method comprising: ]
0.99999166	1412	[ providing an electrode assembly comprising a first electrode and a second electrode, wherein the first electrode and the second electrode are configured to couple to the first surface of the implant, and ]	[ providing an implant having a first surface and a second surface, wherein the first surface is configured to receive a plurality of electrodes; ]
0.9999752	1413	[ wherein the first surface is configured to be positioned on the first electrode; and ]	[ providing an electrode assembly comprising a first electrode and a second electrode, wherein the first electrode and the second electrode are configured to couple to the first surface of the implant, and ]
0.9999672	1414	[ providing an electrode assembly comprising a first electrode and a second electrode, wherein the first electrode and the second electrode are configured to couple to the second surface of the implant, and ]	[ wherein the first surface is configured to be positioned on the first electrode; and ]
0.9999827	1415	[ wherein the first surface is not configured to be positioned on the second electrode. ]	[ providing an electrode assembly comprising a first electrode and a second electrode, wherein the first electrode and the second electrode are configured to couple to the second surface of the implant, and ]
0.9998857	1416	[ administering to the subject an effective amount of a composition comprising a therapeutically effective amount of a pharmaceutically effective amount of an anti-TNF antibody, wherein the anti-TNF antibody comprises a heavy chain variable region and a light chain variable region; and ]	[ A method of treating a disease in a subject comprising: ]
0.999992	1417	[ administering to the subject a composition containing an effective amount of the composition. ]	[ administering to the subject an effective amount of a composition comprising a therapeutically effective amount of a pharmaceutically effective amount of an anti-TNF antibody, wherein the anti-TNF antibody comprises a heavy chain variable region and a light chain variable region; and ]
0.9875887	1418	[ 1. ]	[ An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.9999895	1419	[ providing a surgical instrument; ]	[ A method for determining a location for a surgical instrument, the method comprising: ]
0.99973935	1420	[ providing a plurality of sensors; and ]	[ providing a surgical instrument; ]
0.9999862	1421	[ receiving, by a processor, data from each of the plurality of sensors, ]	[ providing a plurality of sensors; and ]
0.9999912	1422	[ wherein a plurality of the plurality of sensors are located within an anatomical region of the surgical instrument, ]	[ receiving, by a processor, data from each of the plurality of sensors, ]
0.99999213	1423	[ wherein the anatomical region is defined by a plurality of surgical instruments, ]	[ wherein a plurality of the plurality of sensors are located within an anatomical region of the surgical instrument, ]
0.9999882	1424	[ wherein the surgical instrument is configured to be inserted through a surgical opening in a body of a patient, and ]	[ wherein the anatomical region is defined by a plurality of surgical instruments, ]
0.99999213	1425	[ wherein the surgical instrument is configured to be positioned at least partially within the anatomical region, ]	[ wherein the surgical instrument is configured to be inserted through a surgical opening in a body of a patient, and ]
0.9999851	1426	[ wherein the plurality of the plurality of sensors are located within the anatomical region, and ]	[ wherein the surgical instrument is configured to be positioned at least partially within the anatomical region, ]
0.99999094	1427	[ wherein the plurality of sensors are configured to receive data from the surgical instrument. ]	[ wherein the plurality of the plurality of sensors are located within the anatomical region, and ]
0.9609243	1428	[ a first housing; ]	[ An apparatus comprising: ]
0.9999845	1429	[ an actuator configured to be mounted to the first housing, the actuator comprising: ]	[ a first housing; ]
0.9857755	1430	[ a housing body; ]	[ an actuator configured to be mounted to the first housing, the actuator comprising: ]
0.99998486	1431	[ an actuator body configured to engage with the housing body, the actuator body comprising: ]	[ a housing body; ]
0.9999919	1432	[ a first actuator body having a first end and a second end, wherein the first end is configured to engage with the housing body, and ]	[ an actuator body configured to engage with the housing body, the actuator body comprising: ]
0.999992	1433	[ the second end is configured to engage with the housing body; ]	[ a first actuator body having a first end and a second end, wherein the first end is configured to engage with the housing body, and ]
0.9994404	1434	[ at least one actuator body coupled to the first end of the first actuator body; and ]	[ the second end is configured to engage with the housing body; ]
0.9999907	1435	[ a first coupling member configured to engage the first end of the actuator body; ]	[ at least one actuator body coupled to the first end of the first actuator body; and ]
0.9613752	1436	[ a second housing; ]	[ a first coupling member configured to engage the first end of the actuator body; ]
0.9999366	1437	[ a first actuator body having a first end and a second end, wherein the first end is configured to engage with the first housing, and ]	[ a second housing; ]
0.99999154	1438	[ the second end is configured to engage with the first housing; and ]	[ a first actuator body having a first end and a second end, wherein the first end is configured to engage with the first housing, and ]
0.9996137	1439	[ at least one actuator body coupled to the first end of the first actuator body; ]	[ the second end is configured to engage with the first housing; and ]
0.94838625	1440	[ a second housing; ]	[ at least one actuator body coupled to the first end of the first actuator body; ]
0.9999647	1441	[ a second actuator body having a first end and a second end, wherein the first end is configured to engage with the second housing, and ]	[ a second housing; ]
0.99999154	1442	[ the second end is configured to engage with the second housing; and ]	[ a second actuator body having a first end and a second end, wherein the first end is configured to engage with the second housing, and ]
0.9998123	1443	[ at least one actuator body coupled to the first end of the second actuator body. ]	[ the second end is configured to engage with the second housing; and ]
0.016047012	1444	[ an agonist for the receptor for a peptide having the structure (SEQ ID NO: ]	[ A method of treating a patient suffering from a chronic pain syndrome comprising administering to the patient a composition comprising an effective amount of a compound selected from the group consisting of: ]
0.9993678	1445	[ 4) or a pharmaceutically acceptable salt thereof; ]	[ an agonist for the receptor for a peptide having the structure (SEQ ID NO: ]
0.9987889	1446	[ an antagonist for the receptor for a peptide having the structure (SEQ ID NO: ]	[ 4) or a pharmaceutically acceptable salt thereof; ]
0.999244	1447	[ 4) or a pharmaceutically acceptable salt thereof; ]	[ an antagonist for the receptor for a peptide having the structure (SEQ ID NO: ]
0.99928683	1448	[ a pharmaceutically acceptable carrier; and ]	[ 4) or a pharmaceutically acceptable salt thereof; ]
0.9991768	1449	[ a pharmaceutically acceptable composition. ]	[ a pharmaceutically acceptable carrier; and ]
0.9992299	1450	[ 4. ]	[ A method of producing an isolated polypeptide comprising the sequence of SEQ ID NO: ]
0.9993692	1451	[ 1 and SEQ ID NO: ]	[ A method of producing a polypeptide comprising a nucleic acid encoding a peptide comprising a first amino acid sequence and a second amino acid sequence different from the first amino acid sequence, the first and second amino acid sequences being complementary, wherein the first and second amino acid sequences are selected from the group consisting of SEQ ID NO: ]
0.999329	1452	[ 2, and ]	[ 1 and SEQ ID NO: ]
0.9962107	1453	[ wherein the polypeptide has an amino acid sequence having a length greater than about 100 nucleotides. ]	[ 2, and ]
0.99620557	1454	[ a) a sequence having a sequence of amino acids having the sequence of SEQ ID NO: 1, 2, 4, 6, 7, 8 or 9; and ]	[ A method of producing a compound having an effective amount of an amino acid sequence selected from the group consisting of: ]
0.9999913	1455	[ b) a sequence of amino acids that is at least 95% identical to SEQ ID NO: 1, 2, 4, 6, 7, 8, 9, or 10. ]	[ a) a sequence having a sequence of amino acids having the sequence of SEQ ID NO: 1, 2, 4, 6, 7, 8 or 9; and ]
0.9999367	1456	[ administering to the disease a therapeutically effective amount of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or derivative thereof, wherein R1 is a first alkyl group, a substituted alkyl group, or a substituted substituted alkyl group; ]	[ A method for treating a disease in a mammal, the method comprising: ]
0.9998072	1457	[ R2 is a second alkyl group; and ]	[ administering to the disease a therapeutically effective amount of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or derivative thereof, wherein R1 is a first alkyl group, a substituted alkyl group, or a substituted substituted alkyl group; ]
0.999982	1458	[ R3 is a third alkyl group. ]	[ R2 is a second alkyl group; and ]
0.9958677	1459	[ 2. ]	[ An isolated nucleic acid molecule encoding a protein comprising a nucleic acid sequence comprising the sequence set forth in SEQ ID NO: ]
0.005956027	1460	[ 1, or a pharmaceutically acceptable salt thereof, or a combination thereof, and ]	[ A method of treating an inflammatory bowel disease, comprising administering to a patient a composition comprising a pharmaceutically acceptable carrier, wherein said carrier is a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.99687	1461	[ wherein the composition is administered to a patient. ]	[ 1, or a pharmaceutically acceptable salt thereof, or a combination thereof, and ]
0.999153	1462	[ or a pharmaceutically acceptable salt thereof, wherein: ]	[ A method of treating a patient with an inflammatory disease comprising administering to the patient a therapeutically effective amount of a compound of the formula: ]
0.014841343	1463	[ X represents an integer from 1 to 4; and ]	[ or a pharmaceutically acceptable salt thereof, wherein: ]
0.006530807	1464	[ R represents H, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable salt thereof; ]	[ X represents an integer from 1 to 4; and ]
0.99819297	1465	[ R2 and R3 are independently selected from the group consisting of hydrogen, alkyl, alkoxy, heteroaryl, alkyloxy, alkylamino, alkylaminoalkyl, alkylaminoaryl, heteroarylalkyl, alkylarylalkyl, heteroarylarylalkyl, alkylarylalkylalkyl or alkylsulfonyl. ]	[ R represents H, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable salt thereof; ]
0.9897642	1466	[ a housing having a first opening and a second opening; ]	[ An apparatus for providing a patient with an infusion therapy device, comprising: ]
0.99955326	1467	[ a first infusion pump configured to provide a first infusion of an infusion fluid into the patient's body through the first opening; ]	[ a housing having a first opening and a second opening; ]
0.99999225	1468	[ a second infusion pump configured to provide a second infusion of the infusion fluid into the patient's body through the second opening; ]	[ a first infusion pump configured to provide a first infusion of an infusion fluid into the patient's body through the first opening; ]
0.9999919	1469	[ a first valve configured to allow the first infusion to pass through the first opening and the second opening; ]	[ a second infusion pump configured to provide a second infusion of the infusion fluid into the patient's body through the second opening; ]
0.99999225	1470	[ a second valve configured to allow the second infusion to pass through the second opening; ]	[ a first valve configured to allow the first infusion to pass through the first opening and the second opening; ]
0.9999888	1471	[ a first pump configured to provide a first pump of the infusion fluid to the first infusion pump; ]	[ a second valve configured to allow the second infusion to pass through the second opening; ]
0.9999924	1472	[ a second pump configured to provide a second pump of the infusion fluid to the second infusion pump; ]	[ a first pump configured to provide a first pump of the infusion fluid to the first infusion pump; ]
0.9999422	1473	[ a first valve configured to allow the first pump to pass through the first opening and the second opening; and ]	[ a second pump configured to provide a second pump of the infusion fluid to the second infusion pump; ]
0.99999225	1474	[ a second valve configured to allow the second pump to pass through the second opening. ]	[ a first valve configured to allow the first pump to pass through the first opening and the second opening; and ]
0.9982175	1475	[ providing a first material; ]	[ A method for producing an implantable device comprising: ]
0.99999225	1476	[ providing a second material; ]	[ providing a first material; ]
0.9999728	1477	[ providing a first electrode; ]	[ providing a second material; ]
0.9999918	1478	[ providing a second electrode; and ]	[ providing a first electrode; ]
0.9999646	1479	[ providing a first material and a second material, wherein each material comprises a plurality of electrodes; ]	[ providing a second electrode; and ]
0.9999261	1480	[ applying a pressure to each electrode to generate a pressure wave; ]	[ providing a first material and a second material, wherein each material comprises a plurality of electrodes; ]
0.9999908	1481	[ applying a current to each electrode to produce an electrical current; and ]	[ applying a pressure to each electrode to generate a pressure wave; ]
0.999992	1482	[ applying a voltage to each electrode to produce an electric current. ]	[ applying a current to each electrode to produce an electrical current; and ]
0.9917149	1483	[ an implantable device; and ]	[ An apparatus for treating a patient, the apparatus comprising: ]
0.9940806	1484	[ a plurality of sensors, wherein the plurality of sensors is configured to detect a condition of the patient, and ]	[ an implantable device; and ]
0.999992	1485	[ wherein each of the plurality of sensors is configured to detect a different type of sensor, and ]	[ a plurality of sensors, wherein the plurality of sensors is configured to detect a condition of the patient, and ]
0.99999225	1486	[ wherein each of the plurality of sensors is configured to detect a different type of condition. ]	[ wherein each of the plurality of sensors is configured to detect a different type of sensor, and ]
0.0027689093	1487	[ a) providing an isolated polypeptide having a sequence having at least 95% sequence identity with SEQ ID NO: ]	[ A method of producing a pharmaceutical composition for use in treating a condition in a mammal, the method comprising: ]
0.99996924	1488	[ 1, wherein said polypeptide is a human immunodeficiency virus (HIV) polypeptide; and ]	[ a) providing an isolated polypeptide having a sequence having at least 95% sequence identity with SEQ ID NO: ]
0.99996734	1489	[ b) contacting said isolated polypeptide with a pharmaceutical composition comprising a pharmaceutically active agent to produce a pharmaceutical composition having a pharmaceutically active agent in the form of an effective amount of at least one of an active substance or a pharmaceutical composition, wherein the pharmaceutical composition is a pharmaceutically active agent comprising a pharmaceutically active agent selected from the group consisting of: an active substance, a pharmaceutical agent, and ]	[ 1, wherein said polypeptide is a human immunodeficiency virus (HIV) polypeptide; and ]
0.00023988164	1490	[ a pharmaceutically acceptable salt thereof; ]	[ b) contacting said isolated polypeptide with a pharmaceutical composition comprising a pharmaceutically active agent to produce a pharmaceutical composition having a pharmaceutically active agent in the form of an effective amount of at least one of an active substance or a pharmaceutical composition, wherein the pharmaceutical composition is a pharmaceutically active agent comprising a pharmaceutically active agent selected from the group consisting of: an active substance, a pharmaceutical agent, and ]
0.99927694	1491	[ wherein the pharmaceutical composition comprises at least one active substance and at least one pharmaceutically acceptable salt. ]	[ a pharmaceutically acceptable salt thereof; ]
0.5454564	1492	[ a pharmaceutically acceptable salt or ester of an amino acid selected from the group consisting of: ]	[ A method of treating a disease comprising administering to a subject in need thereof an effective amount of a composition comprising: ]
0.99337643	1493	[ (i) the amino acid sequence of SEQ ID NO: ]	[ a pharmaceutically acceptable salt or ester of an amino acid selected from the group consisting of: ]
0.9988483	1494	[ 2; and ]	[ (i) the amino acid sequence of SEQ ID NO: ]
0.968996	1495	[ (ii) an amino acid selected from the group consisting of: ]	[ 2; and ]
0.9997718	1496	[ (A) a sequence selected from the group consisting of amino acids 1 to 8 of SEQ ID NO: ]	[ (ii) an amino acid selected from the group consisting of: ]
0.99807537	1497	[ 2; and ]	[ (A) a sequence selected from the group consisting of amino acids 1 to 8 of SEQ ID NO: ]
0.99842924	1498	[ (B) an amino acid sequence selected from the group consisting of amino acids 1 to 8 of SEQ ID NO: ]	[ 2; and ]
0.99732745	1499	[ 2. ]	[ (B) an amino acid sequence selected from the group consisting of amino acids 1 to 8 of SEQ ID NO: ]
0.9633915	1500	[ a housing; ]	[ An apparatus comprising: ]
0.9775873	1501	[ a support member; and ]	[ a housing; ]
0.99997425	1502	[ an elongate member extending from the housing and configured to be disposed in a plane of the support member, wherein the elongate member comprises a first end, a second end, and ]	[ a support member; and ]
0.99999166	1503	[ a third end, wherein the first end and the second end are connected to the elongate member by a first and a second connection member, the first connection member and the second connection member are configured to be disposed at a first and second location on the elongate member, the first location being in a plane perpendicular to the plane of the support member, and ]	[ an elongate member extending from the housing and configured to be disposed in a plane of the support member, wherein the elongate member comprises a first end, a second end, and ]
0.99999225	1504	[ the second location being in a plane parallel to the plane of the support member, wherein the first and second locations are configured to receive the first and second connections member, the elongate member being configured to be positioned between the first and second locations, the first and second locations being configured to be in a substantially parallel relationship to one another, the first and second connections member being configured to be disposed at a location in between the first and second locations, the first and second locations being configured to be in a substantially parallel relationship to one another, and ]	[ a third end, wherein the first end and the second end are connected to the elongate member by a first and a second connection member, the first connection member and the second connection member are configured to be disposed at a first and second location on the elongate member, the first location being in a plane perpendicular to the plane of the support member, and ]
0.9999893	1505	[ the elongate member being configured to be disposed in an elongate position relative to the support member; wherein the elongate member comprises a first end, a second end, and ]	[ the second location being in a plane parallel to the plane of the support member, wherein the first and second locations are configured to receive the first and second connections member, the elongate member being configured to be positioned between the first and second locations, the first and second locations being configured to be in a substantially parallel relationship to one another, the first and second connections member being configured to be disposed at a location in between the first and second locations, the first and second locations being configured to be in a substantially parallel relationship to one another, and ]
0.9999881	1506	[ a third end, wherein the first end and the second end are configured to be disposed in the plane perpendicular to the plane of the support member and the third end is disposed in the plane parallel to the plane of the support member. ]	[ the elongate member being configured to be disposed in an elongate position relative to the support member; wherein the elongate member comprises a first end, a second end, and ]
0.99995136	1507	[ providing a first device for providing a first treatment to a patient, the first device including a first electrode and a first conductive material, the first electrode being electrically connected to a first electrode of the first device, the first conductive material being electrically connected to a first conductive material of the first electrode; ]	[ A method of providing a medical treatment to a patient, comprising: ]
0.99999213	1508	[ providing a second device for providing a second treatment to the patient, the second device including a second electrode and a second conductive material, the second electrode being electrically connected to a second electrode of the second device, the second conductive material being electrically connected to a second conductive material of the second electrode; and ]	[ providing a first device for providing a first treatment to a patient, the first device including a first electrode and a first conductive material, the first electrode being electrically connected to a first electrode of the first device, the first conductive material being electrically connected to a first conductive material of the first electrode; ]
0.99994147	1509	[ electrically coupling the first electrode and the second electrode to each other to form a first connection between the first electrode and the second electrode. ]	[ providing a second device for providing a second treatment to the patient, the second device including a second electrode and a second conductive material, the second electrode being electrically connected to a second electrode of the second device, the second conductive material being electrically connected to a second conductive material of the second electrode; and ]
0.0005467135	1510	[ (a) an amino acid sequence of SEQ. ID NO: ]	[ A method for treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a compound selected from the group consisting of: ]
0.99744546	1511	[ 2; ]	[ (a) an amino acid sequence of SEQ. ID NO: ]
0.9991062	1512	[ (b) a nucleic acid sequence of SEQ. ID NO: ]	[ 2; ]
0.9995296	1513	[ 4; ]	[ (b) a nucleic acid sequence of SEQ. ID NO: ]
0.99935657	1514	[ (c) an amino acid sequence of SEQ. ID NO: ]	[ 4; ]
0.9991867	1515	[ 8; and ]	[ (c) an amino acid sequence of SEQ. ID NO: ]
0.99908245	1516	[ (d) a nucleic acid sequence of SEQ. ID NO: ]	[ 8; and ]
0.99890304	1517	[ 10. ]	[ (d) a nucleic acid sequence of SEQ. ID NO: ]
0.996274	1518	[ a) a first implantable medical device having a plurality of electrodes, wherein each electrode comprises a first portion having a first electrode surface and a second portion having a second electrode surface, wherein the first portion and second portion have a plurality of electrodes; and ]	[ Apparatus for the treatment of a patient, comprising: ]
0.99999225	1519	[ b) at least one second implantable medical device having a plurality of electrodes and a plurality of electrodes, wherein each electrode comprises a first portion having a first electrode surface and a second portion having a second electrode surface, wherein the first portion and the second portion each have a plurality of electrodes, and ]	[ a) a first implantable medical device having a plurality of electrodes, wherein each electrode comprises a first portion having a first electrode surface and a second portion having a second electrode surface, wherein the first portion and second portion have a plurality of electrodes; and ]
0.99999225	1520	[ wherein each of the plurality of electrodes has at least one of a first electrode surface and a second electrode surface, wherein the second portion of each electrode is disposed within the first portion of a second implantable medical device and the second portion of each electrode is disposed within the first portion of a first implantable medical device. ]	[ b) at least one second implantable medical device having a plurality of electrodes and a plurality of electrodes, wherein each electrode comprises a first portion having a first electrode surface and a second portion having a second electrode surface, wherein the first portion and the second portion each have a plurality of electrodes, and ]
0.9973724	1521	[ administering to said patient an effective amount of an effective dose of an antibody or antigen-binding fragment thereof that specifically binds to an amino acid sequence of SEQ ID NO: 1 or a fragment thereof that specifically binds to SEQ ID NO: 1; ]	[ A method for treating a patient having an abnormal heart rate, comprising: ]
0.99999213	1522	[ wherein the antibody or antigen-binding fragment of the effective dose of the antibody or antigen-binding fragment thereof is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and ]	[ administering to said patient an effective amount of an effective dose of an antibody or antigen-binding fragment thereof that specifically binds to an amino acid sequence of SEQ ID NO: 1 or a fragment thereof that specifically binds to SEQ ID NO: 1; ]
0.99999225	1523	[ SEQ ID NO: 4, wherein the amino acid sequence of the antibody or antigen-binding fragment of the effective dose of said antibody or antigen-binding fragment thereof is SEQ ID NO: 1 or SEQ ID NO: 2, and ]	[ wherein the antibody or antigen-binding fragment of the effective dose of the antibody or antigen-binding fragment thereof is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and ]
0.99999225	1524	[ wherein the amino acid sequence of said antibody or antigen-binding fragment thereof is SEQ ID NO: 3. ]	[ SEQ ID NO: 4, wherein the amino acid sequence of the antibody or antigen-binding fragment of the effective dose of said antibody or antigen-binding fragment thereof is SEQ ID NO: 1 or SEQ ID NO: 2, and ]
0.97759056	1525	[ a) a housing; ]	[ A system for providing an implantable medical device to a patient, said system comprising: ]
0.9998085	1526	[ b) an implantable medical device having a first portion having an implantable medical device interface and a second portion having a medical device; ]	[ a) a housing; ]
0.9999907	1527	[ c) at least one first sensor configured to detect a first signal indicative of a first position of the first portion of the medical device; ]	[ b) an implantable medical device having a first portion having an implantable medical device interface and a second portion having a medical device; ]
0.99999225	1528	[ d) at least one second sensor configured to detect a second signal indicative of a second position of the second portion of the medical device; ]	[ c) at least one first sensor configured to detect a first signal indicative of a first position of the first portion of the medical device; ]
0.9999739	1529	[ e) at least one processor coupled with said at least one first sensor and said at least one second sensor; ]	[ d) at least one second sensor configured to detect a second signal indicative of a second position of the second portion of the medical device; ]
0.99999225	1530	[ f) at least one memory coupled to said at least one first sensor and said at least one second sensor; and ]	[ e) at least one processor coupled with said at least one first sensor and said at least one second sensor; ]
0.9998235	1531	[ g) a processor configured to receive said first signal and said second signal and to determine a first position and a second position of the implantable medical device interface based on said detected first signal and said detected second signal and said first position and said second position, wherein said processor further comprises a memory for storing said determined first position and said determined second position. ]	[ f) at least one memory coupled to said at least one first sensor and said at least one second sensor; and ]
0.9999888	1532	[ a) contacting the isolated peptide with an antibody that specifically binds to a protein of the human immunodeficiency virus type 1; and ]	[ A method of producing an isolated peptide comprising: ]
0.99999213	1533	[ b) detecting a binding of the isolated peptide to the antibody. ]	[ a) contacting the isolated peptide with an antibody that specifically binds to a protein of the human immunodeficiency virus type 1; and ]
0.99991083	1534	[ administering to the patient in need of said treatment a composition comprising: ]	[ A method of treating a patient having a condition that inhibits the production of an antibody, wherein said patient is a patient with an inflammatory bowel disease or a patient with an autoimmune disorder, comprising: ]
0.9982029	1535	[ (a) a therapeutically effective amount of a peptide selected from the group consisting of SEQ ID NO: ]	[ administering to the patient in need of said treatment a composition comprising: ]
0.99974173	1536	[ 2; SEQ ID NO: ]	[ (a) a therapeutically effective amount of a peptide selected from the group consisting of SEQ ID NO: ]
0.99997854	1537	[ 3; SEQ ID NO: ]	[ 2; SEQ ID NO: ]
0.9999778	1538	[ 6; SEQ ID NO: ]	[ 3; SEQ ID NO: ]
0.99997246	1539	[ 8; SEQ ID NO: ]	[ 6; SEQ ID NO: ]
0.9999764	1540	[ 9; SEQ ID NO: ]	[ 8; SEQ ID NO: ]
0.99997723	1541	[ 10; SEQ ID NO: ]	[ 9; SEQ ID NO: ]
0.9999845	1542	[ 11; SEQ ID NO: ]	[ 10; SEQ ID NO: ]
0.9999807	1543	[ 12; SEQ ID NO: ]	[ 11; SEQ ID NO: ]
0.999982	1544	[ 13; SEQ ID NO: ]	[ 12; SEQ ID NO: ]
0.99998116	1545	[ 14; SEQ ID NO: ]	[ 13; SEQ ID NO: ]
0.99998283	1546	[ 16; SEQ ID NO: ]	[ 14; SEQ ID NO: ]
0.9999802	1547	[ 17; SEQ ID NOS: ]	[ 16; SEQ ID NO: ]
0.00029522524	1548	[ 1, ]	[ 17; SEQ ID NOS: ]
0.9810735	1549	[ 2 and 3; ]	[ 1, ]
0.007894412	1550	[ (b) a pharmaceutically acceptable carrier; ]	[ 2 and 3; ]
0.99930143	1551	[ (c) at least one of the amino acids of said peptide selected from the group consisting of SEQ ID NO: ]	[ (b) a pharmaceutically acceptable carrier; ]
0.99844223	1552	[ 2; ]	[ (c) at least one of the amino acids of said peptide selected from the group consisting of SEQ ID NO: ]
0.0011825281	1553	[ (d) a pharmaceutically acceptable salt thereof, and ]	[ 2; ]
0.9999275	1554	[ (e) a pharmaceutically acceptable carrier. ]	[ (d) a pharmaceutically acceptable salt thereof, and ]
0.9996333	1555	[ a) a human antibody comprising a nucleic acid sequence encoding a nucleic acid sequence having a sequence sequence selected from the group consisting of SEQ ID NO: ]	[ A method for treating a subject having an inflammatory disease comprising administering to said subject a therapeutically effective amount of an antibody that specifically binds to the human immunodeficiency virus-1 (HIV-1) protein, wherein the antibody is selected from the group consisting of: ]
0.99964535	1556	[ 2, SEQ ID NO: ]	[ a) a human antibody comprising a nucleic acid sequence encoding a nucleic acid sequence having a sequence sequence selected from the group consisting of SEQ ID NO: ]
0.99996316	1557	[ 3 and SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.9997522	1558	[ 4, and ]	[ 3 and SEQ ID NO: ]
0.998398	1559	[ b) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: ]	[ 4, and ]
0.997776	1560	[ 2. ]	[ b) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: ]
0.9997675	1561	[ (i) the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and ]	[ A method for the production of a polypeptide comprising a first amino acid sequence and a second amino acid sequence, the second amino acid sequence being a sequence selected from the group consisting of: ]
0.99986637	1562	[ SEQ ID NO: 11; ]	[ (i) the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and ]
0.9999616	1563	[ (ii) the amino acid sequence of SEQ ID NO: 12; ]	[ SEQ ID NO: 11; ]
0.9999912	1564	[ (iii) the amino acid sequence of SEQ ID NO: 13; and ]	[ (ii) the amino acid sequence of SEQ ID NO: 12; ]
0.999941	1565	[ (iv) a sequence having at least 95% sequence identity to the first amino acid sequence. ]	[ (iii) the amino acid sequence of SEQ ID NO: 13; and ]
0.99966025	1566	[ R2 is H; ]	[ A method for producing a composition comprising a compound of formula (I) or an pharmaceutically acceptable salt thereof, wherein R1 is H, a C1H-C2H-alkyl, or a C1H-C1H-alkyl; and ]
0.993415	1567	[ wherein R1 is H, a C1H-C2H-alkyl, or a C1H-C1H-alkyl; and ]	[ R2 is H; ]
0.99852896	1568	[ R2 is H; and ]	[ wherein R1 is H, a C1H-C2H-alkyl, or a C1H-C1H-alkyl; and ]
0.99887806	1569	[ wherein the composition comprises at least one compound of formula (III) or an pharmaceutically acceptable salt thereof. ]	[ R2 is H; and ]
0.999977	1570	[ a first device configured to provide an initial therapeutic agent to a patient; ]	[ A system for providing a patient with a therapeutic agent, the system comprising: ]
0.9999914	1571	[ a second device configured to deliver a second therapeutic agent to the patient; and ]	[ a first device configured to provide an initial therapeutic agent to a patient; ]
0.9864188	1572	[ a processor configured to: ]	[ a second device configured to deliver a second therapeutic agent to the patient; and ]
0.99817777	1573	[ receive an input from the first device; ]	[ a processor configured to: ]
0.99989295	1574	[ determine an amount of the first therapeutic agent to be delivered to the patient based on the input; ]	[ receive an input from the first device; ]
0.99999225	1575	[ determine an amount of the second therapeutic agent to be delivered to the patient based on the input; ]	[ determine an amount of the first therapeutic agent to be delivered to the patient based on the input; ]
0.99999225	1576	[ determine a time interval for delivering the second therapeutic agent based on the time interval; ]	[ determine an amount of the second therapeutic agent to be delivered to the patient based on the input; ]
0.9999924	1577	[ determine whether to deliver the first therapeutic agent at a first time interval and a second time interval; and ]	[ determine a time interval for delivering the second therapeutic agent based on the time interval; ]
0.9999924	1578	[ determine whether to deliver the second therapeutic agent at a second time interval and a third time interval different than the first time interval. ]	[ determine whether to deliver the first therapeutic agent at a first time interval and a second time interval; and ]
0.99998903	1579	[ 3, wherein said nucleotide sequence comprises the amino acid sequence of SEQ ID NO: ]	[ An isolated nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence of SEQ ID NO: ]
0.999984	1580	[ 3, wherein the amino acid sequence of SEQ ID NO: 3 is at least 95% identical to SEQ ID NO: ]	[ 3, wherein said nucleotide sequence comprises the amino acid sequence of SEQ ID NO: ]
0.99998796	1581	[ 3, wherein the nucleotide sequence of SEQ ID NO: ]	[ 3, wherein the amino acid sequence of SEQ ID NO: 3 is at least 95% identical to SEQ ID NO: ]
0.011492056	1582	[ 3 is selected from the group consisting of: ]	[ 3, wherein the nucleotide sequence of SEQ ID NO: ]
0.9965545	1583	[ SEQ ID NO: 3: ]	[ 3 is selected from the group consisting of: ]
0.99998844	1584	[ SEQ ID NO: 4: ]	[ SEQ ID NO: 3: ]
0.9999864	1585	[ SEQ ID NO: 6: ]	[ SEQ ID NO: 4: ]
0.9999517	1586	[ SEQ ID NO: 8, ]	[ SEQ ID NO: 6: ]
0.9999902	1587	[ SEQ ID NO: 9, ]	[ SEQ ID NO: 8, ]
0.999982	1588	[ SEQ ID NO: 10, and ]	[ SEQ ID NO: 9, ]
0.99997604	1589	[ SEQ ID NO: 11. ]	[ SEQ ID NO: 10, and ]
0.9983632	1590	[ (a) SEQ ID NO: 1; ]	[ A method of treating a cancer in a subject comprising administering an effective amount of a polypeptide comprising a nucleic acid sequence selected from the group consisting of: ]
0.99998844	1591	[ (b) SEQ ID NO: 2; ]	[ (a) SEQ ID NO: 1; ]
0.99999	1592	[ (c) SEQ ID NO: 3; ]	[ (b) SEQ ID NO: 2; ]
0.99998856	1593	[ (d) SEQ ID NO: 4; and ]	[ (c) SEQ ID NO: 3; ]
0.9999596	1594	[ (e) SEQ ID NO: 5, wherein the nucleic acid sequence of the polypeptide comprises the amino acid sequence of SEQ ID NO: 1. ]	[ (d) SEQ ID NO: 4; and ]
0.9998903	1595	[ a first patient-specific delivery system comprising: ]	[ A system for treating a patient, comprising: ]
0.9999825	1596	[ a first delivery system delivery device configured to deliver a first dose of a therapeutically acceptable drug to a first patient, wherein the first delivery system delivery device is configured to deliver the first dose of the therapeutically acceptable drug to the first patient in a first dose delivery sequence; and ]	[ a first patient-specific delivery system comprising: ]
0.9999759	1597	[ a second patient-specific delivery system comprising: ]	[ a first delivery system delivery device configured to deliver a first dose of a therapeutically acceptable drug to a first patient, wherein the first delivery system delivery device is configured to deliver the first dose of the therapeutically acceptable drug to the first patient in a first dose delivery sequence; and ]
0.9999654	1598	[ a second delivery system delivery device configured to deliver a second dose of the therapeutically acceptable drug to the first patient in a second dose delivery sequence, the second dose delivery sequence being different than the first dose delivery sequence, and ]	[ a second patient-specific delivery system comprising: ]
0.99999225	1599	[ wherein the delivery device is configured to deliver a second dose of the therapeutically acceptable drug to a patient in the first dose delivery sequence, ]	[ a second delivery system delivery device configured to deliver a second dose of the therapeutically acceptable drug to the first patient in a second dose delivery sequence, the second dose delivery sequence being different than the first dose delivery sequence, and ]
0.99999225	1600	[ wherein the delivery device is configured to deliver the first dose of the therapeutically acceptable drug to the patient in the first dose delivery sequence, and ]	[ wherein the delivery device is configured to deliver a second dose of the therapeutically acceptable drug to a patient in the first dose delivery sequence, ]
0.99999225	1601	[ the delivery device is configured to deliver the second dose of the therapeutically acceptable drug to the patient in the second dose delivery sequence. ]	[ wherein the delivery device is configured to deliver the first dose of the therapeutically acceptable drug to the patient in the first dose delivery sequence, and ]
0.010874509	1602	[ a) an isolated antibody or antigen binding fragment thereof; and ]	[ A system for treating a patient with a condition in which a patient is suffering from an inflammatory disorder, the system comprising: ]
0.99997115	1603	[ b) a therapeutically effective amount of an effective amount of the antibody, wherein: ]	[ a) an isolated antibody or antigen binding fragment thereof; and ]
0.99984705	1604	[ (i) said antibody is a monoclonal antibody, and ]	[ b) a therapeutically effective amount of an effective amount of the antibody, wherein: ]
0.99995816	1605	[ wherein the monoclonal antibody is a human antibody, a human antibody, a human monoclonal antibody, a human antibody, a human monoclonal polypeptide, a human polypeptide, or a human polypeptide having the amino acid sequence of SEQ ID NO: ]	[ (i) said antibody is a monoclonal antibody, and ]
0.99936575	1606	[ 1 or SEQ ID NO: ]	[ wherein the monoclonal antibody is a human antibody, a human antibody, a human monoclonal antibody, a human antibody, a human monoclonal polypeptide, a human polypeptide, or a human polypeptide having the amino acid sequence of SEQ ID NO: ]
0.9998348	1607	[ 2; or (ii) said monoclonal antibody is a human antibody, a human antibody, a human antibody, a human monoclonal antibody, a human monoclonal polypeptide, a human polypeptide, or a human polypeptide having the amino acid sequence of SEQ ID NO: ]	[ 1 or SEQ ID NO: ]
0.9997321	1608	[ 1 or SEQ ID NO: ]	[ 2; or (ii) said monoclonal antibody is a human antibody, a human antibody, a human antibody, a human monoclonal antibody, a human monoclonal polypeptide, a human polypeptide, or a human polypeptide having the amino acid sequence of SEQ ID NO: ]
0.99891686	1609	[ 2. ]	[ 1 or SEQ ID NO: ]
0.9995809	1610	[ (i) providing a first pharmaceutical composition comprising an effective amount of a compound of formula (1): ]	[ A method for treating a disease in a mammal comprising: ]
0.99859864	1611	[ or a pharmaceutically acceptable salt thereof; and ]	[ (i) providing a first pharmaceutical composition comprising an effective amount of a compound of formula (1): ]
0.99893516	1612	[ (ii) administering to said mammal a therapeutically effective amount of said compound or pharmaceutically acceptable salt thereof. ]	[ or a pharmaceutically acceptable salt thereof; and ]
0.9955129	1613	[ 2. ]	[ A method for treating a disease or condition, comprising administering an effective amount of a composition comprising an effective amount of a polysaccharide, wherein the composition comprises a polysaccharide comprising the amino acid sequence of SEQ ID NO: ]
0.9992256	1614	[ or a pharmaceutically acceptable salt thereof, wherein: ]	[ A method for treating a disease or condition in a mammal, comprising administering a therapeutically effective amount of a compound of formula (I): ]
0.9725302	1615	[ X represents a C1-C30 alkyl group; ]	[ or a pharmaceutically acceptable salt thereof, wherein: ]
0.9999001	1616	[ R1 represents an alkyl group having at least one hydrogen atom; ]	[ X represents a C1-C30 alkyl group; ]
0.99995434	1617	[ R3 and R5 represent an alkyl group having an alkyl group group ring, a heterocyclic ring, or a cycloalkyl group, wherein the heterocyclic ring and the cycloalkyl group are each independently hydrogen atom-containing; and ]	[ R1 represents an alkyl group having at least one hydrogen atom; ]
0.9998535	1618	[ R6 represents a hydrogen or a C1-C30 alkoxy group; ]	[ R3 and R5 represent an alkyl group having an alkyl group group ring, a heterocyclic ring, or a cycloalkyl group, wherein the heterocyclic ring and the cycloalkyl group are each independently hydrogen atom-containing; and ]
0.9999871	1619	[ R8 represents an alkoxy group having at least one carbon atom; ]	[ R6 represents a hydrogen or a C1-C30 alkoxy group; ]
0.99986017	1620	[ R9 represents a hydrogen atom, a C1-C30 alkyl group, or a heterocyclyl group, or a cycloalkyl group; or a pharmaceutically acceptable salt thereof. ]	[ R8 represents an alkoxy group having at least one carbon atom; ]
0.031244017	1621	[ receiving a plurality of data sets from an external device; ]	[ A method comprising: ]
0.99998736	1622	[ determining whether a first data set is present in a first data set; ]	[ receiving a plurality of data sets from an external device; ]
0.99999213	1623	[ determining a first value associated with the first data set based on the received plurality of data sets; and ]	[ determining whether a first data set is present in a first data set; ]
0.9999924	1624	[ determining a second value associated with the second data set based on the first value. ]	[ determining a first value associated with the first data set based on the received plurality of data sets; and ]
0.9999263	1625	[ an opening at the proximal end, the device comprising: ]	[ A device for the insertion into a patient's stomach or stomach wall of an elongate, flexible tube having a proximal end, a distal end, and ]
0.04126765	1626	[ a body portion; ]	[ an opening at the proximal end, the device comprising: ]
0.9980033	1627	[ a first end portion, wherein a portion of the first end portion is adapted to be inserted into a stomach of a patient and a portion of the first end portion is adapted to be disposed within a stomach wall of the patient; and ]	[ a body portion; ]
0.99999225	1628	[ a second end portion, wherein the second end portion is adapted to be disposed within a stomach wall of the patient; ]	[ a first end portion, wherein a portion of the first end portion is adapted to be inserted into a stomach of a patient and a portion of the first end portion is adapted to be disposed within a stomach wall of the patient; and ]
0.99140733	1629	[ the device further comprising: ]	[ a second end portion, wherein the second end portion is adapted to be disposed within a stomach wall of the patient; ]
0.9930266	1630	[ a first portion having a proximal end, wherein the first portion is disposed within a distal opening of the tube and is configured for insertion within a stomach wall of the patient; and ]	[ the device further comprising: ]
0.9999924	1631	[ a second portion having a proximal end, wherein the second portion is disposed within a distal opening of the tube and is configured and adapted for insertion into a stomach wall of the patient; ]	[ a first portion having a proximal end, wherein the first portion is disposed within a distal opening of the tube and is configured for insertion within a stomach wall of the patient; and ]
0.99999225	1632	[ wherein the tube is adapted to be inserted through the stomach wall of the patient and the tube further comprises a first end portion and a second end portion, the first and second ends of the first portion being configured to engage the stomach wall of the patient and the second end portion of the tube being disposed in a distal opening of the tube and the second end portion of the tube being disposed within the opening of the stomach wall of the patient. ]	[ a second portion having a proximal end, wherein the second portion is disposed within a distal opening of the tube and is configured and adapted for insertion into a stomach wall of the patient; ]
0.9967116	1633	[ 2. ]	[ An isolated antibody or antigen binding fragment thereof that binds to a polypeptide of SEQ ID NO: ]
0.9999256	1634	[ receiving, by a first medical device, a first patient-specific medical treatment request from the first medical device; ]	[ A method of providing medical treatment to a patient, comprising: ]
0.99999225	1635	[ receiving, by a second medical device, a second patient-specific medical treatment request from the second medical device; ]	[ receiving, by a first medical device, a first patient-specific medical treatment request from the first medical device; ]
0.99999225	1636	[ determining, by the first device, a first treatment plan for the patient based at least in part on the received first patient-specific medical treatment request; ]	[ receiving, by a second medical device, a second patient-specific medical treatment request from the second medical device; ]
0.99999225	1637	[ determining, by the first device, a second treatment plan for the patient based at least in part on the received second patient-specific medical treatment request; ]	[ determining, by the first device, a first treatment plan for the patient based at least in part on the received first patient-specific medical treatment request; ]
0.99999106	1638	[ receiving, by the first medical device, a first medical treatment request from the second medical device; ]	[ determining, by the first device, a second treatment plan for the patient based at least in part on the received second patient-specific medical treatment request; ]
0.9999924	1639	[ receiving, by the second medical device, a second medical treatment request from the second device; ]	[ receiving, by the first medical device, a first medical treatment request from the second medical device; ]
0.99999154	1640	[ receiving, by the first device, a first treatment plan for the patient based at least in part on the received first treatment plan and the received first treatment request; ]	[ receiving, by the second medical device, a second medical treatment request from the second device; ]
0.99999225	1641	[ determining, by the first device, a first treatment plan for the patient based at least in part on the received first treatment plan and the received first treatment request; and ]	[ receiving, by the first device, a first treatment plan for the patient based at least in part on the received first treatment plan and the received first treatment request; ]
0.99999225	1642	[ receiving, by the second device, a second treatment plan for the patient based at least in part on the received second medical treatment request. ]	[ determining, by the first device, a first treatment plan for the patient based at least in part on the received first treatment plan and the received first treatment request; and ]
0.9997112	1643	[ providing a biopsy sample comprising a tumor tissue, the tumor tissue having a tumor site and an extracellular matrix; ]	[ A method of treating a patient having a cancer, comprising: ]
0.9999584	1644	[ exposing the tumor tissue to an agent that specifically inhibits the growth of the cancer; ]	[ providing a biopsy sample comprising a tumor tissue, the tumor tissue having a tumor site and an extracellular matrix; ]
0.99999225	1645	[ exposing the tumor site to an agent that specifically inhibits the proliferation of the cancer; ]	[ exposing the tumor tissue to an agent that specifically inhibits the growth of the cancer; ]
0.99999225	1646	[ exposing a second tumor site to the agent that specifically inhibits proliferation of the tumor; and ]	[ exposing the tumor site to an agent that specifically inhibits the proliferation of the cancer; ]
0.009414128	1647	[ administering to said patient a therapeutically effective amount of a composition comprising a polypeptide selected from the group consisting of SEQ ID NO: ]	[ exposing a second tumor site to the agent that specifically inhibits proliferation of the tumor; and ]
0.9996196	1648	[ 2, SEQ ID NO: ]	[ administering to said patient a therapeutically effective amount of a composition comprising a polypeptide selected from the group consisting of SEQ ID NO: ]
0.99999	1649	[ 4, SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.9999887	1650	[ 6, SEQ ID NO: ]	[ 4, SEQ ID NO: ]
0.99998677	1651	[ 8, SEQ ID NO: ]	[ 6, SEQ ID NO: ]
0.99998856	1652	[ 10, SEQ ID NO: ]	[ 8, SEQ ID NO: ]
0.99998844	1653	[ 14, SEQ ID NO: ]	[ 10, SEQ ID NO: ]
0.999869	1654	[ 16, and ]	[ 14, SEQ ID NO: ]
0.9996712	1655	[ SEQ ID NO: ]	[ 16, and ]
0.9998149	1656	[ 18. ]	[ SEQ ID NO: ]
0.00024170014	1657	[ a. preparing an isolated polypeptide from a plant having the amino acid sequence of SEQ ID NO: ]	[ A method for the preparation of a pharmaceutical composition comprising: ]
0.9911618	1658	[ 1; ]	[ a. preparing an isolated polypeptide from a plant having the amino acid sequence of SEQ ID NO: ]
0.047406975	1659	[ b. preparing a pharmaceutically acceptable carrier, the carrier having a molecular weight of from about 10 to about 500 daltons; and ]	[ 1; ]
0.9999887	1660	[ c. introducing into the composition a pharmaceutical agent comprising a pharmaceutically acceptable carrier, wherein the carrier is an isolated polypeptide from a plant having the amino acid sequence of SEQ ID NO: ]	[ b. preparing a pharmaceutically acceptable carrier, the carrier having a molecular weight of from about 10 to about 500 daltons; and ]
0.981899	1661	[ 1. ]	[ c. introducing into the composition a pharmaceutical agent comprising a pharmaceutically acceptable carrier, wherein the carrier is an isolated polypeptide from a plant having the amino acid sequence of SEQ ID NO: ]
0.9997335	1662	[ (a) providing a first therapeutic agent, the first therapeutic agent comprising a compound selected from the group consisting of: (i) a pharmaceutically acceptable salt thereof, (ii) an amino acid sequence of at least 95% sequence identity to SEQ ID NO: ]	[ A method of treating or preventing the progression of a disease or condition comprising the steps of: ]
0.977416	1663	[ 1, and ]	[ (a) providing a first therapeutic agent, the first therapeutic agent comprising a compound selected from the group consisting of: (i) a pharmaceutically acceptable salt thereof, (ii) an amino acid sequence of at least 95% sequence identity to SEQ ID NO: ]
0.97927606	1664	[ (iii) at least one of the amino acids selected from the group consisting of: (i) a pharmaceutically acceptable salt thereof, (ii) an amino acid sequence of at least 95% sequence identity to SEQ ID NO: ]	[ 1, and ]
0.9928503	1665	[ 1; and ]	[ (iii) at least one of the amino acids selected from the group consisting of: (i) a pharmaceutically acceptable salt thereof, (ii) an amino acid sequence of at least 95% sequence identity to SEQ ID NO: ]
0.012563587	1666	[ (b) administering the first therapeutic agent to a subject in need for treatment, the subject having an inflammatory disease or condition. ]	[ 1; and ]
0.9997396	1667	[ at least one medical treatment device; ]	[ A system for providing a medical treatment to a patient, the system comprising: ]
0.99985504	1668	[ at least one sensor; ]	[ at least one medical treatment device; ]
0.96330786	1669	[ a processor configured to: ]	[ at least one sensor; ]
0.9992335	1670	[ receive at least one medical treatment device data; ]	[ a processor configured to: ]
0.999992	1671	[ generate an indication for a treatment of the at least one medical treatment device; ]	[ receive at least one medical treatment device data; ]
0.9999919	1672	[ determine a first treatment parameter of the medical treatment device; and ]	[ generate an indication for a treatment of the at least one medical treatment device; ]
0.99999225	1673	[ determine a second treatment parameter of the medical treatment device; ]	[ determine a first treatment parameter of the medical treatment device; and ]
0.99906737	1674	[ the processor configured to: ]	[ determine a second treatment parameter of the medical treatment device; ]
0.9991509	1675	[ receive the at least one medical treatment device data; ]	[ the processor configured to: ]
0.9999913	1676	[ generate a first indication of a first treatment parameter of the medical treatment device based on at least a first of the first treatment parameter of the medical treatment device and a first of the second treatment parameters; ]	[ receive the at least one medical treatment device data; ]
0.99999225	1677	[ generate a second indication of a second treatment parameter of the medical treatment device based on at least a second of the first treatment parameter of the medical treatment device and at least one of the second treatment parameter of the medical treatment device; and ]	[ generate a first indication of a first treatment parameter of the medical treatment device based on at least a first of the first treatment parameter of the medical treatment device and a first of the second treatment parameters; ]
0.99999225	1678	[ generate a first treatment parameter for the medical treatment device based on at least a first of the first treatment parameter and at least a second of the second treatment parameter; wherein the first treatment parameter is a first of the first treatment parameter and a first of the second treatment parameter, and ]	[ generate a second indication of a second treatment parameter of the medical treatment device based on at least a second of the first treatment parameter of the medical treatment device and at least one of the second treatment parameter of the medical treatment device; and ]
0.99999225	1679	[ wherein the first treatment parameter is a first of at least one of the first treatment parameter and the second treatment parameter. ]	[ generate a first treatment parameter for the medical treatment device based on at least a first of the first treatment parameter and at least a second of the second treatment parameter; wherein the first treatment parameter is a first of the first treatment parameter and a first of the second treatment parameter, and ]
0.999688	1680	[ a plurality of treatment electrodes, the electrodes being configured to be placed on a patient's body, the electrodes being configured to be placed on a patient's body in an arrangement that is substantially parallel to the patient's spine and to be positioned in the patient's spine; and ]	[ An apparatus for treating a patient comprising: ]
0.99999213	1681	[ a plurality of treatment modules, each module being configured to be positioned on an electrode of the plurality of treatment electrodes, the treatment modules being configured to be positioned in the patient's spinal column and to provide treatment for a disease of the patient's body. ]	[ a plurality of treatment electrodes, the electrodes being configured to be placed on a patient's body, the electrodes being configured to be placed on a patient's body in an arrangement that is substantially parallel to the patient's spine and to be positioned in the patient's spine; and ]
0.99995697	1682	[ at least one blood vessel; ]	[ An apparatus for treating a patient having a disease characterized by a reduced ability to regulate blood flow in the blood vessel, comprising: ]
0.99999166	1683	[ at least one blood vessel pump for delivering at least one of blood from said at least one blood vessel to a patient; and ]	[ at least one blood vessel; ]
0.99999225	1684	[ at least one blood vessel controller for controlling said at least one blood vessel, wherein said at least one blood vessel controller comprises: ]	[ at least one blood vessel pump for delivering at least one of blood from said at least one blood vessel to a patient; and ]
0.99999225	1685	[ at least one blood vessel controller module configured to control at least one of the blood vessel pump and the at least one blood vessel controller module, wherein said at least one blood vessel controller module is configured to control the at least one blood vessel pump and the at least one blood vessel controller module, and ]	[ at least one blood vessel controller for controlling said at least one blood vessel, wherein said at least one blood vessel controller comprises: ]
0.99999225	1686	[ wherein said at least one blood vessel controller module comprises: ]	[ at least one blood vessel controller module configured to control at least one of the blood vessel pump and the at least one blood vessel controller module, wherein said at least one blood vessel controller module is configured to control the at least one blood vessel pump and the at least one blood vessel controller module, and ]
0.99998987	1687	[ a blood vessel pump module; ]	[ wherein said at least one blood vessel controller module comprises: ]
0.99999225	1688	[ a blood vessel controller module configured to control at least one of a blood vessel pump and a blood vessel controller module, wherein the blood vessel controller module and the blood vessel pump module are each configured to control a different one of the blood vessel pump and the blood vessel controller module, and ]	[ a blood vessel pump module; ]
0.99998784	1689	[ wherein the blood volume of the at least one blood vessel is configured to vary according to a patient's condition; and ]	[ a blood vessel controller module configured to control at least one of a blood vessel pump and a blood vessel controller module, wherein the blood vessel controller module and the blood vessel pump module are each configured to control a different one of the blood vessel pump and the blood vessel controller module, and ]
0.9999682	1690	[ a blood vessel control module configured to control the blood vessel pump module and the blood vessel controller module. ]	[ wherein the blood volume of the at least one blood vessel is configured to vary according to a patient's condition; and ]
0.90067196	1691	[ receiving a plurality of images of a patient; ]	[ A method comprising: ]
0.9999652	1692	[ identifying at least one image from the plurality of images; and ]	[ receiving a plurality of images of a patient; ]
0.9999665	1693	[ generating a first image of the patient based on the at least one image, wherein the first image comprises at least one image of the at least one patient. ]	[ identifying at least one image from the plurality of images; and ]
0.99937564	1694	[ 2 to the human IL-6 receptor, wherein the IL-6 receptor is a member of the IL-6 receptor complex, and ]	[ A method of treating an autoimmune disease in a mammal comprising administering to said mammal an amount of a compound that specifically inhibits the binding of the polypeptide of SEQ ID NO: ]
0.99761814	1695	[ wherein the compound is selected from a group consisting of a polypeptide of SEQ ID NO: ]	[ 2 to the human IL-6 receptor, wherein the IL-6 receptor is a member of the IL-6 receptor complex, and ]
0.99980074	1696	[ 1, SEQ ID NO: ]	[ wherein the compound is selected from a group consisting of a polypeptide of SEQ ID NO: ]
0.99998844	1697	[ 2, SEQ ID NO: ]	[ 1, SEQ ID NO: ]
0.99999	1698	[ 4, SEQ ID No: ]	[ 2, SEQ ID NO: ]
0.99998796	1699	[ 5, SEQ ID NO: ]	[ 4, SEQ ID No: ]
0.99998975	1700	[ 6, SEQ ID NO: ]	[ 5, SEQ ID NO: ]
0.9999857	1701	[ 7, SEQ ID NO: ]	[ 6, SEQ ID NO: ]
0.9995664	1702	[ 8, and ]	[ 7, SEQ ID NO: ]
0.99930966	1703	[ SEQ ID NO: ]	[ 8, and ]
0.99975806	1704	[ 9. ]	[ SEQ ID NO: ]
0.9994247	1705	[ or a pharmaceutically acceptable salt thereof; ]	[ A method for treating a disease in a patient comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of: a) a compound of formula (I): ]
1.4407969e-05	1706	[ b) an amino acid sequence having the sequence of SEQ ID NO: ]	[ or a pharmaceutically acceptable salt thereof; ]
1.4996232e-05	1707	[ 1 or 2; or a compound of formula (II): ]	[ b) an amino acid sequence having the sequence of SEQ ID NO: ]
0.9987657	1708	[ or a pharmaceutically acceptable salt thereof. ]	[ 1 or 2; or a compound of formula (II): ]
0.9997272	1709	[ 4, SEQ ID NO: ]	[ A method of treating a patient, comprising administering to the patient in need thereof an effective amount of an anti-CD4-mediated antibody or an anti-CD4-mediated antigen-binding fragment thereof, wherein the anti-CD4-mediated antibody or anti-CD4-mediated antigen-binding fragment thereof comprises a CDR1 or CDR2 sequence selected from the group consisting of SEQ ID NO: ]
0.9999887	1710	[ 6, SEQ ID NO: ]	[ 4, SEQ ID NO: ]
0.99998677	1711	[ 8, SEQ ID NO: ]	[ 6, SEQ ID NO: ]
0.9999883	1712	[ 9, SEQ ID NO: ]	[ 8, SEQ ID NO: ]
0.9999889	1713	[ 11, SEQ ID NO: ]	[ 9, SEQ ID NO: ]
0.9999881	1714	[ 13, SEQ ID NO: ]	[ 11, SEQ ID NO: ]
0.9998653	1715	[ 16, and ]	[ 13, SEQ ID NO: ]
0.9996712	1716	[ SEQ ID NO: ]	[ 16, and ]
0.9997285	1717	[ 17, and ]	[ SEQ ID NO: ]
0.9996388	1718	[ wherein said anti-CD4-mediated antibody or anti-CD4-mediated antigen-binding fragment thereof is effective in treating the patient. ]	[ 17, and ]
0.0022967674	1719	[ a) an implantable device having a plurality of electrodes, wherein each of the electrodes is adapted to receive an electrical signal from a target tissue, wherein the electrical signal is generated by a plurality of electrodes; ]	[ Apparatus for the treatment of a patient with cancer or an immune-related disease, comprising: ]
0.9999912	1720	[ b) at least one electrode having a first electrode and a second electrode, wherein the first electrode is configured to receive the electrical signal generated by the plurality of electrodes; ]	[ a) an implantable device having a plurality of electrodes, wherein each of the electrodes is adapted to receive an electrical signal from a target tissue, wherein the electrical signal is generated by a plurality of electrodes; ]
0.99999225	1721	[ c) at least one electrode having a third electrode, wherein the second electrode is configured to receive the electrical signal generated by the plurality of electrodes, and ]	[ b) at least one electrode having a first electrode and a second electrode, wherein the first electrode is configured to receive the electrical signal generated by the plurality of electrodes; ]
0.99998486	1722	[ the third electrode is configured to generate an electrical signal that is different from the electrical signal received by the first electrode; and ]	[ c) at least one electrode having a third electrode, wherein the second electrode is configured to receive the electrical signal generated by the plurality of electrodes, and ]
0.9998832	1723	[ d) an implantable device having an electrode array, wherein at least one electrode in the electrode array is configured to be connected to the first electrode and the second electrode, and ]	[ the third electrode is configured to generate an electrical signal that is different from the electrical signal received by the first electrode; and ]
0.9999912	1724	[ the electrode array is configured to receive at least one electrical signal generated by the first electrode and to receive at least one electrical signal generated by the second electrode. ]	[ d) an implantable device having an electrode array, wherein at least one electrode in the electrode array is configured to be connected to the first electrode and the second electrode, and ]
0.99911755	1725	[ providing a plurality of electrodes; ]	[ A method for the production of an implantable medical device comprising: ]
0.9999913	1726	[ providing a plurality of electrodes having a first electrode surface and a second electrode surface; ]	[ providing a plurality of electrodes; ]
0.99999094	1727	[ providing a plurality of electrodes having a first electrode electrode surface and a second electrode surface, wherein the first electrode surface has an outer surface that is a surface of an implantable medical device, the first electrode surface has a first surface that has an outer surface that is a surface of an implantable medical device, the second electrode surface has a second surface that has an outer surface that is a surface of an implantable medical device, and ]	[ providing a plurality of electrodes having a first electrode surface and a second electrode surface; ]
0.9999914	1728	[ the outer surface of the first electrode surface has a first thickness that is less than the first thickness of the second electrode surface; and ]	[ providing a plurality of electrodes having a first electrode electrode surface and a second electrode surface, wherein the first electrode surface has an outer surface that is a surface of an implantable medical device, the first electrode surface has a first surface that has an outer surface that is a surface of an implantable medical device, the second electrode surface has a second surface that has an outer surface that is a surface of an implantable medical device, and ]
0.9999291	1729	[ providing a plurality of electrodes having a first electrode surface and a second electrode surface. ]	[ the outer surface of the first electrode surface has a first thickness that is less than the first thickness of the second electrode surface; and ]
0.99024034	1730	[ a first housing; ]	[ A device for a medical instrument, comprising: ]
0.9999769	1731	[ a first body member disposed in said first housing and having a first end, a second end, and ]	[ a first housing; ]
0.0007183357	1732	[ a proximal portion; ]	[ a first body member disposed in said first housing and having a first end, a second end, and ]
0.00141681	1733	[ an outer surface disposed between said first body member and said first housing; ]	[ a proximal portion; ]
0.9999913	1734	[ a first connector disposed between the first body member and said first connector; ]	[ an outer surface disposed between said first body member and said first housing; ]
0.99999046	1735	[ a first end of a second connector disposed in said outer surface of said first connector; ]	[ a first connector disposed between the first body member and said first connector; ]
0.99999225	1736	[ a second end of a second connector disposed in said outer surface of said first connector; ]	[ a first end of a second connector disposed in said outer surface of said first connector; ]
0.9998227	1737	[ a third connector disposed in the first housing; and ]	[ a second end of a second connector disposed in said outer surface of said first connector; ]
0.99999225	1738	[ a fourth connector disposed in the first housing; ]	[ a third connector disposed in the first housing; and ]
0.99994004	1739	[ wherein the first housing and the first body member are configured to couple with each other to form a first coupling; ]	[ a fourth connector disposed in the first housing; ]
0.99999225	1740	[ wherein the first body member is configured to couple with the first housing; ]	[ wherein the first housing and the first body member are configured to couple with each other to form a first coupling; ]
0.99998987	1741	[ wherein the second connector is configured to couple with the second housing; and ]	[ wherein the first body member is configured to couple with the first housing; ]
0.9999912	1742	[ wherein the fourth connector is configured to couple with the third connector. ]	[ wherein the second connector is configured to couple with the second housing; and ]
0.9999821	1743	[ providing a first medical device; ]	[ A method of providing a medical device to a patient, comprising: ]
0.9999924	1744	[ providing a second medical device; ]	[ providing a first medical device; ]
0.9999908	1745	[ providing at least one first medical device interface; and ]	[ providing a second medical device; ]
0.99999225	1746	[ providing at least one first medical device interface interface; ]	[ providing at least one first medical device interface; and ]
0.99999034	1747	[ wherein the first and second medical device interfaces are coupled to one another by a first interface and a second interface, the first and second interfaces being configured to provide communication between at least one first medical device interface and at least one second medical device, the first interface being coupled to the first medical device and the second interface to the second medical device. ]	[ providing at least one first medical device interface interface; ]
0.9971981	1748	[ a first implantable medical device having a first implantable medical device interface; ]	[ A system for treating a patient with a cancer comprising: ]
0.999985	1749	[ a plurality of second medical devices; ]	[ a first implantable medical device having a first implantable medical device interface; ]
0.9999876	1750	[ at least one first medical device interface disposed within the system, each first medical device having a first medical device interface, the first medical devices having a first interface; ]	[ a plurality of second medical devices; ]
0.9999924	1751	[ at least one second medical device interface disposed within the system, the at least one second medical device interface having a second interface; ]	[ at least one first medical device interface disposed within the system, each first medical device having a first medical device interface, the first medical devices having a first interface; ]
0.99999225	1752	[ at least one first medical device interface and at least one second medical device interface disposed within the system, the at least one first medical device interface and at least one second medical device interface each including a second interface; and ]	[ at least one second medical device interface disposed within the system, the at least one second medical device interface having a second interface; ]
0.99999225	1753	[ a first device interface disposed within the first implantable medical device, the first device interface including at least one first device interface and at least one second device interface, the second device interface including a second interface, wherein the first device interface includes an interface that is configured to receive data from at least one of the at least one medical device interface and the at least second medical device interface. ]	[ at least one first medical device interface and at least one second medical device interface disposed within the system, the at least one first medical device interface and at least one second medical device interface each including a second interface; and ]
0.99880123	1754	[ an implantable medical device; ]	[ A system for treating a patient, comprising: ]
0.99998796	1755	[ an electrical stimulation system for generating electrical signals to the implantable medical device, wherein the system includes an implantable electrical stimulation circuit configured to receive electrical signals from the implantable medical device, wherein the electrical stimulation system includes a first circuit configured to generate electrical stimulation signals to the implantable medical device, and ]	[ an implantable medical device; ]
0.99999225	1756	[ a second circuit configured to generate a signal to the implantable medical device, wherein the first circuit and the second circuit are configured to receive the electrical stimulation signals and to generate a signal; ]	[ an electrical stimulation system for generating electrical signals to the implantable medical device, wherein the system includes an implantable electrical stimulation circuit configured to receive electrical signals from the implantable medical device, wherein the electrical stimulation system includes a first circuit configured to generate electrical stimulation signals to the implantable medical device, and ]
0.9998443	1757	[ a processor configured to process the signal to determine whether the signal has been received; and ]	[ a second circuit configured to generate a signal to the implantable medical device, wherein the first circuit and the second circuit are configured to receive the electrical stimulation signals and to generate a signal; ]
0.99997306	1758	[ a display configured to display a patient-specific information associated with the signal. ]	[ a processor configured to process the signal to determine whether the signal has been received; and ]
0.95410234	1759	[ wherein: ]	[ A method of producing a compound of Formula II: ]
0.99163705	1760	[ R1 is hydrogen, a substituted or unsubstituted alkyl, a substituted alkenyl, a substituted alkynyl, an substituted aliphatic alkyl, or a substituted alkynylalkyl; and ]	[ wherein: ]
0.9983999	1761	[ R2 is a hydrogen atom or a halogen atom; ]	[ R1 is hydrogen, a substituted or unsubstituted alkyl, a substituted alkenyl, a substituted alkynyl, an substituted aliphatic alkyl, or a substituted alkynylalkyl; and ]
0.9999306	1762	[ R3 is a hydrogen atom or an alkyl group having a C1-4alkyl group; ]	[ R2 is a hydrogen atom or a halogen atom; ]
0.9999918	1763	[ R4 is a hydrogen atom or an alkyl group having a C1-4alkyl group; ]	[ R3 is a hydrogen atom or an alkyl group having a C1-4alkyl group; ]
0.9999132	1764	[ R5 is a hydrogen atom or a halogen atom; and ]	[ R4 is a hydrogen atom or an alkyl group having a C1-4alkyl group; ]
0.9999242	1765	[ R6 is a hydrogen atom or an alkyl group having a C1-4alkyl group. ]	[ R5 is a hydrogen atom or a halogen atom; and ]
0.9916665	1766	[ a first portion of a flexible material; and ]	[ A device for treating a wound, said device comprising: ]
0.99995756	1767	[ a second portion of the flexible material, said flexible material having a first surface and a second surface, said first portion of the flexible material being adapted to receive a first portion of a tissue, said first surface being adapted to be exposed to a first surface of a wound; ]	[ a first portion of a flexible material; and ]
0.9999912	1768	[ wherein said first surface of said first portion of the flexible material has a thickness of less than 10&#xb0; ]	[ a second portion of the flexible material, said flexible material having a first surface and a second surface, said first portion of the flexible material being adapted to receive a first portion of a tissue, said first surface being adapted to be exposed to a first surface of a wound; ]
0.007931824	1769	[ m, and ]	[ wherein said first surface of said first portion of the flexible material has a thickness of less than 10&#xb0; ]
0.019638048	1770	[ said second portion of the flexible material has a thickness greater than 10&#xb0; ]	[ m, and ]
0.9340584	1771	[ m. ]	[ said second portion of the flexible material has a thickness greater than 10&#xb0; ]
0.97411627	1772	[ an implantable medical device; ]	[ A system, comprising: ]
0.99998844	1773	[ an implantable medical device controller coupled to the implantable medical device; and ]	[ an implantable medical device; ]
0.99999225	1774	[ a memory coupled to the implantable medical device controller and to the implantable medical device, the memory storing instructions for controlling the implantable medical device, the instructions including: ]	[ an implantable medical device controller coupled to the implantable medical device; and ]
0.9999919	1775	[ an instruction for controlling the implantable medical device based at least in part on a medical condition of a patient; and, ]	[ a memory coupled to the implantable medical device controller and to the implantable medical device, the memory storing instructions for controlling the implantable medical device, the instructions including: ]
0.9999924	1776	[ an instruction for providing an implantable medical device to the patient based on the medical condition of the patient. ]	[ an instruction for controlling the implantable medical device based at least in part on a medical condition of a patient; and, ]
0.99999225	1777	[ a) a monoclonal antibody or fragment thereof that binds to the human CD4+ T cell receptor; and ]	[ A method of treating a patient having an inflammatory disease comprising administering to the patient an effective amount of a therapeutically effective amount of an isolated monoclonal antibody or fragment thereof that binds to an epitope of the human CD4+ T cell receptor, wherein said antibody or fragment thereof is selected from the group consisting of: ]
0.99999225	1778	[ b) an antibody or fragment thereof that binds to the human CD4+ T cell receptor. ]	[ a) a monoclonal antibody or fragment thereof that binds to the human CD4+ T cell receptor; and ]
0.9991621	1779	[ providing a first device for administering to a patient a therapeutically effective amount of an antibody comprising a fragment of SEQ ID NO: 1 and an antigen binding fragment thereof; ]	[ A method for treating a condition in a patient comprising: ]
0.9999924	1780	[ providing a second device for administering to a patient a therapeutically effective amount of an antigen binding fragment of SEQ ID NO: 2 and an antigen binding fragment thereof; ]	[ providing a first device for administering to a patient a therapeutically effective amount of an antibody comprising a fragment of SEQ ID NO: 1 and an antigen binding fragment thereof; ]
0.999992	1781	[ providing an antigen-binding fragment of SEQ ID NO: 2 and an antigen-binding fragment of SEQ ID NO: 2, wherein the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is an antigen-binding fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2; and ]	[ providing a second device for administering to a patient a therapeutically effective amount of an antigen binding fragment of SEQ ID NO: 2 and an antigen binding fragment thereof; ]
0.9899519	1782	[ administering the first device and the second device to the patient. ]	[ providing an antigen-binding fragment of SEQ ID NO: 2 and an antigen-binding fragment of SEQ ID NO: 2, wherein the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is an antigen-binding fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2 and the antigen binding fragment is a fragment of SEQ ID NO: 2; and ]
0.9996791	1783	[ 4 or SEQ ID NO: ]	[ A method for the treatment of a subject having a condition that is associated with an increased risk of developing an autoimmune disease comprising administering to the subject a therapeutically effective amount of a polypeptide having a sequence of SEQ ID NO: ]
0.99903405	1784	[ 5, and ]	[ 4 or SEQ ID NO: ]
0.99798656	1785	[ wherein the polypeptide is selected from the group consisting of SEQ ID NO: ]	[ 5, and ]
0.9997433	1786	[ 1, SEQ ID NO: ]	[ wherein the polypeptide is selected from the group consisting of SEQ ID NO: ]
0.99998844	1787	[ 2, SEQ ID NO: ]	[ 1, SEQ ID NO: ]
0.99998915	1788	[ 3, SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.99983823	1789	[ 4, and ]	[ 3, SEQ ID NO: ]
0.99934655	1790	[ SEQ ID NO: ]	[ 4, and ]
0.9996561	1791	[ 5. ]	[ SEQ ID NO: ]
0.9999814	1792	[ a proximal body portion; ]	[ A device for treating an organ of the body, the device comprisinga body portion having a first end and a second end and a proximal end and a distal end, the body portion comprising: ]
0.9999826	1793	[ a distal body portion; ]	[ a proximal body portion; ]
0.99998856	1794	[ a first end portion extending proximally from the body portion; ]	[ a distal body portion; ]
0.99999046	1795	[ a distal end portion extending distal of the first end portion; and ]	[ a first end portion extending proximally from the body portion; ]
0.9999386	1796	[ a distal body portion having a distal end portion and an inner surface, the inner surface having a distal end portion that is proximal of the first end portion and a proximal end portion that is proximal of the distal end portion, wherein the inner surface is configured to be in fluid communication with the first end portion, and ]	[ a distal end portion extending distal of the first end portion; and ]
0.99999225	1797	[ the inner surface is configured to be in fluid communication with the distal end portion; ]	[ a distal body portion having a distal end portion and an inner surface, the inner surface having a distal end portion that is proximal of the first end portion and a proximal end portion that is proximal of the distal end portion, wherein the inner surface is configured to be in fluid communication with the first end portion, and ]
0.999992	1798	[ wherein the proximal body portion has an inner surface that is configured to be in fluid communication with the distal body portion and the inner surface is configured to be in fluid communication with the distal end portion. ]	[ the inner surface is configured to be in fluid communication with the distal end portion; ]
0.99999225	1799	[ b) at least one electrode for applying the treatment agent to the patient's skin, the at least one electrode having a plurality of conductive fibers, wherein the at least one electrode comprises a conductive fiber having a conductive material, wherein the at least one conductive fiber is configured to contact the patient's skin, wherein the conductive fiber has a plurality of conductive fibers, each of the plurality of conductive fibers having a conductive material, wherein the plurality of conductive fibers have a plurality of conductive fibers, each of the plurality of conductive fibers having a conductive material, wherein the plurality of conductive fibers have a length, and ]	[ A system for treating a disease or condition, comprisinga) a plurality of electrodes for applying a treatment agent to a patient's skin, wherein the plurality of electrodes comprises at least two electrodes each having a plurality of electrodes, wherein each of the plurality of electrodes comprises a plurality of electrodes; and ]
0.99999225	1800	[ wherein the conductive fiber has a conductive material, wherein the length of the conductive fibers is shorter than a length of the conductive material of the conductive fibers, and ]	[ b) at least one electrode for applying the treatment agent to the patient's skin, the at least one electrode having a plurality of conductive fibers, wherein the at least one electrode comprises a conductive fiber having a conductive material, wherein the at least one conductive fiber is configured to contact the patient's skin, wherein the conductive fiber has a plurality of conductive fibers, each of the plurality of conductive fibers having a conductive material, wherein the plurality of conductive fibers have a plurality of conductive fibers, each of the plurality of conductive fibers having a conductive material, wherein the plurality of conductive fibers have a length, and ]
0.9999924	1801	[ wherein the length of the conductive fibers is shorter than a length of the conductive material of the conductive fibers. ]	[ wherein the conductive fiber has a conductive material, wherein the length of the conductive fibers is shorter than a length of the conductive material of the conductive fibers, and ]
0.9999602	1802	[ a) an oral composition comprising a pharmaceutically acceptable carrier; ]	[ A method of treating a disease comprising administering to a subject in need thereof an effective amount of an effective amount of a pharmaceutically acceptable carrier, wherein said effective amount of said carrier is selected from the group consisting of: ]
0.9998591	1803	[ b) a pharmaceutically acceptable carrier in a liquid form; ]	[ a) an oral composition comprising a pharmaceutically acceptable carrier; ]
0.9999895	1804	[ c) a liquid composition comprising a pharmaceutically acceptable carrier; ]	[ b) a pharmaceutically acceptable carrier in a liquid form; ]
0.9999912	1805	[ d) a liquid composition in which said carrier is not present and wherein said carrier is present in an amount sufficient to treat said disease; ]	[ c) a liquid composition comprising a pharmaceutically acceptable carrier; ]
0.999984	1806	[ wherein said carrier is selected from the group consisting of: ]	[ d) a liquid composition in which said carrier is not present and wherein said carrier is present in an amount sufficient to treat said disease; ]
0.9990735	1807	[ a) a pharmaceutically acceptable carrier in a liquid form; ]	[ wherein said carrier is selected from the group consisting of: ]
0.99998856	1808	[ b) a liquid composition comprising a pharmaceutically acceptable carrier; ]	[ a) a pharmaceutically acceptable carrier in a liquid form; ]
0.9999913	1809	[ c) a liquid composition in which said carrier is present; ]	[ b) a liquid composition comprising a pharmaceutically acceptable carrier; ]
0.996903	1810	[ d) a pharmaceutically acceptable carrier; ]	[ c) a liquid composition in which said carrier is present; ]
0.99997723	1811	[ e) a pharmaceutically acceptable carrier in a liquid form; and ]	[ d) a pharmaceutically acceptable carrier; ]
0.9999864	1812	[ f) a pharmaceutically acceptable carrier in a solid form. ]	[ e) a pharmaceutically acceptable carrier in a liquid form; and ]
0.99870193	1813	[ providing a plurality of patient-specific antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; ]	[ A method for the treatment of a patient, comprising the steps of: ]
0.9999924	1814	[ contacting the patient with the plurality of patient-specific antibodies, wherein the plurality of antibodies are selected from the group consisting of a plurality of antibodies that are selected from the group consisting of: a) a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; and ]	[ providing a plurality of patient-specific antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; ]
0.99999225	1815	[ b) antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein that is not the same as the human papillomavirus (HPV) subtype 1 protein; and ]	[ contacting the patient with the plurality of patient-specific antibodies, wherein the plurality of antibodies are selected from the group consisting of a plurality of antibodies that are selected from the group consisting of: a) a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; and ]
0.9996878	1816	[ administering the plurality of patient-specific antibodies to the patient; ]	[ b) antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein that is not the same as the human papillomavirus (HPV) subtype 1 protein; and ]
0.9999324	1817	[ wherein the plurality of antibodies are selected from the group consisting of: a) a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; and ]	[ administering the plurality of patient-specific antibodies to the patient; ]
0.99999225	1818	[ b) antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein that is not the same as the human papillomavirus (HPV) subtype 1 protein; and ]	[ wherein the plurality of antibodies are selected from the group consisting of: a) a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; and ]
0.9999924	1819	[ wherein the plurality of antibodies are selected from the group consisting of a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; and ]	[ b) antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein that is not the same as the human papillomavirus (HPV) subtype 1 protein; and ]
0.9999628	1820	[ administering the plurality of patient-specific antibodies to the patient, ]	[ wherein the plurality of antibodies are selected from the group consisting of a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; and ]
0.99996805	1821	[ wherein the plurality of antibodies are selected from the group consisting of a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; and ]	[ administering the plurality of patient-specific antibodies to the patient, ]
0.9999924	1822	[ wherein the plurality of antibodies are selected from the group consisting of a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein that is not the same as the human papillomavirus (HPV) subtype 1 protein. ]	[ wherein the plurality of antibodies are selected from the group consisting of a plurality of antibodies that specifically binds to a human papillomavirus (HPV) subtype 1 protein; and ]
0.99990225	1823	[ administering to the subject a composition comprising: ]	[ A method for treating an inflammatory disease in a subject, comprising: ]
0.9825315	1824	[ (a) a polymeric matrix comprising a polymeric polymer and a polymeric polyamide, wherein the polymeric polymer comprises a polymeric polymer having a polymeric polymerizable portion and a nonpolymerizable portion; ]	[ administering to the subject a composition comprising: ]
0.00031039555	1825	[ (b) a pharmaceutically acceptable carrier; and ]	[ (a) a polymeric matrix comprising a polymeric polymer and a polymeric polyamide, wherein the polymeric polymer comprises a polymeric polymer having a polymeric polymerizable portion and a nonpolymerizable portion; ]
0.99980456	1826	[ (c) a pharmaceutically acceptable agent, wherein the composition is effective to treat the inflammatory disease, wherein the polymeric matrix comprises a polymeric polyamide and the polymeric polymer comprises a polymeric polyamide. ]	[ (b) a pharmaceutically acceptable carrier; and ]
0.9820925	1827	[ an elongate body having a first end, a second end, and ]	[ An implantable device, comprising: ]
0.9999918	1828	[ a proximal end; the elongate body having a first longitudinal axis and a second longitudinal axis; the first longitudinal axis and the second longitudinal axis intersect at an end of the elongate body; the first longitudinal axis is substantially parallel with the second longitudinal axis; and ]	[ an elongate body having a first end, a second end, and ]
0.99999213	1829	[ a first electrode positioned at a proximal end of the elongate body, the first electrode having a first end and a second end; the second end of the second electrode is positioned at the proximal end of the elongate body; the second end of the first electrode and the second end of the second electrode are spaced from each other by a first distance, and ]	[ a proximal end; the elongate body having a first longitudinal axis and a second longitudinal axis; the first longitudinal axis and the second longitudinal axis intersect at an end of the elongate body; the first longitudinal axis is substantially parallel with the second longitudinal axis; and ]
0.999992	1830	[ the first and second ends of the first and second electrodes are spaced from each other by a second distance, the first and second distances being substantially equal. ]	[ a first electrode positioned at a proximal end of the elongate body, the first electrode having a first end and a second end; the second end of the second electrode is positioned at the proximal end of the elongate body; the second end of the first electrode and the second end of the second electrode are spaced from each other by a first distance, and ]
0.9993131	1831	[ (a) obtaining a first set of data from a patient, wherein the first set of data comprises at least one set of medical information; ]	[ A method for the treatment of a patient with a disease or condition, comprising the steps of: ]
0.9999907	1832	[ (b) identifying a second set of data from the first set of data; ]	[ (a) obtaining a first set of data from a patient, wherein the first set of data comprises at least one set of medical information; ]
0.9999913	1833	[ (c) obtaining a second set of data from at least one other source; ]	[ (b) identifying a second set of data from the first set of data; ]
0.9999876	1834	[ (d) comparing at least one set of medical information from the second set of data to a predetermined medical information; wherein the second set of data comprises at least one set of information that is not from a first set of medical information and that is not from a second set of medical information; ]	[ (c) obtaining a second set of data from at least one other source; ]
0.9999924	1835	[ (e) determining whether a difference exists between the predetermined medical information and the second set of medical information based on the comparison; and ]	[ (d) comparing at least one set of medical information from the second set of data to a predetermined medical information; wherein the second set of data comprises at least one set of information that is not from a first set of medical information and that is not from a second set of medical information; ]
0.9999914	1836	[ (f) if the difference exists, treating the patient with a therapy. ]	[ (e) determining whether a difference exists between the predetermined medical information and the second set of medical information based on the comparison; and ]
0.97991073	1837	[ a first portion having an outer circumference and an inner circumference; ]	[ A device for the placement in a patient's body, comprising: ]
0.999992	1838	[ a second portion having an inner circumference and an outer circumference; ]	[ a first portion having an outer circumference and an inner circumference; ]
0.99994683	1839	[ at least a first portion and at least a second portion having a plurality of first and second ends, wherein the first portion is adapted to be placed in the patient's body and the second portion is adapted to be inserted in the patient's body; ]	[ a second portion having an inner circumference and an outer circumference; ]
0.9999654	1840	[ a first portion having a first end and a second end, wherein the first portion is disposed in a first region of the second portion and the second portion is disposed in a second region of the second portion, wherein the first end of the first portion and the first end of the second portion define a first region of a first portion and a second region of a second portion, wherein the first region is a first region of the second portion and the second region is a second region of the first portion and the second portion; ]	[ at least a first portion and at least a second portion having a plurality of first and second ends, wherein the first portion is adapted to be placed in the patient's body and the second portion is adapted to be inserted in the patient's body; ]
0.99999213	1841	[ at least a first portion having a first end and a second end, wherein the first portion and the first end of the first portion define a first region of the first portion and a second region of a second portion, and ]	[ a first portion having a first end and a second end, wherein the first portion is disposed in a first region of the second portion and the second portion is disposed in a second region of the second portion, wherein the first end of the first portion and the first end of the second portion define a first region of a first portion and a second region of a second portion, wherein the first region is a first region of the second portion and the second region is a second region of the first portion and the second portion; ]
0.9999914	1842	[ wherein the first region of the first portion and the second region of the second portion are different than the first region of the second portion; ]	[ at least a first portion having a first end and a second end, wherein the first portion and the first end of the first portion define a first region of the first portion and a second region of a second portion, and ]
0.99999	1843	[ a first portion having a first end and a second end, wherein the first portion and the first end of the first portion define a first region of a first portion and a second region of a second portion, wherein the first region is a first region of the second portion and the second region is a second region of the first portion and the second portion; and ]	[ wherein the first region of the first portion and the second region of the second portion are different than the first region of the second portion; ]
0.99999213	1844	[ a second portion having a first end and a second end, wherein the second portion and the second end of the first portion define an outer region of the second portion and the second region of the second portion. ]	[ a first portion having a first end and a second end, wherein the first portion and the first end of the first portion define a first region of a first portion and a second region of a second portion, wherein the first region is a first region of the second portion and the second region is a second region of the first portion and the second portion; and ]
0.9951807	1845	[ providing a first implantable medical device (IMD) having a first implantable device interface (IID) and a second interface (IIID), the first IMD having a first IMD interface and the second IMD having a second IMD interface; ]	[ A method of treating a patient, comprising: ]
0.99999225	1846	[ receiving, by a processor, a first command from a user, the first IMD having a first IMD interface and the second IMD having a second IMD interface; and ]	[ providing a first implantable medical device (IMD) having a first implantable device interface (IID) and a second interface (IIID), the first IMD having a first IMD interface and the second IMD having a second IMD interface; ]
0.99999213	1847	[ receiving a second command from a user, the second IMD having a second IMD interface, ]	[ receiving, by a processor, a first command from a user, the first IMD having a first IMD interface and the second IMD having a second IMD interface; and ]
0.9999919	1848	[ wherein the first IMD interface comprises a first communication port and the second IMD interface comprises a first communication port and the first IMD is configured for use with a first implantable medical device (IMD) and a second IMD. ]	[ receiving a second command from a user, the second IMD having a second IMD interface, ]
0.9999924	1849	[ (a) introducing an antibody comprising a nucleic acid sequence encoding a human immunodeficiency virus (HIV) polypeptide into a subject with said disorder of immune system or said condition of immune system; and ]	[ A method for treating a subject with a condition in which the subject has a disorder of the immune system or a condition of the immune system that results from a mutation in a gene of a human immunoglobulin (HIV) gene, wherein said HIV gene comprises a mutation in a gene that is expressed by a portion of the human immunoglobulin (HIV) gene, comprising: ]
0.9999924	1850	[ (b) administering an effective amount of said antibody to said subject, wherein said subject has said disorder of immune system or said condition of immune system. ]	[ (a) introducing an antibody comprising a nucleic acid sequence encoding a human immunodeficiency virus (HIV) polypeptide into a subject with said disorder of immune system or said condition of immune system; and ]
0.99952936	1851	[ R1 and R2 each independently hydrogen; and ]	[ A method for treating a disease or condition in a subject, the disease or condition including a cancer, the method comprising administering to the subject a compound of formula I, wherein: ]
0.9997745	1852	[ R4 and R5 are independently hydrogen or alkyl, wherein: ]	[ R1 and R2 each independently hydrogen; and ]
0.9999871	1853	[ R3 is independently hydrogen or alkyl, wherein: ]	[ R4 and R5 are independently hydrogen or alkyl, wherein: ]
0.99684525	1854	[ R4 is optionally substituted with one or more alkyl groups; and ]	[ R3 is independently hydrogen or alkyl, wherein: ]
0.99195355	1855	[ the compound is a pharmaceutically acceptable salt or a pharmaceutically acceptable carrier. ]	[ R4 is optionally substituted with one or more alkyl groups; and ]
0.96336657	1856	[ a first housing; ]	[ A device comprising: ]
0.9981263	1857	[ a first drive member; ]	[ a first housing; ]
0.9999782	1858	[ a first drive shaft; ]	[ a first drive member; ]
0.9999846	1859	[ a first drive gear; and ]	[ a first drive shaft; ]
0.9999393	1860	[ a first drive shaft shaft; ]	[ a first drive gear; and ]
0.018784905	1861	[ wherein: ]	[ a first drive shaft shaft; ]
0.05363038	1862	[ the first drive member is a first drive member having first and second drive members, wherein the first drive member has a first end and a second end; and ]	[ wherein: ]
0.9999919	1863	[ the first drive member has a first drive member drive gear having first and second drive gears, wherein the first drive member is a first drive member drive gear having a first and second drive gears, and ]	[ the first drive member is a first drive member having first and second drive members, wherein the first drive member has a first end and a second end; and ]
0.9999919	1864	[ wherein the first drive member has a first and second drive shaft shaft shaft, and ]	[ the first drive member has a first drive member drive gear having first and second drive gears, wherein the first drive member is a first drive member drive gear having a first and second drive gears, and ]
0.9999871	1865	[ wherein the first drive member is configured to drive a first drive member, and ]	[ wherein the first drive member has a first and second drive shaft shaft shaft, and ]
0.9999908	1866	[ the first drive member has a first drive shaft drive gear having a first and second drive shaft shaft shaft, and ]	[ wherein the first drive member is configured to drive a first drive member, and ]
0.9999864	1867	[ wherein the first and second drive shaft shafts have different drive shafts. ]	[ the first drive member has a first drive shaft drive gear having a first and second drive shaft shaft shaft, and ]
0.99922407	1868	[ or a pharmaceutically acceptable salt thereof; ]	[ A method for treating a disease or condition in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound selected from the group consisting of a compound of formula I: ]
0.9795786	1869	[ wherein: ]	[ or a pharmaceutically acceptable salt thereof; ]
0.994146	1870	[ R1 is hydrogen or a salt thereof; ]	[ wherein: ]
0.99998784	1871	[ R2 is hydrogen or a salt thereof; ]	[ R1 is hydrogen or a salt thereof; ]
0.99998343	1872	[ R3 is hydrogen or a salt thereof; ]	[ R2 is hydrogen or a salt thereof; ]
0.9999863	1873	[ R4 is hydrogen or a salt thereof; ]	[ R3 is hydrogen or a salt thereof; ]
0.9999862	1874	[ R5 is hydrogen or a salt thereof; ]	[ R4 is hydrogen or a salt thereof; ]
0.9999505	1875	[ R6 is hydrogen or a salt thereof; orR7 is hydrogen or a salt thereof; ]	[ R5 is hydrogen or a salt thereof; ]
0.99997187	1876	[ R8 is hydrogen or a salt thereof; ]	[ R6 is hydrogen or a salt thereof; orR7 is hydrogen or a salt thereof; ]
0.99997425	1877	[ R9 is hydrogen, or a salt thereof; ]	[ R8 is hydrogen or a salt thereof; ]
0.9999527	1878	[ R10 is hydrogen or a salt thereof; ]	[ R9 is hydrogen, or a salt thereof; ]
0.9999852	1879	[ R11 is hydrogen, or a salt thereof; orwherein R1 is hydrogen or a salt thereof. ]	[ R10 is hydrogen or a salt thereof; ]
0.96911937	1880	[ wherein: ]	[ A method of treating a patient in need of such treatment, comprising administering to said patient an effective amount of an effective amount of an effective amount of a compound having the formula: ]
0.995752	1881	[ R1 and R2 are hydrogen; ]	[ wherein: ]
0.99963355	1882	[ R1 and R2 each independently is hydrogen; ]	[ R1 and R2 are hydrogen; ]
0.9988386	1883	[ R1 and R2 are independently selected from the group consisting of H, C1-C4alkyl, C1-C4alkoxy, C1-C4alkenyl, C1-C4alkoxy-C1-C4alkoxy, and ]	[ R1 and R2 each independently is hydrogen; ]
0.99999106	1884	[ C1-C4alkenyl-C1-C4alkoxy; ]	[ R1 and R2 are independently selected from the group consisting of H, C1-C4alkyl, C1-C4alkoxy, C1-C4alkenyl, C1-C4alkoxy-C1-C4alkoxy, and ]
0.9894748	1885	[ R3 and R4 each independently is hydrogen; ]	[ C1-C4alkenyl-C1-C4alkoxy; ]
0.9999887	1886	[ R3 and R4 each independently is hydrogen; ]	[ R3 and R4 each independently is hydrogen; ]
0.9997054	1887	[ R4 is hydrogen; and ]	[ R3 and R4 each independently is hydrogen; ]
0.9994173	1888	[ R5 is hydrogen or a C1-C4alkyl group; ]	[ R4 is hydrogen; and ]
0.99999094	1889	[ R5 is hydrogen or a C1-C4alkyl group. ]	[ R5 is hydrogen or a C1-C4alkyl group; ]
0.0069415397	1890	[ a) a housing; ]	[ A device for providing a therapeutic treatment to a patient, comprising: ]
0.9999317	1891	[ b) at least one electrode positioned within the housing and having a proximal end, a distal end and a longitudinal axis; and ]	[ a) a housing; ]
0.99999154	1892	[ c) a plurality of electrodes positioned in the housing and having a proximal end, a distal end and an axis of rotation; and ]	[ b) at least one electrode positioned within the housing and having a proximal end, a distal end and a longitudinal axis; and ]
0.9997806	1893	[ wherein the device includes at least one electrode for each of a plurality of electrodes, the at least one electrode for each of a plurality of electrodes having a proximal end and a distal end, the at least one electrode for each of the plurality of electrodes having a longitudinal axis, the at least one electrode for the plurality of electrodes having a longitudinal axis being substantially parallel with the longitudinal axis of the device and the device being adapted to be implanted within a body. ]	[ c) a plurality of electrodes positioned in the housing and having a proximal end, a distal end and an axis of rotation; and ]
0.99999225	1894	[ providing a plurality of electrodes having a first electrode surface area and a second electrode surface area; ]	[ A method for producing an implantable medical device comprising a first electrode having a first electrode surface and a plurality of electrodes, the first electrode surface having a first electrode surface area, the first electrode surface area being larger than the plurality of electrodes, the method comprising: ]
0.9999924	1895	[ providing a plurality of first and second electrodes having a first electrode surface area and a second electrode surface area; ]	[ providing a plurality of electrodes having a first electrode surface area and a second electrode surface area; ]
0.9999924	1896	[ providing a plurality of first and second electrodes having a first electrode surface area and a second electrode surface area; ]	[ providing a plurality of first and second electrodes having a first electrode surface area and a second electrode surface area; ]
0.9999924	1897	[ providing a plurality of first and second electrodes having a first electrode surface area and a second electrode surface area; ]	[ providing a plurality of first and second electrodes having a first electrode surface area and a second electrode surface area; ]
0.9999924	1898	[ providing a first plurality of first electrodes having a first electrode surface area and a second electrode surface area; ]	[ providing a plurality of first and second electrodes having a first electrode surface area and a second electrode surface area; ]
0.9999924	1899	[ providing a first plurality of first electrodes having a first electrode surface area and a second electrode surface area; ]	[ providing a first plurality of first electrodes having a first electrode surface area and a second electrode surface area; ]
0.9999924	1900	[ providing a first plurality of second electrodes having a first electrode surface area and a second electrode surface area; ]	[ providing a first plurality of first electrodes having a first electrode surface area and a second electrode surface area; ]
0.9999924	1901	[ providing a first plurality of first electrodes having a first electrode surface area and a second electrode surface area; and ]	[ providing a first plurality of second electrodes having a first electrode surface area and a second electrode surface area; ]
0.9999924	1902	[ providing a first plurality of second electrodes having a first electrode surface area and a second electrode surface area. ]	[ providing a first plurality of first electrodes having a first electrode surface area and a second electrode surface area; and ]
0.99948573	1903	[ 1 or SEQ ID NO: ]	[ A method for treating a patient with a condition associated with an increase in the level of a protein in a cell, the method comprising administering to the patient a therapeutically effective amount of a protein in a cell that comprises a protein having the amino acid sequence of SEQ ID NO: ]
0.99891686	1904	[ 2. ]	[ 1 or SEQ ID NO: ]
0.99949706	1905	[ providing an implantable medical device having an implantable cardiac device and an electrical circuit, the electrical circuit including a first electrical conductor for supplying power to the implantable cardiac device; ]	[ A method for the treatment of a patient having a heart failure comprising: ]
0.9994004	1906	[ providing a first electrode; ]	[ providing an implantable medical device having an implantable cardiac device and an electrical circuit, the electrical circuit including a first electrical conductor for supplying power to the implantable cardiac device; ]
0.9999908	1907	[ providing a first electrode electrode; ]	[ providing a first electrode; ]
0.99999154	1908	[ providing a second electrode; ]	[ providing a first electrode electrode; ]
0.999992	1909	[ providing a second electrode; ]	[ providing a second electrode; ]
0.9999819	1910	[ providing an electrically insulative membrane between the first and second electrodes, the electrically insulative membrane comprising a first electrode layer and a second electrode layer; ]	[ providing a second electrode; ]
0.99999213	1911	[ providing an insulative membrane between the first and second electrodes; ]	[ providing an electrically insulative membrane between the first and second electrodes, the electrically insulative membrane comprising a first electrode layer and a second electrode layer; ]
0.99990964	1912	[ providing a first electrode layer; ]	[ providing an insulative membrane between the first and second electrodes; ]
0.99999213	1913	[ providing a second electrode layer; ]	[ providing a first electrode layer; ]
0.99998987	1914	[ providing a first insulator layer; ]	[ providing a second electrode layer; ]
0.99999225	1915	[ providing a second insulator layer; ]	[ providing a first insulator layer; ]
0.9999702	1916	[ providing an insulative membrane between the first and second insulators; and ]	[ providing a second insulator layer; ]
0.999992	1917	[ applying an electrical current through the insulative membrane, the insulative membrane being electrically insulative to the first and second electrodes. ]	[ providing an insulative membrane between the first and second insulators; and ]
0.9999918	1918	[ (1) determining a level of the first amino acid sequence in the sample; ]	[ A method for determining a level of a protein in a sample, the protein having at least one protein domain comprising a first amino acid sequence and a first domain comprising a second amino acid sequence, wherein said first amino acid sequence is different from said first domain, said method comprising: ]
0.999992	1919	[ (2) determining a level of the first domain in the sample; ]	[ (1) determining a level of the first amino acid sequence in the sample; ]
0.999992	1920	[ (3) determining a level of the second amino acid sequence in the sample; ]	[ (2) determining a level of the first domain in the sample; ]
0.99999225	1921	[ (4) determining a level of the first amino acid sequence in the sample; ]	[ (3) determining a level of the second amino acid sequence in the sample; ]
0.99999213	1922	[ (5) determining a level of the second domain in the sample; and ]	[ (4) determining a level of the first amino acid sequence in the sample; ]
0.99999225	1923	[ (6) determining a level of the first protein domain in the sample. ]	[ (5) determining a level of the second domain in the sample; and ]
0.99986565	1924	[ providing a pharmaceutical composition comprising a first pharmaceutical agent and a second pharmaceutical agent, the first pharmaceutical agent having an affinity for the first pharmaceutical agent, the second pharmaceutical agent having an affinity for the second pharmaceutical agent; and ]	[ A method for producing a therapeutic composition comprising: ]
0.9957867	1925	[ providing a pharmaceutically acceptable carrier, ]	[ providing a pharmaceutical composition comprising a first pharmaceutical agent and a second pharmaceutical agent, the first pharmaceutical agent having an affinity for the first pharmaceutical agent, the second pharmaceutical agent having an affinity for the second pharmaceutical agent; and ]
0.9999628	1926	[ wherein the carrier is a composition of a pharmaceutically acceptable carrier and a pharmaceutically acceptable carrier-containing material, ]	[ providing a pharmaceutically acceptable carrier, ]
0.998738	1927	[ wherein the first pharmaceutical agent and the second pharmaceutical agent are selected from the group consisting of: ]	[ wherein the carrier is a composition of a pharmaceutically acceptable carrier and a pharmaceutically acceptable carrier-containing material, ]
0.9999888	1928	[ (i) an anionic pharmaceutical agent having an affinity for the first pharmaceutical agent; and ]	[ wherein the first pharmaceutical agent and the second pharmaceutical agent are selected from the group consisting of: ]
0.99999	1929	[ (ii) a pharmaceutically acceptable salt of the anionic pharmaceutical agent, ]	[ (i) an anionic pharmaceutical agent having an affinity for the first pharmaceutical agent; and ]
0.9994535	1930	[ wherein the composition comprises a pharmaceutically acceptable carrier and a pharmaceutically acceptable carrier-containing material. ]	[ (ii) a pharmaceutically acceptable salt of the anionic pharmaceutical agent, ]
0.9946097	1931	[ (a) a pharmaceutically acceptable excipient; and ]	[ A method of treating a patient with an inflammatory disorder comprising administering to said patient an effective amount of a composition comprising: ]
0.9997806	1932	[ (b) a pharmaceutically acceptable carrier; ]	[ (a) a pharmaceutically acceptable excipient; and ]
0.999035	1933	[ wherein said excipient is a pharmaceutically acceptable excipient, and ]	[ (b) a pharmaceutically acceptable carrier; ]
0.9999888	1934	[ wherein the composition comprises a pharmaceutically acceptable excipient. ]	[ wherein said excipient is a pharmaceutically acceptable excipient, and ]
0.9995981	1935	[ providing a skin-care product comprising a polymeric composition comprising a polypeptide having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: ]	[ A method for treating a subject having a condition in which a patient's skin is exposed to ultraviolet radiation, comprising: ]
0.9999924	1936	[ 3, wherein the composition is a skin-care composition comprising a polymeric composition having a polypeptide having a amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: ]	[ providing a skin-care product comprising a polymeric composition comprising a polypeptide having an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: ]
0.996872	1937	[ 3; ]	[ 3, wherein the composition is a skin-care composition comprising a polymeric composition having a polypeptide having a amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: ]
0.00405906	1938	[ exposing a patient to a UV radiation that is at least about 10 times higher than the UV radiation received from the skin-care product; and ]	[ 3; ]
0.9999918	1939	[ treating the skin-care product with the polymeric composition to treat the condition. ]	[ exposing a patient to a UV radiation that is at least about 10 times higher than the UV radiation received from the skin-care product; and ]
0.99769896	1940	[ a first end, a second end and a first end-side surface, said first end being disposed in a longitudinal direction and said second end being disposed in a longitudinal direction; ]	[ An implant for use in an implantable cardiac device, said implant comprising: ]
0.99999225	1941	[ a first electrode disposed on a first side of the first end-side surface of said implant and having an electrode surface, said electrode surface being substantially perpendicular to the longitudinal direction and substantially perpendicular to the second side of the first end-side surface of said implant; ]	[ a first end, a second end and a first end-side surface, said first end being disposed in a longitudinal direction and said second end being disposed in a longitudinal direction; ]
0.99999225	1942	[ a second electrode disposed on a second side of the second end-side surface of said implant and having an electrode surface, said electrode surface being substantially perpendicular to the longitudinal direction and substantially perpendicular to the first side of the second end-side surface of said implant, and ]	[ a first electrode disposed on a first side of the first end-side surface of said implant and having an electrode surface, said electrode surface being substantially perpendicular to the longitudinal direction and substantially perpendicular to the second side of the first end-side surface of said implant; ]
0.99999225	1943	[ having a plurality of first and second electrodes disposed on said first and second side of said first end-side surface of said implant; ]	[ a second electrode disposed on a second side of the second end-side surface of said implant and having an electrode surface, said electrode surface being substantially perpendicular to the longitudinal direction and substantially perpendicular to the first side of the second end-side surface of said implant, and ]
0.99999213	1944	[ an outer surface of said second end-side surface of said implant being substantially parallel to a first longitudinal axis; and ]	[ having a plurality of first and second electrodes disposed on said first and second side of said first end-side surface of said implant; ]
0.9999914	1945	[ a plurality of first and second electrodes disposed at a location between the first and second electrodes, said plurality of first and second electrodes being disposed on the outer surface of said second end-side surface of said implant, and ]	[ an outer surface of said second end-side surface of said implant being substantially parallel to a first longitudinal axis; and ]
0.9999895	1946	[ said first and second electrodes each having a first end and a second end, ]	[ a plurality of first and second electrodes disposed at a location between the first and second electrodes, said plurality of first and second electrodes being disposed on the outer surface of said second end-side surface of said implant, and ]
0.9975827	1947	[ wherein said outer surface of said second end-side surface of said implant has a first surface and a second surface, said first and second surfaces being substantially perpendicular to the first and second longitudinal directions, and ]	[ said first and second electrodes each having a first end and a second end, ]
0.99995005	1948	[ wherein the plurality of first and second electrodes are disposed on the first and second sides of said first and second surfaces. ]	[ wherein said outer surface of said second end-side surface of said implant has a first surface and a second surface, said first and second surfaces being substantially perpendicular to the first and second longitudinal directions, and ]
0.9999887	1949	[ (2) providing a second sample, wherein the first and second samples are each provided at different times and at different locations, ]	[ A method for the detection of a substance in a sample of blood, comprising the steps of (1) providing a first sample having a first concentration of the substance, and ]
0.99995506	1950	[ (3a) obtaining a first set of data from the first sample; and ]	[ (2) providing a second sample, wherein the first and second samples are each provided at different times and at different locations, ]
0.99999225	1951	[ (3b) obtaining a second set of data from the second sample, wherein the first and second sets of data are each obtained at different times and at different locations. ]	[ (3a) obtaining a first set of data from the first sample; and ]
0.9996903	1952	[ a) an increased susceptibility to a disease or condition; ]	[ A method for treating an individual having a disorder characterized by at least one of: ]
0.9999913	1953	[ b) an increased risk of developing a disease or condition; and ]	[ a) an increased susceptibility to a disease or condition; ]
0.999969	1954	[ c) a decreased ability to perform activities of daily living, the method comprising administering to the individual a therapeutically effective amount of a compound selected from the group consisting of: ]	[ b) an increased risk of developing a disease or condition; and ]
0.9985607	1955	[ a compound selected from the group consisting of: ]	[ c) a decreased ability to perform activities of daily living, the method comprising administering to the individual a therapeutically effective amount of a compound selected from the group consisting of: ]
0.9980081	1956	[ a pharmaceutically acceptable salt thereof, and ]	[ a compound selected from the group consisting of: ]
0.9995846	1957	[ a pharmaceutically acceptable carrier, and ]	[ a pharmaceutically acceptable salt thereof, and ]
0.9990221	1958	[ a pharmaceutically acceptable salt thereof, ]	[ a pharmaceutically acceptable carrier, and ]
0.99902785	1959	[ wherein the disorder is a disease characterized by an increased susceptibility to the disease or condition. ]	[ a pharmaceutically acceptable salt thereof, ]
0.99996686	1960	[ (a) administering to the subject a therapeutically effective amount of an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a protein that is a target for the treatment of the disease; and ]	[ A method for treating a patient with a disease comprising: ]
0.99999225	1961	[ (b) administering to the subject a therapeutically effective amount of an isolated polypeptide comprising an amino acid sequence that encodes a polypeptide that binds to a protein that is a target for the treatment of the disease, ]	[ (a) administering to the subject a therapeutically effective amount of an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a protein that is a target for the treatment of the disease; and ]
0.9999912	1962	[ wherein the polypeptide binds to the protein. ]	[ (b) administering to the subject a therapeutically effective amount of an isolated polypeptide comprising an amino acid sequence that encodes a polypeptide that binds to a protein that is a target for the treatment of the disease, ]
0.999323	1963	[ an implantable medical device comprising a plurality of electrodes; and ]	[ An apparatus for the treatment of a patient, comprising: ]
0.99999034	1964	[ a first electrode positioned on the implantable medical device and configured to deliver electrical signals to a patient, the first electrode configured to generate a first electrical stimulation signal and a second electrical stimulation signal; ]	[ an implantable medical device comprising a plurality of electrodes; and ]
0.9999924	1965	[ wherein the first electrode is configured to deliver the first electrical stimulation signal and the second electrical stimulation signal to the patient; ]	[ a first electrode positioned on the implantable medical device and configured to deliver electrical signals to a patient, the first electrode configured to generate a first electrical stimulation signal and a second electrical stimulation signal; ]
0.99999225	1966	[ wherein the first electrode is configured to deliver the second electrical stimulation signal to the patient; and ]	[ wherein the first electrode is configured to deliver the first electrical stimulation signal and the second electrical stimulation signal to the patient; ]
0.9999924	1967	[ wherein the second electrode is configured to deliver the first electrical stimulation signal to the patient, ]	[ wherein the first electrode is configured to deliver the second electrical stimulation signal to the patient; and ]
0.9999924	1968	[ wherein the first and second electrical stimulation signals are delivered by the same first electrode. ]	[ wherein the second electrode is configured to deliver the first electrical stimulation signal to the patient, ]
0.9516787	1969	[ 1. ]	[ A method of treating a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of a composition comprising a polypeptide having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: ]
0.99972326	1970	[ a first drug delivery tube having a first end; and ]	[ An apparatus for providing a therapeutic dose of a drug comprising: ]
0.99999225	1971	[ an intermediate drug delivery tube having a second end, ]	[ a first drug delivery tube having a first end; and ]
0.9999924	1972	[ wherein the intermediate drug delivery tube includes a first end and an opposite second end, and ]	[ an intermediate drug delivery tube having a second end, ]
0.99999225	1973	[ wherein a first portion of the first end of the first drug delivery tube is disposed in communication with a first portion of the intermediate drug delivery tube, and ]	[ wherein the intermediate drug delivery tube includes a first end and an opposite second end, and ]
0.99999225	1974	[ wherein a first portion of the intermediate drug delivery tube is disposed in communication with a second portion of the first drug delivery tube. ]	[ wherein a first portion of the first end of the first drug delivery tube is disposed in communication with a first portion of the intermediate drug delivery tube, and ]
0.9990779	1975	[ an ophthalmic composition. ]	[ A method for the treatment of a subject in need thereof comprising administering to said subject a composition comprising a pharmaceutically acceptable carrier, wherein the carrier is selected from the group consisting of a pharmaceutical composition, an oral composition, and ]
0.99914765	1976	[ providing a first therapeutic agent; ]	[ A method of treating a patient suffering from an acute myeloid leukemia comprising: ]
0.99999213	1977	[ administering a first dose of the first therapeutic agent to the patient, ]	[ providing a first therapeutic agent; ]
0.99999225	1978	[ wherein the first dose of the first therapeutic agent comprises an active component and a non-active component, wherein the active component comprises an amino acid sequence that is different than the amino acid sequence of a non-active component of the first therapeutic agent, and ]	[ administering a first dose of the first therapeutic agent to the patient, ]
0.9999924	1979	[ wherein the non-active component comprises an amino acid sequence that is different than the amino acid sequence of the active component of the first therapeutic agent. ]	[ wherein the first dose of the first therapeutic agent comprises an active component and a non-active component, wherein the active component comprises an amino acid sequence that is different than the amino acid sequence of a non-active component of the first therapeutic agent, and ]
0.996947	1980	[ 2. ]	[ A method for producing a compound of formula I, in a pharmaceutical composition comprising an isolated polypeptide, wherein said polypeptide comprises a nucleotide sequence encoding a nucleic acid sequence of SEQ ID NO: ]
0.99997294	1981	[ (a) obtaining a plurality of tumor images of the subject from a plurality of imaging devices, each image having an intensity of light emitted from the subject; ]	[ A method for determining the presence or absence of a tumor in a subject comprising: ]
0.99999225	1982	[ (b) determining the intensity of light emitted from the subject based on the plurality of tumor images; ]	[ (a) obtaining a plurality of tumor images of the subject from a plurality of imaging devices, each image having an intensity of light emitted from the subject; ]
0.99999213	1983	[ (c) determining a location of the subject in each image based on the intensity of light emitted from the subject and the location of the subject, wherein determining the location of the subject in each image is performed using a computer; ]	[ (b) determining the intensity of light emitted from the subject based on the plurality of tumor images; ]
0.99999225	1984	[ (d) determining the size of the tumor in each image based on the intensity of light emitted from the subject and the location of the subject, wherein determining the size of the tumor in each image is performed using a computer; ]	[ (c) determining a location of the subject in each image based on the intensity of light emitted from the subject and the location of the subject, wherein determining the location of the subject in each image is performed using a computer; ]
0.9999919	1985	[ (e) determining a tumor volume based on the tumor image; and ]	[ (d) determining the size of the tumor in each image based on the intensity of light emitted from the subject and the location of the subject, wherein determining the size of the tumor in each image is performed using a computer; ]
0.99999034	1986	[ (f) comparing the size of the tumor in each image to a predetermined threshold. ]	[ (e) determining a tumor volume based on the tumor image; and ]
0.99999225	1987	[ (a) determining whether a first member of said group of objects is a member of the group of objects; ]	[ A method for determining whether an object is a member of a group of objects comprising: ]
0.99999225	1988	[ (b) determining whether a second member of said group of objects is a member of the group of objects; and ]	[ (a) determining whether a first member of said group of objects is a member of the group of objects; ]
0.99999225	1989	[ (c) if said first member is a member of the group of objects, determining whether the second member is a member of the object; ]	[ (b) determining whether a second member of said group of objects is a member of the group of objects; and ]
0.99999213	1990	[ (d) if said second member is a member of the group of objects, determining whether the second member is a member of the object; ]	[ (c) if said first member is a member of the group of objects, determining whether the second member is a member of the object; ]
0.99999213	1991	[ (e) if said second member is a member of the group of objects, determining whether the first member is a member of the group of objects; ]	[ (d) if said second member is a member of the group of objects, determining whether the second member is a member of the object; ]
0.99999213	1992	[ (f) if said second member is a member of the group of objects, determining whether the first member is a member of the group of objects; and ]	[ (e) if said second member is a member of the group of objects, determining whether the first member is a member of the group of objects; ]
0.99999225	1993	[ (g) if said first member is a member of the group of objects: ]	[ (f) if said second member is a member of the group of objects, determining whether the first member is a member of the group of objects; and ]
0.99999225	1994	[ (1) if said first member is a member of the group of objects, determining whether the first member is a member of the group of objects; and ]	[ (g) if said first member is a member of the group of objects: ]
0.99999213	1995	[ (2) if said first member is a member of the group of objects, determining whether the first member is a member of the object. ]	[ (1) if said first member is a member of the group of objects, determining whether the first member is a member of the group of objects; and ]
0.9961545	1996	[ a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: ]	[ A method for treating an inflammatory disorder, comprising administering to a patient in need thereof an effective amount of an isolated antibody, comprising: ]
0.99881136	1997	[ 2; ]	[ a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: ]
0.9978333	1998	[ b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: ]	[ 2; ]
0.99827576	1999	[ 3; ]	[ b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: ]
0.99682283	2000	[ c) an amino acid sequence that is at least 95% identical to SEQ ID NO: 2, and ]	[ 3; ]
0.9969132	2001	[ wherein the heavy chain variable region and light chain variable region are bound to the same heavy chain variable region and the same light chain variable region; and ]	[ c) an amino acid sequence that is at least 95% identical to SEQ ID NO: 2, and ]
0.9999894	2002	[ d) a light chain variable region comprising the amino acid sequence of SEQ ID NO: ]	[ wherein the heavy chain variable region and light chain variable region are bound to the same heavy chain variable region and the same light chain variable region; and ]
0.999196	2003	[ 4. ]	[ d) a light chain variable region comprising the amino acid sequence of SEQ ID NO: ]
0.99474216	2004	[ at least one first electrode; ]	[ A device for the treatment of a patient, the device comprising: ]
0.99985385	2005	[ a second electrode; and ]	[ at least one first electrode; ]
0.9997471	2006	[ at least one control device for selectively controlling the at least one first electrode and the at least one second electrode, wherein the control device includes a first electrode, a second electrode, and ]	[ a second electrode; and ]
0.040640846	2007	[ a first control circuit; and ]	[ at least one control device for selectively controlling the at least one first electrode and the at least one second electrode, wherein the control device includes a first electrode, a second electrode, and ]
0.0008501038	2008	[ wherein the first electrode and the second electrode are positioned at different locations in a first portion of the device, the first electrode including a first portion of an electrode body and a second portion of the electrode body, the second portion of the electrode body including a first portion of an electrode wall, the first portion of the electrode wall including a first portion of a plurality of first electrodes, each of the first electrodes including a first portion of a plurality of second electrodes, and ]	[ a first control circuit; and ]
0.9999877	2009	[ each of the first electrodes including a first portion of a plurality of second electrodes. ]	[ wherein the first electrode and the second electrode are positioned at different locations in a first portion of the device, the first electrode including a first portion of an electrode body and a second portion of the electrode body, the second portion of the electrode body including a first portion of an electrode wall, the first portion of the electrode wall including a first portion of a plurality of first electrodes, each of the first electrodes including a first portion of a plurality of second electrodes, and ]
0.07781637	2010	[ an elongate shaft having a proximal end and a distal end, said elongate shaft including a plurality of elongate shaft members, each elongate shaft member having a proximal end and a distal end, wherein said elongate shaft members are connected by a connecting member, said connecting member including a plurality of connecting members, each connecting member including a distal end and a proximal end; ]	[ An apparatus for the placement of a medical instrument, comprising: ]
0.99999166	2011	[ a plurality of elongate members having a first end and a second end, each of said plurality of elongate members including at least one elongate member extending through the elongate shaft member, said at least one elongate member including a first elongate member extending through the elongate shaft member and a second elongate member extending through the elongate shaft member, wherein each of said elongate members includes an outer surface and an inner surface, wherein the inner surface of each of said plurality of elongate members is configured to be positioned on a portion of the elongate shaft member; and ]	[ an elongate shaft having a proximal end and a distal end, said elongate shaft including a plurality of elongate shaft members, each elongate shaft member having a proximal end and a distal end, wherein said elongate shaft members are connected by a connecting member, said connecting member including a plurality of connecting members, each connecting member including a distal end and a proximal end; ]
0.9997936	2012	[ a plurality of flexible members having a proximal end, a distal end, and ]	[ a plurality of elongate members having a first end and a second end, each of said plurality of elongate members including at least one elongate member extending through the elongate shaft member, said at least one elongate member including a first elongate member extending through the elongate shaft member and a second elongate member extending through the elongate shaft member, wherein each of said elongate members includes an outer surface and an inner surface, wherein the inner surface of each of said plurality of elongate members is configured to be positioned on a portion of the elongate shaft member; and ]
0.99999213	2013	[ a distal edge, each of said plurality of flexible members including a proximal end, an outer surface, and ]	[ a plurality of flexible members having a proximal end, a distal end, and ]
0.9999914	2014	[ a distal end, wherein the proximal end and the distal end of each of said plurality of flexible members are configured to be positioned on the proximal and distal ends of the elongate shaft members. ]	[ a distal edge, each of said plurality of flexible members including a proximal end, an outer surface, and ]
0.9998338	2015	[ providing a first therapeutic agent, wherein said first therapeutic agent comprises an active agent; ]	[ A method of treating a disease in a patient, said method comprising: ]
0.9999924	2016	[ administering to said patient a second therapeutic agent, wherein said second therapeutic agent comprises a non-active agent; and ]	[ providing a first therapeutic agent, wherein said first therapeutic agent comprises an active agent; ]
0.99999225	2017	[ administering to said patient a third therapeutic agent, wherein said third therapeutic agent comprises a non-active agent. ]	[ administering to said patient a second therapeutic agent, wherein said second therapeutic agent comprises a non-active agent; and ]
0.99938	2018	[ providing a first material; ]	[ A method for producing an implant comprising: ]
0.9999918	2019	[ providing a second material, the first material and the second material having different molecular structures; and ]	[ providing a first material; ]
0.9998053	2020	[ providing a first polymer comprising a first polymer component and a second polymer component, wherein the first polymer is a polymeric polymer and the second polymer is a polymer. ]	[ providing a second material, the first material and the second material having different molecular structures; and ]
0.99992836	2021	[ (a) the amino acid sequence of SEQ ID NO: ]	[ A method of treating a patient with a cancer comprising administering an effective amount of an anti-TNF-alpha antibody or an anti-TNF-alpha antibody/antibody complex comprising the amino acid sequence of the following amino acid sequence: ]
0.0005676405	2022	[ 2, ]	[ (a) the amino acid sequence of SEQ ID NO: ]
0.00010612069	2023	[ (b) the amino acid sequence of SEQ ID NO: ]	[ 2, ]
9.87374e-05	2024	[ 3, ]	[ (b) the amino acid sequence of SEQ ID NO: ]
4.6995927e-05	2025	[ (c) the amino acid sequence of SEQ ID NO, ]	[ 3, ]
0.9999914	2026	[ (d) the amino acid sequence of SEQ ID NO: ]	[ (c) the amino acid sequence of SEQ ID NO, ]
0.99926335	2027	[ 4, and ]	[ (d) the amino acid sequence of SEQ ID NO: ]
0.9988913	2028	[ (e) the amino acid sequence of SEQ ID NO: ]	[ 4, and ]
0.99929047	2029	[ 5. ]	[ (e) the amino acid sequence of SEQ ID NO: ]
0.9999919	2030	[ 2, wherein the HCV comprises a heavy chain variable region comprising a C1-C4 alkyl group and a heavy chain variable region comprising a C2-C4 alkyl group, and ]	[ A method for treating a patient having a heart disease, the method comprising administering to the patient an effective amount of an antibody comprising a heavy chain variable region (HVCR) that specifically binds to a heavy chain variable region (HCV) comprising a heavy chain variable region of SEQ ID NO: ]
0.9999924	2031	[ wherein the heavy chain variable region is located at a position of greater affinity than the HCV. ]	[ 2, wherein the HCV comprises a heavy chain variable region comprising a C1-C4 alkyl group and a heavy chain variable region comprising a C2-C4 alkyl group, and ]
0.003923107	2032	[ M. ]	[ A method for treating a patient suffering from an inflammatory disease, comprising administering to a patient in need thereof, an effective amount of an antibody or antibody fragment thereof, wherein the antibody or antibody fragment has a molecular weight of less than about 1 000 &#x3bc; ]
0.063914694	2033	[ 1. ]	[ A method for treating a patient suffering from an inflammatory disease comprising administering to the patient an effective amount of an antibody that specifically binds to an antigen-binding domain of a protein comprising the sequence of SEQ ID NO: ]
0.9993668	2034	[ 2 or SEQ ID NO: ]	[ An isolated antibody that binds to a polypeptide comprising a sequence of the amino acid sequence of SEQ ID NO: ]
0.9997924	2035	[ 3 and that specifically binds to a polypeptide comprising a sequence of a polypeptide of SEQ ID NO: ]	[ 2 or SEQ ID NO: ]
0.99969995	2036	[ 2 or SEQ ID NO: ]	[ 3 and that specifically binds to a polypeptide comprising a sequence of a polypeptide of SEQ ID NO: ]
0.9995609	2037	[ 3, wherein said antibody is a monoclonal antibody. ]	[ 2 or SEQ ID NO: ]
0.9982583	2038	[ at least one medical device; ]	[ An apparatus for providing a patient with a medical treatment, the apparatus comprising: ]
0.99311936	2039	[ a processor; ]	[ at least one medical device; ]
0.9978593	2040	[ a memory; and ]	[ a processor; ]
0.9992742	2041	[ a controller configured to execute instructions stored in the memory to: ]	[ a memory; and ]
0.99924064	2042	[ receive a first request from a user for medical information; ]	[ a controller configured to execute instructions stored in the memory to: ]
0.99999225	2043	[ receive a second request for medical information from a user; ]	[ receive a first request from a user for medical information; ]
0.9999449	2044	[ identify a medical device associated with the user; ]	[ receive a second request for medical information from a user; ]
0.9999913	2045	[ identify a first medical device that is associated with a medical condition of the user, wherein the first medical device is associated with the medical condition; and ]	[ identify a medical device associated with the user; ]
0.99999225	2046	[ identify a second medical device that is associated with a different medical condition than the first medical device. ]	[ identify a first medical device that is associated with a medical condition of the user, wherein the first medical device is associated with the medical condition; and ]
0.07480538	2047	[ a first portion having a first end and a second end; ]	[ An implantable device for a medical device comprising: ]
0.99988973	2048	[ a plurality of conductive electrodes arranged in the first portion; ]	[ a first portion having a first end and a second end; ]
0.994423	2049	[ a first electrode configured to be implanted in a patient's body; and ]	[ a plurality of conductive electrodes arranged in the first portion; ]
0.9997038	2050	[ at least one second electrode, wherein the plurality of conductive electrodes are arranged on a first side of the first portion and on a second side of the first portion, and ]	[ a first electrode configured to be implanted in a patient's body; and ]
0.999936	2051	[ the first and second electrodes are configured to be implanted on a same side of the patient's body, ]	[ at least one second electrode, wherein the plurality of conductive electrodes are arranged on a first side of the first portion and on a second side of the first portion, and ]
0.025046187	2052	[ wherein the first portion is a hollow body having a diameter of less than about 0.01 mm, and ]	[ the first and second electrodes are configured to be implanted on a same side of the patient's body, ]
0.99999213	2053	[ the second portion is a hollow body having a diameter of less than about 0.01 mm. ]	[ wherein the first portion is a hollow body having a diameter of less than about 0.01 mm, and ]
0.99998045	2054	[ a) a first electrode configured to deliver a therapeutic treatment to a subject; and, ]	[ A system for providing a therapeutic treatment to a subject, the system comprising: ]
0.9999918	2055	[ b) a second electrode coupled to the first electrode and configured to deliver a therapeutic treatment; and, ]	[ a) a first electrode configured to deliver a therapeutic treatment to a subject; and, ]
0.99999046	2056	[ c) an implantable device configured to be implanted in the subject, the implantable device comprising a first electrode configured to deliver a therapeutic treatment to the subject; a second electrode coupled to the first electrode, the second electrode configured to be implanted in the subject; a control circuit coupled to the implantable device, the control circuit configured to control the implantable device to deliver the therapeutic treatment to the subject; and, ]	[ b) a second electrode coupled to the first electrode and configured to deliver a therapeutic treatment; and, ]
0.9999918	2057	[ a sensor coupled to the implantable device, the sensor configured to detect a change in a physiological state of the subject. ]	[ c) an implantable device configured to be implanted in the subject, the implantable device comprising a first electrode configured to deliver a therapeutic treatment to the subject; a second electrode coupled to the first electrode, the second electrode configured to be implanted in the subject; a control circuit coupled to the implantable device, the control circuit configured to control the implantable device to deliver the therapeutic treatment to the subject; and, ]
0.015885863	2058	[ providing a first medical device comprising a first electrode and a second electrode, wherein the first electrode is configured to receive a first medical device implant; ]	[ A method comprising: ]
0.9999914	2059	[ providing a medical device comprising a second electrode, the medical device comprising a second electrode and a third electrode; ]	[ providing a first medical device comprising a first electrode and a second electrode, wherein the first electrode is configured to receive a first medical device implant; ]
0.99997926	2060	[ coupling the first and second electrodes of the first electrode and the second electrode of the second electrode to a first medical device; ]	[ providing a medical device comprising a second electrode, the medical device comprising a second electrode and a third electrode; ]
0.99999225	2061	[ coupling the second and third electrodes of the first electrode and the second electrode of the second electrode to a second medical device; and ]	[ coupling the first and second electrodes of the first electrode and the second electrode of the second electrode to a first medical device; ]
0.99999225	2062	[ coupling the first and second electrodes of the second electrode and the third electrode of the first electrode to a third medical device. ]	[ coupling the second and third electrodes of the first electrode and the second electrode of the second electrode to a second medical device; and ]
0.9999008	2063	[ a) administering to the patient an effective amount of a polypeptide comprising a nucleic acid sequence encoding an amino acid sequence having a amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: ]	[ A method for treating a patient having a disease characterized by a reduced ability to regulate a gene expression level, the method comprising the steps of: ]
0.9999918	2064	[ 1, wherein the polypeptide is an isolated polypeptide comprising a nucleic acid sequence encoding the gene encoding a human polypeptide having the amino acid sequence of SEQ ID NO: ]	[ a) administering to the patient an effective amount of a polypeptide comprising a nucleic acid sequence encoding an amino acid sequence having a amino acid sequence that is at least 95% identical to the sequence of SEQ ID NO: ]
0.9782866	2065	[ 1. ]	[ 1, wherein the polypeptide is an isolated polypeptide comprising a nucleic acid sequence encoding the gene encoding a human polypeptide having the amino acid sequence of SEQ ID NO: ]
0.9999782	2066	[ a first device configured to treat the patient; and ]	[ A system for treating a patient with a cancer comprising a first and a second device, the system comprising: ]
0.99999166	2067	[ a second device configured to treat the patient, the first device comprising a first device-specific device and a second device-specific device, ]	[ a first device configured to treat the patient; and ]
0.999992	2068	[ the first and second device-specific devices comprising: ]	[ a second device configured to treat the patient, the first device comprising a first device-specific device and a second device-specific device, ]
0.99999046	2069	[ a first device-specific device configured to treat cancer; and ]	[ the first and second device-specific devices comprising: ]
0.99999225	2070	[ a second device-specific device configured to treat a patient with cancer, ]	[ a first device-specific device configured to treat cancer; and ]
0.9727964	2071	[ wherein: ]	[ a second device-specific device configured to treat a patient with cancer, ]
0.019377498	2072	[ the first device-specific device comprises an implantable device, ]	[ wherein: ]
0.99999213	2073	[ wherein the first device-specific device is configured to treat a patient with cancer, and ]	[ the first device-specific device comprises an implantable device, ]
0.9999924	2074	[ wherein the second device-specific device comprises a first device-specific device configured to treat a patient with cancer, and ]	[ wherein the first device-specific device is configured to treat a patient with cancer, and ]
0.91415113	2075	[ wherein: ]	[ wherein the second device-specific device comprises a first device-specific device configured to treat a patient with cancer, and ]
0.057155456	2076	[ the first device-specific device is configured to be implanted in a patient's body; and, ]	[ wherein: ]
0.99999225	2077	[ the second device-specific device is configured to be implanted in the patient's body; and, ]	[ the first device-specific device is configured to be implanted in a patient's body; and, ]
0.99999225	2078	[ the first device-specific device is configured to be implanted in the patient's body in the presence of a first agent and the second device-specific device is configured to be implanted in the patient's body in the presence of a second agent. ]	[ the second device-specific device is configured to be implanted in the patient's body; and, ]
0.9998586	2079	[ (a) administering to the patient a therapeutically effective amount of a compound selected from the group consisting of: ]	[ A method of treating a cancer in a patient, comprising: ]
0.9928663	2080	[ (i) an antibody that specifically binds to an epitope of a human CD4+ T cell, and ]	[ (a) administering to the patient a therapeutically effective amount of a compound selected from the group consisting of: ]
0.9999924	2081	[ (ii) an antibody that specifically binds to a human antigen that is different from the human antigen that binds to the epitope of the human CD4+ T cell; and ]	[ (i) an antibody that specifically binds to an epitope of a human CD4+ T cell, and ]
0.99972135	2082	[ (b) administering to the patient a therapeutic agent, wherein the therapeutic agent comprises a pharmaceutically acceptable carrier. ]	[ (ii) an antibody that specifically binds to a human antigen that is different from the human antigen that binds to the epitope of the human CD4+ T cell; and ]
0.9998549	2083	[ providing a pharmaceutical composition comprising a pharmaceutically acceptable carrier; ]	[ A method of producing a pharmaceutical composition comprising: ]
0.99996865	2084	[ contacting the pharmaceutically acceptable carrier with an active substance, wherein the active substance is a pharmaceutically acceptable carrier; ]	[ providing a pharmaceutical composition comprising a pharmaceutically acceptable carrier; ]
0.999992	2085	[ contacting a pharmaceutically acceptable carrier with an active substance that is a non-active substance, and ]	[ contacting the pharmaceutically acceptable carrier with an active substance, wherein the active substance is a pharmaceutically acceptable carrier; ]
0.99998784	2086	[ wherein the non-active substance is a non-active substance; and ]	[ contacting a pharmaceutically acceptable carrier with an active substance that is a non-active substance, and ]
0.9999887	2087	[ contacting the pharmaceutically acceptable carrier with an active substance that is a pharmaceutically acceptable carrier, wherein the active substance is a non-active substance. ]	[ wherein the non-active substance is a non-active substance; and ]
0.99997485	2088	[ a. obtaining a first set of heart condition information from an electronic medical device; ]	[ A method for determining whether an individual has a heart condition, the method comprising: ]
0.99999225	2089	[ b. obtaining, from a first user, a second set of heart condition information, wherein each of the first set of heart condition information and the second set of heart condition information includes information about a first heart condition and information about a second heart condition; ]	[ a. obtaining a first set of heart condition information from an electronic medical device; ]
0.99999213	2090	[ c. comparing each of a first set of the first set of heart condition information and the second set of the first set of heart condition information to a predetermined threshold; ]	[ b. obtaining, from a first user, a second set of heart condition information, wherein each of the first set of heart condition information and the second set of heart condition information includes information about a first heart condition and information about a second heart condition; ]
0.99999225	2091	[ d. comparing a first heart condition of the first set of the first set of heart condition information to a first predetermined condition; and ]	[ c. comparing each of a first set of the first set of heart condition information and the second set of the first set of heart condition information to a predetermined threshold; ]
0.99999225	2092	[ e. comparing the first predetermined condition of the first set of the first set of heart condition information to a second predetermined condition. ]	[ d. comparing a first heart condition of the first set of the first set of heart condition information to a first predetermined condition; and ]
0.9997255	2093	[ administering a therapeutically effective amount of a pharmaceutically acceptable salt thereof. ]	[ A method for treating an inflammatory bowel disease comprising administering a therapeutically effective amount of an anti-CD3 antibody or antigen-binding fragment thereof, to a subject in need of said treatment, and ]
0.9996232	2094	[ a) a therapeutically effective amount of an anti-inflammatory agent; ]	[ A method for treating an autoimmune disorder, comprising administering to a patient suffering from an autoimmune disorder a composition comprising: ]
0.9999808	2095	[ b) an anti-inflammatory agent that inhibits or reduces the expression or activity of a protein that is associated with the autoimmune disorder, wherein the antibody binds to the anti-inflammatory agent; and ]	[ a) a therapeutically effective amount of an anti-inflammatory agent; ]
0.9999285	2096	[ c) an antibody that specifically binds to an epitope selected from the group consisting of the amino acid sequence of SEQ ID NO: 1, a sequence of SEQ ID NO: 2, a sequence of SEQ ID NO: 3, or an epitope of SEQ ID NO: 4. ]	[ b) an anti-inflammatory agent that inhibits or reduces the expression or activity of a protein that is associated with the autoimmune disorder, wherein the antibody binds to the anti-inflammatory agent; and ]
0.999936	2097	[ providing a medical device comprising an implantable device having a first electrode and a second electrode; ]	[ A method of providing a medical device to a patient, said method comprising: ]
0.99998856	2098	[ providing a first electrode and a second electrode; ]	[ providing a medical device comprising an implantable device having a first electrode and a second electrode; ]
0.99993837	2099	[ electrically coupling a first electrode and a second electrode to the implantable device; ]	[ providing a first electrode and a second electrode; ]
0.9988973	2100	[ providing a plurality of electrodes; ]	[ electrically coupling a first electrode and a second electrode to the implantable device; ]
0.9998336	2101	[ providing a first electrical current between the first electrode and the second electrode; and ]	[ providing a plurality of electrodes; ]
0.99998856	2102	[ electrically coupling a plurality of electrodes to each of the plurality of electrodes, the first electrical current and the second electrical current being electrically coupled to the implantable device. ]	[ providing a first electrical current between the first electrode and the second electrode; and ]
0.9978522	2103	[ administering a therapeutically effective amount of a compound selected from the group consisting of: ]	[ A method for treating a patient having a heart failure, comprising: ]
0.99530387	2104	[ (a) a compound of Formula I: ]	[ administering a therapeutically effective amount of a compound selected from the group consisting of: ]
0.9999517	2105	[ or (b) a combination of Formula I and Formula II: ]	[ (a) a compound of Formula I: ]
0.9995683	2106	[ or (c) a compound selected from the group consisting of: ]	[ or (b) a combination of Formula I and Formula II: ]
0.99967873	2107	[ (i) a compound of Formula III: ]	[ or (c) a compound selected from the group consisting of: ]
0.9999099	2108	[ or (ii) a compound selected from the group consisting of: ]	[ (i) a compound of Formula III: ]
0.99974984	2109	[ (i) a compound of Formula II: ]	[ or (ii) a compound selected from the group consisting of: ]
0.9999896	2110	[ and(iii) a compound of Formula III: ]	[ (i) a compound of Formula II: ]
0.96004146	2111	[ wherein: ]	[ and(iii) a compound of Formula III: ]
0.99461114	2112	[ (a) is a hydrogen atom; and ]	[ wherein: ]
0.9998499	2113	[ (b) is an amino-acid. ]	[ (a) is a hydrogen atom; and ]
0.008769039	2114	[ a housing having a first side, a second side, and ]	[ A system, comprising: ]
0.9999411	2115	[ a third side, the first side having a top and a bottom; ]	[ a housing having a first side, a second side, and ]
0.98706263	2116	[ a first support member having a first end and a second end; ]	[ a third side, the first side having a top and a bottom; ]
0.9999918	2117	[ a first support member member having a first end and a second end; and ]	[ a first support member having a first end and a second end; ]
0.99999106	2118	[ a second support member member having a first end and a second end, wherein the second side of the housing is configured to receive the first support member member and the second side of the housing is configured to receive the second support member member, the first support member member and the second support member member being disposed within the first and second support member members. ]	[ a first support member member having a first end and a second end; and ]
0.9986412	2119	[ administering to the subject a therapeutically effective amount of a polypeptide selected from the group consisting of SEQ ID NO: ]	[ A method for treating an inflammatory condition in a subject in need thereof, comprising: ]
0.99971133	2120	[ 1, SEQ ID NO: ]	[ administering to the subject a therapeutically effective amount of a polypeptide selected from the group consisting of SEQ ID NO: ]
0.99998844	2121	[ 2, SEQ ID NO: ]	[ 1, SEQ ID NO: ]
0.99998915	2122	[ 3, SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.99998844	2123	[ 5, SEQ ID NO: ]	[ 3, SEQ ID NO: ]
0.9999894	2124	[ 8, SEQ ID NO: ]	[ 5, SEQ ID NO: ]
0.99998856	2125	[ 10, SEQ ID NO: ]	[ 8, SEQ ID NO: ]
0.9999893	2126	[ 12, SEQ ID NO: ]	[ 10, SEQ ID NO: ]
0.9999888	2127	[ 14, SEQ ID NO: ]	[ 12, SEQ ID NO: ]
0.9999727	2128	[ 16 and SEQ ID NO: ]	[ 14, SEQ ID NO: ]
0.99975675	2129	[ 17, wherein the polypeptide is a polypeptide having the amino acid sequence of SEQ ID NO: ]	[ 16 and SEQ ID NO: ]
0.026264554	2130	[ 1. ]	[ 17, wherein the polypeptide is a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.99999225	2131	[ (a) providing an immunogenic agent to a patient having a condition characterized by a reduced level of a protein that comprises the heavy chain variable chain variable region, the immunogenic agent comprising a heavy chain variable chain variable region of the following structure (A): ]	[ A method of treating a patient having a condition characterized by a reduced level of a protein that comprises a heavy chain variable chain variable region comprising: ]
0.99999213	2132	[ (B) wherein A is the heavy chain variable region of the heavy chain variable chain variable region of the protein; ]	[ (a) providing an immunogenic agent to a patient having a condition characterized by a reduced level of a protein that comprises the heavy chain variable chain variable region, the immunogenic agent comprising a heavy chain variable chain variable region of the following structure (A): ]
0.99998903	2133	[ (C) wherein C is a variable region; ]	[ (B) wherein A is the heavy chain variable region of the heavy chain variable chain variable region of the protein; ]
0.99999225	2134	[ (D) wherein D is a variable region; ]	[ (C) wherein C is a variable region; ]
0.99999225	2135	[ (E) wherein E is a variable region; ]	[ (D) wherein D is a variable region; ]
0.99999225	2136	[ (F) wherein F is a variable region; and ]	[ (E) wherein E is a variable region; ]
0.99999046	2137	[ (G) wherein G and E together form a variable chain variable region of the protein. ]	[ (F) wherein F is a variable region; and ]
0.9978775	2138	[ a first medical instrument; and ]	[ A system for treating an inflammatory disorder, the system comprising: ]
0.99999213	2139	[ a second medical instrument, ]	[ a first medical instrument; and ]
0.9999919	2140	[ wherein the first and second medical instruments are configured to be inserted into an individual's body, ]	[ a second medical instrument, ]
0.99999213	2141	[ wherein each of the first and second medical instruments comprises: ]	[ wherein the first and second medical instruments are configured to be inserted into an individual's body, ]
0.0001379299	2142	[ (a) an elongate body having a first side and a second side; ]	[ wherein each of the first and second medical instruments comprises: ]
0.99999106	2143	[ (b) a first electrode disposed within the elongate body and configured to be electrically connected to the first side of the first medical instrument and configured to be electrically connected to a first electrode on the second side of the first medical instrument; ]	[ (a) an elongate body having a first side and a second side; ]
0.99999225	2144	[ (c) a first connector disposed within the elongate body and configured to be electrically connected to the first side of the first medical instrument and configured to be electrically connected to the second side of the first medical instrument; ]	[ (b) a first electrode disposed within the elongate body and configured to be electrically connected to the first side of the first medical instrument and configured to be electrically connected to a first electrode on the second side of the first medical instrument; ]
0.99999213	2145	[ (d) a second connector disposed within the elongate body and configured to be electrically connected to a second side of the second medical instrument; ]	[ (c) a first connector disposed within the elongate body and configured to be electrically connected to the first side of the first medical instrument and configured to be electrically connected to the second side of the first medical instrument; ]
0.9999924	2146	[ (e) an electrical connector disposed within the elongate body and configured to be electrically connected to the first side, the second side, and ]	[ (d) a second connector disposed within the elongate body and configured to be electrically connected to a second side of the second medical instrument; ]
5.6321012e-05	2147	[ the first electrode; ]	[ (e) an electrical connector disposed within the elongate body and configured to be electrically connected to the first side, the second side, and ]
0.0007239759	2148	[ (f) a plurality of electrodes disposed within the elongate body and configured to be connected to the electrical connectors; ]	[ the first electrode; ]
0.9999889	2149	[ (g) a plurality of electrodes disposed within the second medical instrument, wherein each of the plurality of electrodes is configured to be connected to a corresponding electrode on the second medical instrument; and ]	[ (f) a plurality of electrodes disposed within the elongate body and configured to be connected to the electrical connectors; ]
0.99999213	2150	[ (h) a plurality of conductors disposed within the second medical instrument, wherein each of the plurality of conductors is configured to be connected to the electrical connectors. ]	[ (g) a plurality of electrodes disposed within the second medical instrument, wherein each of the plurality of electrodes is configured to be connected to a corresponding electrode on the second medical instrument; and ]
0.9998128	2151	[ providing an eye lens comprising an optical system having an optical axis and a plurality of optical elements; ]	[ A method of treating an eye, comprising: ]
0.99998236	2152	[ positioning the optical system in a patient's eye; and ]	[ providing an eye lens comprising an optical system having an optical axis and a plurality of optical elements; ]
0.99993014	2153	[ applying a therapeutic dose of an effective amount of an anti-inflammatory agent to the eye lens to treat an inflammatory disorder of the eye. ]	[ positioning the optical system in a patient's eye; and ]
0.99498653	2154	[ 2. ]	[ A method for treating an inflammatory disease in a patient comprising administering to the patient an effective amount of a compound having an effective amount of a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.9960576	2155	[ 3. ]	[ An isolated antibody that specifically binds to an epitope comprising the amino acid sequence of SEQ ID NO: ]
0.9943205	2156	[ a first delivery device having a first delivery tube having a first end and a second end; ]	[ A system for providing a therapeutic dose of a pharmaceutical agent to a subject, comprising: ]
0.99999225	2157	[ an infusion device having a second delivery tube having a second end, said second end having a first end and a second end, said first delivery tube and infusion device having a first delivery tube end and a second delivery tube end; ]	[ a first delivery device having a first delivery tube having a first end and a second end; ]
0.99999225	2158	[ a first delivery tube assembly including a first delivery tube and a second delivery tube; ]	[ an infusion device having a second delivery tube having a second end, said second end having a first end and a second end, said first delivery tube and infusion device having a first delivery tube end and a second delivery tube end; ]
0.9999924	2159	[ an infusion device assembly including a second delivery tube assembly and a first infusion device; ]	[ a first delivery tube assembly including a first delivery tube and a second delivery tube; ]
0.9999924	2160	[ a first delivery tube assembly assembly including a first delivery tube assembly end and a second delivery tube assembly end, wherein said first delivery tube assembly end includes a first delivery tube assembly end opening and a second delivery tube assembly end opening, wherein said second delivery tube assembly end includes a second delivery tube assembly end opening, wherein said first delivery tube assembly end includes a first delivery tube opening and a second deliver tube opening, wherein said infusion device assembly including a second delivery tube assembly end opening and an infusion device opening, wherein said infusion device assembly end includes a second delivery tube opening and a second infusion tube opening. ]	[ an infusion device assembly including a second delivery tube assembly and a first infusion device; ]
0.999992	2161	[ 2 to said heart failure patient, wherein the polypeptide is an amino acid sequence selected from the group consisting of SEQ ID NO: ]	[ A method of treating a patient having a heart failure, the method comprising administering a therapeutically effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.9996735	2162	[ 1 and SEQ ID NO: ]	[ 2 to said heart failure patient, wherein the polypeptide is an amino acid sequence selected from the group consisting of SEQ ID NO: ]
0.9995931	2163	[ 2. ]	[ 1 and SEQ ID NO: ]
0.9998455	2164	[ providing a composition comprising a first polymeric material and a second polymeric material, wherein the first and second polymeric materials are each composed of a first polymeric material and a second polymeric material; ]	[ A method of producing a composition, the method comprising the steps of: ]
0.99999225	2165	[ contacting the first and second polymeric materials with a first solvent, wherein the first solvent is a water solvent; and, ]	[ providing a composition comprising a first polymeric material and a second polymeric material, wherein the first and second polymeric materials are each composed of a first polymeric material and a second polymeric material; ]
0.99999225	2166	[ contacting the second polymer material with a second solvent, wherein the second solvent is a water solvent. ]	[ contacting the first and second polymeric materials with a first solvent, wherein the first solvent is a water solvent; and, ]
0.9878611	2167	[ an electrode assembly; and ]	[ An implantable device comprising: ]
0.017401654	2168	[ a first and second conductive element having a conductivity, ]	[ an electrode assembly; and ]
0.9999839	2169	[ wherein the first and second conductive elements are disposed within the electrode assembly and are electrically interconnected, ]	[ a first and second conductive element having a conductivity, ]
0.9999918	2170	[ wherein the first and second conductive elements are disposed in a first position and the second position is opposite to the first position, and ]	[ wherein the first and second conductive elements are disposed within the electrode assembly and are electrically interconnected, ]
0.99999225	2171	[ wherein the first position is in a first position with the first and second conductive elements in a first configuration, ]	[ wherein the first and second conductive elements are disposed in a first position and the second position is opposite to the first position, and ]
0.99999225	2172	[ wherein the first and second conductive elements are disposed in a second position and the second position is opposite to the first position, and ]	[ wherein the first position is in a first position with the first and second conductive elements in a first configuration, ]
0.99999225	2173	[ wherein the second position is in a second position with the first and second conductive elements in a second configuration, and ]	[ wherein the first and second conductive elements are disposed in a second position and the second position is opposite to the first position, and ]
0.9999893	2174	[ wherein the first and second configurations have different conductivity characteristics. ]	[ wherein the second position is in a second position with the first and second conductive elements in a second configuration, and ]
0.9222258	2175	[ 1. ]	[ A method of treating a patient with an inflammatory disease or condition in a patient, comprising administering to said patient an isolated peptide having at least 95% sequence identity to the sequence of SEQ ID NO: ]
0.99998343	2176	[ a salt of an ester-containing ester; and ]	[ A method of producing a compound having a molecular weight of about 1.2 to about 1.5 g/mol, wherein said compound is selected from the group consisting of a pharmaceutically acceptable salt, a pharmaceutically acceptable salt-containing salt, a pharmaceutically acceptable ester, a pharmaceutically acceptable ester-containing salts, an alkoxy ester, an alkoxy ester-containing salt, an alkoxy ester-containing ester, a pharmaceutically acceptable ester, a pharmaceutically acceptable ester-containing ester, a salt of an ester, a salt of an ester-containing salt, a salt of a salt of an ester-containing ester, a salt of a salt-containing salt, a salt of a salt-containing ester, and ]
0.9684598	2177	[ wherein the compound is selected from the group consisting of: ]	[ a salt of an ester-containing ester; and ]
0.9939476	2178	[ an amino acid substitution; a substitution of a substituent selected from the group consisting of an amino acid and a hydrophobic group; and ]	[ wherein the compound is selected from the group consisting of: ]
0.9999881	2179	[ an amino acid substitution, ]	[ an amino acid substitution; a substitution of a substituent selected from the group consisting of an amino acid and a hydrophobic group; and ]
0.009299582	2180	[ wherein the compound has a molecular weight of about 1.5 to about 2.0 g/mol, and ]	[ an amino acid substitution, ]
0.99989116	2181	[ wherein a concentration of said compound is less than 0.1% by weight of the compound. ]	[ wherein the compound has a molecular weight of about 1.5 to about 2.0 g/mol, and ]
0.99882	2182	[ a) a pharmaceutical agent; ]	[ A method for treating a patient having a heart failure comprising administering an effective amount of a composition comprising: ]
0.99899465	2183	[ b) at least one compound of the formula: ]	[ a) a pharmaceutical agent; ]
0.9969536	2184	[ wherein R1 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; ]	[ b) at least one compound of the formula: ]
0.9999902	2185	[ R2 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; ]	[ wherein R1 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; ]
0.9999645	2186	[ R3 and R4 each independently are hydrogen, alkyl, aryl, alkenyl and alkenyl group; ]	[ R2 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; ]
0.9999821	2187	[ R5 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; ]	[ R3 and R4 each independently are hydrogen, alkyl, aryl, alkenyl and alkenyl group; ]
0.9999913	2188	[ R6 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; ]	[ R5 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; ]
0.99999094	2189	[ R7 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; and ]	[ R6 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; ]
0.9998945	2190	[ R8 is hydrogen; ]	[ R7 is hydrogen, alkyl, aryl, alkenyl and alkenyl group; and ]
0.00035816745	2191	[ wherein the composition is administered in a dose effective to treat the patient with the heart failure. ]	[ R8 is hydrogen; ]
0.99755704	2192	[ 2. ]	[ A method for treating a patient with a disease comprising administering to the patient an effective amount of a therapeutically effective amount of a polypeptide comprising a sequence having the amino acid position of the sequence in SEQ ID NO: ]
0.9632413	2193	[ wherein: ]	[ A method of treating an inflammatory disorder in a patient, comprising administering to said patient a therapeutically effective amount of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof: ]
0.987587	2194	[ R1, R2 and R3 each independently represent one of the amino acid substitutions of the amino acid substitutions of formula (I): ]	[ wherein: ]
0.99143463	2195	[ R4 and R5 are independently selected from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 alkoxycarbonyl, and ]	[ R1, R2 and R3 each independently represent one of the amino acid substitutions of the amino acid substitutions of formula (I): ]
0.99998367	2196	[ R6 and R7 are independently selected from hydrogen, C1-C6 alkyl, C1-C6 alkylcarbonyl, and ]	[ R4 and R5 are independently selected from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 alkoxycarbonyl, and ]
0.99998784	2197	[ C1-C6 alkylcarbonyl. ]	[ R6 and R7 are independently selected from hydrogen, C1-C6 alkyl, C1-C6 alkylcarbonyl, and ]
0.9936766	2198	[ 3. ]	[ A method of treating a disease comprising administering to a patient suffering from a cancer, wherein said cancer is a cancer associated with an epithelial cell, an effective amount of a compound selected from a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable carrier, wherein the compound comprises an amino acid sequence at least 95% identical to SEQ ID NO: ]
0.008009599	2199	[ a) a plurality of skin grafts having a plurality of grafts each having an outer surface, the outer surface being configured to receive a skin graft; ]	[ An apparatus for treating a patient with a condition of the skin of the patient, comprising: ]
0.9999895	2200	[ b) a plurality of electrodes, each electrode being configured for receiving a tissue graft; and ]	[ a) a plurality of skin grafts having a plurality of grafts each having an outer surface, the outer surface being configured to receive a skin graft; ]
0.99999225	2201	[ c) a plurality of electrodes, each electrode being configured for receiving a skin graft. ]	[ b) a plurality of electrodes, each electrode being configured for receiving a tissue graft; and ]
0.0241279	2202	[ a medical device; ]	[ A system for providing a medical treatment for a subject in need thereof, comprising: ]
0.99997497	2203	[ a first sensor configured to sense a first signal from the medical device; ]	[ a medical device; ]
0.999992	2204	[ a second sensor configured to sense a second signal from the medical device, wherein the second sensor is configured to detect a difference in an electrical current between the first and second sensors; ]	[ a first sensor configured to sense a first signal from the medical device; ]
0.99999225	2205	[ a processor configured to determine a difference between the first and second signals from the first and second sensors, wherein the difference is a difference between a first signal from the medical device and a second signal from a second sensor, wherein the second sensor is a sensor that is configured to detect an electrical current from a body of a subject; and ]	[ a second sensor configured to sense a second signal from the medical device, wherein the second sensor is configured to detect a difference in an electrical current between the first and second sensors; ]
0.9946925	2206	[ a display configured to display a first image of a first portion of the subject, wherein the first image comprises a first image of the first portion and a first portion of the subject is a second image of the first portion, wherein the first portion comprises a first portion of the subject and the second portion comprises a second portion of the subject, wherein the first portion and the second portion are configured to be overlapped, and ]	[ a processor configured to determine a difference between the first and second signals from the first and second sensors, wherein the difference is a difference between a first signal from the medical device and a second signal from a second sensor, wherein the second sensor is a sensor that is configured to detect an electrical current from a body of a subject; and ]
0.99999225	2207	[ wherein the second portion comprises a second portion of the subject, wherein the second image comprises a second image of the second portion and a second portion of the subject is a third image of the second portion. ]	[ a display configured to display a first image of a first portion of the subject, wherein the first image comprises a first image of the first portion and a first portion of the subject is a second image of the first portion, wherein the first portion comprises a first portion of the subject and the second portion comprises a second portion of the subject, wherein the first portion and the second portion are configured to be overlapped, and ]
0.9998087	2208	[ (A) a first amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: ]	[ An isolated polypeptide having a nucleic acid sequence comprising: ]
0.99537367	2209	[ 1; and ]	[ (A) a first amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: ]
0.9975916	2210	[ (B) a second amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: ]	[ 1; and ]
0.97679955	2211	[ 1. ]	[ (B) a second amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: ]
0.6958856	2212	[ a body having at least one surface that is capable of receiving a fluid and having a first surface and an opposing second surface; ]	[ A device for treating an inflammatory disease, comprising: ]
0.995048	2213	[ a first fluid reservoir having a first fluid volume and a second fluid volume, the first fluid volume and the second fluid volume being different from each other; ]	[ a body having at least one surface that is capable of receiving a fluid and having a first surface and an opposing second surface; ]
0.9999924	2214	[ a second fluid reservoir having a first fluid volume and a second fluid volume, the second fluid volume and the first fluid volume being different from each other; and ]	[ a first fluid reservoir having a first fluid volume and a second fluid volume, the first fluid volume and the second fluid volume being different from each other; ]
0.9999914	2215	[ a fluid flow control device configured to control the first fluid volume and the second fluid volume, ]	[ a second fluid reservoir having a first fluid volume and a second fluid volume, the second fluid volume and the first fluid volume being different from each other; and ]
0.9998615	2216	[ wherein the device comprises a first fluid reservoir and a second fluid reservoir. ]	[ a fluid flow control device configured to control the first fluid volume and the second fluid volume, ]
0.9980755	2217	[ R1 is hydrogen, alkyl, alkenyl, alkenylalkyl, alkylalkyl, alkenylalkoxy, alkylalkoxyalkyl, alkylalkoxyalkyl, or a pharmaceutically acceptable salt thereof. ]	[ A method for producing a compound of formula (I) wherein: ]
0.00053280033	2218	[ a) an elongate body having an outer surface, an inner surface, a first end portion and a second end portion, wherein said outer surface is configured to be positioned between said inner and outer surfaces; ]	[ An apparatus for treating a patient, comprising: ]
0.99999213	2219	[ b) a first electrode disposed within said elongate body and configured to be electrically coupled to said inner and outer surfaces; and ]	[ a) an elongate body having an outer surface, an inner surface, a first end portion and a second end portion, wherein said outer surface is configured to be positioned between said inner and outer surfaces; ]
0.99999225	2220	[ c) a second electrode disposed within said elongate body and configured to be electrically coupled to said outer surface; ]	[ b) a first electrode disposed within said elongate body and configured to be electrically coupled to said inner and outer surfaces; and ]
0.99999213	2221	[ d) wherein said first electrode comprises a first electrode portion and a second electrode portion, said first electrode portion being configured to be disposed within said elongate body; and ]	[ c) a second electrode disposed within said elongate body and configured to be electrically coupled to said outer surface; ]
0.9999918	2222	[ e) wherein said second electrode portion comprises a third electrode portion and a fourth electrode portion, wherein said first electrode portion and said second electrode portion are configured to be electrically coupled to said third electrode portion and said fourth electrode portion, respectively. ]	[ d) wherein said first electrode comprises a first electrode portion and a second electrode portion, said first electrode portion being configured to be disposed within said elongate body; and ]
0.9873439	2223	[ wherein: ]	[ A device for providing a therapeutic dose of a pharmaceutical composition comprising an effective amount of at least one compound of the formula: ]
0.99451786	2224	[ X1, X2, Y1, Y2 and Y3 are independently selected from a group consisting of hydrogen, alkyl, alkenyl, alkenylalkyl and aryl; ]	[ wherein: ]
0.99911314	2225	[ R1, R2, R3 and R4 are independently selected from the group consisting of H and C1-C4 alkyl; and ]	[ X1, X2, Y1, Y2 and Y3 are independently selected from a group consisting of hydrogen, alkyl, alkenyl, alkenylalkyl and aryl; ]
0.9999907	2226	[ R5, R6 and R7 are independently selected from the group consisting of H and C1-C4 alkyl. ]	[ R1, R2, R3 and R4 are independently selected from the group consisting of H and C1-C4 alkyl; and ]
0.999992	2227	[ (a) contacting said antibody or antigen binding fragment with an antibody or antigen binding fragment of a human or animal cell, wherein the antibody or antigen binding fragment is a monoclonal antibody, an antigen-binding fragment of said antibody or antigen binding fragment of said human or animal cell, or an antigen-binding fragment of a human or animal cell that binds to said monoclonal antibody; ]	[ A method for producing an isolated antibody or antigen binding fragment of said antibody or antigen binding fragment comprising: ]
0.99999225	2228	[ (b) contacting said antibody or antigen binding fragment with a human antibody that is a humanized antibody or antigen-binding fragment thereof that is a monoclonal antibody or an antigen-binding fragment of said human antibody; and ]	[ (a) contacting said antibody or antigen binding fragment with an antibody or antigen binding fragment of a human or animal cell, wherein the antibody or antigen binding fragment is a monoclonal antibody, an antigen-binding fragment of said antibody or antigen binding fragment of said human or animal cell, or an antigen-binding fragment of a human or animal cell that binds to said monoclonal antibody; ]
0.99999225	2229	[ (c) contacting said antibody or antigen binding fragment with said human or animal cell. ]	[ (b) contacting said antibody or antigen binding fragment with a human antibody that is a humanized antibody or antigen-binding fragment thereof that is a monoclonal antibody or an antigen-binding fragment of said human antibody; and ]
0.99932075	2230	[ SEQ ID NO: ]	[ A method for treating a patient suffering from an inflammatory bowel disease comprising administering an effective amount of a composition comprising an isolated peptide comprising an amino acid sequence selected from the group consisting of: ]
0.996198	2231	[ 1; ]	[ SEQ ID NO: ]
0.9962088	2232	[ SEQ ID NO: ]	[ 1; ]
0.9996574	2233	[ 2; and ]	[ SEQ ID NO: ]
0.9993673	2234	[ SEQ ID NO: ]	[ 2; and ]
0.9993173	2235	[ 3. ]	[ SEQ ID NO: ]
0.9996487	2236	[ a nucleotide sequence having at least 90% sequence identity with SEQ ID NO: 2; and ]	[ An isolated nucleic acid molecule encoding a protein comprising: ]
0.99999225	2237	[ a nucleotide sequence having at least 90% sequence identity with SEQ ID NO: 1. ]	[ a nucleotide sequence having at least 90% sequence identity with SEQ ID NO: 2; and ]
0.99999225	2238	[ providing an implantable medical system comprising: ]	[ A method of providing an implantable medical system, comprising: ]
0.9989717	2239	[ a first electrode configured to be coupled to an implantable medical device and configured to generate a signal; ]	[ providing an implantable medical system comprising: ]
0.999992	2240	[ a second electrode configured to be coupled to the implantable medical device; and ]	[ a first electrode configured to be coupled to an implantable medical device and configured to generate a signal; ]
0.9999788	2241	[ an actuator configured to be coupled with the first electrode and the second electrode, the actuator being configured to provide a first force to the first electrode, and ]	[ a second electrode configured to be coupled to the implantable medical device; and ]
0.9999919	2242	[ a second force to the second electrode, the first and second forces being coupled to the actuator, wherein: ]	[ an actuator configured to be coupled with the first electrode and the second electrode, the actuator being configured to provide a first force to the first electrode, and ]
0.9999871	2243	[ the first force is a first force applied by the first electrode; and ]	[ a second force to the second electrode, the first and second forces being coupled to the actuator, wherein: ]
0.99999225	2244	[ the second force is a second force applied by the second electrode. ]	[ the first force is a first force applied by the first electrode; and ]
0.99999094	2245	[ 1 or a polypeptide comprising the amino acid sequence of SEQ ID NO: ]	[ A method of treating a patient suffering from an autoimmune disorder, comprising administering to the patient in need thereof an effective amount of a pharmaceutically acceptable composition that comprises an effective amount of a polypeptide comprising an amino acid sequence that encodes a polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: ]
0.9988225	2246	[ 2. ]	[ 1 or a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.97470564	2247	[ A&#x2032; ]	[ A method for treating a subject having a disease or condition, the method comprising administering to the subject a therapeutically effective amount of an isolated antibody or antigen-binding fragment thereof that binds to a polypeptide comprising the following sequence: ]
0.00055628904	2248	[ (SEQ ID NO: ]	[ A&#x2032; ]
0.9997002	2249	[ 1) or a pharmaceutically acceptable salt thereof, wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: ]	[ (SEQ ID NO: ]
0.9728	2250	[ 1. ]	[ 1) or a pharmaceutically acceptable salt thereof, wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: ]
0.9999881	2251	[ (a) forming a polymeric material from a polymer; ]	[ A method for the production of a polymeric material comprising the steps of: ]
0.9999683	2252	[ (b) forming a polymerizable layer on said polymerizable layer; ]	[ (a) forming a polymeric material from a polymer; ]
0.9999924	2253	[ (c) forming a polymerizable layer on said polymeric material; and ]	[ (b) forming a polymerizable layer on said polymerizable layer; ]
0.99999225	2254	[ (d) forming a polymerizable layer on said polymeric material, said step (c) further including the steps of (a) and (b), wherein said polymerizable layer includes at least one polymerizable polymer having an average molecular weight of less than about 500, ]	[ (c) forming a polymerizable layer on said polymeric material; and ]
0.9975017	2255	[ 000, ]	[ (d) forming a polymerizable layer on said polymeric material, said step (c) further including the steps of (a) and (b), wherein said polymerizable layer includes at least one polymerizable polymer having an average molecular weight of less than about 500, ]
0.9990177	2256	[ 000 daltons. ]	[ 000, ]
0.99412495	2257	[ providing a compound comprising a pharmaceutically acceptable salt, wherein the compound is a pharmaceutically acceptable salt of the compound selected from the group consisting of: ]	[ A method for producing a therapeutic compound, the method comprising: ]
0.6363231	2258	[ a) a salt of a pharmaceutically acceptable salt of an amino acid of SEQ ID NO: ]	[ providing a compound comprising a pharmaceutically acceptable salt, wherein the compound is a pharmaceutically acceptable salt of the compound selected from the group consisting of: ]
0.9955407	2259	[ 1; and ]	[ a) a salt of a pharmaceutically acceptable salt of an amino acid of SEQ ID NO: ]
0.012932294	2260	[ b) a salt of a pharmaceutically acceptable salt of an amino acid of SEQ ID NO: ]	[ 1; and ]
0.9972873	2261	[ 2. ]	[ b) a salt of a pharmaceutically acceptable salt of an amino acid of SEQ ID NO: ]
0.9843875	2262	[ wherein: ]	[ A method of providing an effective dose of an effective amount of a compound of the formula (I): ]
0.99516356	2263	[ X is a first or a second C1-C6 alkyl group; ]	[ wherein: ]
0.9999896	2264	[ X is a first or a second C3-C6 alkyl group; ]	[ X is a first or a second C1-C6 alkyl group; ]
0.999734	2265	[ X is a C1-C6 alkyl ring; ]	[ X is a first or a second C3-C6 alkyl group; ]
0.9999347	2266	[ R1 is a first or a second C1-C6 alkyl group; and ]	[ X is a C1-C6 alkyl ring; ]
0.9999392	2267	[ R2 and R3 are each independently a C1-C4 alkyl group; ]	[ R1 is a first or a second C1-C6 alkyl group; and ]
0.9999865	2268	[ R4 is a first or a second C1-C4 alkyl group; ]	[ R2 and R3 are each independently a C1-C4 alkyl group; ]
0.99997306	2269	[ R5 and R6 are each independently a C1-C4 alkyl group; ]	[ R4 is a first or a second C1-C4 alkyl group; ]
0.9999869	2270	[ R7 is a first or a second C1-C4 alkyl group; and ]	[ R5 and R6 are each independently a C1-C4 alkyl group; ]
0.99998724	2271	[ R8 is a first or a second C3-C6 alkyl group. ]	[ R7 is a first or a second C1-C4 alkyl group; and ]
0.010834662	2272	[ a) providing a substrate having a first surface and a second surface, the first surface and the second surface having a first thickness and a second thickness that is greater than the first surface; ]	[ A method for the production of an implantable medical device comprising: ]
0.9999409	2273	[ b) forming a first layer of a polymer on the substrate; ]	[ a) providing a substrate having a first surface and a second surface, the first surface and the second surface having a first thickness and a second thickness that is greater than the first surface; ]
0.99999213	2274	[ c) forming a second layer of the polymer on the first surface of the substrate; and ]	[ b) forming a first layer of a polymer on the substrate; ]
0.99999213	2275	[ d) forming a third layer of the polymer on the first surface, the second layer of the polymer, and ]	[ c) forming a second layer of the polymer on the first surface of the substrate; and ]
0.99999213	2276	[ the third layer of the polymer on the second surface of the substrate. ]	[ d) forming a third layer of the polymer on the first surface, the second layer of the polymer, and ]
0.96380246	2277	[ a housing; ]	[ An apparatus, comprising: ]
0.96566886	2278	[ a plurality of sensors configured to sense a plurality of physiological parameters; ]	[ a housing; ]
0.9999894	2279	[ a processor configured to determine a set of physiological parameters based on a first physiological parameter and a second physiological parameter, wherein determining a first physiological parameter comprises determining whether a first physiological parameter is present in a first set of physiological parameters; ]	[ a plurality of sensors configured to sense a plurality of physiological parameters; ]
0.99999166	2280	[ a memory storing a first set of first physiological parameters; and ]	[ a processor configured to determine a set of physiological parameters based on a first physiological parameter and a second physiological parameter, wherein determining a first physiological parameter comprises determining whether a first physiological parameter is present in a first set of physiological parameters; ]
0.99999225	2281	[ a processor configured to determine a set of second physiological parameters based on a second physiological parameter. ]	[ a memory storing a first set of first physiological parameters; and ]
0.9760439	2282	[ a housing; ]	[ A device for providing a first treatment to a patient, comprising: ]
0.014034939	2283	[ a first treatment device having a first end and a second end; ]	[ a housing; ]
0.99455357	2284	[ an actuator coupled to the first device; ]	[ a first treatment device having a first end and a second end; ]
0.99909544	2285	[ a first electrode coupled to the first end of the first treatment device and configured to be positioned on a surface of a patient; ]	[ an actuator coupled to the first device; ]
0.9999924	2286	[ a second electrode coupled to the second end of the first treatment device and configured to be positioned on a surface of the patient; ]	[ a first electrode coupled to the first end of the first treatment device and configured to be positioned on a surface of a patient; ]
0.99999213	2287	[ a first electrode coupled to the first electrode and configured to be positioned on a surface of the patient; ]	[ a second electrode coupled to the second end of the first treatment device and configured to be positioned on a surface of the patient; ]
0.99999213	2288	[ a second electrode coupled to the second end of the second treatment device and configured to be positioned on a surface of the patient; and ]	[ a first electrode coupled to the first electrode and configured to be positioned on a surface of the patient; ]
0.999992	2289	[ at least one electrode coupled to the first electrode and configured to be disposed on the surface of the patient, ]	[ a second electrode coupled to the second end of the second treatment device and configured to be positioned on a surface of the patient; and ]
0.9999398	2290	[ wherein, when the first electrode is positioned on the surface, the actuator is coupled to the first device and the first electrode is coupled to the first electrode, and ]	[ at least one electrode coupled to the first electrode and configured to be disposed on the surface of the patient, ]
0.9999902	2291	[ the second electrode is coupled to the second device and the second electrode, ]	[ wherein, when the first electrode is positioned on the surface, the actuator is coupled to the first device and the first electrode is coupled to the first electrode, and ]
0.99998367	2292	[ wherein, when the first electrode is positioned on the surface, the actuator is coupled to the first device and the first electrode is coupled to the first electrode, the second electrode is coupled to the actuator, and ]	[ the second electrode is coupled to the second device and the second electrode, ]
0.999992	2293	[ the second electrode is coupled to the actuator and the second device, ]	[ wherein, when the first electrode is positioned on the surface, the actuator is coupled to the first device and the first electrode is coupled to the first electrode, the second electrode is coupled to the actuator, and ]
0.9999856	2294	[ wherein, when the actuator is coupled to the actuator, a first portion of the first electrode is positioned on the surface of the patient, the second portion of the second electrode is positioned on the surface of the patient, and ]	[ the second electrode is coupled to the actuator and the second device, ]
0.99999225	2295	[ when the actuator is coupled to the actuator, a second portion of the first electrode is positioned on the surface of the patient and when the actuator is coupled to the actuator the second portion of the first electrode is positioned on the surface of the patient. ]	[ wherein, when the actuator is coupled to the actuator, a first portion of the first electrode is positioned on the surface of the patient, the second portion of the second electrode is positioned on the surface of the patient, and ]
0.9978294	2296	[ 2. ]	[ An isolated nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ. ID NO: ]
0.9999794	2297	[ providing a first therapeutic agent; ]	[ A method of providing a therapeutic dose of a therapeutic agent, comprising: ]
0.99999225	2298	[ providing a second therapeutic agent; and ]	[ providing a first therapeutic agent; ]
0.9999893	2299	[ mixing the first and second therapeutic agents, wherein the first therapeutic agent is a first compound of Formula I, the second therapeutic agent is a second compound of Formula I, the first compound being a compound of Formula I or an ester thereof and the second compound is a compound of Formula II, wherein the first and second therapeutic agents are administered to a patient. ]	[ providing a second therapeutic agent; and ]
0.99999106	2300	[ providing a patient-specific medical device; ]	[ A method of providing a patient with a medical device comprising: ]
0.99994624	2301	[ providing at least one medical device component, said medical device component including at least one of a first medical device, a second medical device and a third medical device; ]	[ providing a patient-specific medical device; ]
0.99999213	2302	[ providing a first patient-specific device component; ]	[ providing at least one medical device component, said medical device component including at least one of a first medical device, a second medical device and a third medical device; ]
0.9999924	2303	[ providing a second patient-specific device component; and ]	[ providing a first patient-specific device component; ]
0.9999918	2304	[ providing a fourth medical device component; ]	[ providing a second patient-specific device component; and ]
0.9999893	2305	[ wherein the first medical device is a first medical device and the second medical device is a second medical device; ]	[ providing a fourth medical device component; ]
0.99999166	2306	[ wherein the first medical device component is a first medical device component and the second medical device component is a second medical device component; ]	[ wherein the first medical device is a first medical device and the second medical device is a second medical device; ]
0.9999924	2307	[ wherein the first medical device component is a first medical device component and the second medical device is a second medical device component; ]	[ wherein the first medical device component is a first medical device component and the second medical device component is a second medical device component; ]
0.9999924	2308	[ wherein the first medical device component is a first medical device component and the second medical device component is a second medical device component; ]	[ wherein the first medical device component is a first medical device component and the second medical device is a second medical device component; ]
0.99999225	2309	[ wherein the fourth medical device component is a fourth medical device component; and ]	[ wherein the first medical device component is a first medical device component and the second medical device component is a second medical device component; ]
0.99999225	2310	[ wherein the first medical device component is a first medical device component. ]	[ wherein the fourth medical device component is a fourth medical device component; and ]
0.9993943	2311	[ providing a first therapeutic agent, the first therapeutic agent comprising a first therapeutic agent composition comprising a first compound selected from the group consisting of: ]	[ A method for treating a disease or disorder in a subject comprising: ]
0.0002794266	2312	[ a) a compound of formula (I) wherein R1 is a hydrogen atom, a substituted or unsubstituted alkyl group, an alkyl group having a C1-C6 carbon atoms, or a substituted or unsubstituted cycloalkyl group, and ]	[ providing a first therapeutic agent, the first therapeutic agent comprising a first therapeutic agent composition comprising a first compound selected from the group consisting of: ]
0.99992716	2313	[ R2 is an alkyl group having a C3-C8 carbon atom; ]	[ a) a compound of formula (I) wherein R1 is a hydrogen atom, a substituted or unsubstituted alkyl group, an alkyl group having a C1-C6 carbon atoms, or a substituted or unsubstituted cycloalkyl group, and ]
0.99983644	2314	[ b) a compound of formula (II) wherein R1 is a hydrogen atom or a substituted or unsubstituted alkyl group and R2 is an alkyl group having a C1-C6 carbon atom; and ]	[ R2 is an alkyl group having a C3-C8 carbon atom; ]
0.9999875	2315	[ wherein the first compound is selected from the group consisting of a first compound of formula (I) and a first compound of formula (II) wherein R1 is a hydrogen atom, a substituted or unsubstituted alkyl group, an alkyl group having a C1-C6 carbon atom, an alkyl group having a C3-C8 carbon atom or a substituted or unsubstituted cycloalkyl group, and ]	[ b) a compound of formula (II) wherein R1 is a hydrogen atom or a substituted or unsubstituted alkyl group and R2 is an alkyl group having a C1-C6 carbon atom; and ]
0.99999094	2316	[ R2 is an alkyl group having a C3-C8 carbon atom or an substituted or unsubstituted cycloalkyl group; and ]	[ wherein the first compound is selected from the group consisting of a first compound of formula (I) and a first compound of formula (II) wherein R1 is a hydrogen atom, a substituted or unsubstituted alkyl group, an alkyl group having a C1-C6 carbon atom, an alkyl group having a C3-C8 carbon atom or a substituted or unsubstituted cycloalkyl group, and ]
0.0002574538	2317	[ wherein the first therapeutic agent is administered to a subject. ]	[ R2 is an alkyl group having a C3-C8 carbon atom or an substituted or unsubstituted cycloalkyl group; and ]
0.9959984	2318	[ a) a compound selected from the group consisting of: ]	[ A method of treating a patient, comprising administering to the patient a composition comprising: ]
0.00044721374	2319	[ (a) the amino acid sequence of SEQ ID NO: ]	[ a) a compound selected from the group consisting of: ]
0.99797565	2320	[ 3, and ]	[ (a) the amino acid sequence of SEQ ID NO: ]
0.99349254	2321	[ (b) an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, and ]	[ 3, and ]
0.99985874	2322	[ SEQ ID NO: 4. ]	[ (b) an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, and ]
0.9962153	2323	[ a first medical imaging device configured to acquire a first image; ]	[ A system for treating a patient with cancer, comprising: ]
0.99999213	2324	[ a second medical imaging device configured to acquire a second image; and ]	[ a first medical imaging device configured to acquire a first image; ]
0.99998415	2325	[ a processor configured to determine whether the first and second images match at a point of interest (POI) and to generate an indication of whether the patient is at risk for cancer based on the image acquisition. ]	[ a second medical imaging device configured to acquire a second image; and ]
0.9997967	2326	[ SEQ ID NO: 3. ]	[ An isolated polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and ]
0.996506	2327	[ an analyte sensor; and ]	[ Apparatus for measuring the concentration of a substance in an object, said apparatus comprising: ]
0.9930004	2328	[ an output device for outputting a signal indicative of the concentration of said substance in said object, said output device comprising: ]	[ an analyte sensor; and ]
0.9920089	2329	[ a first sensor; and ]	[ an output device for outputting a signal indicative of the concentration of said substance in said object, said output device comprising: ]
0.99997413	2330	[ an output device coupled to said first sensor, said output device being configured to receive the signal from the analyte sensor, ]	[ a first sensor; and ]
0.9999901	2331	[ wherein said first sensor comprises a first electrode and a first electrode layer, ]	[ an output device coupled to said first sensor, said output device being configured to receive the signal from the analyte sensor, ]
0.99999225	2332	[ wherein said first electrode layer comprises a first electrode layer and a second electrode layer, and ]	[ wherein said first sensor comprises a first electrode and a first electrode layer, ]
0.99999154	2333	[ wherein the first electrode layer comprises a first electrode layer and a second electrode layer, and ]	[ wherein said first electrode layer comprises a first electrode layer and a second electrode layer, and ]
0.9999912	2334	[ wherein said first electrode layer is configured to receive a first electrode layer, and ]	[ wherein the first electrode layer comprises a first electrode layer and a second electrode layer, and ]
0.9999069	2335	[ the output device comprises a second electrode layer and a second electrode layer. ]	[ wherein said first electrode layer is configured to receive a first electrode layer, and ]
0.9992417	2336	[ a medical device having at least one medical device interface configured to interface with at least one medical device, the medical device having an internal volume; and ]	[ A system for providing a medical treatment to a patient comprising: ]
0.99995816	2337	[ a medical device controller configured to: ]	[ a medical device having at least one medical device interface configured to interface with at least one medical device, the medical device having an internal volume; and ]
0.99994063	2338	[ receive a first medical device request from a first medical device; ]	[ a medical device controller configured to: ]
0.99999166	2339	[ determine a first medical device type from at least two different medical device types; ]	[ receive a first medical device request from a first medical device; ]
0.99999225	2340	[ determine a first medical device type from at least two different types of medical devices; ]	[ determine a first medical device type from at least two different medical device types; ]
0.999992	2341	[ receive at least one medical device request from a second medical device that is different from the first medical device type; ]	[ determine a first medical device type from at least two different types of medical devices; ]
0.99999213	2342	[ determine at least one medical device type from at least two medical devices that have a similar medical device type, the at least two medical devices including a first medical device type, a second medical device type, or both of the first and second medical device types; ]	[ receive at least one medical device request from a second medical device that is different from the first medical device type; ]
0.9999924	2343	[ determine at least one medical device type from at least two medical device types that have the same medical device type, the at least two medical devices including the first medical device type, the second medical device type, or both of the first and second medical device types; and ]	[ determine at least one medical device type from at least two medical devices that have a similar medical device type, the at least two medical devices including a first medical device type, a second medical device type, or both of the first and second medical device types; ]
0.99999225	2344	[ provide a first medical device to the patient based at least in part on a determination of a second medical device type from a first set of medical device types. ]	[ determine at least one medical device type from at least two medical device types that have the same medical device type, the at least two medical devices including the first medical device type, the second medical device type, or both of the first and second medical device types; and ]
0.9991629	2345	[ a pharmaceutically acceptable carrier; and ]	[ A method for treating a subject having a cancer comprising administering to the subject an effective amount of a compound selected from the group consisting of: ]
0.99979275	2346	[ a therapeutically effective amount of a pharmaceutically acceptable agent, the therapeutically acceptable agent being a pharmaceutically acceptable carrier, ]	[ a pharmaceutically acceptable carrier; and ]
0.99970454	2347	[ wherein the carrier is a pharmaceutically acceptable carrier having at least 95% homogeneity with respect to the composition, wherein the carrier has a molecular weight of less than about 10 000 &#x3bc; ]	[ a therapeutically effective amount of a pharmaceutically acceptable agent, the therapeutically acceptable agent being a pharmaceutically acceptable carrier, ]
0.0036507116	2348	[ m, ]	[ wherein the carrier is a pharmaceutically acceptable carrier having at least 95% homogeneity with respect to the composition, wherein the carrier has a molecular weight of less than about 10 000 &#x3bc; ]
0.005622256	2349	[ wherein the carrier is an isolated polypeptide comprising at least one of the amino acid sequences set forth as SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and ]	[ m, ]
0.9997131	2350	[ SEQ ID NO: 7. ]	[ wherein the carrier is an isolated polypeptide comprising at least one of the amino acid sequences set forth as SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, and ]
0.9999924	2351	[ administering to the patient a substance that inhibits a substance that is present in the substance; ]	[ A method of treating a patient having a condition in which the patient's brain is damaged by a substance that is present in the substance, the method comprising: ]
0.9999924	2352	[ administering to the patient a substance that inhibits a substance that is present in the substance; ]	[ administering to the patient a substance that inhibits a substance that is present in the substance; ]
0.9999924	2353	[ administering to the patient a substance that inhibits a substance that is present in the substance; ]	[ administering to the patient a substance that inhibits a substance that is present in the substance; ]
0.9999924	2354	[ administering to the patient a substance that inhibits a substance that is present in the substance; ]	[ administering to the patient a substance that inhibits a substance that is present in the substance; ]
0.9999924	2355	[ administering to the patient a substance that inhibits a substance that is present in the substance; ]	[ administering to the patient a substance that inhibits a substance that is present in the substance; ]
0.9999924	2356	[ administering to the patient a substance that inhibits a substance that is present in the substance; and ]	[ administering to the patient a substance that inhibits a substance that is present in the substance; ]
0.9999924	2357	[ administering to the patient a substance that inhibits a substance that is present in the substance. ]	[ administering to the patient a substance that inhibits a substance that is present in the substance; and ]
0.9999031	2358	[ administering to said patient a therapeutically effective amount of an isolated nucleotide, wherein said isolated nucleotide comprises a nucleotide sequence having a amino acid sequence having a nucleotide sequence sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: ]	[ A method for treating a patient having a tumor comprising: ]
0.9959621	2359	[ 3. ]	[ administering to said patient a therapeutically effective amount of an isolated nucleotide, wherein said isolated nucleotide comprises a nucleotide sequence having a amino acid sequence having a nucleotide sequence sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: ]
0.9995433	2360	[ (a) a therapeutically effective amount of a polypeptide, antigen-binding fragment, a peptide and a pharmaceutically acceptable salt thereof, and ]	[ A method of treating an autoimmune disease, comprising administering a composition comprising: ]
0.99990594	2361	[ (b) a pharmaceutically acceptable carrier, wherein the composition is administered in a dosage form that is effective to treat the autoimmune disease. ]	[ (a) a therapeutically effective amount of a polypeptide, antigen-binding fragment, a peptide and a pharmaceutically acceptable salt thereof, and ]
0.9999919	2362	[ a plurality of transducer elements, the first and second transducer elements configured to receive signals from the plurality of transducer elements, wherein each of the plurality of transducer elements is arranged to be disposed within a respective of a first and a second body cavity, the first and second bodies of the plurality of transducer elements being disposed within the first and second body cavity. ]	[ An implantable medical system comprising a plurality of transducer elements, the system including a plurality of transducer elements, each of the plurality of transducer elements comprising a first transducer element, a second transducer element, and ]
0.9993887	2363	[ providing a first therapeutic agent, said first therapeutic agent comprising a compound selected from the group consisting of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2; and ]	[ A method for treating a disease in a patient in need thereof, comprising: ]
0.9999924	2364	[ a second therapeutic agent, said second therapeutic agent comprising a compound selected from the group consisting of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2. ]	[ providing a first therapeutic agent, said first therapeutic agent comprising a compound selected from the group consisting of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2; and ]
0.96286136	2365	[ wherein: ]	[ A method of treating a disease or condition in a patient, said method comprising administering to said patient a composition comprising a compound having the formula: ]
0.9943362	2366	[ R1 and R2 are independently H, C1-C4 alkyl, C1-C4 alkenyl, C1-C4 alkoxy, C1-C4 alkylene, C3-C6 alkyl, C3-C6 alkoxyalkyl, or C3-C6 alkoxycarbonyl, wherein R1 and R2 are selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkylene, C3-C6 alkylcarbonyl, C1-C4 alkylene, C3-C6 alkylenealkyl, C1-C6 alkylcarbonyl, and ]	[ wherein: ]
0.9998907	2367	[ C1-C4 alkoxyalkyl; and ]	[ R1 and R2 are independently H, C1-C4 alkyl, C1-C4 alkenyl, C1-C4 alkoxy, C1-C4 alkylene, C3-C6 alkyl, C3-C6 alkoxyalkyl, or C3-C6 alkoxycarbonyl, wherein R1 and R2 are selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkylene, C3-C6 alkylcarbonyl, C1-C4 alkylene, C3-C6 alkylenealkyl, C1-C6 alkylcarbonyl, and ]
0.99986136	2368	[ R3 and R4 are independently selected from the group consisting of H, C1-C4 alkyl, C1-C4 alkenyl, C1-C4 alkoxy, C3-C6 alkyl, C3-C6 alkoxyalkyl, C1-C6 alkylcarbonyl, and ]	[ C1-C4 alkoxyalkyl; and ]
0.9998654	2369	[ C1-C4 alkoxycarbonyl. ]	[ R3 and R4 are independently selected from the group consisting of H, C1-C4 alkyl, C1-C4 alkenyl, C1-C4 alkoxy, C3-C6 alkyl, C3-C6 alkoxyalkyl, C1-C6 alkylcarbonyl, and ]
0.99294865	2370	[ a first chamber; ]	[ An apparatus for providing a therapeutic dose, comprising: ]
0.99999166	2371	[ a second chamber; ]	[ a first chamber; ]
0.99998796	2372	[ a first pump configured for providing a first dose of a therapeutic substance into the first chamber; ]	[ a second chamber; ]
0.99999225	2373	[ at least one first pump controller configured for controlling the first pump to deliver the first dose of the therapeutic substance into the first chamber; and ]	[ a first pump configured for providing a first dose of a therapeutic substance into the first chamber; ]
0.99999225	2374	[ an actuator operatively coupled to the first pump, the actuator configured to provide a second dose of the therapeutic substance into the second chamber, ]	[ at least one first pump controller configured for controlling the first pump to deliver the first dose of the therapeutic substance into the first chamber; and ]
0.9999777	2375	[ wherein the first chamber is positioned in a first position, the first chamber is positioned in a second position, and ]	[ an actuator operatively coupled to the first pump, the actuator configured to provide a second dose of the therapeutic substance into the second chamber, ]
0.999992	2376	[ the first chamber is positioned between the second position and the first position. ]	[ wherein the first chamber is positioned in a first position, the first chamber is positioned in a second position, and ]
0.9999821	2377	[ providing a first medical device; ]	[ A method of providing a medical device to a patient, comprising: ]
0.99999225	2378	[ providing a second medical device; and ]	[ providing a first medical device; ]
0.99999094	2379	[ providing a first medical device to the patient, wherein the first medical device is configured for use by a first patient; ]	[ providing a second medical device; and ]
0.9999924	2380	[ providing a second medical device to the patient; ]	[ providing a first medical device to the patient, wherein the first medical device is configured for use by a first patient; ]
0.9999907	2381	[ providing a medical device to be used by the patient, the medical device being configured for use by a second patient; ]	[ providing a second medical device to the patient; ]
0.9999919	2382	[ providing a first medical device to the first patient, wherein the first medical device is configured for use by the second patient; and ]	[ providing a medical device to be used by the patient, the medical device being configured for use by a second patient; ]
0.99999225	2383	[ providing an electronic device, the electronic device being configured for use by the first patient and the second patient. ]	[ providing a first medical device to the first patient, wherein the first medical device is configured for use by the second patient; and ]
0.99398524	2384	[ (a) a pharmaceutically acceptable salt of the polypeptide of SEQ ID NO: ]	[ A method for treating an inflammatory disease in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising: ]
0.9983175	2385	[ 2; ]	[ (a) a pharmaceutically acceptable salt of the polypeptide of SEQ ID NO: ]
0.0026902696	2386	[ (b) a pharmaceutically acceptable carrier; and ]	[ 2; ]
0.99994004	2387	[ (c) a pharmaceutically acceptable excipient; ]	[ (b) a pharmaceutically acceptable carrier; and ]
0.9999714	2388	[ wherein said excipient is a polypeptide of SEQ ID NO. 2. ]	[ (c) a pharmaceutically acceptable excipient; ]
0.99971193	2389	[ a) administering to said patient a first pharmaceutical composition comprising a pharmaceutically acceptable carrier, wherein said first pharmaceutical composition is a pharmaceutically acceptable carrier; and ]	[ A method of treating a patient suffering from chronic obstructive pulmonary disease (COPD), wherein said method is adapted to treat the COPD, wherein said method comprises: ]
0.99999225	2390	[ b) administering to said patient a second pharmaceutical composition comprising a pharmaceutically acceptable carrier, wherein said second pharmaceutical composition is a pharmaceutically acceptable carrier, wherein said first and second pharmaceutical compositions are administered to said patient in a combination, wherein said second pharmaceutical composition comprises at least two different pharmaceutical components. ]	[ a) administering to said patient a first pharmaceutical composition comprising a pharmaceutically acceptable carrier, wherein said first pharmaceutical composition is a pharmaceutically acceptable carrier; and ]
0.99998724	2391	[ administering a compound to a subject in need thereof to treat the cancer; and ]	[ A method for treating a cancer comprising: ]
0.9999894	2392	[ administering a therapeutically effective amount of the compound to the subject in need thereof, wherein the compound is selected from the group consisting of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable carrier salt, a pharmaceutically acceptable salt, and ]	[ administering a compound to a subject in need thereof to treat the cancer; and ]
0.9998903	2393	[ a pharmaceutically acceptable carrier salt. ]	[ administering a therapeutically effective amount of the compound to the subject in need thereof, wherein the compound is selected from the group consisting of a pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, a pharmaceutically acceptable carrier salt, a pharmaceutically acceptable salt, and ]
0.99780124	2394	[ an optical system having a first optical element and a second optical element; ]	[ An apparatus for treating an eye, the apparatus comprising: ]
0.9999888	2395	[ a first optical element disposed in the first optical system; ]	[ an optical system having a first optical element and a second optical element; ]
0.9999913	2396	[ a second optical element disposed in the optical system and having a substantially perpendicular surface, the second optical element being substantially parallel to the first optical element; ]	[ a first optical element disposed in the first optical system; ]
0.99998784	2397	[ a first optical system member disposed in the optical system, the first optical system member being configured to be disposed in the eye; and ]	[ a second optical element disposed in the optical system and having a substantially perpendicular surface, the second optical element being substantially parallel to the first optical element; ]
0.9999918	2398	[ a second optical system member disposed in the optical system, the second optical system member being configured to be disposed in a position adjacent to the first optical system member, the second optical system member being disposed substantially parallel to the first optical system member, the second optical system member having an outer surface, the second optical system member having a substantially perpendicular surface, the outer surface defining a plurality of optical elements and a plurality of optical paths, each of the optical paths being configured to be disposed in a substantially perpendicular direction, the plurality of optical paths including a plurality of paths extending in parallel from a center of a plurality of optical elements in a substantially perpendicular direction, each of the optical elements including a plurality of optical elements, the plurality of optical elements including a plurality of optical elements, each of the optical elements including a plurality of optical elements, the plurality of optical elements including a plurality of optical elements, and ]	[ a first optical system member disposed in the optical system, the first optical system member being configured to be disposed in the eye; and ]
0.999388	2399	[ a first plurality of optical path segments, each of the plurality of optical paths including a plurality of optical paths extending in parallel from a center of a plurality of optical elements in a substantially perpendicular direction, each of the optical paths including a plurality of optical paths extending in parallel from a center of a plurality of optical elements in the substantially perpendicular direction. ]	[ a second optical system member disposed in the optical system, the second optical system member being configured to be disposed in a position adjacent to the first optical system member, the second optical system member being disposed substantially parallel to the first optical system member, the second optical system member having an outer surface, the second optical system member having a substantially perpendicular surface, the outer surface defining a plurality of optical elements and a plurality of optical paths, each of the optical paths being configured to be disposed in a substantially perpendicular direction, the plurality of optical paths including a plurality of paths extending in parallel from a center of a plurality of optical elements in a substantially perpendicular direction, each of the optical elements including a plurality of optical elements, the plurality of optical elements including a plurality of optical elements, each of the optical elements including a plurality of optical elements, the plurality of optical elements including a plurality of optical elements, and ]
0.9995615	2400	[ 1, SEQ ID NO: ]	[ An isolated nucleic acid comprising an amino acid sequence selected from the group consisting of SEQ ID NO: ]
0.99998844	2401	[ 2, SEQ ID NO: ]	[ 1, SEQ ID NO: ]
0.99998915	2402	[ 3, SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.9999895	2403	[ 4, SEQ ID NO: ]	[ 3, SEQ ID NO: ]
0.99998796	2404	[ 5, SEQ ID NO: ]	[ 4, SEQ ID NO: ]
0.99998975	2405	[ 6, SEQ ID NO: ]	[ 5, SEQ ID NO: ]
0.9999857	2406	[ 7, SEQ ID NO: ]	[ 6, SEQ ID NO: ]
0.99998665	2407	[ 8, SEQ ID NO: ]	[ 7, SEQ ID NO: ]
0.9998871	2408	[ 9, and ]	[ 8, SEQ ID NO: ]
0.9996106	2409	[ SEQ ID NO: ]	[ 9, and ]
0.9997342	2410	[ 10. ]	[ SEQ ID NO: ]
0.9992017	2411	[ or a pharmaceutically acceptable salt thereof. ]	[ A method for treating a disease or condition, comprising administering to a subject a therapeutically effective amount of a compound of formula (I): ]
0.01698549	2412	[ a) a first medical device; and ]	[ A system for treating a disease in a subject comprising: ]
0.99999	2413	[ b) a second medical device, wherein the first medical device and the second medical device are configured to provide treatment to a subject, the system further comprising: ]	[ a) a first medical device; and ]
0.9999777	2414	[ i. a medical device comprising a first medical device, a first implantable medical device, and ]	[ b) a second medical device, wherein the first medical device and the second medical device are configured to provide treatment to a subject, the system further comprising: ]
0.999992	2415	[ a second implantable medical device, ]	[ i. a medical device comprising a first medical device, a first implantable medical device, and ]
0.9999864	2416	[ ii. the first medical device and the second medical device are configured to be implanted in a first patient, ]	[ a second implantable medical device, ]
0.9999924	2417	[ iii. the first medical device and the second medical device are configured to be implantable in a second patient, ]	[ ii. the first medical device and the second medical device are configured to be implanted in a first patient, ]
0.99999213	2418	[ iv. the medical device is configured such that the first and second medical devices are configured such that a first portion of the first medical device is configured to be implanted into a portion of a patient's body and a second portion of the first medical device is configured to be inserted into an interior of the second patient, and ]	[ iii. the first medical device and the second medical device are configured to be implantable in a second patient, ]
0.9998061	2419	[ v. wherein at least one of: ]	[ iv. the medical device is configured such that the first and second medical devices are configured such that a first portion of the first medical device is configured to be implanted into a portion of a patient's body and a second portion of the first medical device is configured to be inserted into an interior of the second patient, and ]
0.9920832	2420	[ i) at least a portion of at least a portion of the medical device is configured to be implanted within a portion of the second patient, and ]	[ v. wherein at least one of: ]
0.99999225	2421	[ ii) at least a portion of a portion of the medical device is configured to be implanted within a portion of an interior of the second patient, ]	[ i) at least a portion of at least a portion of the medical device is configured to be implanted within a portion of the second patient, and ]
0.9999924	2422	[ iv) at least a portion of the first medical device is configured to be implanted within a portion of an exterior of a patient's body, and ]	[ ii) at least a portion of a portion of the medical device is configured to be implanted within a portion of an interior of the second patient, ]
0.9999924	2423	[ v) at least a portion of the second medical device is configured to be implanted into a portion of an interior of the patient's body. ]	[ iv) at least a portion of the first medical device is configured to be implanted within a portion of an exterior of a patient's body, and ]
0.99998486	2424	[ a) providing an implantable medical device; and ]	[ A method for producing an implantable medical device comprising: ]
0.9999821	2425	[ b) providing a plurality of electrodes; ]	[ a) providing an implantable medical device; and ]
0.9999919	2426	[ c) providing a plurality of electrodes; ]	[ b) providing a plurality of electrodes; ]
0.9999716	2427	[ wherein the plurality of electrodes comprises a first electrode, a second electrode, and ]	[ c) providing a plurality of electrodes; ]
0.016864954	2428	[ an outer layer; ]	[ wherein the plurality of electrodes comprises a first electrode, a second electrode, and ]
0.023726491	2429	[ wherein the first electrode comprises an electrode core, and ]	[ an outer layer; ]
0.99997795	2430	[ wherein the second electrode comprises a first layer of conductive material; and ]	[ wherein the first electrode comprises an electrode core, and ]
0.99994457	2431	[ wherein the outer layer comprises a second layer of conductive material; ]	[ wherein the second electrode comprises a first layer of conductive material; and ]
0.9999914	2432	[ and wherein the outer layer comprises a conductive layer having a conductivity of at least 50% and having an average conductivity of less than about 10% and a conductivity at least equal to the average conductivity of the first layer of conductive material. ]	[ wherein the outer layer comprises a second layer of conductive material; ]
0.9894013	2433	[ a pharmaceutically acceptable salt thereof. ]	[ A method for treating a disease in a subject, comprising administering to the subject an effective amount of a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier, wherein the carrier is selected from the group consisting of a polypeptide, a peptide, a polypeptide fragment, a polypeptide, a polypeptide fragment, a polypeptide, a peptide, a peptide fragment, a peptide, a polypeptide fragment, a peptide fragment, a polypeptide fragment, a polypeptide fragment, a polypeptide fragment, a polypeptide, a polypeptide fragment, a polypeptide fragment, a polypeptide fragment, a polypeptide fragment, a polypeptide fragment, a polypeptide fragment, a polypeptide fragments, a polypeptides, and ]
0.9999788	2434	[ an aperture therethrough; an implantable medical device disposed in the housing, the implantable medical device having a proximal end, a distal end, a first end, a second end, a third end, and ]	[ A device for providing an implantable medical device to a user of the medical device, the device comprising: a housing having a first opening, a second opening, a third opening, and ]
0.01711031	2435	[ a plurality of first, second, and ]	[ an aperture therethrough; an implantable medical device disposed in the housing, the implantable medical device having a proximal end, a distal end, a first end, a second end, a third end, and ]
0.9952441	2436	[ third openings; a first electrode disposed within the first opening of the housing; an actuator configured to be disposed within the first opening of the housing and configured to move the actuator within the first opening of said housing; and ]	[ a plurality of first, second, and ]
0.9999913	2437	[ a first sensor configured to be disposed within an aperture of the second opening of said housing, the first sensor configured to detect an electrical signal from the first electrode, the first sensor configured to detect a signal from the second electrode, the second electrode and the third electrode, and ]	[ third openings; a first electrode disposed within the first opening of the housing; an actuator configured to be disposed within the first opening of the housing and configured to move the actuator within the first opening of said housing; and ]
0.99997735	2438	[ to determine a position of the second electrode and the third electrode. ]	[ a first sensor configured to be disposed within an aperture of the second opening of said housing, the first sensor configured to detect an electrical signal from the first electrode, the first sensor configured to detect a signal from the second electrode, the second electrode and the third electrode, and ]
0.99952245	2439	[ 1, SEQ ID NO: ]	[ A method of producing an isolated polypeptide comprising the amino acids of SEQ ID NO: ]
0.9993255	2440	[ 2, and ]	[ 1, SEQ ID NO: ]
0.99885654	2441	[ SEQ ID NO: ]	[ 2, and ]
0.999602	2442	[ 3, wherein said isolated polypeptide has the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: ]	[ SEQ ID NO: ]
0.99961853	2443	[ 2, or SEQ ID NO: ]	[ 3, wherein said isolated polypeptide has the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: ]
0.9983816	2444	[ 3. ]	[ 2, or SEQ ID NO: ]
0.99952567	2445	[ a) a heart disease, ]	[ A method for treating a patient having at least one of: ]
0.99997795	2446	[ b) a heart defect, or ]	[ a) a heart disease, ]
0.9994635	2447	[ c) an inflammatory condition, comprising administering to the patient an effective amount of an isolated polypeptide comprising the amino acid sequence as shown in SEQ ID NO: ]	[ b) a heart defect, or ]
0.99998915	2448	[ 2, wherein said isolated polypeptide has the ability to inhibit the activity of the polypeptide of SEQ ID NO: ]	[ c) an inflammatory condition, comprising administering to the patient an effective amount of an isolated polypeptide comprising the amino acid sequence as shown in SEQ ID NO: ]
0.9999924	2449	[ 2, wherein said isolated polypeptide has the ability to inhibit the activity of a polypeptide of SEQ ID NO: ]	[ 2, wherein said isolated polypeptide has the ability to inhibit the activity of the polypeptide of SEQ ID NO: ]
0.9999924	2450	[ 2, wherein said isolated polypeptide has the ability to inhibit the activity of a polypeptide of SEQ ID NO: ]	[ 2, wherein said isolated polypeptide has the ability to inhibit the activity of a polypeptide of SEQ ID NO: ]
0.9999924	2451	[ 2, wherein said isolated polypeptide has the ability to inhibit the activity of a polypeptide of SEQ ID NO: ]	[ 2, wherein said isolated polypeptide has the ability to inhibit the activity of a polypeptide of SEQ ID NO: ]
0.9999893	2452	[ 2, wherein said isolated polypeptide is effective to treat the heart disease. ]	[ 2, wherein said isolated polypeptide has the ability to inhibit the activity of a polypeptide of SEQ ID NO: ]
0.9999888	2453	[ 3 and a polypeptide having a sequence of amino acids from SEQ ID NO: ]	[ A method for treating an inflammatory condition in a patient comprising administering to said patient an effective amount of a compound selected from the group consisting of a polypeptide having a sequence of amino acids from SEQ ID NO: ]
0.9993092	2454	[ 4. ]	[ 3 and a polypeptide having a sequence of amino acids from SEQ ID NO: ]
0.9992823	2455	[ a) a therapeutically effective amount of a pharmaceutically acceptable salt; and ]	[ A method for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising: ]
0.9999255	2456	[ b) a pharmaceutically acceptable carrier, salt, or carrier combination thereof, wherein the composition is a pharmaceutically acceptable carrier, salt, or combination thereof, wherein the composition comprises: ]	[ a) a therapeutically effective amount of a pharmaceutically acceptable salt; and ]
0.9983707	2457	[ (a) a pharmaceutically acceptable salt, and ]	[ b) a pharmaceutically acceptable carrier, salt, or carrier combination thereof, wherein the composition is a pharmaceutically acceptable carrier, salt, or combination thereof, wherein the composition comprises: ]
0.99987745	2458	[ (b) a pharmaceutically acceptable carrier, salt, or carrier combination thereof. ]	[ (a) a pharmaceutically acceptable salt, and ]
0.99911565	2459	[ (a) administering a therapeutically effective amount of an effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: ]	[ A method for treating a subject in need thereof, the method comprising: ]
0.99642026	2460	[ 1 to said subject in need thereof; ]	[ (a) administering a therapeutically effective amount of an effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.014083674	2461	[ (b) determining a level of a polypeptide comprising the amino acid sequence of SEQ ID NO: ]	[ 1 to said subject in need thereof; ]
0.9998926	2462	[ 1 in the subject in need thereof, wherein the level is greater than or equal to a threshold level; and ]	[ (b) determining a level of a polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.99998605	2463	[ (c) administering an effective amount of a pharmaceutically acceptable salt of the effective amount to the subject in need thereof. ]	[ 1 in the subject in need thereof, wherein the level is greater than or equal to a threshold level; and ]
0.99999166	2464	[ administering to the patient an effective amount of an anti-inflammatory agent to reduce the inflammatory bowel disease; and ]	[ A method for the treatment of a patient having an inflammatory bowel disease in which the patient has a disorder of intestinal permeability, the method comprising: ]
0.99998975	2465	[ administering to the patient an effective amount of an effective amount of a therapeutically acceptable composition, ]	[ administering to the patient an effective amount of an anti-inflammatory agent to reduce the inflammatory bowel disease; and ]
0.99997187	2466	[ wherein the therapeutically acceptable composition comprises: ]	[ administering to the patient an effective amount of an effective amount of a therapeutically acceptable composition, ]
0.9855848	2467	[ a) at least one of a polypeptide or a peptide having a amino acid sequence that is at least 80% identical to SEQ ID NO: ]	[ wherein the therapeutically acceptable composition comprises: ]
0.009564358	2468	[ 4, ]	[ a) at least one of a polypeptide or a peptide having a amino acid sequence that is at least 80% identical to SEQ ID NO: ]
0.00077201205	2469	[ wherein the at least one of the polypeptide or the peptide comprises a peptide having a sequence that is at least 80% identical to SEQ ID NO: ]	[ 4, ]
0.004063232	2470	[ 5, ]	[ wherein the at least one of the polypeptide or the peptide comprises a peptide having a sequence that is at least 80% identical to SEQ ID NO: ]
0.0016648077	2471	[ wherein the peptide comprises a peptide having a amino acid sequence that comprises a sequence that is at least 95% identical to SEQ ID NO: ]	[ 5, ]
0.008114432	2472	[ 6, ]	[ wherein the peptide comprises a peptide having a amino acid sequence that comprises a sequence that is at least 95% identical to SEQ ID NO: ]
0.009543128	2473	[ wherein the peptide has a sequence that is at least 95% identical to SEQ ID NO: ]	[ 6, ]
0.99889356	2474	[ 7, or a combination thereof. ]	[ wherein the peptide has a sequence that is at least 95% identical to SEQ ID NO: ]
0.9978794	2475	[ (a) administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable salt of a polypeptide having the amino acid sequence of SEQ ID NO: ]	[ A method of treating a disease comprising: ]
0.999401	2476	[ 2 or an isolated fragment thereof; and ]	[ (a) administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable salt of a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.99907327	2477	[ (b) administering to the subject an effective amount of a therapeutically effective amount of a pharmaceutically acceptable carrier, wherein the carrier is a pharmaceutically acceptable salt of a polypeptide having the amino acid sequence of SEQ ID NO: ]	[ 2 or an isolated fragment thereof; and ]
0.9994655	2478	[ 2 or an isolated fragment thereof. ]	[ (b) administering to the subject an effective amount of a therapeutically effective amount of a pharmaceutically acceptable carrier, wherein the carrier is a pharmaceutically acceptable salt of a polypeptide having the amino acid sequence of SEQ ID NO: ]
0.9999734	2479	[ the nucleic acid is a nucleotide sequence selected from SEQ ID NO: ]	[ An isolated nucleic acid comprising the amino acid sequence of SEQ ID NO: 2, wherein: ]
0.99902976	2480	[ 2 and SEQ ID NO: 2; and ]	[ the nucleic acid is a nucleotide sequence selected from SEQ ID NO: ]
0.9977597	2481	[ the nucleic acid is selected from the group consisting of SEQ ID NO: ]	[ 2 and SEQ ID NO: 2; and ]
0.99969053	2482	[ 2, SEQ ID NO: ]	[ the nucleic acid is selected from the group consisting of SEQ ID NO: ]
0.99998915	2483	[ 3, SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.9999895	2484	[ 4, SEQ ID NO: ]	[ 3, SEQ ID NO: ]
0.99998796	2485	[ 5, SEQ ID NO: ]	[ 4, SEQ ID NO: ]
0.99998975	2486	[ 6, SEQ ID NO: ]	[ 5, SEQ ID NO: ]
0.9999857	2487	[ 7, SEQ ID NO: ]	[ 6, SEQ ID NO: ]
0.99998665	2488	[ 8, SEQ ID NO: ]	[ 7, SEQ ID NO: ]
0.9998871	2489	[ 9, and ]	[ 8, SEQ ID NO: ]
0.9996106	2490	[ SEQ ID NO: ]	[ 9, and ]
0.9997342	2491	[ 10. ]	[ SEQ ID NO: ]
0.9976433	2492	[ a) a compound selected from the group consisting of a compound of formula (I) or a salt thereof, and ]	[ A method for treating a subject in need thereof, comprising administering to the subject a composition comprising: ]
0.99625707	2493	[ b) at least one other substance; ]	[ a) a compound selected from the group consisting of a compound of formula (I) or a salt thereof, and ]
0.99999166	2494	[ wherein the at least one other substance is selected from the group consisting of a polysaccharide and a polysaccharide-containing polysaccharide; ]	[ b) at least one other substance; ]
0.999992	2495	[ wherein the polysaccharide is selected from the group consisting of a polysaccharide, a polysaccharide-containing polysaccharide, a polysaccharide-containing polysaccharide, and ]	[ wherein the at least one other substance is selected from the group consisting of a polysaccharide and a polysaccharide-containing polysaccharide; ]
0.9999908	2496	[ a polysaccharidose-containing polysaccharide; and ]	[ wherein the polysaccharide is selected from the group consisting of a polysaccharide, a polysaccharide-containing polysaccharide, a polysaccharide-containing polysaccharide, and ]
0.99999154	2497	[ wherein the polysaccharide-containing polysaccharide is selected from the group consisting of a polysaccharide, a polysaccharide-containing polysaccharide, and ]	[ a polysaccharidose-containing polysaccharide; and ]
0.9999696	2498	[ a monosaccharide; and ]	[ wherein the polysaccharide-containing polysaccharide is selected from the group consisting of a polysaccharide, a polysaccharide-containing polysaccharide, and ]
0.99997103	2499	[ wherein the polysaccharide-containing polysaccharide is selected from the group consisting of a polysaccharide, a polysaccharide-containing polysaccharide, and ]	[ a monosaccharide; and ]
0.9999703	2500	[ a monosaccharide. ]	[ wherein the polysaccharide-containing polysaccharide is selected from the group consisting of a polysaccharide, a polysaccharide-containing polysaccharide, and ]
0.9999907	2501	[ a) providing an implantable medical device having at least one electrode and at least one conductive material, the at least one conductive material comprising at least one conductive material having a conductive material properties that are different from a conductive material properties of the at least one conductive material of the implantable medical device; and ]	[ A method of providing an implantable medical device comprising: ]
0.99999213	2502	[ b) providing a plurality of conductive material electrodes, each electrode having an outer surface that is electrically conductive, wherein at least a portion of the at least one conductive material is electrically conductive, wherein each electrode comprises a conductive material that is electrically conductive and that has a conductive material properties that are different from conductive material properties of the at least one conductive material of the implantable medical device, and ]	[ a) providing an implantable medical device having at least one electrode and at least one conductive material, the at least one conductive material comprising at least one conductive material having a conductive material properties that are different from a conductive material properties of the at least one conductive material of the implantable medical device; and ]
0.9999924	2503	[ wherein the conductive material properties are different from the conductive material properties of the at least one conductive material of the implantable medical device, ]	[ b) providing a plurality of conductive material electrodes, each electrode having an outer surface that is electrically conductive, wherein at least a portion of the at least one conductive material is electrically conductive, wherein each electrode comprises a conductive material that is electrically conductive and that has a conductive material properties that are different from conductive material properties of the at least one conductive material of the implantable medical device, and ]
0.99999225	2504	[ wherein the conductive material properties include a conductive material property of the conductive material having the conductive material properties of at least a portion of the conductive material, and ]	[ wherein the conductive material properties are different from the conductive material properties of the at least one conductive material of the implantable medical device, ]
0.99999225	2505	[ a conductive material property of the conductive material having a conductive material properties that are different from conductive material properties of the at least one conductive material of the implantable medical device. ]	[ wherein the conductive material properties include a conductive material property of the conductive material having the conductive material properties of at least a portion of the conductive material, and ]
0.9904254	2506	[ 1, and ]	[ A method of producing a polypeptide comprising a first amino acid sequence, wherein the first amino acid sequence is a nucleotide sequence of SEQ ID No: ]
0.9947753	2507	[ wherein the polypeptide comprises a polypeptide-binding domain comprising a nucleic acid sequence of SEQ ID NO: ]	[ 1, and ]
0.0011329236	2508	[ 2, ]	[ wherein the polypeptide comprises a polypeptide-binding domain comprising a nucleic acid sequence of SEQ ID NO: ]
0.01003802	2509	[ the method comprising: ]	[ 2, ]
0.0015325557	2510	[ a) contacting the first amino acid sequence of the polypeptide with a first polypeptide binding domain of an antibody that binds the first amino acid sequence of the polypeptide; ]	[ the method comprising: ]
0.99999213	2511	[ b) contacting the first polypeptide binding domain of the antibody with a second polypeptide binding domain of the antibody, wherein the second polypeptide binding domain comprises a nucleic acid sequence of SEQ ID NO: ]	[ a) contacting the first amino acid sequence of the polypeptide with a first polypeptide binding domain of an antibody that binds the first amino acid sequence of the polypeptide; ]
0.9982405	2512	[ 3; and ]	[ b) contacting the first polypeptide binding domain of the antibody with a second polypeptide binding domain of the antibody, wherein the second polypeptide binding domain comprises a nucleic acid sequence of SEQ ID NO: ]
0.9974226	2513	[ c) contacting the first polypeptide binding domain with a second polypeptide binding domain of the antibody. ]	[ 3; and ]
0.9994074	2514	[ 2 or SEQ ID NO: ]	[ A system for the treatment of an inflammatory disorder comprising an antibody or antigen-binding fragment thereof which specifically binds to an inflammatory protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: ]
0.99963343	2515	[ 3, wherein the system comprises an antibody or antigen-binding fragment thereof, and ]	[ 2 or SEQ ID NO: ]
0.9999634	2516	[ an antigen binding agent which specifically binds to said antibody or antigen-binding fragment thereof. ]	[ 3, wherein the system comprises an antibody or antigen-binding fragment thereof, and ]
0.99985135	2517	[ providing a patient-specific therapeutic agent; and ]	[ A method for treating a patient suffering from a disease comprising: ]
0.9999908	2518	[ administering to the patient a therapeutically effective amount of the patient-specific therapeutic agent to treat the disease. ]	[ providing a patient-specific therapeutic agent; and ]
0.99768937	2519	[ an in vitro cell-based method comprising: ]	[ A system for the treatment of cancer, comprising: ]
0.99999213	2520	[ a) providing an in vitro cell-based method for the treatment of cancer, wherein the in vitro cell-based method comprises: ]	[ an in vitro cell-based method comprising: ]
0.99998677	2521	[ i) providing a cell-based cell culture; and ]	[ a) providing an in vitro cell-based method for the treatment of cancer, wherein the in vitro cell-based method comprises: ]
0.9999882	2522	[ ii) introducing the in vitro cell-based cell culture to a cell-based tumor in the cell-based tumor, wherein the cell-based tumor is a cancer cell, wherein the tumor has a cell-based surface; and ]	[ i) providing a cell-based cell culture; and ]
0.99999225	2523	[ b) measuring the expression of a tumor-specific antigen in the cell-based cell culture, wherein measuring the expression of the tumor-specific antigen in the cell-based cell culture is a method for detecting whether or not a tumor is in a metastasis state. ]	[ ii) introducing the in vitro cell-based cell culture to a cell-based tumor in the cell-based tumor, wherein the cell-based tumor is a cancer cell, wherein the tumor has a cell-based surface; and ]
0.9999912	2524	[ a polypeptide having a fourth amino acid sequence and a fourth amino acid sequence having at least 90% identity to the amino acid sequence of the fourth amino acid sequence. ]	[ A method for treating a subject suffering from a disease or disorder, comprising administering to the subject an effective amount of a composition comprising a compound selected from the group consisting of a polypeptide, a peptide, a peptide fragment, a fragment of a peptide, a polypeptide having a first amino acid sequence and an amino acid sequence having at least 90% identity to the amino acid sequence of the first amino acid sequence of the composition, a polypeptide having a second amino acid sequence and a second amino acid sequence having at least 90% identity to the amino acid sequence of the second amino acid sequence, a polypeptide having a third amino acid sequence and a third amino acid sequence having at least 90% identity to the amino acid sequence of the third amino acid sequence, and ]
0.9970795	2525	[ an implantable medical device having a first and a second chamber, the first chamber being in fluid communication with a blood vessel and the second chamber being in fluid communication with a blood vessel; ]	[ A system for the treatment of a patient having a condition of a heart, comprising: ]
0.9998877	2526	[ a first blood pressure sensor configured to sense blood pressure within said first chamber; ]	[ an implantable medical device having a first and a second chamber, the first chamber being in fluid communication with a blood vessel and the second chamber being in fluid communication with a blood vessel; ]
0.99999225	2527	[ a blood pressure monitoring device configured to monitor a blood pressure within said first chamber; and ]	[ a first blood pressure sensor configured to sense blood pressure within said first chamber; ]
0.99999213	2528	[ a blood flow control device configured to control a flow of blood through said first chamber, wherein said flow control device is configured to control said first chamber to maintain a first blood pressure within a predetermined range, and, wherein said blood flow control device is configured to control a blood pressure within said second chamber to maintain a second blood pressure within a predetermined range. ]	[ a blood pressure monitoring device configured to monitor a blood pressure within said first chamber; and ]
0.005289311	2529	[ a first sensor that detects a presence of a first substance in a fluid; ]	[ A system for providing an indication of a patient's status, comprising: ]
0.99998486	2530	[ a processor that receives a first signal from the first sensor, wherein the first signal comprises a plurality of data points, and ]	[ a first sensor that detects a presence of a first substance in a fluid; ]
0.99999225	2531	[ wherein the first signal is received from a plurality of sensors, wherein the processor is adapted to process each of the plurality of sensor data points in a manner that determines whether the first signal is a first signal indicative of an indication of a patient's status; ]	[ a processor that receives a first signal from the first sensor, wherein the first signal comprises a plurality of data points, and ]
0.9988005	2532	[ a second sensor that detects a presence of a second substance in the fluid, wherein the second substance is different from the first substance; ]	[ wherein the first signal is received from a plurality of sensors, wherein the processor is adapted to process each of the plurality of sensor data points in a manner that determines whether the first signal is a first signal indicative of an indication of a patient's status; ]
0.9996779	2533	[ a processor that receives a second signal that is different from the first signal; ]	[ a second sensor that detects a presence of a second substance in the fluid, wherein the second substance is different from the first substance; ]
0.9982614	2534	[ a third sensor that senses the presence of an object in the fluid, wherein the third substance is different from the first substance; and ]	[ a processor that receives a second signal that is different from the first signal; ]
0.99999225	2535	[ a second sensor that detects the presence of a third substance in the fluid, wherein the second substance is different from the first substance. ]	[ a third sensor that senses the presence of an object in the fluid, wherein the third substance is different from the first substance; and ]
0.99999166	2536	[ wherein the anti-tumor agent is a compound of formula I: ]	[ A method of treating an inflammatory condition comprising administering an effective amount of an anti-tumor agent to a subject, wherein the anti-tumor agent has an anti-tumor agent binding affinity, wherein the anti-tumor agent is an anti-TGF-beta-2 (ATG-2) antagonist, and ]
0.9954389	2537	[ or a pharmaceutically acceptable salt thereof. ]	[ wherein the anti-tumor agent is a compound of formula I: ]
0.9924843	2538	[ a housing; ]	[ An implantable medical instrument, comprising: ]
0.9746629	2539	[ a first portion having an opening for receiving a first implantable device, wherein the first portion is configured to be implanted within a body cavity of a patient; and ]	[ a housing; ]
0.99999225	2540	[ a second portion having an opening for receiving a second implantable device; ]	[ a first portion having an opening for receiving a first implantable device, wherein the first portion is configured to be implanted within a body cavity of a patient; and ]
0.9999541	2541	[ wherein the first and second portions are configured to be inserted within a first cavity of the body cavity of the patient and configured to be positioned in the first and second openings of the housing to be in contact with the patient's body cavity. ]	[ a second portion having an opening for receiving a second implantable device; ]
0.9993475	2542	[ providing a first medical device; ]	[ A method of providing a medical treatment for a patient in need of such treatment comprising: ]
0.9999924	2543	[ providing a second medical device; ]	[ providing a first medical device; ]
0.9999918	2544	[ providing a first medical treatment device; ]	[ providing a second medical device; ]
0.99999225	2545	[ providing a second medical treatment device; ]	[ providing a first medical treatment device; ]
0.99998987	2546	[ receiving a patient's request for a first medical treatment; ]	[ providing a second medical treatment device; ]
0.9999924	2547	[ receiving a patient's request for a second medical treatment; ]	[ receiving a patient's request for a first medical treatment; ]
0.9999434	2548	[ providing a first medical device; ]	[ receiving a patient's request for a second medical treatment; ]
0.9999924	2549	[ providing a second medical device; ]	[ providing a first medical device; ]
0.9999918	2550	[ providing a first medical treatment device; ]	[ providing a second medical device; ]
0.99999225	2551	[ providing a second medical treatment device; ]	[ providing a first medical treatment device; ]
0.99999225	2552	[ providing a first medical treatment device; and ]	[ providing a second medical treatment device; ]
0.9999913	2553	[ receiving a patient's request for a first medical treatment. ]	[ providing a first medical treatment device; and ]
0.9996946	2554	[ a sensor array comprising: ]	[ A system for monitoring and controlling a plurality of sensors, comprising: ]
0.9999869	2555	[ a first sensor array; and ]	[ a sensor array comprising: ]
0.999992	2556	[ a second sensor array, each of the first sensor array and the second sensor array being configured for sensing a different one of a number of sensor inputs; and ]	[ a first sensor array; and ]
0.9999901	2557	[ a processor coupled to said first and second sensors, wherein the processor is configured to receive a plurality of sensor inputs from said first and second sensors, wherein the processor is configured to determine whether a first input from said first sensor array is a first input to a first sensor input and whether a second input from said second sensor array is a second input to a second sensor input, and ]	[ a second sensor array, each of the first sensor array and the second sensor array being configured for sensing a different one of a number of sensor inputs; and ]
0.99999225	2558	[ to determine whether a second input from said second sensor array is a second input to a first sensor input, wherein the processor determines if a first sensor input is a first sensor input and if a second sensor input is a second sensor input, and ]	[ a processor coupled to said first and second sensors, wherein the processor is configured to receive a plurality of sensor inputs from said first and second sensors, wherein the processor is configured to determine whether a first input from said first sensor array is a first input to a first sensor input and whether a second input from said second sensor array is a second input to a second sensor input, and ]
0.9999919	2559	[ to determine if the processor is configured to control said first and second sensors. ]	[ to determine whether a second input from said second sensor array is a second input to a first sensor input, wherein the processor determines if a first sensor input is a first sensor input and if a second sensor input is a second sensor input, and ]
0.99998343	2560	[ identifying a mutation that causes the mutation, wherein said mutation is selected from the group consisting of mutations of a polypeptide, a polypeptide comprising a sequence that comprises the amino acid sequence of SEQ ID NO: ]	[ A method of treating a patient with a condition that is caused by a mutation in a gene comprising: ]
0.99439704	2561	[ 1, and ]	[ identifying a mutation that causes the mutation, wherein said mutation is selected from the group consisting of mutations of a polypeptide, a polypeptide comprising a sequence that comprises the amino acid sequence of SEQ ID NO: ]
0.99278235	2562	[ a polypeptide comprising an amino acid sequence that comprises the sequence of SEQ ID NO: ]	[ 1, and ]
0.9951924	2563	[ 1; ]	[ a polypeptide comprising an amino acid sequence that comprises the sequence of SEQ ID NO: ]
0.99297935	2564	[ administering to the patient a therapeutically effective amount of the mutation, wherein the mutation is a mutation that causes the mutation; ]	[ 1; ]
0.9999865	2565	[ detecting the mutation in a biological sample; ]	[ administering to the patient a therapeutically effective amount of the mutation, wherein the mutation is a mutation that causes the mutation; ]
0.99999225	2566	[ determining the mutation to cause the mutation in a biological sample by comparing the mutation detected in said biological sample with a mutation detected in a sample from a patient; and ]	[ detecting the mutation in a biological sample; ]
0.9999906	2567	[ administering to the patient a therapeutically effective amount of the mutation, ]	[ determining the mutation to cause the mutation in a biological sample by comparing the mutation detected in said biological sample with a mutation detected in a sample from a patient; and ]
0.9999864	2568	[ wherein the mutation is selected from the group consisting of mutations of a polypeptide, a polypeptide comprising a sequence that comprises the amino acid sequence of SEQ ID NO: ]	[ administering to the patient a therapeutically effective amount of the mutation, ]
0.98731846	2569	[ 1, and ]	[ wherein the mutation is selected from the group consisting of mutations of a polypeptide, a polypeptide comprising a sequence that comprises the amino acid sequence of SEQ ID NO: ]
0.99278235	2570	[ a polypeptide comprising an amino acid sequence that comprises the sequence of SEQ ID NO: ]	[ 1, and ]
0.96988016	2571	[ 1. ]	[ a polypeptide comprising an amino acid sequence that comprises the sequence of SEQ ID NO: ]
0.9996171	2572	[ 2, SEQ ID NO: ]	[ An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: ]
0.99998915	2573	[ 3, SEQ ID NO: ]	[ 2, SEQ ID NO: ]
0.9999895	2574	[ 4, SEQ ID NO: ]	[ 3, SEQ ID NO: ]
0.99998796	2575	[ 5, SEQ ID NO: ]	[ 4, SEQ ID NO: ]
0.99998975	2576	[ 6, SEQ ID NO: ]	[ 5, SEQ ID NO: ]
0.9999857	2577	[ 7, SEQ ID NO: ]	[ 6, SEQ ID NO: ]
0.9999578	2578	[ 8 and SEQ ID NO: ]	[ 7, SEQ ID NO: ]
0.9997894	2579	[ 9. ]	[ 8 and SEQ ID NO: ]
0.9999877	2580	[ (a) receiving an image of a first object from a camera, the image comprising a plurality of points, wherein each of the plurality of points is located on a surface of the first object and the plurality of points are located in a first plane of the image; ]	[ A method for determining a position of a first object, the method comprising the steps of: ]
0.9999924	2581	[ (b) receiving an image of a second object from said camera, said second object being located on a surface of the second object and the plurality of points are located in a second plane of the image that is substantially parallel with the first plane, wherein the first plane is substantially perpendicular to said second plane and said first object is positioned in a first position in said first plane; and ]	[ (a) receiving an image of a first object from a camera, the image comprising a plurality of points, wherein each of the plurality of points is located on a surface of the first object and the plurality of points are located in a first plane of the image; ]
0.99999213	2582	[ (c) determining, based on said image, the position of said first object in said first plane by: ]	[ (b) receiving an image of a second object from said camera, said second object being located on a surface of the second object and the plurality of points are located in a second plane of the image that is substantially parallel with the first plane, wherein the first plane is substantially perpendicular to said second plane and said first object is positioned in a first position in said first plane; and ]
0.99999225	2583	[ (i) determining the first object's position in said second plane; and ]	[ (c) determining, based on said image, the position of said first object in said first plane by: ]
0.9999924	2584	[ (ii) calculating a first position in the first plane based on a distance between the first object and said first object. ]	[ (i) determining the first object's position in said second plane; and ]
0.9991648	2585	[ (a) an isolated peptide having the amino acid sequence of SEQ ID NO: 1, ]	[ A method of treating an autoimmune disease in a subject comprising administering to the subject a composition comprising: ]
0.999992	2586	[ (b) at least a portion of the isolated peptide having the amino acid sequence of SEQ ID NO: 2, and ]	[ (a) an isolated peptide having the amino acid sequence of SEQ ID NO: 1, ]
0.99998665	2587	[ (c) a pharmaceutically acceptable carrier, wherein the at least a portion of said isolated peptide is selected from the group consisting of: ]	[ (b) at least a portion of the isolated peptide having the amino acid sequence of SEQ ID NO: 2, and ]
0.99997616	2588	[ (i) an isolated peptide having SEQ ID NO: 2, and ]	[ (c) a pharmaceutically acceptable carrier, wherein the at least a portion of said isolated peptide is selected from the group consisting of: ]
0.99999154	2589	[ (ii) an isolated peptide having a amino acid sequence of SEQ ID NO: 3, ]	[ (i) an isolated peptide having SEQ ID NO: 2, and ]
0.9999827	2590	[ wherein the peptide has the amino acid sequence of SEQ ID NO: 3. ]	[ (ii) an isolated peptide having a amino acid sequence of SEQ ID NO: 3, ]
0.9999896	2591	[ a heart defect detection unit that detects a cardiac defect in the animal; ]	[ A system for treating an animal having a heart defect, the system comprising: ]
0.99995434	2592	[ an animal control unit that controls an operation of an animal; ]	[ a heart defect detection unit that detects a cardiac defect in the animal; ]
0.99993813	2593	[ a heart defect detection unit that detects a heart defect in an animal having the heart defect; ]	[ an animal control unit that controls an operation of an animal; ]
0.99999225	2594	[ an animal therapy unit that provides a treatment of the cardiac defect in the animal; ]	[ a heart defect detection unit that detects a heart defect in an animal having the heart defect; ]
0.9999918	2595	[ a heart defect detection unit configured to detect a cardiac defect in an animal having the heart defect; ]	[ an animal therapy unit that provides a treatment of the cardiac defect in the animal; ]
0.99999213	2596	[ an animal therapy unit configured to deliver a treatment of the cardiac defect in the animal; and ]	[ a heart defect detection unit configured to detect a cardiac defect in an animal having the heart defect; ]
0.99813074	2597	[ a control unit configured to: ]	[ an animal therapy unit configured to deliver a treatment of the cardiac defect in the animal; and ]
0.9991698	2598	[ receive a cardiac signal from the heart defect detection unit; ]	[ a control unit configured to: ]
0.999992	2599	[ determine a heart defect in the animal having the cardiac defect based on the cardiac signal; and ]	[ receive a cardiac signal from the heart defect detection unit; ]
0.9999924	2600	[ determine whether the animal is at risk of developing the cardiac defect based on the determined heart defect, ]	[ determine a heart defect in the animal having the cardiac defect based on the cardiac signal; and ]
0.9999914	2601	[ wherein a cardiac signal from the heart defect detection unit is used to determine whether the cardiac defect is in the heart defect detection unit. ]	[ determine whether the animal is at risk of developing the cardiac defect based on the determined heart defect, ]
0.99945945	2602	[ a housing having an interior and a peripheral surface, wherein the peripheral surface of the housing is configured to be implanted within a patient's body and wherein a first end of the first end of the housing is configured for insertion into a patient; and ]	[ An implantable medical device, comprising: ]
0.9999821	2603	[ a first electrode configured for implantation into the patient's body, the first electrode having a first end configured for implantation into the body and an opposite second end configured to be inserted into the peripheral surface of the first end, the first end of the first end being configured to be inserted into a region of the body adjacent to an area of the first end configured to be inserted into the patient's body. ]	[ a housing having an interior and a peripheral surface, wherein the peripheral surface of the housing is configured to be implanted within a patient's body and wherein a first end of the first end of the housing is configured for insertion into a patient; and ]
0.9984547	2604	[ a pharmaceutically acceptable carrier, wherein: ]	[ A method for treating a disease in a subject comprising administering a therapeutically effective amount of at least one of: a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 each independently represent one or more amino acids of formula (I) or a pharmaceutically acceptable salt thereof; and ]
0.99915063	2605	[ R1 and R2 each independently represent one or more amino acids of formula (I) or a pharmaceutically acceptable salt thereof; and ]	[ a pharmaceutically acceptable carrier, wherein: ]
0.99952817	2606	[ R3 represents a hydrogen atom, a C1-C4 alkyl or a C1-C4 alkenyl; ]	[ R1 and R2 each independently represent one or more amino acids of formula (I) or a pharmaceutically acceptable salt thereof; and ]
0.99866295	2607	[ wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof is a compound selected from the group consisting of an antibody, an antigen-binding fragment of a antibody, an antibody-like fragment of an antibody, an antigen-binding fragment of an antibody, an antigen-binding fragment of an antigen-binding fragment, and ]	[ R3 represents a hydrogen atom, a C1-C4 alkyl or a C1-C4 alkenyl; ]
0.99995184	2608	[ a fragment of a fragment of an antibody. ]	[ wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof is a compound selected from the group consisting of an antibody, an antigen-binding fragment of a antibody, an antibody-like fragment of an antibody, an antigen-binding fragment of an antibody, an antigen-binding fragment of an antigen-binding fragment, and ]
0.019069666	2609	[ a) providing a first device having a first end and a second end, the first device including a first body and a second body; ]	[ A method comprising: ]
0.99999225	2610	[ b) providing a second device including a first end and a second end, the second end of the first device having a first end portion and a second end portion; ]	[ a) providing a first device having a first end and a second end, the first device including a first body and a second body; ]
0.99999106	2611	[ c) providing a plurality of first and second electrodes connected to the first and second ends of the first device; ]	[ b) providing a second device including a first end and a second end, the second end of the first device having a first end portion and a second end portion; ]
0.99999225	2612	[ d) providing a plurality of second electrodes connected to the first and second ends of the second device; ]	[ c) providing a plurality of first and second electrodes connected to the first and second ends of the first device; ]
0.99999225	2613	[ e) connecting the plurality of first and second electrodes to the first and second ends of the first and second devices; ]	[ d) providing a plurality of second electrodes connected to the first and second ends of the second device; ]
0.9999294	2614	[ f) providing a plurality of first and second conductive members; ]	[ e) connecting the plurality of first and second electrodes to the first and second ends of the first and second devices; ]
0.99999225	2615	[ g) providing a plurality of second conductive members; and ]	[ f) providing a plurality of first and second conductive members; ]
0.999982	2616	[ h) connecting the second end of each of the first and second devices to the first end of the plurality of second conductive members. ]	[ g) providing a plurality of second conductive members; and ]
0.92010236	2617	[ detecting, by a processor, a first signal indicative of an activity of an animal; ]	[ A method comprising: ]
0.9999924	2618	[ detecting, by the processor, a second signal indicative of an activity of the animal; and ]	[ detecting, by a processor, a first signal indicative of an activity of an animal; ]
0.99999213	2619	[ determining, by the processor, whether the first or the second signal is indicative of a first activity or a second activity, ]	[ detecting, by the processor, a second signal indicative of an activity of the animal; and ]
0.9999924	2620	[ wherein the second activity is determined based on a difference between the first signal and the second signal. ]	[ determining, by the processor, whether the first or the second signal is indicative of a first activity or a second activity, ]
0.9966799	2621	[ 2. ]	[ A method of treating a patient having an abnormal heart rhythm comprising administering to said patient a therapeutically effective amount of a therapeutically effective amount of an isolated polypeptide, said polypeptide comprising an amino acid sequence having at least 80% identity to SEQ ID NO: ]
0.9998919	2622	[ an amino acid salt of SEQ ID NO: 2; ]	[ A method of treating an individual suffering from a disease comprising administering to said individual in need thereof a therapeutically effective amount of a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: 2, wherein said salt is selected from the group consisting of: ]
0.99999166	2623	[ an amino acid salt of SEQ ID NO: 3; ]	[ an amino acid salt of SEQ ID NO: 2; ]
0.999977	2624	[ a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: 2; and ]	[ an amino acid salt of SEQ ID NO: 3; ]
0.9999883	2625	[ a pharmaceutically acceptable salt of SEQ ID NO: 3. ]	[ a pharmaceutically acceptable salt of the amino acid sequence set forth in SEQ ID NO: 2; and ]
0.9997174	2626	[ 2 and SEQ ID NO: ]	[ A method for treating a disease in a subject, comprising administering to the subject an effective amount of a therapeutically effective amount of an antibody, wherein the antibody comprises an antigenic fragment thereof, wherein the antibody binds to a polypeptide selected from the group consisting of SEQ ID NO: ]
0.99905723	2627	[ 3. ]	[ 2 and SEQ ID NO: ]
0.9997874	2628	[ providing to the patient a composition comprising a therapeutically effective amount of a compound of formula I: ]	[ A method of treating a patient suffering from a disease or disorder comprising: ]
0.9780952	2629	[ wherein: ]	[ providing to the patient a composition comprising a therapeutically effective amount of a compound of formula I: ]
0.9918241	2630	[ R1 is a hydrogen, alkyl, alkenyl, alkynyl, heterocyclic, or heteroaryl group having at least one of a hydrogen atom or a halogen atom; ]	[ wherein: ]
0.999992	2631	[ R2 is a hydrogen, alkyl, alkenyl, alkynyl, heterocyclic, or heteroaryl group having at least one of a halogen atom or a hydrogen atom; and ]	[ R1 is a hydrogen, alkyl, alkenyl, alkynyl, heterocyclic, or heteroaryl group having at least one of a hydrogen atom or a halogen atom; ]
0.99284524	2632	[ R1, R2, and ]	[ R2 is a hydrogen, alkyl, alkenyl, alkynyl, heterocyclic, or heteroaryl group having at least one of a halogen atom or a hydrogen atom; and ]
0.99570304	2633	[ R3 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heterocyclic, and ]	[ R1, R2, and ]
0.9961217	2634	[ heteroaryl groups; and ]	[ R3 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heterocyclic, and ]
0.99964726	2635	[ R1 is a hydrogen, alkyl, alkenyl, alkynyl, heterocyclic or heteroaryl group having at least one of a halogen atom, a hydrogen atom, a hydrogen atom, an alkyl, a alkenyl, a alkynyl, a cycloalkyl group, an alkynyl, or heterocyclic group; and ]	[ heteroaryl groups; and ]
0.0006220004	2636	[ a pharmaceutically acceptable carrier; and ]	[ R1 is a hydrogen, alkyl, alkenyl, alkynyl, heterocyclic or heteroaryl group having at least one of a halogen atom, a hydrogen atom, a hydrogen atom, an alkyl, a alkenyl, a alkynyl, a cycloalkyl group, an alkynyl, or heterocyclic group; and ]
0.99930096	2637	[ administering to the patient in an amount effective to treat the disease or disorder. ]	[ a pharmaceutically acceptable carrier; and ]
0.99839956	2638	[ 2 to a patient in need thereof. ]	[ A method for the treatment of a patient, comprising administering a therapeutically effective amount of a composition comprising a therapeutically effective amount of a polypeptide comprising an amino acid sequence of SEQ ID NO: ]
0.99913687	2639	[ a) a first device having a first end and a second end, the first end being adapted for insertion into the patient and the second end being adapted for attachment to a first portion of an external body; ]	[ A device for providing a therapeutic effect to a patient, comprising: ]
0.99999225	2640	[ b) a second device having a second end and adapted for insertion into an external body, the second end being adapted for attachment to a second portion of the external body, the first and second devices having a first and second end; ]	[ a) a first device having a first end and a second end, the first end being adapted for insertion into the patient and the second end being adapted for attachment to a first portion of an external body; ]
0.9999883	2641	[ c) an adhesive disposed between the first device and the second device, the adhesive being configured to adhere to the first device and the second device to create an adhesion relationship; ]	[ b) a second device having a second end and adapted for insertion into an external body, the second end being adapted for attachment to a second portion of the external body, the first and second devices having a first and second end; ]
0.99998844	2642	[ d) a first portion of the first end of the first device being adapted for insertion into a portion of a patient's body that is not adapted for insertion into a portion of the patient's body that is adapted for insertion into the second device; and ]	[ c) an adhesive disposed between the first device and the second device, the adhesive being configured to adhere to the first device and the second device to create an adhesion relationship; ]
0.9999882	2643	[ e) an adhesive disposed between the second device and the first device. ]	[ d) a first portion of the first end of the first device being adapted for insertion into a portion of a patient's body that is not adapted for insertion into a portion of the patient's body that is adapted for insertion into the second device; and ]
0.97857964	2644	[ wherein: ]	[ A method of treating a cancer in a subject, the method comprising administering to the subject an effective amount of a compound having the structure: ]
0.9945374	2645	[ R1 is a hydrogen atom, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaryl heteroatom or an alkyl group; ]	[ wherein: ]
0.99999213	2646	[ R2 is a hydrogen atom, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaryl heteroatom or an alkyl group; and ]	[ R1 is a hydrogen atom, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaryl heteroatom or an alkyl group; ]
0.9999913	2647	[ R1 and R2 together form a C-terminal or a C-terminal-substituted heteroaryl or heteroaryl heteroatom, and ]	[ R2 is a hydrogen atom, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaryl heteroatom or an alkyl group; and ]
0.96542335	2648	[ wherein: ]	[ R1 and R2 together form a C-terminal or a C-terminal-substituted heteroaryl or heteroaryl heteroatom, and ]
0.9663934	2649	[ R1 is a substituted or unsaturated C-terminal, and ]	[ wherein: ]
0.99998486	2650	[ the C-terminal is substituted or unsubstituted, and ]	[ R1 is a substituted or unsaturated C-terminal, and ]
0.9999871	2651	[ the unsaturated C-terminal is a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaryl heteroatom or an alkyl group; and ]	[ the C-terminal is substituted or unsubstituted, and ]
0.9999919	2652	[ R1 and R2 together form a C-terminal or a C-terminal-substituted heteroaryl or heteroaryl heteroatom. ]	[ the unsaturated C-terminal is a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaryl heteroatom or an alkyl group; and ]
0.051821962	2653	[ a first portion; ]	[ A device for treating a patient, comprising: ]
0.9999684	2654	[ a second portion, wherein the first and second portions are configured to be placed in contact with one another, and ]	[ a first portion; ]
0.9999888	2655	[ wherein the first portion and the second portion are configured to be disposed in a substantially parallel relationship, wherein the first portion and the second portion are configured to be disposed in a substantially parallel relationship, and ]	[ a second portion, wherein the first and second portions are configured to be placed in contact with one another, and ]
0.9974023	2656	[ wherein the first, second, and ]	[ wherein the first portion and the second portion are configured to be disposed in a substantially parallel relationship, wherein the first portion and the second portion are configured to be disposed in a substantially parallel relationship, and ]
0.9960085	2657	[ third portions are disposed in a substantially parallel relationship; wherein the first portion is disposed in a substantially flat configuration; ]	[ wherein the first, second, and ]
0.9991461	2658	[ wherein the first, second, and ]	[ third portions are disposed in a substantially parallel relationship; wherein the first portion is disposed in a substantially flat configuration; ]
0.9994311	2659	[ fourth portions are disposed in a substantially flat configuration; wherein the first, second, and ]	[ wherein the first, second, and ]
0.9999924	2660	[ third portions are disposed in a substantially flat configuration; and ]	[ fourth portions are disposed in a substantially flat configuration; wherein the first, second, and ]
0.99848914	2661	[ wherein the first, second, and ]	[ third portions are disposed in a substantially flat configuration; and ]
0.99700314	2662	[ fourth portions are configured to be disposed in a substantially parallel relationship. ]	[ wherein the first, second, and ]
0.9972549	2663	[ providing an implantable therapeutic device; ]	[ A method for treating a subject, comprising: ]
0.9999913	2664	[ inserting an implantable therapeutic device into the subject, wherein the implantable therapeutic device is adapted to be placed within a patient's tissue; ]	[ providing an implantable therapeutic device; ]
0.97768825	2665	[ providing a first electrode and a second electrode; ]	[ inserting an implantable therapeutic device into the subject, wherein the implantable therapeutic device is adapted to be placed within a patient's tissue; ]
0.9998877	2666	[ providing a first electrode electrode having a plurality of electrodes arranged in a first configuration, the first electrode electrode electrode having a first electrode electrode surface and a second electrode electrode surface, the first electrode electrode surface and the second electrode surface being disposed in a second configuration, the second configuration being a configuration different from the first configuration; ]	[ providing a first electrode and a second electrode; ]
0.99998236	2667	[ inserting a second electrode electrode into a region of the subject's tissue adjacent to the first electrode electrode; and ]	[ providing a first electrode electrode having a plurality of electrodes arranged in a first configuration, the first electrode electrode electrode having a first electrode electrode surface and a second electrode electrode surface, the first electrode electrode surface and the second electrode surface being disposed in a second configuration, the second configuration being a configuration different from the first configuration; ]
0.9999082	2668	[ providing a third electrode electrode having a plurality of electrodes arranged in a third configuration, the third configurations having a plurality of electrodes arranged in the second configuration, the second configuration, and ]	[ inserting a second electrode electrode into a region of the subject's tissue adjacent to the first electrode electrode; and ]
0.999992	2669	[ the third configuration being different from the first configuration, the second configuration, and ]	[ providing a third electrode electrode having a plurality of electrodes arranged in a third configuration, the third configurations having a plurality of electrodes arranged in the second configuration, the second configuration, and ]
0.9999914	2670	[ the third configuration. ]	[ the third configuration being different from the first configuration, the second configuration, and ]
0.9958001	2671	[ a first electrode having a first electrode surface; ]	[ A device for providing a first therapeutic effect to a patient, the first device comprising: ]
0.9999906	2672	[ a second electrode having a second electrode surface, the second electrode surface being adjacent to the first electrode surface; ]	[ a first electrode having a first electrode surface; ]
0.9999838	2673	[ an insulating layer between the first electrode and the second electrode surface; ]	[ a second electrode having a second electrode surface, the second electrode surface being adjacent to the first electrode surface; ]
0.999987	2674	[ an outer surface of the insulating layer; and ]	[ an insulating layer between the first electrode and the second electrode surface; ]
0.9999918	2675	[ an inner surface of the insulating layer, ]	[ an outer surface of the insulating layer; and ]
0.99999166	2676	[ wherein the outer surface of the insulating layer is configured to be disposed within a cavity of the patient, and ]	[ an inner surface of the insulating layer, ]
0.99999225	2677	[ wherein the inner surface of the insulating layer is configured to be disposed within a cavity of the patient. ]	[ wherein the outer surface of the insulating layer is configured to be disposed within a cavity of the patient, and ]
0.9985935	2678	[ wherein R1 is a C1-C6 alkyl or C1-C6 cycloalkyl; ]	[ A method for producing a composition comprising a compound of formula I: ]
0.99999034	2679	[ R2 is a C1-C6 alkyl or C1-C6 cycloalkyl; ]	[ wherein R1 is a C1-C6 alkyl or C1-C6 cycloalkyl; ]
0.9999889	2680	[ R3 is a C1-C6 alkyl or C1-C6 cycloalkyl; or R6 is a cycloalkyl or a C1-C6 alkoxy; and ]	[ R2 is a C1-C6 alkyl or C1-C6 cycloalkyl; ]
0.9999901	2681	[ R7 is a C1-C6 alkyl or a C1-C6 cycloalkyl; ]	[ R3 is a C1-C6 alkyl or C1-C6 cycloalkyl; or R6 is a cycloalkyl or a C1-C6 alkoxy; and ]
0.99999046	2682	[ wherein R8 is a C1-C6 alkyl or C1-C6 cycloalkyl; ]	[ R7 is a C1-C6 alkyl or a C1-C6 cycloalkyl; ]
0.9999888	2683	[ wherein R9 is a C1-C6 alkyl or a C1-C6 cycloalkyl; ]	[ wherein R8 is a C1-C6 alkyl or C1-C6 cycloalkyl; ]
0.99997413	2684	[ wherein R10 is a C1-C6 alkyl or a C1-C6 cycloalkyl; or R11 is a C1-C6 alkyl or a C1-C6 cycloalkyl, wherein the alkyls are selected from the group consisting of alkyl, C1-6alkyl, C3-C8alkyl, C4-C10alkyl, C6-C8alkyl, C6-C8alkenyl, C6-C8alkynyl and C6-C8alkoxyalkyl; ]	[ wherein R9 is a C1-C6 alkyl or a C1-C6 cycloalkyl; ]
0.9999901	2685	[ wherein R13 is a C1-C6 alkyl or a C1-C6 cycloalkyl. ]	[ wherein R10 is a C1-C6 alkyl or a C1-C6 cycloalkyl; or R11 is a C1-C6 alkyl or a C1-C6 cycloalkyl, wherein the alkyls are selected from the group consisting of alkyl, C1-6alkyl, C3-C8alkyl, C4-C10alkyl, C6-C8alkyl, C6-C8alkenyl, C6-C8alkynyl and C6-C8alkoxyalkyl; ]
0.9981091	2686	[ an elongate body having a proximal end and a distal end, the elongate body having a proximal end and a distal end; ]	[ A device for the insertion and removal of a catheter into a body cavity of an animal, the device comprising: ]
0.9999914	2687	[ a first portion of the elongate body having a proximal end and a distal end, the first portion of the elongate body being adapted to be inserted into a catheter and a second portion of the elongate body having a proximal end and a distal end, the second portion of the elongate body being adapted to be removed from the catheter; ]	[ an elongate body having a proximal end and a distal end, the elongate body having a proximal end and a distal end; ]
0.9999924	2688	[ a first portion of the elongate body having a proximal end and a distal end, the first portion of the elongate body being adapted for being inserted into a catheter and a second portion of the elongate body having a proximal end and a distal end, the second portion of the elongate body being adapted for being removed from the catheter; and ]	[ a first portion of the elongate body having a proximal end and a distal end, the first portion of the elongate body being adapted to be inserted into a catheter and a second portion of the elongate body having a proximal end and a distal end, the second portion of the elongate body being adapted to be removed from the catheter; ]
0.99999225	2689	[ a second portion of the elongate body having a proximal end and a distal end, the second portion of the elongate body being adaptably adapted to be removed from the catheter and adapted to be inserted into a catheter and a distal end, the first portion of the elongate body being adapted to be inserted into the body cavity of the animal, the second portion of the elongate body being adapted to be removed from the catheter and adapted to be inserted into a catheter, wherein the second portion of the elongate body is adapted to be inserted into the body cavity of the animal, the first portion of the elongate body is adapted to be removed from the catheter and the second portion of the elongate body is adapted to be inserted into the catheter. ]	[ a first portion of the elongate body having a proximal end and a distal end, the first portion of the elongate body being adapted for being inserted into a catheter and a second portion of the elongate body having a proximal end and a distal end, the second portion of the elongate body being adapted for being removed from the catheter; and ]
0.020328995	2690	[ 1. ]	[ An isolated nucleic acid encoding a protein of the type comprising a polypeptide having a nucleic acid sequence having at least 95% identity to SEQ ID NO: ]
0.0018559757	2691	[ providing a first implantable medical device (IMD); ]	[ A method for the treatment of an animal, said method comprising the steps of: ]
0.99999225	2692	[ providing at least one second implantable medical device (SIMD); ]	[ providing a first implantable medical device (IMD); ]
0.9999428	2693	[ providing a first medical device interface (MIDI); and ]	[ providing at least one second implantable medical device (SIMD); ]
0.99999213	2694	[ providing a second medical device interface (MIDDI); ]	[ providing a first medical device interface (MIDI); and ]
0.99998236	2695	[ wherein said first and second IMD are connected to said MIDI and said MIDDI, and ]	[ providing a second medical device interface (MIDDI); ]
0.99999213	2696	[ wherein the first IMD and the second IMD are connected to said MIDDI, and ]	[ wherein said first and second IMD are connected to said MIDI and said MIDDI, and ]
0.9999924	2697	[ wherein said IMD and the second IMD have a common interface, wherein the common interface includes a plurality of channels, wherein said plurality of channels are arranged in a first direction and wherein the first IMD is connected to the first MIDDI and the second IMD is connected to the second MIDDI, and ]	[ wherein the first IMD and the second IMD are connected to said MIDDI, and ]
0.99999213	2698	[ wherein said first and second IMD each have an interface, wherein the first IMD and the second IMD each have a plurality of ports, wherein said plurality of ports are arranged in a second direction, and ]	[ wherein said IMD and the second IMD have a common interface, wherein the common interface includes a plurality of channels, wherein said plurality of channels are arranged in a first direction and wherein the first IMD is connected to the first MIDDI and the second IMD is connected to the second MIDDI, and ]
0.99999225	2699	[ wherein said first IMD and the second IMD are connected to each other. ]	[ wherein said first and second IMD each have an interface, wherein the first IMD and the second IMD each have a plurality of ports, wherein said plurality of ports are arranged in a second direction, and ]
0.9633915	2700	[ a housing; ]	[ An apparatus comprising: ]
0.99953055	2701	[ an input device coupled to the housing, the input device including: a plurality of input elements, each input element including a plurality of input elements; ]	[ a housing; ]
0.99998987	2702	[ a plurality of control elements disposed in communication with the input elements, the plurality of control elements configured to control operation of the plurality of input elements; ]	[ an input device coupled to the housing, the input device including: a plurality of input elements, each input element including a plurality of input elements; ]
0.009175334	2703	[ a processor configured to: ]	[ a plurality of control elements disposed in communication with the input elements, the plurality of control elements configured to control operation of the plurality of input elements; ]
0.9974796	2704	[ receive input from the input devices; ]	[ a processor configured to: ]
0.99788886	2705	[ generate, by the processor, a plurality of signals, the signals comprising at least one of a first signal and a second signal, wherein each of the first signal and the second signal is associated with a different input element; and ]	[ receive input from the input devices; ]
0.99999154	2706	[ determine, by the processor, whether to operate the plurality of input elements based on the first signal and the second signal, ]	[ generate, by the processor, a plurality of signals, the signals comprising at least one of a first signal and a second signal, wherein each of the first signal and the second signal is associated with a different input element; and ]
0.99904317	2707	[ wherein the processor is further configured to: ]	[ determine, by the processor, whether to operate the plurality of input elements based on the first signal and the second signal, ]
0.9866414	2708	[ determine whether to operate the input elements based on the first signal and the second signal; ]	[ wherein the processor is further configured to: ]
0.9999924	2709	[ determine whether to operate the input elements based on the first signal and the second signal; and ]	[ determine whether to operate the input elements based on the first signal and the second signal; ]
0.9999924	2710	[ determine whether to operate the plurality of input elements based on the first signal and the second signal. ]	[ determine whether to operate the input elements based on the first signal and the second signal; and ]
0.9999912	2711	[ a first implantable medical device (IMD) having a first body and a first implantation device; ]	[ A system for providing an implantable medical device (IMD) to a patient, said system comprising: ]
0.99999225	2712	[ a second implantable medical device (IMD) having a second body and a second implantation device; ]	[ a first implantable medical device (IMD) having a first body and a first implantation device; ]
0.99727887	2713	[ a first sensor configured to sense an external environment; ]	[ a second implantable medical device (IMD) having a second body and a second implantation device; ]
0.99999225	2714	[ a second sensor configured to sense an internal environment; ]	[ a first sensor configured to sense an external environment; ]
0.9978879	2715	[ a first controller configured for controlling a first IMD to perform a first operation; and ]	[ a second sensor configured to sense an internal environment; ]
0.9999924	2716	[ a second controller configured for controlling a second IMD to perform the first operation, ]	[ a first controller configured for controlling a first IMD to perform a first operation; and ]
0.9999918	2717	[ wherein the first and second IMDs are configured to be implanted in a patient, and ]	[ a second controller configured for controlling a second IMD to perform the first operation, ]
0.999992	2718	[ wherein the first IMDD and the second IMDD are configured to be implanted in a patient's body. ]	[ wherein the first and second IMDs are configured to be implanted in a patient, and ]
0.9979538	2719	[ 2. ]	[ An isolated nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: ]
0.015828378	2720	[ a) providing a catheter having a distal end and a proximal end; ]	[ A method for the treatment of an animal, comprising the steps of: ]
0.9999913	2721	[ b) providing a catheter-invasive implant having an implant tip at the distal end of the catheter; ]	[ a) providing a catheter having a distal end and a proximal end; ]
0.9999919	2722	[ c) providing a catheter-invasive implant-invasive implant assembly having an inlet and an outlet; ]	[ b) providing a catheter-invasive implant having an implant tip at the distal end of the catheter; ]
0.99999225	2723	[ d) inserting the catheter-invasive implant assembly into a body part of a patient; ]	[ c) providing a catheter-invasive implant-invasive implant assembly having an inlet and an outlet; ]
0.99999225	2724	[ e) inserting a catheter-invasive implant-invasive implant assembly into a body part of the animal, wherein the catheter-invasive implant assembly is adapted to be implanted within the body part; and ]	[ d) inserting the catheter-invasive implant assembly into a body part of a patient; ]
0.9999924	2725	[ f) applying an ultrasonic therapy to the catheter-invasive implant assembly. ]	[ e) inserting a catheter-invasive implant-invasive implant assembly into a body part of the animal, wherein the catheter-invasive implant assembly is adapted to be implanted within the body part; and ]
0.999992	2726	[ wherein the CD4T protein is encoded by an isolated nucleotide sequence that encodes a nucleotide sequence that comprises at least 95% sequence identity with the nucleotide sequence encoding the CD4T protein, wherein the CD4T protein is expressed by a T cells, and ]	[ A method of treating an individual with a disease comprising administering to the individual a therapeutically effective amount of an isolated nucleic acid molecule that encodes the human CD4+ T cell receptor (CD4T) protein, wherein the CD4T protein comprises a CD4T-like region, and ]
0.99999166	2727	[ wherein the T cells are a T lymphoma cell or a T lymphoma cell expressing CD4T. ]	[ wherein the CD4T protein is encoded by an isolated nucleotide sequence that encodes a nucleotide sequence that comprises at least 95% sequence identity with the nucleotide sequence encoding the CD4T protein, wherein the CD4T protein is expressed by a T cells, and ]
0.97724015	2728	[ wherein: ]	[ A method of treating a patient having a heart disease comprising administering to the patient a therapeutically effective amount of a compound of formula I: ]
0.06748817	2729	[ R1, R2 and R3 each independently comprise the amino acid sequence of SEQ ID NO: ]	[ wherein: ]
0.9923969	2730	[ 1, and ]	[ R1, R2 and R3 each independently comprise the amino acid sequence of SEQ ID NO: ]
0.00018125003	2731	[ R5 is selected from the group consisting of: ]	[ 1, and ]
0.00010558339	2732	[ (1) an amino acid sequence of SEQ ID NO: ]	[ R5 is selected from the group consisting of: ]
0.9999571	2733	[ 1, or (2) a sequence having a sequence of at least 90% sequence identity to SEQ ID NO: ]	[ (1) an amino acid sequence of SEQ ID NO: ]
0.98478436	2734	[ 1, ]	[ 1, or (2) a sequence having a sequence of at least 90% sequence identity to SEQ ID NO: ]
0.03255583	2735	[ wherein: ]	[ 1, ]
0.99642736	2736	[ R5 is a C1-5 alkyl or a C1-4alkyl; and ]	[ wherein: ]
0.99990726	2737	[ R6 is a C1-5 alkoxy, ]	[ R5 is a C1-5 alkyl or a C1-4alkyl; and ]
0.9992016	2738	[ wherein the compound of formula I is a pharmaceutically acceptable salt or ester, ]	[ R6 is a C1-5 alkoxy, ]
0.03526815	2739	[ wherein the heart disease is a coronary heart disease, and ]	[ wherein the compound of formula I is a pharmaceutically acceptable salt or ester, ]
0.9999919	2740	[ the heart disease is a coronary heart disease associated with a coronary artery disease. ]	[ wherein the heart disease is a coronary heart disease, and ]
0.9993635	2741	[ wherein R1 is a C1-6 alkyl, C1-6 alkoxy, C1-6 alkyl-C1-6 alkoxyalkyl, C1-6 alkoxyalkyl, C1-6 alkyl-C1-6 alkyl-C1-6 alkoxyalkyl, or C3-6 alkylamino; ]	[ A method for treating an inflammatory disorder comprising administering to an individual a compound of formula I or a pharmaceutically acceptable salt thereof: ]
0.99998844	2742	[ X is a C1-6 alkyl, C1-6 alkoxy, C1-6 alkyl-C1-6 alkyl-C1-6 alkyl-C1-6 alkoxyalkyl or C3-6 alkylamino; and ]	[ wherein R1 is a C1-6 alkyl, C1-6 alkoxy, C1-6 alkyl-C1-6 alkoxyalkyl, C1-6 alkoxyalkyl, C1-6 alkyl-C1-6 alkyl-C1-6 alkoxyalkyl, or C3-6 alkylamino; ]
0.99998677	2743	[ R2 is a C1-6 alkoxy, C1-6 alkyl or C1-6 alkyl-C1-6 alkyl-C1-6 alkyl-C1-6 alkoxyalkyl. ]	[ X is a C1-6 alkyl, C1-6 alkoxy, C1-6 alkyl-C1-6 alkyl-C1-6 alkyl-C1-6 alkoxyalkyl or C3-6 alkylamino; and ]
0.99949515	2744	[ a first patient care device; ]	[ A system for providing a plurality of different treatment options for a patient in need of treatment, said system comprising: ]
0.99999225	2745	[ a second patient care device; ]	[ a first patient care device; ]
0.99999225	2746	[ a third patient care device; and ]	[ a second patient care device; ]
0.99999225	2747	[ a fourth patient care device. ]	[ a third patient care device; and ]
0.00029559506	2748	[ 2 or a pharmaceutically acceptable salt thereof. ]	[ A method for treating a subject suffering from an inflammatory disorder comprising administering to the subject a composition comprising an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: ]
0.97701675	2749	[ a body having a first surface and an opposite second surface; ]	[ An implantable device for delivering a drug to an organ of a patient, comprising: ]
0.99694806	2750	[ an implantable device having a first portion having a plurality of first electrodes and a plurality of second electrodes; and ]	[ a body having a first surface and an opposite second surface; ]
0.9999901	2751	[ a first fluid delivery system configured to deliver the first fluid from the implantable device into a first fluid channel in the body; ]	[ an implantable device having a first portion having a plurality of first electrodes and a plurality of second electrodes; and ]
0.99999154	2752	[ a first fluid delivery channel having a first fluid outlet; ]	[ a first fluid delivery system configured to deliver the first fluid from the implantable device into a first fluid channel in the body; ]
0.9999902	2753	[ a first fluid conduit having a first fluid conduit outlet; and ]	[ a first fluid delivery channel having a first fluid outlet; ]
0.9999865	2754	[ a first fluid delivery system having a first fluid delivery channel outlet, ]	[ a first fluid conduit having a first fluid conduit outlet; and ]
0.9999876	2755	[ wherein the first portion is configured to be inserted into a first fluid channel in the body and the first fluid channel outlet is configured to be inserted into a second fluid channel in the body, ]	[ a first fluid delivery system having a first fluid delivery channel outlet, ]
0.99999213	2756	[ wherein the first fluid channel is configured to be inserted into the second fluid channel and the second fluid channel outlet is configured to be inserted into the first fluid channel outlet in the body. ]	[ wherein the first portion is configured to be inserted into a first fluid channel in the body and the first fluid channel outlet is configured to be inserted into a second fluid channel in the body, ]
0.9984006	2757	[ an optical system for producing an optical beam; ]	[ An apparatus for the treatment of an eye, comprising: ]
0.997027	2758	[ at least one light source; ]	[ an optical system for producing an optical beam; ]
0.9999691	2759	[ at least one light detector for detecting a first light beam emitted from the at least one light source; ]	[ at least one light source; ]
0.99996626	2760	[ a first light source control circuit configured to control a first light beam source for producing an optical beam; ]	[ at least one light detector for detecting a first light beam emitted from the at least one light source; ]
0.9999913	2761	[ a first light detector control circuit configured to control a first light detector for detecting the first light beam; ]	[ a first light source control circuit configured to control a first light beam source for producing an optical beam; ]
0.9999901	2762	[ a second light source control circuit, configured to control a second light source for producing an optical beam; ]	[ a first light detector control circuit configured to control a first light detector for detecting the first light beam; ]
0.99999154	2763	[ a second light detector control circuit, configured to control a second light detector for detecting the second light beam; ]	[ a second light source control circuit, configured to control a second light source for producing an optical beam; ]
0.99957234	2764	[ an optical path connecting the first and the second light sources; and ]	[ a second light detector control circuit, configured to control a second light detector for detecting the second light beam; ]
0.9999906	2765	[ an output device configured to output an output of the optical path to a display device; ]	[ an optical path connecting the first and the second light sources; and ]
0.9999877	2766	[ wherein the optical path is configured to be configured to be coupled to an external light source, the external light source having a first wavelength, the optical path being configured to be coupled to the external light source, wherein the optical path is configured to have an optical path length that is shorter than the optical path length of the external light source. ]	[ an output device configured to output an output of the optical path to a display device; ]
0.99985886	2767	[ administering to the patient a therapeutically effective amount of an isolated polypeptide, wherein said isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: ]	[ A method for the treatment of a patient having cancer, the method comprising: ]
0.0118815545	2768	[ 1, 2, and ]	[ administering to the patient a therapeutically effective amount of an isolated polypeptide, wherein said isolated polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: ]
0.98016274	2769	[ 4; ]	[ 1, 2, and ]
0.99709153	2770	[ wherein said isolated polypeptide is selected from the group consisting of: ]	[ 4; ]
0.99929273	2771	[ (a) the amino acid sequence of SEQ ID NO: ]	[ wherein said isolated polypeptide is selected from the group consisting of: ]
0.9981014	2772	[ 2; ]	[ (a) the amino acid sequence of SEQ ID NO: ]
0.9985695	2773	[ (b) the amino acid sequence of SEQ ID NO: ]	[ 2; ]
0.9982331	2774	[ 3; ]	[ (b) the amino acid sequence of SEQ ID NO: ]
0.9978002	2775	[ (c) the sequence of the amino acid sequence of SEQ ID NO: ]	[ 3; ]
0.9986468	2776	[ 2; and ]	[ (c) the sequence of the amino acid sequence of SEQ ID NO: ]
0.9989409	2777	[ (d) the sequence of the amino acid sequence of SEQ ID NO: ]	[ 2; and ]
0.99949014	2778	[ 4; and ]	[ (d) the sequence of the amino acid sequence of SEQ ID NO: ]
0.9979845	2779	[ wherein said isolated polypeptide comprises an antigenic component. ]	[ 4; and ]
0.9998635	2780	[ (a) an antibody fragment comprising a first fragment and a second fragment; and ]	[ An isolated antibody that specifically binds to the human immunodeficiency virus type 1 antigen (HIV-1) comprising: ]
0.9999883	2781	[ (b) a nucleic acid molecule that specifically binds the first fragment of the antibody. ]	[ (a) an antibody fragment comprising a first fragment and a second fragment; and ]
0.9999883	2782	[ bioabsorbable, biodegradable, and ]	[ A method of producing a biodegradable, biodegradable, and ]
0.9999907	2783	[ bioabsorbable, biodegradable, and ]	[ bioabsorbable, biodegradable, and ]
0.99996936	2784	[ biodegradable, biodegradable and bioabsorbable, biodegradable and bioabsorbable, bioabsorbable, biodegradable, and ]	[ bioabsorbable, biodegradable, and ]
0.9999908	2785	[ bioabsorbable, bioabsorbable, biodegradable, and ]	[ biodegradable, biodegradable and bioabsorbable, biodegradable and bioabsorbable, bioabsorbable, biodegradable, and ]
0.99999094	2786	[ bioabsorbable, biodegradable, and ]	[ bioabsorbable, bioabsorbable, biodegradable, and ]
0.99998605	2787	[ bioabsorbable polymer, wherein the biodegradable and bioabsorbable polymer comprises a polymeric composition comprising a polymer having a molecular weight of at least 100, ]	[ bioabsorbable, biodegradable, and ]
0.99562496	2788	[ 000, and ]	[ bioabsorbable polymer, wherein the biodegradable and bioabsorbable polymer comprises a polymeric composition comprising a polymer having a molecular weight of at least 100, ]
0.987519	2789	[ wherein the biodegradable polymer comprises a polymer having a molecular weight of at least 100, ]	[ 000, and ]
0.99999213	2790	[ 000 and the biodegradable polymer comprises a polymer having a molecular weight of less than 100, ]	[ wherein the biodegradable polymer comprises a polymer having a molecular weight of at least 100, ]
0.9997478	2791	[ 000, ]	[ 000 and the biodegradable polymer comprises a polymer having a molecular weight of less than 100, ]
0.99563557	2792	[ and wherein the biodegradable and bioabsorbable polymer is a biodegradable, biodegradable, and ]	[ 000, ]
0.99998355	2793	[ bioabsorbable polymer comprising a polymer having a molecular weight of at least 100, ]	[ and wherein the biodegradable and bioabsorbable polymer is a biodegradable, biodegradable, and ]
0.9999913	2794	[ 000 and a biodegradable polymer comprising a polymer having a molecular weight of at least 100, ]	[ bioabsorbable polymer comprising a polymer having a molecular weight of at least 100, ]
0.999992	2795	[ 000 and a bioabsorbable polymer comprising a polymer having a molecular weight of less than 100, ]	[ 000 and a biodegradable polymer comprising a polymer having a molecular weight of at least 100, ]
0.99931884	2796	[ 000. ]	[ 000 and a bioabsorbable polymer comprising a polymer having a molecular weight of less than 100, ]
